New reporters of protein trafficking and protein-protein interactions in live cells by Fernández Suárez, Marta
New reporters of protein trafficking and
protein-protein interactions in live cells
by
Marta Fernmndez Suarez
B.S. Chemical Engineering (1999)
Institut Quimic de Sarria (Spain)
M.S. Chemical Engineering (2001)
Institut Quimic de Sarria (Spain)
Submitted to the Department of Chemistry
in Partial Fulfillment of the Requirements for the
Degree of Doctor of Philosophy
at the
Massachusetts Institute of Technology
June 2008
© 2008 Massachusetts Institute of Technology
All rights reserved
MASSACH•,r - IN SiTE
OF TE~NOLOGY
FJUN 10 2008
LIBRARIES
ARCHNES
Signature of the Author:
Certified by:
)epati&ient of Chemistry
May 29, 2008
"-IATe Y. Ting
Pfizer-Laubach Associate Professor of Chemistry
Thesis Supervisor
Accepted by:
S Robert W. Field
Chairman, Departmental Committee on Graduate Students
This doctoral thesis has been examined by a committee of the Department of Chemistry
as follows:
/7
Barbara Imperiali
Class of 1922 Professor of Chemistry and Professor of Biology
Alice Y. Ting
Pfizer-Laubach Associate sor of Chemistry
hesis Supervisor
' DaviV Bartel
Professor of Biology
Member, Whitehead Institute
Investigator, Howard Hughes Medical Institute
New reporters of protein trafficking and
protein-protein interactions in live cells
by
Marta Fernindez Sudrez
Submitted to the Department of Chemistry
on May 29, 2008 in partial fulfillment of the
requirements for the Degree of Doctor of Philosophy
ABSTRACT
Here, we describe our attempts to harness the exquisite specificity of natural
protein and RNA enzymes to develop improved methods to study protein localization and
protein-protein interactions in live cells. We first attempted to detect endogenous protein-
protein interactions (PPIs) in live cells by means of a ribozyme complementation assay,
but we found that the strategy was limited by the interaction affinity constraints and by
low ribozyme activity in cells. We then sought to still detect interactions among
endogenous proteins but in fixed cells. We devised an improved immunofluorescence
(IF) technique, in which the antibodies are conjugated to an enzyme-substrate pair. We
chose E. coli biotin ligase (BirA), which catalyzes the covalent ligation of biotin to a 15-
amino acid recognition sequence (AP). Only upon PPI would BirA be in close enough
proximity to biotinylate the AP. Although the use of proximity biotinylation within the IF
scheme proved challenging because of the geometric rigidity of the antibody conjugates,
we later successfully applied the concept to the study of recombinant proteins in live
cells, where BirA and AP were each genetically fused to the proteins of interest. We
demonstrated that this method offers a combination of high spatial and temporal
resolution with a low rate of false positives. We engineered the BirA/AP affinity to
reduce background and eliminate false positives, while still allowing robust detection of
relatively transient PPIs (half-life > 1 minute). We demonstrated that the methodology
exhibits high specificity for the detection of PPIs in living mammalian cells, with a fold
induction in the detected signal upon PPI of - 5-25. Using FRB-FKBP12 system as a
model, the BirA/AP(-3) pair was also able to quantitatively predict interaction KIds.
Importantly, we showed that proximity biotinylation can detect the subcellular
localization of the PPI under study.
We also developed a new method for site-specific labeling of proteins in live
cells. Through rational design, we re-directed E. coli lipoic acid ligase (LplA) to
specifically ligate an unnatural alkyl azide substrate to an engineered 22-amino acid LplA
acceptor peptide (LAP) tag. The alkyl azide can then be selectively derivatized with a
cyclooctyne conjugated to any probe of interest. We first demonstrated that LplA can be
used to label LAP-tagged proteins with Cy3, AlexaFluor568, and biotin at the surface of
living mammalian cells, and we then applied the methodology to one- and two-color cell-
surface receptor labeling. Finally, we also showed that LplA can site-specifically label
intracellular proteins, although the signal/background ratio still needs to be improved.
Thesis Supervisor: Alice Y. Ting
Title: Associate Professor of Chemistry
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Polymerase chain reaction
Pyruvate dehydrogenase complex
Phosphorylated epidermal growth factor receptor
Positron emission tomography
Paraformaldehyde
Pentafluorophenyl
Protein kinase B
Protein kinase C
Phospholipase C y
Phenylmethylsulphonyl fluoride
Polyacrylamide gel electrophoresis
Phosphatidyl inositol 3-kinase
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PPi
PPI
PPTase
PTB
RHR
RIPA
RLuc
RNA
RNase
rNTP
s.d.
Rz
SDS
SELEX
SH2
Shc
Shpl
SMCC
STORM
Sos
Ta
TAP
TBS
TBS-T
TCA
TCEP
TEA
Tet
TFA
TLC
TPP
Tris
WB
WT
YFP
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Pyrophosphate
Protein-protein interaction
Phosphopantetheine transferase
Phosphotyrosine binding motif
Rel homology region
Radioimmuno precipitation assay
Renilla luciferase
Ribonucleic acid
Ribonuclease
Ribonucleotide tri-phosphate
Standard deviation
Ribozyme
Sodium dodecyl sulfate
Systematic evolution of ligands by exponential enrichment
Src homology 2
Src homologus and collagen-like protein
Src homology phosphatase 1
Succinimidyl 4-[N-maleimidomethyl]cyclohexane- 1-carboxylate
Stochastic optical reconstruction microscopy
Son of sevenless protein
Thermoplasma acidophilum
Tandem affinity purification
Tris-buffered saline
TBS + 0.05% Tween 20
Trichloroacetic acid
Tris(2-carboxyethyl)phosphine
Triethylamine
Tetracycline
Trifluoroacetic acid
Thin layer chromatography
Thiamine pyrophosphate
Trishydroxymethylaminomethane
Western blotting
Wild-type
Yellow fluorescence protein
Part I : New reporters for the detection of protein-protein
interactions
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Chapter 1 : Introduction. Methodologies for detecting protein-protein
interactions in cells
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Introduction
The recent characterization of several eukaryotic protein interaction networks has
made it clear that protein interactions determine the outcome of most cellular
processes'-3. Inside cells, protein-protein interactions are instrumental in enzymatic
actions upon protein substrates and in the protein assemblies that govern signal
transduction, cell division, DNA replication, and transcription initiation. Outside cells,
protein interactions allow cells to talk with each other: ligands expressed on the cell
surface often bind protein receptors expressed on adjacent cells, and secreted protein
ligands bind receptors on distant cells. Therefore, identifying and characterizing protein-
protein interactions (PPIs) and their networks is essential for understanding the
mechanisms of biological processes on a molecular level.
Traditionally, the interactions between two recombinantly expressed and purified
proteins were studied in a test tube, where PPIs are mainly governed by the interaction
affinity between the protein partners. In contrast, in the cellular context, other factors
such as spatial confinement, post-translational modifications, and hindering of interaction
surfaces within protein complexes greatly affect the ability of any two given proteins to
interact; ultimately generating a network of PPIs that is tightly regulated in space and
time. For this reason, many new techniques have been developed in recent years that
attempt to study protein-protein interactions in the cellular context.
This chapter describes the most common methods currently available to detect
protein-protein interactions in the cellular context, that is, in cell extracts, in fixed cells,
or in living cells and animals. Focus will be on describing how the methods work and
what their weaknesses and strengths are, in order to set the stage for Chapters 2-4, where
new approaches to overcome current limitations are proposed.
Detecting endogenous protein-protein interactions in cell extracts
The study of protein-protein interactions involving endogenous proteins
frequently relies on the immunoaffinity capture of a protein of interest followed by
identification of co-purifying interactors4 . In this method, the so-called co-
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immunoprecipitation technique (co-IP), the protein of interest is recognized and bound by
a target antibody added to the cell extract. A second antibody, often bound at one end to a
solid matrix, such as a bead, binds to the first antibody, precipitating the complex out of
solution. If the antigen is associated in a complex of proteins, other members of the
complex may be co-precipitated and hence separated from the rest of the cellular milieu.
The subsequent identification of the co-precipitated interacting partners was originally
performed by Western blotting (WB), but this approach required an a priori guess of the
partner identity. Mass spectrometry is now increasingly being applied to the identification
of unknown co-purifying interactors.
Although co-IP followed by WB is still regarded as the gold standard for the
study of cellular PPIs, it has many problems. On the one hand, co-IP is characterized by a
high rate of false positives. The biggest challenge on performing co-IP lies in
distinguishing physiological interactors from unspecific binders; and how well this
separation works depends on the affinity of the antibody for the antigenic site and on the
concentration of the relevant proteins in the extract5. The problem of availability and
affinity of a specific antibody can be solved by fusing an affinity tag to the protein of
interest, but this method defeats the purpose of studying endogenous proteins. On the
other hand, co-IP is also likely to miss transient interactions or interactions with low
affinities, which dissociate during extract preparation, thus leading to false negatives 4.
Finally, because co-IP precipitates proteins from a cell extract, it does not provide any
spatial or temporal information regarding the PPI.
Nonetheless, co-IP coupled to mass spectrometric (MS) analysis has become an
unmatched tool for the identification of new PPIs6. Using MS analysis post-IP,
quantitative proteomics can be used to identify false-positive interactions 7. Quantitative
proteomics is the common name for a set of techniques to differentially label proteins
with stable isotopes and compare their relative abundance in samples analyzed side-by-
side using MS. Using a combination of IP and MS, large-scale mapping of human PPIs
has already been achieved8.
Mass spectrometry has also been combined recently with the classic methods of
affinity purification or tandem affinity purification 9 to yield enormous data sets and
partially map the PPI networks of Saccharomyces cerevisiae2"10' '
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Crosslinking is another classical approach for determining PPIs' 2. Crosslinking is
commonly used as a strategy to minimize the presence of unspecific interactors during
co-IP experiments. In this context, crosslinking is used to covalently link the constituents
of protein complexes so that they can be subjected to stringent salt and detergent washes
after co-IP. Crosslinking also offers the advantage of trapping transient interactions,
which could otherwise not be detected by co-IP. Although non-specific crosslinking
using for example paraformaldehyde has been successfully used 13 ,14 , site-specific
incorporation of a crosslinking probe (usually called photoaffinity probe) is usually
preferred to minimize false positives. The best current methodology for site-specific
photoaffinity probe incorporation is unnatural amino acid mutagenesis' 5-17, but its
application is still limited in mammalian cells because of the prevalence of amber stop
codons and the low suppression efficiencies, which give rise to truncated by-products' 8 .
Other methods for site-specific incorporation of photoaffinity probes have been
described, but their applicability in cells still needs to be demonstrated. For example, Liu
et al. used the tetracysteine labeling tag (see Chapter 5 for a description) to site-
specifically introduce a dihydrophenylalanine crosslinking probe onto the acidic domain
of the VP16 transactivator to demonstrate its interaction with the 26S proteosome in
vitro' 9. Better site-specific targeting methods need to be developed to fully realize the
potential of the in vivo crosslinking technique.
Detecting endogenous protein-protein interactions in fixed samples
As a step forward from co-IP, the immunofluorescence (IF) technique provides
information on the spatial localization of the interacting partners. However, because it
requires cell fixation, it still lacks temporal resolution. In IF, fluorophore-conjugated
antibodies against the target proteins are used to stain a fixed sample, and the presence of
overlap between the two colors reports on protein co-localization 20. Although IF has been
very useful in studying the spatial distribution of proteins that are known interacting
partners, it must be noted that IF cannot in reality distinguish whether two proteins are
truly interacting or are just within the same focal spot in the microscope, that is, co-
localized.
-24-
In conventional lens-based microscopy, such as wide-field or confocal
microscopy, the spatial resolution of IF is limited by the diffraction of light21. This means
that, using excitation light of-~ 400 nm wavelength, which is typical in cell microscopy,
the maximum theoretical lateral spatial resolution that can be achieved is - 150 nm (or -
250 nm in practice) 22. That is, with a conventional microscope, one cannot distinguish
two features that are closer than 250 nm. Because protein sizes range from 25 A x 50 A
for the green fluorescence protein (GFP) to - 250-500 nm for most antibodies, it follows
that the resolution of IF is not enough to distinguish whether two proteins are merely co-
localized or whether they are truly interacting. Many research groups are currently
working on improving the spatial resolution of far-field microscopy by modifying the
physics of fluorophore detection (for a review, see Hell23).
As a response to the need for improving the spatial resolution of IF, other groups
have applied fluorescence resonance energy transfer (FRET) microscopy to the IF
technique. FRET is a quantum mechanical process in which radiationless energy (an
exciton) is transferred over a distance, usually < 80-100 A, from one fluorophore to
another by long-range dipole-dipole coupling24. Upon excitation of the donor
fluorophore, the exciton is transferred and excites the acceptor fluorophore, which
subsequently emits light that is further red-shifted than the donor emission. FRET
requires that the emission spectrum of the donor overlaps with the excitation spectrum of
the acceptor. The efficiency of the transfer depends on the spectral overlap and on the
distance and relative orientation between the two fluorophores. In IF-FRET, each
antibody is then conjugated to the donor or acceptor fluorophore. Because of the FRET
dependence on the distance between fluorophores, the combination of FRET and IF
results in the detection of proteins that are separated by distances of 1-10 nm25. Common
fluorophore pairs used in IF-FRET are the cyanine dyes Cy3-Cy5, the Alexa Fluor 488-
Alexa Fluor 555 dyes, and Fluorescein-Rhodamine. Unfortunately, FRET efficiency is
inversely proportional to the sixth power of the separation between the donor and
acceptor and it is highly dependent on the relative orientation of the fluorophores. This
means that the IF-FRET technique requires that the binding of the antibodies against the
target proteins places the two fluorophores in the appropriate orientation and within a
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short distance range. This has proven difficult in many cases, and thus IF-FRET has not
found widespread use for the detection of cellular PPIs.
Detecting protein-protein interactions in living cells and animals
In order to study PPIs with spatial and temporal resolution and within their native
cellular context, many groups have tried in recent years to develop methods that can
detect PPIs in living cells.
Yeast two-hybrid systems
The introduction of two-hybrid systems established a novel tool for high-
throughput screening and discovery of new protein interactions by means of
transcriptional activation of a reporter26'2 7. It has been estimated that more than 50% of
all protein interactions described in the literature have been detected using the yeast two-
hybrid system 28. In this strategy, a transcription factor is dissected into two domains, a
DNA-binding domain -required for transcription factor binding to DNA- and an
activator domain - required for basal activation of transcription. Each protein of a
potentially interacting partner is then fused to one of the split fragments of the
transcription factor, such that interaction between the two proteins brings the two
domains into close proximity. In such proximity, the two transcription factor fragments
can re-assemble to result in transcription activation.
Although yeast two-hybrid systems revolutionized the study of PPIs, the strategy
has the disadvantage of being limited temporally (i.e., it takes several hours from
activation of transcription until enough protein is expressed and a detectable signal is
generated). Additionally, two-hybrid systems require nuclear translocation of the hybrid
fusion proteins, which is not always possible (e.g., for membrane proteins) 29. To
overcome these limitations, several types of reporters have been developed that utilize
fluorescence and bioluminescence resonance energy transfer (FRET and BRET), or
protein fragment complementation.
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Fluorescence and bioluminescence resonance energy transfer
FRET has been applied to the study of PPIs in two manners. The simplest
configuration is an intermolecular design in which each interacting protein is fused to a
fluorescence protein (FP) donor (e.g., cyan fluorescence protein, CFP) or acceptor (e.g.,
yellow fluorescence protein, YFP) 30, 31. When the two proteins interact, the donor and the
acceptor get close enough to each other to transfer the exciton, resulting in FRET. The
most common FP pair used in intermolecular FRET studies is CFP-YFP, but other pairs
have also been employed, such as BFP-GFP and CFP-dsRed. One of the main
disadvantages of this design is the high rate of false negatives because the PPI may not
result in FRET if the distance between the fluorophore pairs upon PPI is too large. In
addition, false positives may also be seen if the fluorescence protein pairs come into close
proximity even in the absence of a PPI owing to their intrinsic dimerization affinity. The
latter effect can be minimized by using FPs with the A206K mutation, which eliminates
dimerization 32. Additionally, problems arise when the donor and acceptor fusion proteins
are not present in an exact 1:1 ratio, which alters the FRET measurements; although this
artifact can be avoided if fluorescence lifetime imaging microscopy (FLIM) or emission
anisotropy are used for the recording manifold24,33
The second FRET design is based on an intramolecular interaction34 . In this
configuration, the two interacting pairs as well as the FRET donor and acceptor are on a
single polypeptide chain. The intramolecular design ensures that donor and acceptor are
present in a 1:1 ratio and it also eliminates false negatives. Unfortunately, the rate of false
positives increases in this design because of the increased effective concentration of the
detector pair as well as the interacting proteins. Although there are some examples of
intramolecular FRET applications to PPIs34, this design has been predominantly used to
study enzymatic activity (e.g., protease, kinase, and phosphatase activity), membrane
potential, and Ca 2+ oscillations35.
For imaging in animals, bioluminescence is often preferred over fluorescence
because it eliminates the need for an excitation beam, which can result in tissue damage.
Additionally, bioluminescence resonance energy transfer (BRET) eliminates background
cell autofluorescence caused by the excitation light, avoids background from donor
emission, and exhibits an extremely high quantum yield, which results in more sensitive
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measurements of cellular interactions. BRET works much like FRET except that the
donor molecule is not a fluorescence protein or dye, but rather a bioluminescence
protein 36.Currently used BRET pairs consist of Renilla luciferase coupled with either
modified EYFP or GFP37'38. In this design, Renilla luciferase catalyzes the oxidation of
its substrate coelenterazine to produce light with a Xmax of 395 nm. This emission excites
a modified GFP, which then emits the transferred energy at 508 nm. The main
disadvantage of BRET is that no pair has been reported to date that is sufficiently red-
shifted for optimal use in vivo39
Protein fragment complementation assays
Protein complementation assays (PCAs) represent an evolution of the yeast two-
hybrid systems, in which the transcription factor is substituted by a reporter protein or
enzyme. In PCAs, a monomeric reporter protein is rationally divided into two separate
inactive components that can reconstitute function upon association. When these reporter
fragments are fused to interacting proteins, the reporter is re-activated upon association of
the interacting proteins40. PCAs are superior to the traditional two-hybrid methods for
PPI detection, because they can be used in any cell type and within all subcellular
compartments. Because PCA strategies take advantage of the all-or-none nature of
protein folding, the signal generated has a large dynamic range over very narrow
conditions, unlike FRET measurements. PCAs are also more sensitive and technically
less challenging to implement than FRET. However, existing PCAs are limited either by
their spatial resolution (e.g., split-13-lactamase and split-luciferase) or their temporal
resolution (e.g., split-GFP).
The first PCA developed was based on the enzyme dihydrofolate reductase
(DHFR) 41. DHFR converts dihydrofolic acid into tetrahydrofolic acid, which in turn is
transformed into many cellular cofactors. The DHFR-based PCA can be used in two
different ways. The first one is a survival assay, in which null cells lacking DHFR can
only survive if the two target proteins interact and reconstitute DHFR activity42. The
second assay uses a fluorogenic derivative of methotrexate (i.e., an inhibitor of DHFR),
which binds intact DHFR43 . While the first method suffers from lack of temporal
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information, the second one poses great toxicity to the cells under study because
methotrexate inhibits the metabolism of folic acid. For these reasons, the split-DHFR has
not been applied to any biologically relevant studies.
Split-p-galactosidase was developed next and offered some interesting advantages
over split-DHFR such as signal amplification, mammalian live-cell compatibility, and the
fact that its activity can be quantified by biochemical, fluorescent, or chemiluminescence
readouts44 ,4 5. The main weakness of split-p-galactosidase is that it requires substrate
treatment ex-vivo, hence losing any temporal information on the PPI under study.
Split-GFP was the first PCA that was able to provide great spatial resolution
combined with some temporal information. Additionally, a unique characteristic of split-
GFP systems is that they do not require an external small-molecule substrate. The first
demonstration of split-GFP was based on a protein splicing system46. Protein splicing is a
naturally occurring posttranslational processing event in which an intervening intein
domain excises out of a precursor polypeptide in an autocatalytic fashion with
concomitant linkage of the two flanking extein sequences by a native peptide bond47. In
the first report of split-GFP, Ozawa and co-workers fused the N- and C-terminal halves
of a yeast intein to the N- and C-terminal halves of GFP, and each of these fusion
proteins was in turn linked to one of the interacting partners46. When interaction occurred
between the two proteins, the N- and C- terminal halves of the intein were brought into
close proximity and underwent correct folding, which induced a splicing event, thus
linking the N- and C-terminal fragments of GFP directly by a peptide bond. The matured
GFP formed the fluorophore, and the extent of the protein-protein interaction was
evaluated by measuring the fluorescence intensity. Later, this and other split-FP
fragments were also used in a configuration similar to the yeast two-hybrid without the
use of an intein. The split-FP assay, also called bimolecular fluorescence
complementation (BiFC) has been used to study the interactions between the
transcriptions factors Jun-Fos 48 and Myc-Max-Mad49 with high spatial resolution,
allowing for subcellular localization. Although the temporal resolution of GFP has
traditionally been hampered by the need for GFP maturation, which can take up to
several hours, recent work by Demidov and co-workers reported a split-GFP that re-
combined and matured in just a few minutes upon DNA hybridization 50 . It remains to be
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seen whether this maturation kinetics still hold when the two GFP fragments are fused to
proteins and expressed in living cells.
PCAs that employ enzymes instead of proteins offer the added advantage of
signal amplification. The most widely used enzyme complementation assays are those
based on p-lactamase and Renilla or firefly luciferase. Split-P3-lactamase and split-
luciferase are superior to the previously described split-DHFR and split-P-galactosidase
because their fragments are smaller (- 20 kD), there is no endogenous P-lactamase or
luciferase acivity in mammalian cells, and they both use highly sensitive cell-permeant
substrates as a readout. On top of signal amplification, these two systems exhibit
immediate temporal response to a PPI thus improving the temporal resolution of split-
GFP, but their reliance on diffusible small molecule substrates means that they cannot
provide subcellular localization.
P-lactamase was first used as a reporter system by the Tsien laboratory (U.C. San
Diego)51. Zlokarnik and co-workers designed a p-lactamase substrate in which two
fluorophores are attached to the 7 and 3' positions of a cephalosporin ring. In this
configuration, the two fluorophores are close enough to exhibit efficient fluorescence
resonance energy transfer. However, p-lactamase attack splits off the fluorophore on the
3' position, disrupts FRET, and reestablishes fluorescence emission by the coumarin
donor, thus resulting in an increase in the cellular blue-to-green emission signal ratio.
Although p-lactamase has been successfully used to monitor the self-52 and trans-
splicing53 activity of the Tetrahymena group I intron ribozyme, its use to study PPIs has
been restricted to a few proof-of-principle demonstrations. For example, Wehrman and
co-workers, the first ones to use split-P-lactamase, demonstrated its use on the known
interactions between the Jun and Fos transcription factors and between FK206 binding
protein (FKBP) and the FKBP-rapamycin binding domain of the mTor protein (FRB) 54.
In parallel, a different group also developed the same split-P-lactamase PCA and applied
it to the proof-of-principle interactions between the apoptotic proteins Bcl2 and Bad, the
homodimerization of Smad3, and the rapamycin-induced interaction between FKBP and
FRB55. One of the main reasons why p-lactamase has not been used more widely is that
its fluorescence substrate is not taken up equally by different cell types, and, in many
cases, not at all (e.g., plant and yeast)56.
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Split-luciferase offers the same advantages over p-lactamase that we already
mentioned for BRET, based on the fact that luciferase employs a bioluminescence
readout. As previously mentioned, luciferase enzymes oxidize their substrate with
concomitant emission of light. The two luciferase reporters most commonly used in
optical imaging are Renilla luciferase, which uses coelenterazine as a substrate, and
firefly luciferase, which oxidizes D-luciferin. Renilla luciferases (RLuc) generally emit
blue, a property less favorable for in vivo imaging, whereas firefly luciferases (FLuc)
generally emit yellow to red, enhancing their utility in vivo39. Additionally, several
coelenterazine susbtrates of RLuc have been found to be substrates of endogenous
mammalian proteins, which raises concerns on the invasiveness of the strategy57. As with
GFP, luciferases were first used to detect PPIs in an intein-mediated split-firefly
luciferase design 58. Ozawa and co-workers used this technique to study insulin-mediated
phosphorylation of the insulin receptor substrate-i (IRS- 1) and its target p85 subunit of
phosphatidylinositol 3-kinase (PI3K). Although insulin is reported to trigger the kinase
function of the insulin receptor within minutes, the bioluminescence signal was not
observed until after 3 hours of insulin stimulation, which suggests that the split-intein
system suffers from slow kinetic response rates39. In addition, high background
luminescence was observed in cells, possibly owing to the splicing event occurring even
when there was partial association of the intein fragments. Thereafter, both RLuc and
FLuc were used in split-luciferase complementation assays. One of the most successful
examples of split-RLuc is that of Kaihara and co-workers, which showed 25-fold signal
induction after 5 minutes of insulin stimulation when they studied the insulin-mediated
interaction between IRS-1 and PI3K59. In recent years, several groups have tried to
improve the kinetics of split-FLuc; Paulmurugan and co-workers being the first ones to
demonstrate PCAs in living small animals using the interaction of MyoD and Id as test
proteins6°. Probably the most impressive system was developed in the laboratory of
Piwnica-Worms, where split-FLuc resulted in 23-fold signal induction upon interaction
of FKBP and FRB in living mice 61. The versatility of this reporter was also demonstrated
by applying it to the study of two other interactions, that of Cdc25C and 14-3-3& and the
homodimerization of the STAT-1 transcription factor61. Recently, a major step forward
has been taken recently by Stefan and co-workers, with the development of a reversible
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split-RLuc, which allowed them to study the dynamics of G-protein coupled
receptor-induced assembly and disassembly of protein kinase A62
Finally, although most PCAs have only been demonstrated for proof-of-principle
examples, such as the known interaction between FKBP and FRB, some of them have
already been capable of discovering new interactions and mapping out biochemical
pathways. For example, Michnick and co-workers used split-DHFR to map a signal
transduction network that controls initiation of translation in eukaryotes, and identified 14
interactions, of which five have not been observed previously6 3 . Most impressively, the
Michnick group has just recently used the same split-DHFR system to perform a
genomewide in vivo screen for PPIs in Saccharomyces cerevisiae, where they identified
2,770 interactions, most of which had not been previously reported64. Using split-GFP,
Kerppola and co-workers compared the interaction affinity of the different members of
the Myc/Max/Mad families of transcription factor, and found that, contrary to what had
been previously believed, Mad4 is a better interacting partner and can compete with Myc
for binding to Max49. Split-GFP was also used in a cDNA library screening, which
identified novel substrates and regulators of the serine/threonine protein kinase B
(PKB)6 5. Thereafter, using a combination of split-P-lactamase and split-YFP, Remy and
co-workers discovered a new interaction between PKB and the transcription factor
Smad3, which is mediated by insulin but inhibited by transforming growth factor P
(TGF-P), thus finding a link between the TGF-0 and the growth factor signaling
cascades66
Conclusions
Protein-protein interactions are involved in every cellular process ranging from
gene expression and signal transduction to cell division and differentiation. Within this
context, the goal of any method that aims to study protein-protein interactions would be
to reveal not only the partners of particular proteins, but also how tight the interactions
are, which surfaces they use to contact, and where and when contacts occur. Standard
biochemical methods have yielded most of the available information about such
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interactions, but these assays are often limited by the available reagents (e.g., monoclonal
antibodies) or lack the appropriate cellular context. The development of fusion-protein
assays such as the yeast two-hybrid method and the protein-complementation assays has
expanded the potential for studying protein-protein interactions in intact, and specifically
mammalian, cells greatly. Table 1-1 summarizes the weaknesses and strengths of the
methods described in this chapter. It can be readily concluded that none of the existing
methods has yet reached perfection. Furthermore, a comparative study has recently
demonstrated that the combination of the high false-positive and false-negative rates of
most of the available methods results in the fact that only a small percentage of yeast
PPIs is supported by more than one method67.
Ideally, a method for detecting protein-protein interactions should detect
endogenous proteins in a non-invasive manner, with high temporal and spatial resolution,
and with sufficient sensitivity to allow single cell imaging. The following Chapters 2-4
attempt to bridge some of these characteristics. Chapter 2 describes a concept to detect
endogenous protein-protein interactions in live cells. This method represents the ultimate
dream on PPIs detection. Unfortunately, the concept proved difficult to translate into a
real and robust system. For this reason, we sought to develop less ambitious but yet
powerful techniques. Chapter 3 describes an attempt to improve the spatial resolution of
the commonly used immunofluorescence technique so that it can report on real PPIs
rather than mere protein co-localization. Like the classic IF technique, this method can
detect endogenous PPIs but it requires cell fixation and therefore lacks temporal
information. In contrast, Chapter 4 describes a complementary method, which works in
live cells, thus preserving spatial information, but detects recombinant fusion proteins.
The method relies on the enzymatic transfer of biotin by the enzyme biotin ligase to its
acceptor peptide and it represents an improvement over previously reported protein
fragment complementation assays owing to its combined high sensitivity, improved
spatial resolution, and ability to detect transient protein-protein interactions.
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Co-IP/WB
Co-IP or
TAP/MS
IF
IF-FRET
FRET
BRET
Two-hybrid
Split-DHFR
Split-p-
galactosidase
Split-GFP
Split-p-
lactamase
Split-luciferase
MS
Fluorescence
Fluorescence
Fluorescence
Bioluminescence
Fluorescence,
bioluminescence,
PET
Survival assay,
fluorescence
Fluorescence,
absorbance
Fluorescence
Fluorescence
Bioluminescence
Table 1-1: Strategies for detecting protein-protein interactions. Weaknesses and strengths. PPI: protein-protein interaction. IP:
Immunoprecipitation. WB: Western blotting. TAP: tandem-affinity purification. MS: mass spectrometry. IF: immunofluorescence. FRET:
fluorescence resonance energy transfer. BRET: bioluminescence resonance energy transfer. DHFR: dihydrofolate reductase. GFP: green
fluorescence protein. PET: positron emission tomography. (1) The symbol -/4 means that the methods allows confirmation of a new PPI but it
requires an a priori guess of such an interacting partner. (2) As explained in the text, IF can only demonstrate co-localization but not true PPI. (3)
The small-molecule substrates used in these strategies are diffusible, thus loosing subcellular localization. (4) Requirement for nuclear
translocation and transcription activation delays the signal by several hours. (5) The survival assay does not have temporal resolution. (6)
Requirement for GFP maturation may delay the signal by up to few hours.
4' 4\4\
4I
4l
4I
4I
4I
4l
4I
4\
4I
4l
4
-14
-/4
-/4
-/4
-/4
-/4
-/4
-/4
-/4
-/4
41
4\
-/ (2)
-/ (3)
(3)
-/ (3)
-/ (3)
4
4
/ (4)
_ (5)
-/ (6)
4
4
_1/qWB
References
1. Giot,L. et al. A protein interaction map of Drosophila melanogaster. Science 302,
1727-1736 (2003).
2. Krogan,N.J. et al. Global landscape of protein complexes in the yeast
Saccharomyces cerevisiae. Nature 440, 637-643 (2006).
3. Li,S. et al. A map of the interactome network of the metazoan C. elegans. Science
303, 540-543 (2004).
4. Phizicky,E.M. & Fields,S. Protein-protein interactions: methods for detection and
analysis. Microbiol. Rev. 59, 94-123 (1995).
5. Markham,K., Bai,Y. & Schmitt-Ulms,G. Co-immunoprecipitations revisited: an
update on experimental concepts and their implementation for sensitive interactome
investigations of endogenous proteins. Anal. Bioanal. Chem. 389, 461-473 (2007).
6. Kocher,T. & Superti-Furga,G. Mass spectrometry-based functional proteomics:
from molecular machines to protein networks. Nat. Methods 4, 807-815 (2007).
7. Ranish,J.A. et al. The study of macromolecular complexes by quantitative
proteomics. Nat. Genet. 33, 349-355 (2003).
8. Ewing,R.M. et al. Large-scale mapping of human protein-protein interactions by
mass spectrometry. Mol. Syst. Biol. 3, 89 (2007).
9. Berggard,T., Linse,S. & James,P. Methods for the detection and analysis of protein-
protein interactions. Proteomics. 7, 2833-2842 (2007).
10. Gavin,A.C. et al. Functional organization of the yeast proteome by systematic
analysis of protein complexes. Nature 415, 141-147 (2002).
11. Ho,Y. et al. Systematic identification of protein complexes in Saccharomyces
cerevisiae by mass spectrometry. Nature 415, 180-183 (2002).
12. Agou,F., Ye,F. & Veron,M. In vivo protein cross-linking. Methods Mol. Biol. 261,
427-442 (2004).
13. Schmitt-Ulms,G. et al. Binding of neural cell adhesion molecules (N-CAMs) to the
cellular prion protein. J. Mol. Biol. 314, 1209-1225 (2001).
14. Vasilescu,J., Guo,X. & Kast,J. Identification of protein-protein interactions using in
vivo cross-linking and mass spectrometry. Proteomics. 4, 3845-3854 (2004).
15. Chin,J.W. & Schultz,P.G. In vivo photocrosslinking with unnatural amino Acid
mutagenesis. Chembiochem. 3, 1135-1137 (2002).
-35-
16. Farrell,I.S., Toroney,R., Hazen,J.L., Mehl,R.A. & Chin,J.W. Photo-cross-linking
interacting proteins with a genetically encoded benzophenone. Nat. Methods 2, 377-
384 (2005).
17. Hino,N. et al. Protein photo-cross-linking in mammalian cells by site-specific
incorporation of a photoreactive amino acid. Nat. Methods 2, 201-206 (2005).
18. Liu,W., Brock,A., Chen,S., Chen,S. & Schultz,P.G. Genetic incorporation of
unnatural amino acids into proteins in mammalian cells. Nat. Methods 4, 239-244
(2007).
19. Liu,B., Archer,C.T., Burdine,L., Gillette,T.G. & Kodadek,T. Label transfer
chemistry for the characterization of protein-protein interactions. J. Am. Chem. Soc.
129, 12348-12349 (2007).
20. Miyashita,T. Confocal microscopy for intracellular co-localization of proteins.
Methods Mol. Biol. 261, 399-410 (2004).
21. Abbe,E. Beitrage zur Theorie des Mikroskops und der mikroskopischen
Wahrmehmung. Arch. F. Mikroskop. Anat 9, 413-420 (1873).
22. Hell,S.W., Dyba,M. & Jakobs,S. Concepts for nanoscale resolution in fluorescence
microscopy. Curr. Opin. Neurobiol. 14, 599-609 (2004).
23. Hell,S.W. Far-field optical nanoscopy. Science 316, 1153-1158 (2007).
24. Jares-Erijman,E.A. & Jovin,T.M. FRET imaging. Nat. Biotechnol. 21, 1387-1395
(2003).
25. Kenworthy,A.K. Imaging protein-protein interactions using fluorescence resonance
energy transfer microscopy. Methods 24, 289-296 (2001).
26. Chien,C.T., Bartel,P.L., Sternglanz,R. & Fields,S. The two-hybrid system: a method
to identify and clone genes for proteins that interact with a protein of interest. Proc.
Natl. Acad. Sci. U. S. A 88, 9578-9582 (1991).
27. Fields,S. & Song,O. A novel genetic system to detect protein-protein interactions.
Nature 340, 245-246 (1989).
28. Massoud,T.F., Paulmurugan,R., De,A., Ray,P. & Gambhir,S.S. Reporter gene
imaging of protein-protein interactions in living subjects. Curr. Opin. Biotechnol.
18, 31-37 (2007).
29. Parrish,J.R., Gulyas,K.D. & Finley,R.L., Jr. Yeast two-hybrid contributions to
interactome mapping. Curr. Opin. Biotechnol. 17, 387-393 (2006).
-36-
30. Mitra,R.D., Silva,C.M. & Youvan,D.C. Fluorescence resonance energy transfer
between blue-emitting and red-shifted excitation derivatives of the green
fluorescent protein. Gene 173, 13-17 (1996).
31. Miyawaki,A. & Tsien,R.Y. Monitoring protein conformations and interactions by
fluorescence resonance energy transfer between mutants of green fluorescent
protein. Methods Enzymol. 327, 472-500 (2000).
32. Zacharias,D.A., Violin,J.D., Newton,A.C. & Tsien,R.Y. Partitioning of lipid-
modified monomeric GFPs into membrane microdomains of live cells. Science 296,
913-916 (2002).
33. Wallrabe,H. & Periasamy,A. Imaging protein molecules using FRET and FLIM
microscopy. Curr. Opin. Biotechnol. 16, 19-27 (2005).
34. Truong,K. & Ikura,M. The use of FRET imaging microscopy to detect protein-
protein interactions and protein conformational changes in vivo. Curr. Opin. Struct.
Biol. 11, 573-578 (2001).
35. Zhang,J., Campbell,R.E., Ting,A.Y. & Tsien,R.Y. Creating new fluorescent probes
for cell biology. Nat. Rev. Mol. Cell Biol. 3, 906-918 (2002).
36. Pfleger,K.D. & Eidne,K.A. Illuminating insights into protein-protein interactions
using bioluminescence resonance energy transfer (BRET). Nat. Methods 3, 165-174
(2006).
37. Jensen,A.A., Hansen,J.L., Sheikh,S.P. & Brauner-Osborne,H. Probing
intermolecular protein-protein interactions in the calcium-sensing receptor
homodimer using bioluminescence resonance energy transfer (BRET). Eur. J.
Biochem. 269, 5076-5087 (2002).
38. Xu,Y., Piston,D.W. & Johnson,C.H. A bioluminescence resonance energy transfer
(BRET) system: application to interacting circadian clock proteins. Proc. Natl.
Acad. Sci. U. S. A 96, 151-156 (1999).
39. Villalobos,V., Naik,S. & Piwnica-Worms,D. Current state of imaging protein-
protein interactions in vivo with genetically encoded reporters. Annu. Rev. Biomed.
Eng 9, 321-349 (2007).
40. Remy,I. & Michnick,S.W. Mapping biochemical networks with protein-fragment
complementation assays. Methods Mol. Biol. 261, 411-426 (2004).
41. Pelletier,J.N., Campbell-Valois,F.X. & Michnick,S.W. Oligomerization domain-
directed reassembly of active dihydrofolate reductase from rationally designed
fragments. Proc. Natl. Acad. Sci. U. S. A 95, 12141-12146 (1998).
-37-
42. Remy,I., Campbell-Valois,F.X. & Michnick,S.W. Detection of protein-protein
interactions using a simple survival protein-fragment complementation assay based
on the enzyme dihydrofolate reductase. Nat. Protoc. 2, 2120-2125 (2007).
43. Remy,I. & Michnick,S.W. Clonal selection and in vivo quantitation of protein
interactions with protein-fragment complementation assays. Proc. Natl. Acad. Sci.
U. S. A 96, 5394-5399 (1999).
44. Blakely,B.T. et al. Epidermal growth factor receptor dimerization monitored in live
cells. Nat. Biotechnol. 18, 218-222 (2000).
45. Rossi,F., Charlton,C.A. & Blau,H.M. Monitoring protein-protein interactions in
intact eukaryotic cells by beta-galactosidase complementation. Proc. Natl. Acad.
Sci. U. S. A 94, 8405-8410 (1997).
46. Ozawa,T., Nogami,S., Sato,M., Ohya,Y. & Umezawa,Y. A fluorescent indicator for
detecting protein-protein interactions in vivo based on protein splicing. Anal. Chem.
72, 5151-5157 (2000).
47. Noren,C.J., Wang,J. & Perler,F.B. Dissecting the Chemistry of Protein Splicing and
Its Applications. Angew. Chem. Int. Ed Engl. 39, 450-466 (2000).
48. Hu,C.D. & Kerppola,T.K. Simultaneous visualization of multiple protein
interactions in living cells using multicolor fluorescence complementation analysis.
Nat. Biotechnol. 21, 539-545 (2003).
49. Grinberg,A.V., Hu,C.D. & Kerppola,T.K. Visualization of Myc/Max/Mad family
dimers and the competition for dimerization in living cells. Mol. Cell Biol. 24,
4294-4308 (2004).
50. Demidov,V.V. et al. Fast complementation of split fluorescent protein triggered by
DNA hybridization. Proc. Natl. Acad. Sci. U. S. A 103, 2052-2056 (2006).
51. Zlokarnik,G. et al. Quantitation of transcription and clonal selection of single living
cells with beta-lactamase as reporter. Science 279, 84-88 (1998).
52. Hasegawa,S., Jackson,W.C., Tsien,R.Y. & Rao,J. Imaging Tetrahymena ribozyme
splicing activity in single live mammalian cells. Proc. Natl. Acad. Sci. U. S. A 100,
14892-14896 (2003).
53. Hasegawa,S., Choi,J.W. & Rao,J. Single-cell detection of trans-splicing ribozyme
in vivo activity. J. Am. Chem. Soc. 126, 7158-7159 (2004).
54. Wehrman,T., Kleaveland,B., Her,J.H., Balint,R.F. & Blau,H.M. Protein-protein
interactions monitored in mammalian cells via complementation of beta -lactamase
enzyme fragments. Proc. Natl. Acad. Sci. U. S. A 99, 3469-3474 (2002).
-38-
55. Galameau,A., Primeau,M., Trudeau,L.E. & Michnick,S.W. Beta-lactamase protein
fragment complementation assays as in vivo and in vitro sensors of protein protein
interactions. Nat. Biotechnol. 20, 619-622 (2002).
56. Remy,I., Ghaddar,G. & Michnick,S.W. Using the beta-lactamase protein-fragment
complementation assay to probe dynamic protein-protein interactions. Nat. Protoc.
2, 2302-2306 (2007).
57. Pichler,A., Prior,J.L. & Piwnica-Worms,D. Imaging reversal of multidrug
resistance in living mice with bioluminescence: MDR1 P-glycoprotein transports
coelenterazine. Proc. Natl. Acad. Sci. U. S. A 101, 1702-1707 (2004).
58. Ozawa,T., Kaihara,A., Sato,M., Tachihara,K. & Umezawa,Y. Split luciferase as an
optical probe for detecting protein-protein interactions in mammalian cells based on
protein splicing. Anal. Chem. 73, 2516-2521 (2001).
59. Kaihara,A., Kawai,Y., Sato,M., Ozawa,T. & Umezawa,Y. Locating a protein-
protein interaction in living cells via split Renilla luciferase complementation. Anal.
Chem. 75, 4176-4181 (2003).
60. Paulmurugan,R., Umezawa,Y. & Gambhir,S.S. Noninvasive imaging of protein-
protein interactions in living subjects by using reporter protein complementation
and reconstitution strategies. Proc. Natl. Acad. Sci. U. S. A 99, 15608-15613 (2002).
61. Luker,K.E. et al. Kinetics of regulated protein-protein interactions revealed with
firefly luciferase complementation imaging in cells and living animals. Proc. Natl.
Acad. Sci. U. S. A 101, 12288-12293 (2004).
62. Stefan,E. et al. Quantification of dynamic protein complexes using Renilla
luciferase fragment complementation applied to protein kinase A activities in vivo.
Proc. Natl. Acad. Sci. U. S. A 104, 16916-16921 (2007).
63. Remy,I. & Michnick,S.W. Visualization of biochemical networks in living cells.
Proc. Natl. Acad. Sci. U. S. A 98, 7678-7683 (2001).
64. Tarassov,K. et al. An in Vivo Map of the Yeast Protein Interactome. Science
(2008).
65. Remy,I. & Michnick,S.W. A cDNA library functional screening strategy based on
fluorescent protein complementation assays to identify novel components of
signaling pathways. Methods 32, 381-388 (2004).
66. Remy,I., Montmarquette,A. & Michnick,S.W. PKB/Akt modulates TGF-beta
signalling through a direct interaction with Smad3. Nat. Cell Biol. 6, 358-365
(2004).
67. von Mering,C. et al. Comparative assessment of large-scale data sets of protein-
protein interactions. Nature 417, 399-403 (2002).
-39-
Chapter 2: Development of an RNA-based detection of endogenous
protein-protein interactions
The work discussed in this chapter is unpublished. Initial experiments on the original
hammerhead ribozyme greatly benefited from the advice of Ed Curtis (Prof. David Bartel
laboratory, MIT Biology Department). Dan Chinnapen, a post-doctoral fellow in our
laboratory, assisted with the expression and purification of the T7 RNA polymerase used
in the in vitro transcription reactions.
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Introduction
In this chapter we describe the steps taken towards the development of a new
methodology for the detection of endogenous protein-protein interactions (PPIs) in live
cells. With this methodology, we hoped to bridge the ability of immunofluorescence (IF)
and immunoprecipitation (IP) to detect endogenous proteins and the live-cell
compatibility of protein complementation assays (PCAs). Starting from a known
hammerhead ribozyme and a previously reported RNA aptamer against the p50 member
of the NFkB family of transcription factors, we describe our molecular engineering of
novel aptamer-ribozyme fusions capable of both binding the target protein and catalyzing
the cleavage of a reporter substrate in vitro. We also analyze the limitations of the
methodology, which explain the failure of the engineered system to detect the
homodimerization of the p50 protein. Finally, we discuss potential methodology
improvements that could lead to the successful application of this system to the detection
of other interacting protein pairs.
Proposed scheme to detect endogenous protein-protein interactions in live cells
Our overall proposed strategy is analogous to the enzyme complementation assays
(ECAs). We chose ECAs as our starting platform because they already offer many of the
desired properties for an ideal PPI detection method: spatial and temporal resolution, high
sensitivity, and live-cell compatibility. In existing ECAs, a reporter enzyme such as P-
lactamase1' 2, luciferase 3' 4, or dihydrofolate reductase (DHFR)5,6 is split into two halves,
each of which is fused to a protein of interest (Figure 2-1A). In the absence of a PPI, the
two enzyme fragments are separated and unable to perform catalysis. In contrast, if the
two proteins of interest interact, the two enzyme fragments are brought into close enough
proximity so that they can re-combine, thereby reconstituting enzyme activity. This
enzymatic activity usually translates into the generation of a fluorescent (e.g. p-lactamase
assays) or luminescent (e.g. luciferase assays) signal. ECAs have been used in live
mammalian cells1' 4' 7 and in animals3 and have shown greater sensitivity than other PCAs
such as the split-GFP8 system owing to their enzymatic signal amplification.
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Figure 2-1: Proposed scheme for the detection of endogenous protein-protein interactions in
living cells. (A) Protein-based detection of recombinant protein-protein interactions via enzyme
fragment complementation (ECA). In ECAs, each half of a reporter enzyme (grey semi-circle) is
fused to one of the interacting protein partners (A and B). If the proteins A and B interact, the two
halves of the enzyme reporter come together and recombine. The reconstituted enzyme is then
capable of catalyzing the conversion of a small-molecule substrate (grey star) into a detectable
(i.e., fluorescent or luminescent) form (green star). (B) RNA-based detection of endogenous
protein-protein interactions. In our detection scheme, each half of a dimeric ribozyme (MzL and
MzR) is fused to an RNA aptamer against one of the interacting partners (a-A and a-B). Upon
interaction of the protein targets, the two halves of the ribozyme come together into an active
conformation capable of cleaving its substrate mRNA. Cleavage of the reporter mRNA ultimately
results in a decrease in the cellular concentration of the reporter.
We then sought to improve ECAs even further by adapting them to the detection
of endogenous PPIs. In order to detect endogenous proteins, the linkage between the
reporter fragment and the protein of interest cannot be generated by genetic fusion. One
approach could involve fusing each reporter half to an antibody against the target protein.
Unfortunately, antibodies are not membrane permeant and are not easily expressed in
mammalian cells. In contrast to antibodies, their RNA counterparts, RNA aptamers, can
be easily introduced into mammalian cells by transfection. Aptamers are nucleic acid
binding species with affinities and specificities that rival those of monoclonal antibodies
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(e.g., aptamer dissociation constants are usually in the picomolar to low nanomolar
range) 9. Typically 15-40 nucleotides (nt) long, the nucleotide chain of DNA and RNA
aptamers folds in solution into a complex three-dimensional shape, which allows the
aptamer to bind tightly against the surface of its target molecule9. Since their first
inception, RNA aptamers have proven very versatile: using systematic evolution of
ligands by exponential enrichment (SELEX) many aptamers have been generated de novo
against a wide variety of ligands, including small molecules, peptides, and proteins' 0. In
general, introduction of RNA sequences into molecular imaging systems is appealing
because they offer simpler means for structure and function prediction than proteins.
We thus decided to translate the concept of enzyme complementation into an all-
RNA assay. Figure 2-1B depicts the proposed scheme. In this case, the reporter is a
heterodimeric ribozyme called the maxizyme (Mz). An RNA sequence selected for high-
affinity binding to the target protein, an RNA aptamer, is then used as the scaffold to join
the ribozyme to the protein of interest. In this manner, the protein fusions used in ECAs
are substituted by an RNA aptamer-ribozyme fusion, an aptazyme, which can both
recognize the endogenous protein and catalyze the signal amplification cascade. Because
aptazymes are genetically encodable, they can be transiently or stably transfected inside
cells and should therefore be able to detect endogenous interactions in a non-invasive
manner.
A similar approach to detecting protein-protein interactions using RNA aptamers
and hammerhead ribozymes had been previously developed by the Famulok lab
(University of Bonn) in collaboration with the Ellington lab (University of Texas)11. In
their system, interaction of any protein partner with the aptamer-binding protein decoys
the protein from the aptamer, which is then capable of hybridizing with an antisense
sequence within the ribozyme. In turn, aptamer hybridization induces a conformational
change in the ribozyme that renders it catalytically inactive. They showed that this
detection scheme was able to report on the binding of the hirudin inhibitor to a-thrombin
in vitro. Unfortunately, in this system, the aptamer binds to the same protein region as its
binding partner, thus acting as a competitive inhibitor. This means that, if the affinity of
the aptamer for its target protein is higher than that of the protein-protein interaction, the
approach will effectively inhibit the PPI rather than reporting on it. For this reason, and
-43 -
because of the need for injection of the molecular beacons used as ribozyme substrates,
this system would be too invasive and possess too low a sensitivity for low-affinity
interactions to be generally applicable in vivo.
The following sections describe our choice of a ribozyme and a reporter enzyme
for our system.
The maxizyme: a dimeric hammerhead ribozyme
A ribozyme (Rz) is an RNA sequence that acts as a chemical catalyst; naturally
occurring ribozymes, for example, catalyze the cleavage or ligation of RNA sequences.
Ribozymes are found in most natural organisms and can be classified into cleaving
ribozymes, which include self-cleaving RNAs and the trans-cleaving ribonuclease P
(RNase P), and splicing ribozymes, which are large RNAs involved in the excision of
introns from precursor RNAs' 2. The self-cleaving ribozymes include the ribosomal RNA,
the smaller hammerhead, hairpin, hepatitis 8 virus (HDV), and Neurospora Varkud
Satellite (VS) ribozymesl3, and the recently discovered riboswitches such as the bacterial
glmS riboswitch' 4 or the human co-transcriptional cleavage (CoTC) ribozymes' 5 .
Additionally, many more ribozymes have been engineered in the past 10 years that
incorporate novel functionalities, such as C-C bond formation 16, and kinase' 7 or
polymerase activity" 9
For several reasons, we chose the hammerhead ribozyme (HHRz) as the catalytic
component of our system (Figure 2-2A). First, HHRz is the smallest naturally occurring
ribozyme capable of performing sequence-specific cleavagel 3. Second, owing to its small
size, ease of redirection to new substrates, and rapid kinetics, the hammerhead ribozyme
is the most widely studied ribozyme and there are many examples of HHRz engineering
to allow cleavage of different substrate RNAs in vitro. Third, the HHRz has been shown
to be, at least partially, active in vivo20 ,2 1. Fourth, although natural HHRzs catalyze self-
cleavage, they were, soon after their initial discovery, engineered to perform multiple-
turnover trans-cleavage 22 , and could thus be capable of signal amplification. Finally, a
heterodimeric hammerhead ribozyme had already been developed by the Taira lab
(University of Tsukuba, Japan). Although a split ribozyme based on the Tetrahymena
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group I intron was reported in 200623, the former was the only dimeric ribozyme reported
at the time when this project was being pursued.
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Figure 2-2: Evolution of the hammerhead ribozyme towards the dimeric maxizyme. (A)
Secondary structure of the minimal hammerhead ribozyme in complex with its substrate (blue).
The original HHRz was modified to identify the minimal essential elements for catalytic activity,
yielding the minimal HHRz shown here. This minimal trans-cleaving HHRz contains three
helical stems - I, II, and III - which flank the nine conserved bases of the catalytic core. Helices I
and III are involved in substrate specificity, whereas the catalytic core is involved in the
formation of the tertiary structure necessary for cleavage24. (B) Secondary structure of a
minizyme in complex with its substrate (blue). The minizyme results from deleting stem II from
the minimal hammerhead ribozyme. The minizyme is inactive as a monomer but has a strong
catalytic activity as a dimer. This homodimer is called a maxizyme. (C) Secondary structure of a
heterodimeric maxizyme resulting from mixing two distinct monomers. The heterodimeric
maxizyme has two different substrate-binding arms and is therefore capable of cleaving two
different substrates (red and green). Image adapted from Amontov and Taira25
The dimeric hammerhead ribozymes developed in the Taira lab, the so-called
maxizymes, were discovered when attempting to replace the stem loop II of the original
HHRz by a short linker (Figure 2-2B). This shortened HHRz, the minizyme, was found to
be inactive as a monomer, but exhibits measurable catalytic activity (kcleav - 2-3 min-) as
a dimer25,26 (Figure 2-2B). By combining two different monomers, one can then design a
heterodimer capable of cleaving two different substrates (Figure 2-2C), although the
overall catalytic efficiency decreases with respect to the homodimer (kcleav
< 0.24 min'1)27. The heterodimeric maxizymes can also be turned into allosterically
regulated ribozymes by deleting one of the catalytic cores and using one of the two
substrate-binding regions as sensor arms. In this design, when the sensor arms pair with
the correct target sequence, the maxizyme is able to adopt the correct conformation and
cleave the target sequence at a different site28. Importantly, all these heterodimeric
maxizymes have been shown to be catalytically active in cells29,30 and in animals31.
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Although the Taira lab has not yet developed any fusion of the maxizyme to an
aptamer, fusions of the minimal hammerhead ribozyme to RNA aptamers similar to those
that are required in our system have been previously engineered. In previously reported
aptazymes, the catalytic activity of the HHRz domain is controlled by ligands interacting
with the aptamer domain 11' 32 . The most useful approach to the design of these
allosterically regulated ribozymes is probably the one developed by the Breaker lab (Yale
University). In this approach, the RNA aptamer is fused to the stem loop II of a minimal
hammerhead ribozyme through a communication module32. In the presence of bound
analyte, the aptamer induces a conformational change in the catalytic core of the
ribozyme, thereby activating (or inhibiting) its catalytic activity. The combined use of
rational design and in vitro evolution of the communication module provided two
allosteric ribozymes with kcat values of - 1 min-1 and a dynamic range for allosteric
activation of 5000-fold in response to cGMP and Co2+ (Ref. 32). It remains to be
demonstrated whether similar aptamer-ribozyme fusions can be developed based on the
heterodimeric maxizyme. It is worth mentioning that, to date, only one naturally
occurring regulated ribozyme has been found. In the glmS aptazyme, glucosamine-6-
phosphate (GlcN6P) serves as a cofactor, which, upon binding to the aptazyme,
participates in the cleaving of the mRNA encoding the GlmS enzyme that synthesizes
GlcN6Pl4
P-lactamase: a sensitive reporter system
We chose p-lactamase as the reporter system because of its demonstrated high
sensitivity (i.e., detection of as little as 100 p-lactamase protein molecules) 33 35, and
because its activity can be detected in live cells by fluorescence microscopy. 3-
lactamases are a family of bacterial enzymes that cleave p-lactams such as penicillins and
cephalosporins very efficiently. The TEM-1 p-lactamase from E. coli was first conceived
as a reporter of gene expression in the laboratory of Roger Tsien (UC San Diego)35.
Figure 2-3 shows the principles of the P-lactamase reporter system. Tsien and co-workers
designed a p-lactamase substrate in which two fluorophores (a coumarin donor and a
fluorescein acceptor) are attached to the 7 and 3' positions of a cephalosporin
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heterocycle. In this configuration, the two fluorophores are close enough to exhibit
efficient fluorescence resonance energy transfer (FRET). However, P-lactamase cleavage
of the cephalosporin results in elimination of the fluorophore from the 3' position,
disrupts FRET, and reestablishes fluorescence emission by the coumarin donor, thus
resulting in an increase in the cellular blue-to-green emission signal ratio. Alternatively,
fluorogenic substrates have also been designed, which transform from non-fluorescent to
brightly fluorescent (- 153-fold enhancement in fluorescence intensity) after p-lactamase
hydrolysis36. Since its inception in 1998, the P-lactamase reporter system has been
extensively used in protein complementation assays to detect protein-protein interaction
in cells'"2'7 and, owing to its high sensitivity, has enabled single-cell monitoring of the
self-33 and trans-splicing34 activities of the Tetrahymena group I intron ribozyme.
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Figure 2-3: The p-lactamase reporter system. In the intact substrate, excitation of a coumarin
donor (left) at 409 nm leads to fluorescence resonance energy transfer (FRET) to the fluorescein
acceptor (right) and re-emission of green light. p-lactamase (Enz) catalyzes the hydrolysis of a
cephalosporin p-lactam ring to generate two products in which the donor and acceptor are
separated. The donor then emits blue fluorescence, whereas the acceptor is quenched. Scheme
adapted from Zlokarnik et a135.
In retrospect, the p-lactamase system does not seem the best option because it has
been shown that its fluorogenic substrate is not taken up by many cell types2. In contrast,
the use of luciferase as a reporter enzyme retains the high sensitivity of P-lactamase but it
has the added advantage that it has been robustly demonstrated both in living cells 3,4 and
in whole animals 37. Furthermore, the use of a bioluminescent signal instead of
fluorescence eliminates the background introduced by the auto-fluorescence of biological
samples.
-47 -
Proof-of-principle: homodimerization of the p50 member of the NFKB family of
transcription factors
Our starting point in the search for an initial proof-of-principle system was the
public aptamer database maintained by the Ellington lab (Austin, Texas)38. Among all
reported RNA aptamers selected against protein targets, we chose the aptamer against the
p50 member of the nuclear factor KB (NFKB) family of transcription factors39 because it
had been extensively characterized both in vitro and in vivo. The 29-nt aptamer had been
initially selected in vitro39 and was later optimized for in vivo binding using yeast genetic
selections 40. This was an important consideration for our system, since most other
reported aptamers are solely selected in vitro, and are therefore not guaranteed to fold
properly and to retain binding specificity for their targets when expressed in living cells.
Despite their lack of sequence identity, the RNA aptamer displays similarly high binding
affinity (Kd = 5.4 + 2.0 nM) as the native consensus DNA target for (p50)2 and it is also
highly selective for the p50 member of the family4o (i.e., it does not recognize p65).
Furthermore, the crystal structure of the aptamer-protein complex had been solved and
showed independent binding of one RNA aptamer molecule to each monomer of the p50
homodimer (Figure 2-4)41. This is essential to our system, which requires aptamer
binding to be independent of the protein-protein interaction. Importantly, this aptamer
was shown to retain its binding ability in yeast cells, where it was able to efficiently
block DNA binding to (p50)240,42 .
NFrB is a family of transcription factors with a conserved DNA-binding domain
and a dimerization region called the Rel homology region (RHR)43. The five known
members of the family (p50, p52, p65, c-Rel, and RelB) dimerize to form several homo-
and heterodimers, which modulate transcription by binding to the regulatory DNA
domains (KB-DNA sites) of numerous genes involved in stress responses such as the
immune response, inflammatory response, and programmed cell death44. The diversity of
the different homo- and heterodimers, each one with distinct binding affinities for the
different target DNAs and for the members of the inhibitor protein family IrB, forms the
basis of the tightly regulated NFKB signaling45.
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Thus, the existence of a selective and high-affinity aptamer for p50 combined
with the wealth of information available on the homodimerization of p50 to form an
active transcriptional regulatory complex, led us to choose this as our model system for
our proof-of-principle aptazyme studies.
Figure 2-4: Crystal structure of the NF-riB (p50)2 complexed to a high-affinity RNA
aptamer. The 2.45A resolution x-ray crystal structure reveals that two RNA molecules (white
backbone with color-coded nucleotides) bind independently of each other to one p50 molecule
(red and blue) within the (p50)2 homodimer. The crystal structure shows that the aptamer binds
through the N-terminal domain of the protein (bottom), and the short linker connecting the N-
terminal domain and the dimerization domain (top). Each p50 monomer uses the same surface to
recognize the distorted RNA major groove as observed in the IKB DNA/p50 complex46.For this
crystal structure, only the Rel homology region of p50 was used. This image was generated from
the original PDB 100A file using DS ViewerPro software.
Results
The hammerhead ribozyme can be modulated to cleave the P-lactamase mRNA
Our initial work focused on independently testing the two major components of
the system: the ribozyme and the aptamer. We started by modulating the minimal
hammerhead ribozyme (HHRz) to cleave the 3-lactamase mRNA. Our initial strategy for
generating ribozyme transcripts was based on PCR amplification of a template plasmid
containing the HHRz downstream of a tRNAVal promoter, used to enhance ribozyme
stability and cytosolic export in cells47, and upstream of a helicase-recruiting sequence,
used to unwind the substrate mRNA thus improving ribozyme cleavage activity48. The
original plasmid containing a HHRz targeted against the luciferase mRNA (pUC-tRNA-
LucRz-CTE) was a gift from Prof. Taira (University of Tsukuba, Japan). We designed
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HHRz targeting three different sequences within the P-lactamase gene, by changing the
nucleotide sequence of the substrate binding arms (helixes I and III in Figure 2-2A). We
chose p-lactamase sequences 1-3 (Figure 2-5), which encompass a GUC (1 & 2) or a
CUC (3) triplet. Although HHRzs can cleave any RNA substrate that contains an NUH
triplet, where N is any nucleotide and H is A, C, or U, it has been shown that the
efficiency of cleavage is higher for GUC and, to a lesser extent, for CUC49 . Additionally,
it is recommended to target sequences that lie either within the first 500 bases of the
transcript or at the very end, as these are less likely to be buried within mRNA tertiary
structures5 .
P-lactamase 3 "
p-lactamase 2 -
P-lactamase 4 )
a-lactamase 1
R1-har~smloe 1
P-lactamase 6
Figure 2-5: Secondary structure of the p-lactamase mRNA as predicted by Mfold. Marked
with lines are all the GUC or CUC triplets present in the transcript. Over the course of this
project, several ribozymes were designed to target triples 1-6. Triplets marked in black lie within
stable stem structures and are likely to be inaccessible, so they were not tested. Triplets in blue
(p-lactamase 2 and 3) were tested but no activity was observed when the hammerhead was
incubated with a transcript containing the first 380 bases of the mRNA (marked by the green
arrowhead). HHRzs designed to cleave the triplets marked in red (p-lactamase 1 and 4-6) showed
varying degrees of cleavage activity.
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HHRzs targeting p-lactamase sequences 1-3 were first cloned into pUC-tRNAal-
CTE, then PCR-amplified using a forward primer containing a T7 promoter sequence,
and finally transcribed using T7 RNA polymerase. The final size of the transcripts was
- 200 nt for the ribozymes and - 400 nt for the p-lactamase substrate. We did not observe
any cleavage activity when the HHRzs were tested in an in vitro reaction with 32P end-
labeled p-lactamase RNA (data not shown). Changing the reaction conditions, such as
pH, time, and ribozyme or substrate concentration did not result in any detectable
cleavage activity.
We then changed our protocol for generating transcripts. Following the advice of
Dr. Ed Curtis (at the time, a graduate student in the Bartel laboratory at MIT), we ordered
short DNA oligonucleotides (- 40-80 nt) containing the HHRz or substrate sequence
followed by a 20-nt T7 promoter sequence needed for recognition by T7 RNA
polymerase. Transcription yields were a lot higher for the short oligos than they were for
the long PCR products. Furthermore, the short HHRz transcript targeting the P-lactamase
target sequence 1 was able to efficiently cleave the 400 nt p-lactamase transcript (Figure
2-6). We did not see any activity for HHRzs 2 and 3, perhaps because their target
sequences lie within more stable stems or are buried within the RNA tertiary structure.
Bla-3 Bla-2 Bla-1 [HHRz]
10 100 - I 10 100 - 10 1 00 in nM I
-a
Figure 2-6: The hammerhead ribozyme can be modulated to cleave the P-lactamase mRNA.
In vitro activity assay of three hammerhead ribozymes targeting p-lactamase target sequences 1-3(see Figure 2-5). Either 10 or 100 nM HHRz was incubated with - 1 nM end-labeled 400 nt 3-
lactamase transcript for 5 minutes at 37 'C. The reaction products were run on a 10% denaturing
acrylamide gel. Negative control reactions (- lanes) were performed in the absence of RNA
enzyme.
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The heterodimeric maxizyme is active in vitro at concentrations higher than 10 nM
In parallel, we started testing the in vitro activity of the heterodimeric maxizyme
(Mz). Among the several published maxizymes, we chose the heterodimeric Mz that
targets the HIV-1 Tat mRNA (Figure 2-2C) because it had been shown to retain its
catalytic activity even in the presence of just one substrate27 . That is, cleavage of the S-19
substrate (red in Figure 2-2C) did not depend on the presence of the S-14 substrate (green
in Figure 2-2C) so long as high Mg2+ concentrations were included in the in vitro
reaction. Presumably, high concentrations of Mg2+ ions were able to stabilize the dimeric
ribozymes in the absence of the second substrate 26 in vitro, whereas other factors are
responsible for stabilization in vivo, where the Mg 2+ concentration is significantly
lower 51. This was an important consideration in our case because fusion of the RNA
aptamers to the maxizyme may have sterically hindered binding of the second substrate.
We therefore prepared transcripts of the left monomer (MzL), the right monomer
(MzR), and the S-19 substrate starting from the corresponding short DNA oligos as
previously described (see Experimental section). As expected, we only observed
ribozyme cleavage activity in the presence of both monomers. Figure 2-7A shows that the
S-19 substrate remains intact after 5 minutes incubation with only MzL or only MzR, but
- 10% cleavage is observed when both monomers are present.
A B
+ - + MzL I - - 0.01 0.1 1 [MzL+MzR] in ÷M
+ + MzR I - + + + Mg2,
Substrate
Cleavage
product
Substrate
Cleavage
product
Figure 2-7: In vitro cleavage activity of the heterodimeric maxizyme. (A) Maxizyme activity
requires presence of both maxizyme monomers. 1 nM end-labeled S-19 substrate was incubated
for 5 minutes in the absence of RNA enzyme (lane 1) or in the presence of 100 nM of each or
both Mz monomers (lanes 2, 3, and 4), and the reaction products were run on a 20% denaturing
acrylamide gel. The intact substrate is 19 nt long, and the 5' cleavage product is 10 nt. (B) The
maxizyme is active at concentrations higher than 10 nM. The in vitro activity assay was
performed as in A except that the reaction was incubated for 1 hour with varying concentrations
of the maxizyme monomers.
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We next sought to find an estimate of the minimum concentration at which the
maxizyme is active in vitro. This is an important parameter of our PPI detection strategy,
which requires that there is no ribozyme activity in the absence of a protein-protein
interaction. We performed the in vitro activity assay at various concentrations of Mz and
observed no detectable cleavage activity when the substrate was incubated in the
presence of 10 nM Mz even after one hour reaction (Figure 2-7B). In contrast, incubation
with maxizyme concentrations higher than 100 nM resulted in - 90% cleavage. It is
worth noting that, because assays were performed under single turnover conditions, the
extent of cleavage reflects the percentage of maxizyme molecules that are adopting a
catalytically active conformation. The results shown in Figure 2-7B are in accordance
with the published kinetic parameters for this maxizyme2 7. With a KM for dimerization of
220 nM (kobs = 0.24 min 1), it is expected that, at 10 nM maxizyme, only - 0.4 nM will be
in dimeric form, and, of those, only - 10% will be in a catalytically active configuration
at any given moment. In contrast, at 100 nM maxizyme, - 25 nM will be in dimeric form,
and even if only 10% is catalytically active, the concentration of active ribozyme is
higher than the total concentration of substrate.
Generating an aptazyme that displays binding to p50 and ribozyme catalytic activity
Initial aptazyme fusions did not bind p50
With an active maxizyme in hand, we next turned our attention to the aptamer
component of our system. The first step on testing the aptamer was the expression of the
wild type (WT) p50 protein and a non-dimerizing mutant (Y267D/L269D) to serve as a
negative control for protein-protein interaction. Plasmids for both proteins were obtained
from Dr. Gourisankar Ghosh and encoded truncated versions of the proteins with just the
Rel homology region (RHR) domains (residues 39-364). The non-dimerizing mutant was
N-terminally His-tagged, and was purified by affinity chromatography. The WT protein
was un-tagged, and was therefore purified by two subsequent anion and cation exchange
chromatographic steps following a published protocol39. Both proteins expressed well in
E. coli BL21 and we were able to routinely obtain purified protein at concentrations
- 60 pM.
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We prepared the aptamer by transcription of the corresponding DNA oligo and we
end-labeled it using [y- 32P] ATP as described in the Experimental section. Aptamer
binding to p50 was tested by a nitrocellulose filter binding assay. We observed a
fractional saturation of aptamer binding of 0.83 + 0.05 at 50 nM p50 (Figure 2-8B, first
bar, and Table 2-1), which is in accordance with the previously reported aptamer
affinity40. To further confirm the validity of our assay conditions, we prepared point
mutations of the aptamer at positions that had been previously postulated to be essential
for protein binding41. Figure 2-8B shows that all three mutations impaired aptamer
binding activity, with mutant 1 (Al 1:U20 to C11 :G20) resulting in lowest binding. Figure
2-8A shows the aptamer secondary structure and highlights its main contacts with p50.
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Figure 2-8: Aptamer binding to p50. (A) Summary of contacts between the RNA aptamer and
p50 as seen in the crystal structure. Watson-Crick base pairs are indicated in red. Residues
predicted to form an internal loop are colored cyan (5') and orange (3'). Yellow ovals represent
phosphates in the RNA backbone contacted by p50. Figure taken from Huang et al41. (B)
Fractional saturation of aptamer binding to p50. Aptamer binding to p50 was tested using a
nitrocellulose filter binding assay with 0.9 nM end-labeled RNA aptamer and 50 nM p50. Each
data point represents the average of three independent experiments. Error bars, 1 s.d. The
mutations were introduced in pairs in an attempt to impair protein binding without disrupting
aptamer secondary structure.
The first generation of aptazyme fusions was constructed by directly joining the
aptamer to the 3' end of the left monomer of the maxizyme or the 5' end of the right
monomer without any extra linkers. Unfortunately, although catalytically active (data not
shown), both fusions displayed a marked decrease in binding to p50. Table 2-1 shows
that the fractions of left and right monomers of the aptazyme fusion (called Az-0) bound
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to p50 were 0.15 ± 0.01 and 0.17 + 0.02, respectively. These numbers are comparable to
those obtained for the non-binding aptamer mutants (e.g., the A12:U19 mutant aptamer
displays a 0.15 + 0.01 fractional saturation at 50 nM p50). This loss of binding capability
can be reasoned based on the predicted secondary structures of the fusions. Figure 2-9
shows that the aptamer secondary structure (Figure 2-9A) is disrupted in the aptazyme
fusions because of base-pairing between the aptamer and the maxizyme domains (Figure
2-9B and C).
A B C 1•Q10
U-A
B A
U--0I I
C--
I IA--U-- 2
-~
- A - U
U /
C--6I IA-U
I I
U--A
I IA-UI I
F -C-B- r
U
S 40
II
U'A-Lý&
Figure 2-9: Predicted secondary structure of the ct-p50 aptamer and the first generation of
aptazyme fusions. (A) Aptamer against p50. (B) Left monomer of the aptazyme fusion (AzL-0).(C) Right monomer of the aptazyme fusion (AzR-0).
Extra complementary strands in the aptazyme stabilizes the aptamer and ribozyme
domains
We then sought to improve the stability of the aptamer fold in the aptazyme
fusions. We pursued two different strategies. First, we introduced two or four extra base
pairs in the aptamer stem to additionally stabilize its fold (Figure 2-10, AzR-1 and 2, and
AzL-3 and 4). Second, we added extra nucleotides at the 3' end of the aptamer in AzL,
complementary to the secondary substrate binding arm of MzL. These extra nucleotides
(Figure 2-10, AzL-1) would play a double role: they prevent formation of incorrect
secondary structure due to mispairing of maxizyme and aptamer bases, and they mimic
the presence of a second maxizyme substrate, thereby stabilizing the maxizyme active
A u
-'~X. ,(
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conformation. Finally, a combination of both strategies was also tested (the combination
of AzL-1 and 3 was called AzL-2).
UA
UA
GC
GC
AzL-4
GC
GC
AzL-3
AAUG AAUG
GGCU a-NF-KB aptamer GGCU a.NF.
UA UA
GUAA GUAA
CGCUU CGCUUUA UAAU AzL-1 AU
UA CCAGGAAGTTTC UA
'GUCCUUCAAAG AGUAGUCUCGG
CG
CG
Maxizyme GC MaxizymeCGleft GC right
uGA GA
UC A5'GAUGAGUCU ACUGUUCUG 3'
3' CUACUCAG?,CUGACAAGAC 5'
Ribozyme substrate
Figure 2-10: Nucleotide sequence of the aptazyme fusions. The RNA aptamer against p50 was
fused to the 3' end of the left monomer of the dimeric maxizyme (MzL) to afford the left
monomer of the aptazyme (AzL, blue) or to the 5' end of the right monomer of the maxizyme(MzR) to create AzR (red). The ribozyme substrate is represented in green. The nucleotides
boxed and in black were later added in order to promote independent folding of the aptamer and
ribozyme domains of the aptazyme fusions.
We transcribed the DNA oligos, end-labeled the transcripts with [32P-y] ATP, and
tested the different constructs for binding to p50. Table 2-1 summarizes the results.
Binding was recovered for all the constructs tested, although to different extents. For
example, addition of two or four extra base pairs at the end of the aptamer stem (AzL-3
and AzL-4) resulted in significantly higher fractional saturations (0.63 + 0.01 and
0.58 + 0.02, respectively) than that of AzL-0 (0.15 ± 0.02); but still lower than the
fractional saturation of the original aptamer (0.83 + 0.05). In contrast, the combination of
aptamer stem stabilization and extra base-pairing of the MzL substrate binding arm
(AzL-2) resulted in a fractional saturation of 0.85 ± 0.03, similar to that obtained for the
aptamer alone. As expected, the differences obtained by adding two or four extra base
pairs to the aptamer stem in AzR were not dramatic, although better binding was
observed for AzR-2, which incorporated four extra base pairs.
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GC
AzR-1
-KB aptamer
UA
UA
GC
GC
AzR-2
Table 2-1: Summary of binding capabilities of the aptamer, maxizyme, and aptazyme
fusions towards the p50 protein. Binding tests were all performed using the nitrocellulose
binding assay with 0.9 nM RNA and 50 nM protein. The results are given as the fraction of total
RNA bound to p50. Unless otherwise noted, the maxizyme domain of the aptazyme fusions
contained five base pairs in the dimerization domain, like the one shown in Figure 2-2C. The
fractional saturation for a maxizyme and an aptazyme with only two bases pairs in the
dimerization stem is also shown (marked with an asterisk *). The complete sequences of all
constructs can be found in the Experimental section (Table 2-3). Each data point represents the
average of three independent experiments. Error bars, 1 s.d. The numbering of the aptazyme
fusions follows the convention described in Figure 2-10.
Construct
NA
HIV-S 19
P-lactamase
p-lactamase*
HIV-S19
p-lactamase
WT
C 11 :G20 mutant
A12:U19 mutant
Double mutant
NA
NA
NA
WT
WT
WT
C11:G20 mutant
A12:U19 mutant
Double mutant
WT
WT
WT
C11:G20 mutant
WT
C11 :G20 mutant
Binding to p50
(as, fractionnl natnrntinn1
0.83 ± 0.05
0.13 ± 0.01
0.15 ± 0.01
0.22 ± 0.03
0.28 + 0.08
0.21 + 0.03
0.19 ± 0.01
0.15 ± 0.02
0.79 ± 0.02
0.85 ± 0.03
0.55 + 0.02
0.50 ± 0.03
0.53 ± 0.05
0.63 ± 0.01
0.58 A 0.02
0.69 ± 0.01
0.19 ± 0.02
0.38 ± 0.03
0.14 ± 0.02
0.42 ± 0.05
0.18 ± 0.02
0.14 ± 0.02
0.17 ± 0.02
0.61 ± 0.06
0.72 ± 0.02
0.49 ± 0.02
0.45 ± 0.09
0.44 ± 0.01
0.75 ± 0.02
0.12 ± 0.01
0.71 ± 0.03
0.13 ± 0.02
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Aptamer
Maxizyme
Aptazyme
We next prepared the point mutations in the aptamer domain of the two best
aptazyme constructs AzL-2 and AzR-2. Surprisingly, we found that none of the three
mutations tested eliminated binding. The fractional saturation of the aptazyme was
reduced to - 0.50 for both AzL and AzR, which was significantly higher than the residual
binding seen for the mutant aptamers (ranging from 0.13-0.22). This led us to
hypothesize that perhaps the maxizyme domain had, by itself, certain affinity for p50. To
test this hypothesis, we estimated the fraction of maxizyme alone that bound to p50 using
the same nitrocellulose binding assay. We observed that, indeed, the maxizyme alone
displayed significant binding to p50 with fractional saturations of 0.28 ± 0.08 for MzR
(5 bp, S-19 substrate) and 0.42 ± 0.05 for MzL (5 bp, S-19 substrate). We also tested the
specificity of the binding, and found that none of the monomers (MzL or MzR) bound to
the unrelated bovine serum albumin (BSA) or to cyan fluorescence protein (CFP). It is
worth noting that binding of the mutant aptazyme fusions was higher than that of the
mutant aptamer or the maxizyme by themselves. We hypothesized that this was caused
by binding cooperativity between the two domains within the context of the fusions,
although initial tests did not seem to confirm this hypothesis (data not shown).
Changing substrate specificity minimizes non-specific binding to p50
In order to find out the reason why the maxizyme monomers were binding to p50
in such a specific manner, we examined their nucleotide sequences and predicted
secondary structures. Table 2-2 compares the nucleotide sequence of the a-p50 RNA
aptamer with that of the maxizyme targeting the S-19 substrate. It was striking to find
that the maxizyme sequences shared as many as 8 nt (MzL-S19) or 9 nt (MzR-S19) with
the aptamer. The predicted secondary structures showed that, although not the lowest
energy structures, both the MzL-S19 and MzR-S19 could fold into alternate structures
with fairly low folding energy, and which closely resembled the aptamer fold (data not
shown). We then sought to eliminate the common sequences by changing the ribozyme
substrate.
Previously, we had found that the hammerhead ribozyme could be modulated to
cleave the p-lactamase mRNA at specific sites (see first section of Results). Based on
those previous experiments, we examined the activity of four different maxizymes
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modulated to cleave at the p-lactamase 1 site or at three other sites (p-lactamase 4-6) that
were expected to be accessible for cleavage (see Figure 2-5).
Table 2-2: Nucleotide sequence comparison for the a-p50 RNA aptamer and several
maxizymes differing in their target sequences. MzL and MzR refer to the left and right
monomers of the heterodimeric maxizyme, respectively. S-19 refers to the 19-mer substrate
targeted by the original maxizyme developed in the Taira lab27. P-lact 1 and 4-6 refer to different
cleavage sites within the p-lactamase mRNA; the numbering is in accordance with that of Figure
2-5. Nucleotides underlined represent the substrate binding arms of the ribozyme, whereas
nucleotides in bold highlight the catalytic core. The nucleotides in red are the ones previously
postulated to be involved in aptamer binding to p50 41. Among those, bold nucleotides mark the
ones that we have mutated to create the non-binding aptamer mutants (All :U20 and C12:G19).
Highlighted in grey is the aptamer nucleotide sequence that was also found in the maxizyme
constructs. Nucleotides in blue represent extra mutations introduced to further differentiate the
aptamer and nucleotide sequences.
Construct RNA Sequence
Aptamer CAUACUUGAAACUGUAAGGUUGGCGUAUG
S-19 GAUGAGUCUCUGAUGAGCGCCGAAACUUCCUGG
p-lact. I AAUAAGGGCCUGAUGAGCGCCGAAGUCUCCUGG
MzL
p-lact. 4 GCGUUUCUGGGUCUGAUGAGCGCCGAAGUCUCCUGG
P-lact. 5 GGGAGGGCUCUGAUGAGCGCCGAAGUCUCCUGG
p-lact. 6 CCATAGUUGCCUCUGAUGAGCGCCGAAGUCUCCUGG
S-19 GGCUCUGAUGAGGCGCGAAACUGUUCUG
p-lact. 1 AAGUCUACAGAGGCGCGAAACACGGAAA
MzR p-lact. 4 AAGUCUACAGAGGCGCGAAAGCAAAAACAGG
p-lact. 5 AAGUCUACAGAGGCGCGAAACCAUCUGG
P-lact. 6 AAGUCUACAGAGGCGCGAACUCCCCGUCG
All four cleavage sites introduced certain degree of dissimilarity between the
aptamer and MzR, but had no effect on MzL (see underlined nucleotides in Table 2-2). In
order to change MzL, we then introduced an ACU to GCU mutation (blue nucleotides in
Table 2-2). We also introduced additional mutations in MzR (blue nucleotides in Table
2-2) to avoid some potential non-productive interactions with the left monomer that had
been predicted by the folding algorithm. We must clarify that all these mutations were
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introduced at the maxizyme secondary binding arms, which do not have any catalytic or
substrate binding function, and should therefore not affect the catalytic activity of the
ribozyme. We tested the four constructs for binding to p50 and we found that, although
reduced, the changes in the binding properties were not as pronounced as we had
anticipated. We observed fractional saturations ranging from 0.1-0.4 (data not shown),
which resemble those obtained for the original maxizyme (0.28 for MzL and 0.42 for
MzR). Only the constructs targeting p-lactamase 6 displayed significantly reduced
background on both monomers with a fractional saturation of 0.21 ± 0.03 for MzL and of
0.18 ± 0.02 for MzR (Table 2-1, Maxizyme with p-lactamase substrate). Although we
could not rationalize why this construct but not the others resulted in decreased binding,
we decided to move forward and incorporate the new maxizyme into an aptazyme fusion.
We were very happy to find that the new aptazyme fusion (Az-2.1) displayed
improved binding behavior. We estimated that the left and right monomers bound the
protein with a fractional saturation of 0.69 ± 0.01 and 0.75 ± 0.02, respectively.
Furthermore, point mutations in the aptamer domain were able to decrease aptazyme
binding to levels similar to the aptamer alone (Table 2-1). In retrospect, the optimization
process may have been more effective had we estimated the signal-to-background ratio
(i.e., binding of the WT versus the point mutation) instead of just binding of the WT
construct from the very beginning. For example, AzL-1, which displayed a fractional
binding saturation of 0.79 ± 0.02, was initially discarded because of low binding, whereas
the final AzL-2.1 optimized monomer showed a 0.69 ± 0.01 fractional saturation.
We next confirmed that the optimized aptazyme fusions retained cleavage
activity, and estimated the maximum concentration at which they showed no detectable
activity. The results are shown in Figure 2-11. We found that, similar to the original
maxizyme (Figure 2-7B), the aptazyme fusion retained ribozyme activity, and that
detectable cleavage was observed at concentrations higher than 10 nM in the absence of a
protein-protein interaction.
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Figure 2-11: In vitro cleavage activity of the optimized aptazyme fusion against a target
sequence in the p-lactamase mRNA. A 24-mer long P-lactamase-6 substrate was combined
with increasing amounts of RNA enzyme, incubated at 37 'C for 1 hour, and the reaction
products run in a 20% denaturing acrylamide gel. Negative controls are also included with no
enzyme added (lane 1), or with just the left (lane 2) or right monomers (lane 2).
To further characterize the optimized aptazyme, we estimated the equilibrium
dissociation constants for p50 binding. We plotted the binding isotherms for AzL and
AzR binding to increasing amounts of protein, and obtained a dissociation constant of
32.5 + 5.1 nM for AzL and 21.5 ± 2.4 nM for AzR, both slightly higher than the reported
Kd for the aptamer (5.4 ± 2 nM)40 . These binding affinities were in accordance with the
values of fractional saturation previously obtained (Table 2-1).
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Figure 2-12: Estimation of equilibrium dissociation constants for p50 binding to the RNA
optimized aptazyme fusions. Nitrocellulose filter binding assays were performed with
radiolabeled left (AzL) or right (AzR) aptazyme monomer in the presence of increasing
concentrations of p50 protein. The fractional saturation of the radiolabeled probe is plotted as a
function of protein concentration for AzL (+) or AzR (*). Error bars indicate standard deviation.
The indicated equilibrium dissociation constant estimates were determined by curve fitting to the
equation described in the Experimental section.
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Finally, Figure 2-13 compares the predicted secondary structures of the original
and the improved aptazyme fusions. The predicted structures, together with the positive
results for binding and cleavage activities, confirmed that the optimization process finally
yielded a fusion construct, where both domains can fold and function independently of
each other.
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Figure 2-13: Secondary structures of the original (A) and optimized (B) aptazyme fusions as
predicted by Mfold. Whereas the maxizyme domain is properly folded in both cases, the two
aptamer domains only fold in a productive conformation in the optimized fusions. In the initial
aptazyme fusions (A), the RNA aptamer fold is disrupted by interactions between the two
aptamer domains and between the aptamer and the secondary binding arm of the left maxizyme
monomer.
Aptazyme activity does not increase in the presence of a protein-protein interaction
NFkB p50 homodimerization affinity is lower than expected in the absence of DNA
binding
We were then ready to examine whether the catalytic activity of the aptazyme
fusion increased in the presence of a protein-protein interaction. Assuming a Kd for p50
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homodimerization in the low nanomolar range, as it had been previously reported52, we
reasoned than incubating the aptazyme fusions in the presence of nanomolar
concentrations of p50 would generate enough protein dimers to result in maxizyme
activation. However, initial tests showed that the cleavage activity of the aptazyme fusion
did not significantly change in the absence or presence of protein. Changing the aptazyme
concentrations from 1-10 nM or the protein concentrations 1 nM-100 nM did not result
in changes in ribozyme activity either (data not shown). We then realized that the
reported nanomolar affinity had been estimated based on DNA gel shift assays, where the
protein is incubated with its target DNA duplex, and protein dimerization is reported as
the amount of protein with shifted mobility (i.e., DNA-bound) in a non-denaturing gel.
As it had been proposed that the target DNA promotes protein homodimerization, the
extent of dimerization in a gel-shift assay does not reflect the intrinsic protein
dimerization affinity in the absence of DNA. Furthermore, we found that Ghosh and co-
workers had previously estimated a low micromolar affinity for p50 homodimerization in
the absence of DNA using analytical ultracentrifugation53
Unfortunately, with a working concentration of 10 nM aptazyme (this was the
maximum concentration that showed no cleavage activity in the absence of protein, see
Figure 2-11), incubation with micromolar concentrations of p50 would result in each
aptazyme monomer binding to a different protein dimer, thus yielding no catalytically
active aptazyme dimers. Based on this finding, we delineated two different approaches
for testing our PPI detection strategy on the p50 homodimerization proof-of-principle:
1. Modifying the aptazyme fusion in order to increase its dimerization
dissociation constant, such that we could work at micromolar concentrations
of both aptazyme and protein.
2. Finding a way to promote p50 dimerization at nanomolar concentrations, such
that we could work with the current aptazyme fusion.
We first focused on approach number one. It had been reported that decreasing
the number of base pairs in the dimerization stem of the maxizyme resulted in higher
dissociation constants from Kd(Sbp) = 220 nM to Kd(3bp) = 550 nM or Kd(2bp) = 1 gtM 27.
Although this report was promising, when we tested the constructs with two or three G-C
base pairs in the dimerization stem, we did not observed any cleavage activity even at
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concentrations significantly above their Kd (up to 10 M). We therefore decided to switch
to the second approach.
Generating an obligate dimer ofp50
We first considered utilizing the small protein myotrophin as a promoter of p50
homodimerization. Myotrophin is a 12kDa protein involved in NFKB-mediated cardiac
hypertrophy 54. Although its mechanism of action is still not clearly understood, it had
been postulated that myotrophin acts as a chaperon to convert the transcriptional
activators p50-p65 heterodimers into the transcriptional repressors p50-p50 and p65-p65
homodimers5 2 . More importantly, contrary to what had been previously suggested55, Chi-
Wang Lin, a graduate student in our laboratory, demonstrated, using a novel crosslinking
assay, that myotrophin could promote p50 homodimerization, at least partially, in the
absence of p65 and DNA duplex56 . We then tested the cleavage activity assay of the
aptazyme fusions in the presence of varying concentrations of p50 and myotrophin but
observed no activation. We hypothesized that the amount of protein dimers formed in the
presence of myotrophin sufficed to be detected in a crosslinking assay but was not
enough to result in detectable aptazyme activation.
It was clear at this point that we needed to find a way of artificially generating an
obligate dimer of p50. We prepared obligate p50 dimers in two different ways: by
chemical crosslinking of purified p50 protein and by recombinant expression of a gene
encoding two p50 ORFs in tandem. In the following paragraphs, we will describe both
approaches.
We first tested the most general crosslinking procedure, based on glutaraldehyde
reaction with primary amines in the lysine side-chain of proteins. Glutaraldehyde
crosslinking of p50 had been previously used to study the p50 dimer interface by Ghosh
and co-workers, who reported optimal reaction conditions at 0.66 giM p50 and 1% w/v
glutaraldehyde53. However, even at such low concentration of p50, our reaction mixtures
contained a high percentage of un-reacted monomer (- 50%) and higher-order oligomers
(- 10%) (data not shown). We then switched to cysteine crosslinking agents reasoning
that, because there are only two cell-surface cysteines present in the p50 RHR4 6, the
crosslinking reaction should mainly yield monomer and dimer, with few higher-order
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oligomers. As expected, crosslinking of p50 with either bis(maleimido) hexane (BMH) or
1,4-Di-[3'-(2'-pyridyldithio)-propionamido]butane (DPDPB) resulted in reaction
mixtures that contained monomer and dimer almost exclusively. After optimizing
reaction time and temperature, and protein and reagent concentrations (see Experimental
section), BMH crosslinking resulted in a monomer to dimer ratio of 0.36 whereas
DPDPB never resulted in a ratio higher than 0.6. Subsequent purification with Ni-NTA
using gradient elution partially separated the monomer (one His6 tag) from the dimer
(two His6 tags), ultimately decreasing the monomer to dimer ratio for the BMH reactions
to - 0.2. We used this purified mixture of monomer and dimer in our aptazyme in vitro
activity assays.
In parallel, we cloned a tandem sequence with two p50 ORFs in the pRSETb
vector. Recombinant expression in BL21 cells using this pRSETb plasmid resulted in
extremely low levels of expressed protein. Addition of varying concentrations of
chemical chaperones such as betaine (2.5-25 mM), glycerol (0.5-5%), and DMSO
(100 mM) did not detectably increase protein expression. We also tried co-expression
with the protein chaperones dnaK, J and E, or GroES and GroEL with no success. Sub-
cloning the tandem p50 sequence into a pET15b vector did however make a dramatic
difference. The tandem p50 dimer expressed at very high levels in BL21 cells
transformed with the (p50)2-pET15b plasmid, although a small amount of p50 monomer
was also observed in the lysates, probably due to tandem proteolysis. The monomer was
separated from the dimer by two subsequent affinity purification steps: first, the lysate
was purified using Ni-NTA agarose (the tandem carried an N-terminal His6 tag); second,
the eluate from the Ni-NTA column was further purified with Anti-FLAG-agarose (the
tandem p50 had a C-terminal FLAG epitope). This purification scheme yielded the
tandem p50 dimer with > 90% purity.
Aptazyme activity does not significantly increase in the presence of an artificial p50
dimer
We next tested the cleavage activity of the aptazyme fusions in the presence of the
artificial p50 dimers. The initial results (Figure 2-14A) suggested that modest levels of
activation were obtained in the presence of either the tandem dimer or the crosslinked
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dimer. Quantification of several experiments like the one shown in Figure 2-14A never
resulted in an activation factor higher than 1.2-fold, where the activation factor was
calculated as the ratio of amount of product formed in the presence and in the absence of
protein. Furthermore, similar activation factors were estimated for the maxizyme alone,
in the absence of an aptamer domain (Figure 2-14B). It is worth noting that the observed
aptazyme and maxizyme activations were both eliminated if the reaction was performed
in the presence of excess a-p50 aptamer but not excess of an unrelated RNA sequence
(data not shown), thus suggesting that activation was indeed caused by binding to the p50
dimer. However, varying the concentrations of aptazyme, maxizyme, and protein did not
improve the ratio of aptazyme activation versus maxizyme activation (data not shown).
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Figure 2-14: In vitro cleavage activity of the optimized aptazymes in the presence of p50
dimer. (A) The cleavage activity of the optimized aptazyme fusions was tested in the presence of
50 nM p50 dimer prepared by either recombinant expression of a tandem dimer (pET lanes) or by
chemical crosslinking of the p50 monomers (BMH lanes). Negative controls are included without
aptazyme (lane 1), without protein (lane 2) or in the presence of only one of the aptazyme
monomers (lanes 3, 4, 6 and 7). (B) The activation of aptazyme cleavage activity (lanes 3-8) was
tested side-by-side with that of the maxizyme constructs (lanes 1 and 2). The cleavage activity of
the maxizyme was assayed in the absence (lanel) or presence (lane 2) of 50 nM p50 tandem
dimer. The aptazyme was assayed in the absence of dimer (lane 6) or in the presence of 50 nm
(lane 7) or 100 nM (lane 8) protein. Negative controls with no aptazyme (lane 3) or in the
presence of only one of the monomers (lanes 4 and 5) were also included.
The maxizyme is active in cells as shown by a luciferase reporter
Finally, in parallel with the in vitro assays, the original maxizyme constructs
targeting the S-19 substrate within the HIV-1 tat gene (Figure 2-2C) were tested for
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in vivo activity. Following a published procedure51, we transfected HeLa cells with a
plasmid encoding a chimeric fusion of the long-terminal repeat (LTR) of HIV- 1 and the
luciferase gene. The LTR of HIV-1 contains regulatory elements that include a trans-
activation responsive element region (TAR), which is a binding site for the HIV-1
regulatory protein Tat. Thus, expression of the Tat protein causes an increase in the
transcription of the LTR-luciferase chimeric gene, ultimately resulting in an increase of
luciferase enzyme expression levels. In contrast, expression of active maxizyme in the
same cells should cause a decrease in the transcript levels of the tat gene, thus resulting in
reduced luciferase activity. The results are shown in Figure 2-15. As expected, luciferase
activity was maximal on cells expressing both the LTR-Luciferase chimeric gene and the
Tat protein. Co-expression with the maxizyme constructs resulted in a - 5-fold reduction
in luciferase activity, and this reduction required both maxizyme monomers. Although it
is clear from Figure 2-15 that the maxizyme was active in live cells, the inhibition of
luciferase activity that we observed in our experiments was 3.5-fold lower than that
obtained by Taira and co-workers, who reported 90% inhibition using the same
maxizyme constructs 51 . We also noticed that our results were hard to reproduce and were
highly variable among samples (see large error bars in Figure 2-15).
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Figure 2-15: Maxizyme cleavage activity in mammalian cells. HeLa cells were transfected
with plasmids for expression of the maxizyme constructs targeting the HIV-1 Tat mRNA (MzL
and MzR), together with plasmids for expression of the Tat protein (Tat) and of the chimeric gene
LTR-Luc, which expresses luciferase upon binding of the Tat protein. Negative controls that
leave out one or more of the plasmids are also included. Luciferase activity was measured in
lysates using the luciferin substrate. Luciferase activity for each sample is reported relative to that
of cells expressing only the LTR-Luciferase and tat genes. Each data point represents the average
of three independent experiments. Error bars, I s.d.
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Discussion on the feasibility of the proposed detection scheme
While many of the problems encountered during the realization of this project are
attributable to poor choice of the proof-of-principle system, we feel that they are mostly a
reflection of the strict requirements of the proposed strategy. The suggested methodology
involves four different binding processes, and, as such, it is governed by four different
binding affinities. This is illustrated in Figure 2-16A. First, we require that the
dissociation constant for dimerization of the aptazyme construct (KdAzL/R) be large enough
such that, in the absence of a PPI, the majority of the aptazyme molecules are in
monomeric (inactive) form. According to the in vivo results reported by Taira on co-
workers, even for the dimeric maxizyme with only two base pairs in the dimerization
stem (in vitro KdMzL/R 1 pM), the percentage of maxizyme molecules present in dimeric
form is enough to result in - 90% inactivation of the gene of interest in mammalian cells.
We must realize that this reported in vivo activity corresponds in our system to the
background activity in the absence of a PPI. Fortunately, the target reporter gene in our
system (e.g., 3-lactamase) is also transfected and thus present at much higher
concentrations than those of the endogenous genes in Taira's reports. This means that,
perhaps, a higher percentage of dimeric aptazyme would be required for complete
inactivation (i.e., although, owing to the signal amplification of the ribozyme catalytic
activity, this may not be the case). It therefore remains unknown what the actual
percentage of active cellular dimeric aptazyme is, and whether introduction of a PPI-
mediated aptazyme dimerization would result in a large enough increase in activity so as
to generate a significant signal-to-background ratio (i.e., in the best protein
complementation assays, the PPI introduces a - 10-fold increase in reporter activity).
This will ultimately depend of both, the KdA zL/R and the actual concentrations of aptazyme
achieved in cells; however, since higher aptazyme concentrations are desired in order to
cover all the protein binding sites, a high KdAzL/R is needed.
Second, the dissociation constant of the PPI (Kd(p 50 )2, or its equivalent for a
different protein pair KdPP') must be higher than that of aptazyme dimerization, to ensure
that the PPI increases the percentage of aptazyme molecules that are in dimeric form.
Third, the affinity of the aptamer should be characterized by a dissociation constant
(KdAz -Prot) low enough to guarantee that, even at the lowest possible aptazyme
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concentration, the majority of the aptazyme molecules are bound to the target protein.
RNA aptamers have been previously selected with picomolar dissociation constants 57 and
thus, this requirement is more easily achieved than the other Kd requirements.
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Figure 2-16: Requirements for the RNA-based detection of endogenous protein-protein
interactions. (A) Description of the four binding events involved in the detection and the
dissociation constants that govern them. KdAzL/R: dissociation constant for aptazyme dimerization.
Kd(PSO)2: dissociation constant for p50 homodimerization. KdAz-p50 dissociation constant for
aptazyme binding to p50. KdAz-Subs: dissociation constant for aptazyme binding to its mRNA
substrate. (B) Simulation of activation factor values for several combinations of KdAz'Prot and
KdAzL/R. The activation factor is calculated as the ratio of the amount of dimeric aptazyme in the
presence and absence of a PPI. The corresponding amounts of dimeric aptazyme were calculated
from the binding equation described in the Experimental section. The total aptazyme
concentration was assumed to be 50 nM in all cases. The total protein concentrations were 50, 60,
and 150 nM for KdAz-Prot 0.1 and 1, 10, and 100 respectively; which were calculated as optimal
(see panel C in this figure). (C) Dependence of the percentage of dimeric activated aptazyme
molecules on the concentration of target proteins. This graph was obtained for a total aptazyme
concentration of 50 nM and the dissociation constants obtained for our optimized aptazyme
constructs, KdAzLM R = 220 nM and KdAz-Prot = 25 nM.
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Ultimately, for this method to be useful, we would need to maximize the
activation factor, that is, the ratio of dimeric aptazyme in the presence versus the absence
of a PPI. Figure 2-16B simulates the values of this activation factor at different
combinations of KdAzP rot and KdAzLR. This simulation quantifies the previous discussion:
highest activation factors are obtained when KdAz-prot is lowest and KdA zL R is highest. It
must also be noted that, assuming an aptazyme concentration in cells of 50 nM (used for
the simulation in Figure 2-16B) the threshold activation factor of 10 is only achieved at
KdAzL/R - 1 IM. If the cellular concentrations of aptazymes are higher, so must the KdAzL/R
be. Finally, Figure 2-16C illustrates the fact that the activation factor varies greatly with
the concentration of target protein. This means that, for a defined set of Kd values,
relatively small changes in protein concentration can result in different aptazyme
activities, thus resulting in false positives.
The preceding discussion on interaction affinities does however not explain our
failure to detect an increase in aptazyme activity in the presence of the obligate p50
dimer. In this context, the effective concentration of p50 is such that it resembles a PPI
with infinitely low KdPP'. This failure thus illustrates yet another constrain of the system:
the geometric requirement. We hypothesize that we did not observe aptazyme activation
because the two aptazyme monomers were not brought into close proximity upon binding
to the p50 obligate dimer. This may have been caused by a short linker in the case of the
tandem dimer or by a p50-p50 interaction geometry created during cysteine crosslinking
that is different from the one revealed by the (p50)2-RNA crystal structure. This
requirement adds another layer of complexity to the already complex aptamer selection
process. Selection of new aptamers to be used in this methodology would require the
inclusion of the necessary steps to ensure that:
1. Aptamer binding does not disrupt the PPI (i.e., it uses a different interaction
surface). This could be done by performing the selection in the presence of the
protein partner.
2. Aptamer binding is not invasive; that is, it does not affect the biological
activity of the target protein. This was not the case in our proof-of-principle,
in which the RNA aptamer binds to the DNA-binding interface. This
requirement may be easily fulfilled in the case of transcription factors, where
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the selection could be performed for example in the presence of the target
DNA. It would however become more complicated for other proteins for
which many PPIs are not well characterized or even unknown.
3. Aptamer binding to both protein partners brings the aptazyme monomers into
close proximity. The ability to find this aptamer would require the a priori
knowledge of how the target proteins interact, and/or a sophisticated SELEX
strategy that incorporated a readout of aptazyme activity.
Furthermore, in vivo genetic selections may be needed post-SELEX to guarantee
that the aptamer retains binding activity when expressed in eukaryotic cells58.
Finally, one of the biggest question marks for this system is whether it has a real
potential to work inside living cells. We already emphasized in the introduction to this
chapter that the relatively simple and repetitive composition of RNA molecules makes
them easy to synthesize, allows for selection of improved characteristics, and makes it
possible to manipulate them in vitro. Problems arise, however, when expressing
exogenous RNAs in vivo, in ensuring correct intracellular localization, providing
protection against nucleolytic attack, ensuring access to target sites, and achieving similar
cleavage activity to that observed in vivo. Work in the Taira lab during the past 10 years
has addressed most of these problems for the maxizyme system. They created hybrid
ribozymes that combine the cleavage activity of the maxizyme with the cytosolic export
activity of a tRNAVal promoter and the unwinding activity of an endogenous RNA
helicase, and showed that these were capable of gene inactivation in a variety of cell-lines
(these efforts have been recently reviewed by Sano and Taira) 59. However, what has not
yet been addressed is the maxizyme need for high Mg2+ concentrations.
Although there have been reports by the Taira group and others of the minimal
hammerhead ribozyme and its maxizyme derivative functioning in vivo20,21, there is also
evidence that the minimal hammerhead ribozyme is not optimal for in vivo function. In
2003, a report provided insight into why natural HHRzs function effectively in the
cellular environments whereas artificial ones do not. Khvorova and co-workers showed
that the non-conserved nucleotides, which had been deleted from the natural Rzs to
obtain the minimal HHRz (and its derivative, the maxizyme), are in fact responsible for
adoption of the appropriate conformation for cleavage 60. The interaction between the
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loops of stem I and stem II (Figure 2-17B), through two Watson-Crick base pairs and
some additional non-Watson-Crick interactions, is required for the correct folding and the
strong activity of the ribozyme at physiological concentrations of Mg2+ (which are - 100
fold lower than the concentrations commonly used in in vitro assays) 61. Both loops are
absent in the trans-cleaving conventional HHRz (Figure 2-17A). It is now believed that
the tertiary interaction stabilizes the catalytic core in the active conformation, with the
metal ion binding site pre-organized, and thus allowing better metal binding62
A B
III III
Figure 2-17: Comparison of secondary structures of the minimal hammerhead ribozyme
(A) and the natural hammerhead ribozyme from tobacco ringspot satellite virus (B). Figure
adapted from Khvorova et a160.
This important finding suggests that the loops of stem I and II should therefore be
incorporated in the design of any ribozyme designed to work inside cells. It is however
hard to imagine how this could be done for the maxizyme, whose stem II has been even
further minimized to serve as the dimerization stem. A completely different ribozyme
platform may thus be needed if we were to design a PPI detection platform with maximal
in vivo activity.
Conclusions
In this chapter we have presented our efforts to develop a new methodology to
detect endogenous protein-protein interactions in live cells. The method is an adaptation
of the classical protein complementation assays, where each half of a reporter protein is
fused to the proteins of interest. In our proposed methodology, we use an RNA aptamer
as a scaffold to detect endogenous proteins, and a dimeric ribozyme as the enzyme to be
complemented upon protein-protein interaction. We call the fusion of the RNA aptamer
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to the dimeric ribozyme an aptazyme. We have described our engineering process to
develop aptazyme fusions where the two domains (aptamer and ribozyme) can fold and
function independently of each other, and we have shown that the engineered aptazymes
are catalytically active in vitro, in the absence of protein, at concentrations higher than
10 nM. The aptazyme fusions can also be modulated to recognize and cleave different
transcripts, such as the mRNA of the p-lactamase enzyme. Additionally, we have shown
that different cleavage sites within the P-lactamase mRNA are more accessible than
others, probably because they lie within loops or unstructured regions of the mRNA. We
also characterized the aptazyme fusions for their binding affinity to the p50 protein and
found their equilibrium dissociation constants (32.5 + 5.1 for AzL and 21.5 ± 2.4 for
AzR). Finally, we have described our efforts to modulate the aptazyme so that its
catalytic activity increases in the presence of a p50 dimer caused by PPI-induced
aptazyme dimerization. Unfortunately, no such activation was ever observed in vitro
under many different assay conditions. We hypothesized that the lack of activation was
caused by incorrect geometry of the p50 dimer, which did not bring the two ribozyme
monomers into close enough proximity to allow for dimerization. This hypothesis
illustrates the geometric requirement of the proposed system. Other system constrains
include the need for strict control of the interaction affinities between the three
components of the system (aptazyme-aptazyme, aptazyme-protein, and PPI), and the
need for selection of aptamers that do not disrupt the biologically-relevant PPIs of the
target protein. Additionally, the recent finding that optimal in vivo ribozyme activity
requires several nucleotide sequences that are missing in our aptazyme further limits the
applicability of this methodology. We propose that, if a similar approach is attempted in
the future, a ribozyme platform different that the maxizyme be used.
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Experimental
RNA in vitro transcription using T7 RNA polymerase
The substrate, aptamer, ribozyme, maxizyme, and aptazyme RNA transcripts
were generated by in vitro transcription using the Ampliscribe T7-Flash Transcription kit
(Epicentre Biotechnologies) following the manufacturer's protocol. DNA templates were
chemically synthesized by MWG, and were added to the transcription reaction without
further purification. Table 2-3 summarizes the DNA templates employed in the
transcription of all the constructs mentioned in the text.
Table 2-3: Oligos used in the in vitro transcription reactions. Nucleotides in italic are needed
for transcription. These anneal to the primer 5' GCGTAATACGACTCA CTATAG 3' to form the
double-stranded T7 promoter that the T7 RNA polymerase recognizes to start transcription.
Highlighted in grey are the nucleotides corresponding to either the substrate or the ribozyme
substrate-binding arms. Nucleotides in blue represent the sequence of the RNA aptamer against
the p50 protein. Of those, the nucleotides in bold highlight the point mutations that disrupt protein
binding; mutant 1 includes a U 11 :A20 to C11 :G20 mutation, mutant 2 includes a G12:C19 to
A12:U19 mutation, and mutant 3 includes both mutations. Nucleotides in red represent the
catalytic core of the ribozyme or maxizyme. Nucleotides in bold represent the dimerization stem
of the maxizyme. Nucleotides in green represent nucleotides added to promote independent
folding of the aptamer and ribozyme domains in the aptazyme fusions. For simplicity, the oligos
used for transcribing the non-binding point mutants of the aptazymes have not been included in
this table. To generate these oligos, please refer to the mutations highlighted in the oligos used to
transcribe the aptamer. The asterisk (*) denotes maxizyme constructs with two base pairs in the
dimerization stem instead of five.
Construct
S19
Bla-1
Bla-2
Bla-3
Bla-4
Bla-5
Bla-6
Bla-6L
Transcription Oligo (5' to 3')
GG CCTATAGTGAGTCGTATTACGC
GGAtO "CCTATAGTGAGTCGTATTACGC
G G CCTATAGTGAGTCGTATTACGC
GGGTCCTATAGTGAGTCGTATTACGC
GG iTni CCTATAGTGAGTCGTATTA CGC
GG6 CCTATAGTGAGTCGTATTACGC
GGAG CCCCTATAGTGAGTCGTATTACGC
GGATAG ACCTATAGTGAGTCGTATTAC GC
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WT GGCATACGCCAACCTTACAGTTTCAAGTATGCCTATAGTGAGTCGTATTACGC
Mut.1 GGCATACGCCAGCCTTACAGCTTCAAGTATGCCTATAGTGAGTCGTATTACGC
Mut.2 GGCATACGCCAATCTTACAATTTCAAGTATGCCTATAGTGAGTCGTATTACGC
Mut.3 GGCATACGCCAGTCTTACAACTTCAAGTATGCCTATAGTGAGTCGTATTACGC
Bla- GG CC TTCGGCGTTTCGGCCTCATCAGGCCTATAGTGAGTCGTATTACGC
Bla-2 GAA GGTTTCGGCGTTTCGGCCTCATCAGGCCTATAGTGAGTCGTATTACGC
Bla-3 GG TT TCGGCGTTTCGGCCTCATCAGACCTATAGTGAGTCGTATTACGC
S-19 GGCCAGGAAGTTTCGGCGCTCATCAGGCTCTCCCTATAGTGAGTCGTATTACGC
S-19* GGCCAGGAAGTTTCGCTCATCAGAGACT CCTATAGTGAGTCGTATTACGC
Blal GGCCAGGAGACTTCGGCGCTCATCAGG CCTATAGTGAGTCGTATTACGC
Left
Bla4 GGCCAGGAGACTTCGGCGCT CATCAG CCTATAGTGAGTCGTATTACGC
Bla5 GGCCAGGAGACTTCGGCGCTCATCAG CCTATAGTGAGTCGTATTACGC
Bla6 GGCCAGGAGACTTCGGCGCTCATCA CTCCTATAGTGAGTCGTATTACGC
S-19 GGAGA TTCGCGCCTCATCAGAGCCCCTATAGTGAGTCGTATTACGC
S-19* GGCAGAACAGTTCGCTCATCAGAGCCCCTATAGTGAGTCGTATTACGC
Blal GGTTT GTTTCGCGCCTCTGTAGACTTCCTATAGTGAGTCGTATTACGC
Right
Bla4 GG TTT TTCGCGCCTCTGTAGACTTCCTATAGTGAGTCGTATTACGC
Bla5 GGCGAT TTCGCGCCTCTGTAGACTTCCTATAGTGAGTCGTATTACGC
Bla6 GG AGTTTCGCGCCTCTGTAGACTTCCTATAGTGAGTCGTATTACGC
GGCATACGCCAACCTTACAGTTTCAAGTATGCCAGGAAGTTTC
0
GGCGCTCATCAGACTCATCCCTATAGTGAGTCGTATTACGC
GGACTTCCTGGCATACGCCAACCTTACAGTTTCAAGTATGCCAGGAAGTTTC
1
GGCGCTCATCAGAGAT CCTATAGTGAGTCGTATTACGC
GGACTTCCTGGTTGGCATACGCCAACCTTACAGTTTCAAGTATGCCTTCCAGGAAGTTTC
•. 2
GGCGCTCATCAGAGACT CCTATAGTGAGTCGTATTACGC
SGGGTCTCCTGGTTGGCATACGCCAATCTTACAATTTCAAGTATGCCTTCCAGGAGACTTC
Left 2.1
GGCCCTCATCAGGG C CCTATAGTGAGTCGTATTACGC
GGGTCTCCTGGTTGGCATACGCCAATCTTACAATTTCAAGTATGCCTTCCAGGAGACTTC
GCT CAT CA GAGCAACTA CCTATAGTGAGTCGTATTACGC
GGGGCATACGCCAACCTTACAGTTTCAAGTATGCCTTCCAGGAAGTTTC3
GGCGCTCATCAGAT CCTATAGTGAGTCGTATTACGC
GGGGAACATACGCýAACCTTACAGTTTCAAGTATGTTCCTTCCAGGAAGTTTC
4
GGCGCTCATCAGAGACTCAT CCTATAGTGAGTCGTATTACGC
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0
1
2
2.1
2.1"
GGCAGAA TTTCGCGCCTCATCAGAGCCCATACGCCAACCTTACAGTTTCAAGTATGCCTAT
AGTGAGTCGTATTACGC
G TTCG•GCCTCATCAGAGCCGGCATACGCCAACCTTACAGTTTCAAGTATGCCC
CTATAGTGAGTCGTATTACGC
G TTCGCGCCTCATCAGAGCCGGAACATACGCCAACCTTACAGTTTCAAGTATGT
TCCCCTATAGTGAGTCGTATTACGC
GCTTCGCGCCTCTGTAGACTTGGAACATACGCCAATCTTACAATTTCAAGTAT
GTTCCCCTATAGTGAGTCGTATTACGC
GGCTTCGCTCTGTAGACTTGGAACATACGCCAATCTTACAATTTCAAGTATGTT
CCCCTATAGTGAGTCGTATTACGC
Before initiating the transcription reaction, 5 ptg of DNA template were combined
with an equimolar amount of the T7 promoter complementary oligo (Table 2-3, legend)
and the mixture was heated to 95 OC and allowed to slowly cool to room temperature to
promote annealing of the two oligos. Thereafter, the remaining components of the
transcription reactions were added: 7.2 pl of each rNTP (final concentration 9 mM), 10 pl
of the 10x reaction buffer provided by the manufacturer, 10 pl T7 RNA polymerase
enzyme, and RNAse-free water to adjust the total volume to 100 pl. The transcription
reaction was allowed to proceed at 42 'C for 30 minutes-2 hours, until a white
precipitated appeared (insoluble complex between Mg2+ ions and inorganic phosphate).
Purification was done by PAGE (10-20% acrylamide) followed by crush and soak RNA
extraction from the acrylamide, and ethanol precipitation. RNA concentration was
estimated by measuring A260 using an extinction coefficient of 40 mL.pg-lcm1 .
Removal of 5' tri-phosphate using calf intestinal phosphatase (CIP)
50 pmoles of RNA were combined with 10 units of CIP enzyme (New England
Biolabs) and phosphatase buffer (New England Biolabs) in a total volume of 10 pL. After
incubation at 37 'C for 1 hour, the reaction was purified by phenol-chloroform extraction
followed by ethanol precipitation. To perform the extractions, the reaction volume was
increased to 50 ptL and NaCl was added to Cf = 0.3 M. Three extractions with 50 p.L of
phenol: chloroform 3:1 were followed by one extraction with an equal volume of
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chloroform (for each extraction, the mixture was vortexed for 2 minutes followed by
centrifugation for 2 minutes). The RNA was then precipitated by addition of 1 jPg of
glycogen and three volumes of ethanol, incubation at - 80 oC for 30 minutes, and
centrifugation at 13,200 rpm for 30 minutes at 4 OC. Thereafter, the resulting pellet was
washed once with cold 70% ethanol, allowed to air-dry, and resuspended in 8 tL of
RNAse-free water.
RNA radioactive end-labeling
De-phosphorylated RNA transcripts were 5' labeled with 32P using T4
polynucleotide kinase (New England Biolabs). 50 pmoles of RNA were combined with
DTT (Cf = 10 mM), 20 units of kinase enzyme, 0.25 [l of [32p-y] ATP (GE Healthcare,
10 gICi/tl), and kinase buffer (New England Biolabs) in a total volume of 50 jtL, and
incubated at 37 'C for 1 hour. Unincorporated [32P-y] ATP was removed by gel filtration
using Sephadex G25 resin (QuickSpin columns, Roche).
In vitro ribozyme activity assay
All ribozyme activity assays were performed under single turnover conditions.
The reaction conditions were as follows: 1 nM end-labeled substrate (5000cpm),
10 nM-1 jiM RNA enzyme (HHRz, Mz or Az), 100 mM NaCl, 1 mM DTT, and 10 mM
MgCl 2, in 10 mM HEPES buffer pH 7.5 or 50 mM Tris pH 8. In some cases, 0.25 iL
RNAsin (RNase inhibitor, Promega) was included in the mixture. The reactions were first
heated to 95 OC for 2 minutes in the absence of MgCl 2, and allowed to cool to 37 'C to
facilitate annealing of the RNA enzyme to its substrate. Thereafter, the reactions were
initiated by addition of 10 mM MgC12. In the cases where the activity of the ribozyme
was assayed in the presence of p50 protein, the mixtures were allowed to cool down to
room temperature before adding the protein, and then incubated at room temperature for
10 minutes to allow binding of the aptamer before initiating the reactions with 10 mM
MgCl 2. After incubation for 5 minutes - 1 hour at 37 "C the reactions were quenched by
addition of an equal volume of gel loading buffer (8 M urea, 25 mM EDTA, 0.25%
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bromophenol blue, 0.25% xylene cyanol, 40% sucrose). The reaction mixtures were
separated on a denaturing 20% acrylamide gel (8 M urea) and the gels were exposed to
phosphor-screens (GE Healthcare) overnight at -20 oC. Autoradiograms were visualized
with a Storm 860 instrument (GE Healthcare).
Bacterial expression and purification of the human p50 protein
The plasmid for expression of p50 was a gift from Prof. Ghosh (UC San Diego)
and it encodes an untagged truncated murine p50 (amino acids residues 39 to 363).
Recombinant expression and purification were essentially done as previously reported by
Lebruska et a139. Briefly, the plasmid was transformed into E. coli BL21 (DE3) cells,
which were amplified in LB media supplemented with 100 pg/mL ampicillin at 37 "C
until OD60 0.2. Protein expression was induced with 0.2 mM isopropyl-p-D-
thiogalactopyranoside (IPTG) for approximately 3 hours, until cells reached OD600 0.9.
Thereafter, cells were harvested by centrifugation (6,000 rpm, 10 minutes, 4 oC) and the
pellet was resuspended in lysis buffer (50 mM NaC1, 2.5 mM PMSF, and protease
inhibitor cocktail in 50 mM Tris, pH 7.5). Cells were lysed by ultrasonic treatment (six
15-second bursts, with 1 minute of cooling to 4 oC between bursts). The extract was
cleared by centrifugation (17,700 g, 10 minutes, 4 "C) and loaded onto a cation exchange
column (22 mL of Q-Sephadex resin, GE Healthcare). Elution from the Q-Sephadex
column was performed with two column volumes of a low salt buffer (50 mM NaC1,
50 mM Tris, pH 7.5) and the eluate was immediately loaded onto an anion exchange
column (60 mL of SP Sepharose Fast Flow resin, GE Healthcare). The protein was then
eluted at lmL/minute using a 50-400 mM NaCI gradient over ten column volumes.
Fractions were analyzed by 12% SDS-PAGE followed by Coomassie staining. Fractions
containing mutant p50 (approx. fractions eluting at 160-190 mM NaCl) were pooled and
dialyzed against aptamer binding buffer (100 mM NaCl and 1 mM DTT in 10 mM
HEPES, pH 7.5). Protein concentrations were measured using the BCA assay (Pierce)
with BSA as the reference standard.
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Bacterial expression and purification of a non-dimerizing mutant of the human p50
protein
The plasmid for expression of the non-dimerizing mutant of p50 was a gift from
Prof. Ghosh (UC San Diego) and encoded an N-terminally Hiss6-tagged truncated p50
(amino acid residues 39-363) with Y267D and L269D point mutations63 . The plasmid
was transformed into E. coli BL21 (DE3) cells, which were amplified in LB media
supplemented with 100 ptg/mL ampicillin at 37 'C until OD600 0.9. Protein expression
was induced with 200 plg/mL isopropyl-j3-D-thiogalactopyranoside (IPTG) at room
temperature overnight. Thereafter, cells were harvested by centrifugation (6,000 rpm,
15 minutes, 4 oC) and the pellet was resuspended in lysis buffer (50 mM Tris base,
300 mM NaCl, pH 7.8) containing 2.5 mM phenylmethylsulfonyl fluoride (PMSF) and
protease inhibitor cocktail (Calbiochem). Cells were lysed by ultrasonic treatment (six
30-second bursts, with 1 minute of cooling to 4 oC between bursts). The extract was
cleared by centrifugation (21,000 rpm, 15 minutes, 4 'C) and the Hiss6-tagged protein was
purified using Ni-NTA agarose (Qiagen). Fractions were analyzed by 12% SDS-PAGE
followed by Coomassie staining. Fractions containing mutant p50 were pooled and
dialyzed against aptamer binding buffer (100 mM NaCl and 1 mM DTT in 10 mM
HEPES pH 7.5). Protein concentrations were measured using the BCA assay (Pierce)
with BSA as the reference standard.
In vitro aptamer binding assay
To determine the fractional saturation of RNA binding to p50, the reaction
conditions were as follows: 0.9 nM end-labeled RNA aptamer or aptazyme fusion
(5000 cpm) and 50 nM p50 protein in binding buffer (100 mM NaCl, and 1 mM DTT in
10 mM HEPES pH 7.5) supplemented with 50 ptg/mL BSA. After incubation at room
temperature for 30 minutes, the reactions were filtered over nitrocellulose membranes,
which had been previously treated with binding buffer. The filters were then washed
twice with ice-cold binding buffer, and air-dried. All the filtering and washing steps were
performed using a vacuum manifold (Millipore). The radioactivity spotted on the filters
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was measured by liquid scintillation counting. Negative control reactions performed in
the absence of p50 were used for background correction.
Determination of equilibrium dissociation constants for p50 binding to the
aptazyme fusions
The determination of the equilibrium dissociation constants was performed as
previously reported by Lebruska et a139. Briefly, individual assays were performed as
described above for the in vitro aptamer binding assay except that varying amounts of
protein were used. The binding isotherms were then plotted and fitted to the equation:
0 [ [T]t + Kd + [p] - ([T]t + Kd + [P]t)2 - 4[P]t[T]t
where 0 is the fractional saturation of the radiolabeled probe, T represents the RNA
probe, P the p50 protein, and the subscript (t) refers to total concentration, and it need not
be assumed that [P]t - [P]free. Curve fitting was performed using Sigma Plot software
(Systat Software Inc.).
Bacterial expression and purification of myotrophin
The plasmid for expression of myotrophin was a gift from Prof. Sivasubramanian
(Baylor College of Medicine, Houston, TX) and encoded the gene for human myotrophin
within a pET3a-51 vector. Recombinant expression and purification were essentially
done as previously reported by Sivasubramanian et a154. Briefly, the plasmid was
transformed into E. coli BL21(DE3) cells, which were amplified in LB media
supplemented with 100 pg/mL ampicillin at 37 oC until OD600 0.2. Protein expression
was induced with 0.1 mM IPTG at room temperature overnight. Thereafter, cells were
harvested by centrifugation (6,000 rpm, 15 minutes, 4 oC) and the pellet was resuspended
in lysis buffer (50 mM Tris base, 75 mM NaCl, pH 8) containing 2.5 mM PMSF and
protease inhibitor cocktail (Calbiochem). Cells were lysed by freeze-thawing three times
and the extract was cleared by centrifugation (21,000 rpm, 15 minutes, 4 'C). Myotrophin
was highly overexpressed in the supernatant and was purified by subsequent separation
steps using first a Centriprep-30 cartridge (30 kD cutoff, Amicon) and then a Centriprep-
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10 (10 kD cutoff, Amicon). Both Centriprep columns were pretreated with 0.1%
diethylpyrocarbonate (DEPC) for 2 hours at 37 TC to remove RNAse. Eluate and
concentrate fractions of both separation steps were analyzed by 19% SDS-PAGE
followed by Coomassie staining. Protein concentration of the concentrate fraction of the
Centriprep-10 column was measured using the BCA assay (Pierce) with BSA as the
reference standard.
Chemical crosslinking of p50 to generate p50 dimers
Glutaraldehyde crosslinking. Purified p50 (0.6 pM)was combined with 0.5% w/v
glutaraldehyde for 15 minutes at 4 OC, followed by 20 minutes of additional incubation in
the presence of 10 mg/ml of sodium borohydride. The reaction mixtures were analyzed
by 10% SDS-PAGE followed by Coomassie or silver staining.
Cysteine crosslinking. Purified p50 was first extensively dialyzed against PBS pH
7.4 to remove the dithiothreitol (DTT) present in the storage buffer. The crosslinking
reaction was then performed by incubation for 30 minutes at 30 oC with a 5-fold molar
excess of either bis(maleimido) hexane (BMH, Pierce) or 1,4-Di-[3'-(2 '-pyridyldithio)-
propionamido]butane (DPDPB, Pierce). Starting concentrations of p50 ranged from
3.5-14 jM. The reaction was quenched by addition of 5 mM DTT.
Construction of the p50-tandem gene for expression of a p50 tandem dimer
The p50 sequence was introduced twice in tandem into the pRSETb vector
(Invitrogen). The first p50 sequence was inserted between BamHI and EcoRI using the
primers 5'CAT GAT AAG GAT CCG GGC CCA TAC CTT CAA ATA TT and 5' CAT
CAT GAA TTC GCC CGA GCC TTC GCC CGA GCC CGG TTT GCC CGA GCC
CGA GGT CGA GCC CGA GCC CTT CTG GCG TTT CCT TTG CAC. The second
p50 sequence was inserted between EcoRI and Hindlllusing the primers 5'GAT AAG
GAA TTC TCG ACC TCG GGC TCG GGC AAA CCG GGC TCG GGC GAA GGC
TCG GGC TCG GGC GGC CCA TAC CTT CAA ATA TT and 5' GAA TTC TCA AGC
TTC TTT GTC GTC GTC GTC TTT GTA GTC CTT CTG GCG TTT CCT TTG
CAC. The former primers also introduce a C-terminal FLAG epitope (in bold) and a 35-
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amino acid (GSGSTSGSGKPGSGEGSGSTSGSGKPGSGEGSGSG) protease-resistant
linker in between the two p50 proteins to allow for proper folding and dimerization
(underlined). To insert the p50 tandem gene into pET15b, the p50-linker-p50-FLAG
sequence was PCR-amplified from pRSETb using the primers 5' CAT CCC CATATG
GGC CCA TAC CTT CAA ATA TTA G and 5' CAT CCC GGA TCC TCG AGT TTG
TCG TCG TCG TCT TTG TAG and ligated into the NdeI and BamHI sites of pET15b
(Novagen) to give (p50)2-pET15b.
Bacterial expression and purification of the p50-tandem dimer
E. coli BL21(DE3) cells transformed with (p50)2-pRSETb or (p50)2-pET15b
expression plasmids were amplified in LB media supplemented with 100 ptg/mL
ampicillin at 37 'C until OD600 0.6. Protein expression was induced with 100 tg/mL
IPTG for 3 hours at 30 oC. Cells were harvested by centrifugation and the pellet was
resuspended in lysis buffer (50 mM Tris base, 300 mM NaC1, pH 7.8) containing 2.5 mM
PMSF and protease inhibitor cocktail (Calbiochem). Cells were lysed by ultrasonic
treatment (six 30-second bursts, with 1 minute of cooling to 4 oC between bursts). The
extract was cleared by centrifugation (17,700 g, 10 minutes, 4 'C) and the N-terminally
Hiss6-tagged protein was purified using Ni-NTA agarose (Qiagen). Fractions were
analyzed by 12-16% SDS-PAGE followed by Coomassie staining and the fractions
containing protein were pooled and dialyzed against TBS (50 mM Tris, 150 mM NaC1,
pH 7.4). Thereafter, the protein mixture (p50 dimer plus monomer) was further purified
using FLAG-M2-agarose (Sigma). After elution with five column volumes of 1 mM
FLAG peptide, the purified dimer was dialyzed against aptamer binding buffer (100 mM
NaCl and 1 mM DTT in 10 mM HEPES pH 7.5). Protein concentrations were measured
using the BCA assay (Pierce) with BSA as the reference standard.
Live cell maxizyme activity assay
The plasmids for expression of the LTR-luciferase chimeric gene (pHyg-LTR-
Luc)64, the Tat protein (pCD-SRacTat) 51 , and the maxizyme constructs (p5L, p5R, and
pD5L/R)51 were a gift of Prof. Taira (Univ. of Tsukuba). HeLa cells were transfected
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with either one or a combination of the above plasmids, and lysates were generated
48 hours after transfection. Luciferase activity in the lysates was measured using the
Luciferase Assay System (Promega) according to the manufacturer's instructions.
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Chapter 3: Proximity biotinylation for the detection of endogenous
protein-protein interactions in fixed samples
The work discussed in this chapter is unpublished. Optimization of the reaction
conditions for the preparation of antibody-biotin ligase conjugates was performed in
collaboration with Laura Martinez-Hemrindez. Part of the work described in this chapter
has also been presented in her Master Thesis.
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Introduction
In the previous chapter, we described our efforts to develop a new protein-protein
interaction (PPI) reporter that could detect endogenous proteins in the live-cell context.
The proposed methodology did however not hold up to its promise because of the strict
geometric and interaction-affinity constraints. In this chapter, we decided to continue our
quest for a method that detects endogenous protein-protein interactions (PPIs), but within
a less challenging context, that of a fixed sample. Although the method described herein
has the limitation of lacking temporal resolution, it should nonetheless display superior
spatial resolution to the method described in Chapter 1, where the diffusion of the
fluorescent i-lactamase substrate resulted in lack of subcellular compartmentalization.
Our proposed approach is a modification of the classic immunofluorescence (IF)
technique. In IF, fluorophore-conjugated antibodies against the target proteins are used to
stain a fixed sample, and the overlap between the two colors reports on protein co-
localization'. At the time when this project was being pursued, IF was the only technique
capable of providing spatial information on endogenous PPIs. However, the spatial
resolution of IF is limited to ~ 250 nm in conventional microscopy 2. Therefore, IF can
only report on protein co-localization but cannot demonstrate whether an interaction is
truly occurring. At the other end of the spatial resolution spectrum, the combination of
fluorescence resonance energy transfer (FRET) and IF results in the detection of proteins
that are separated by distances of 1-10 nm (Ref. 3). Our proposed methodology was thus
an attempt to bridge the 250 nm spatial resolution of classic IF with the 10 nm resolution
of IF-FRET. Figure 3-1 depicts our detection scheme, where the two fluorophores used in
IF have been replaced by an enzyme-substrate pair. Here, each antibody is conjugated to
either the bacterial enzyme biotin ligase (BirA) or its 15-amino acid peptide substrate
(Figure 3-1A). E. coli biotin ligase is a 35 kD enzyme that catalyzes the ATP-dependent
covalent ligation of biotin to a lysine sidechain of a 15-amino acid recognition sequence
called the "acceptor peptide" (AP)4 (Figure 3-1B). Upon addition of biotin to cells, BirA
ligates biotin to the AP only if A and B are in close proximity. Subsequently, biotinylated
AP can be detected with extremely high sensitivity and specificity on fixed cells by
streptavidin staining5.
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We chose BirA-AP as our enzyme-substrate pair because our laboratory has
extensive knowledge of the system, and because Irwin Chen and Mark howarth, in our
lab, had previously established the use of BirA-AP for site-specific protein labeling in the
cellular context6'7. We and others have also shown that BirA can biotinylate the AP when
it is placed in different contexts such as the N- and C-terminus of a protein or in an
internal loop. Additionally, the sequence specificity of BirA is extremely high, as it has
been demonstrated that it does not biotinylate any endogenous mammalian proteins
7
'
8
.
Both properties were important considerations in our system, as they suggest that the
recognition of AP by BirA is not context dependent, and that BirA addition to fixed
samples would result in biotinylation of AP but no other protein, thereby eliminating a
source of false positives.
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Figure 3-1: Proposed scheme for the detection of endogenous protein-protein interactions in
fixed cells. (A) Proximity biotinylation for the immunodetection of endogenous protein-protein
interactions. Each target protein, A and B, is recognized by a specific primary antibody (red or
blue), which is in turn bound by a secondary antibody (grey or black) conjugated to either the E.
coli enzyme biotin ligase (green) or its 15-amino acid peptide substrate sequence (orange). If A
and B are interacting before cell fixation, then biotin ligase will be in close proximity to the
acceptor peptide, and biotin addition will result in biotinylation of the peptide substrate. In
contrast, if the target proteins are not interacting partners, biotin ligase will no be able to bind and
biotinylate the acceptor peptide. (B) E. coli biotin ligase catalyzes the ATP-dependent ligation of
biotin to the e-amino group of a lysine sidechain within a 15-amino acid peptide sequence, called
the acceptor peptide (AP).
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Results
We have divided the work performed towards the development of this
methodology into three main sections: first, development of robust protocols to
chemically conjugate biotin ligase and the acceptor peptide to immunoglobulins; second,
testing of the binding capability and enzymatic activity of the antibody conjugates; and
third, testing the antibody conjugates for immunodetection of endogenous protein-protein
interactions in live cells and in fixed biological samples.
Strategies for antibody derivatization
The unique structural characteristics of antibody molecules offer a number of
choices for modification and conjugation schemes. A detailed illustration of the structure
of an antibody is shown in Figure 3-2. The most basic immunoglobulin (Ig) molecule is
composed of two identical light chains (- 25 kD each chain) and two identical heavy
chains (- 50-75 kD each chain), which are held together by non-covalent interactions as
well as a number of disulfide bonds9. The light chains are disulfide-bonded to the heavy
chains in the CL and CH1 regions, whereas the heavy chains are disulfide-bonded to each
other in the hinge region. There are two antigen binding sites on each IgG, which are
formed by the proximity of the heavy and light chains at the N-terminus of the molecule,
called the hypervariable region9. The antigen binding site is determined not by the linear
sequence of amino acids on each chain, but mostly by the unique orientation of these
groups in the three-dimensional space.
Figure 3-2 highlights the antibody functional groups that are suitable for
conjugation. First, as with any protein, N-terminal and lysine primary amines can be
targeted for crosslinking by amine-reactive groups such as activated esters, ketones, and
aldehydes. One of the most commonly used amine-reactive reagents is
N-hydroxysuccinimide (NHS). Conversely, carboxylate groups present at the C-terminus
of the antibody chains and the sidechains of glutamic and aspartic acid residues can be
activated for example with 1-ethyl-3-[3-dimethylaminopropyl]carbodiimide
hydrochloride (EDC) and then coupled to amine, hydrazide, or hydroxylamine functional
groups. Third, the carbohydrate molecules present in most (but not all) antibodies can be
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oxidized to generate aldehydes, which can then react with exogenous amines. Finally, the
disulfides that hold the heavy chains together at the hinge region can be selectively
cleaved with a reducing agent to create two half-antibody molecules, each containing an
antigen binding site. This preparation exposes free thiols that can be targeted for
conjugation using sulfhydryl-reactive probes such as maleimides or haloacetamides. Out
of the four conjugation schemes, the last two are usually preferred because they employ
functional groups (carbohydrates and sulfhydryls) present only at specific positions of the
immunoglobulin surface and away from the antigen binding site, and are therefore more
likely to preserve antibody binding capability'0 . Thus, with the appropriate selection of
the conjugation chemical reaction and knowledge of antibody structure, the
immunoglobulin molecule can be modified so that its antigen binding potential remains
available after conjugation to biotin ligase or the acceptor peptide.
bindina
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Figure 3-2: Detailed structure of an immunoglobulin G antibody molecule. Each antibody
molecule is composed of two light chains (L subscripts) and two heavy chains (H subscripts).
Each chain has a variable region (VL and VH) and one or more constant regions (CL and CHI, CH2,
etc.). Each antigen binding site is formed by one heavy chain and one light chain (the Fab -
fragment antigen binding - arms). Fc (fraction crystallisable) represents the most conserved part
of the antibody and it is not involved in antigen binding. Functional groups targeted by the
different bioconjugation strategies (e.g., lysine or cysteine residues) are highlighted. Image taken
from the Pierce website.
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Chemical conjugation of the acceptor peptide to IgGs
We conjugated the acceptor peptide to anti-rabbit and anti-mouse
immunoglobulins by employing their carbohydrates (Figure 3-3A). Antibody sugars were
first oxidized using sodium periodate and the resulting aldehydes were immediately
reacted with an excess of acceptor peptide containing a C-terminal hydrazide
functionality. The formed hydrazone was then reduced to a hydrazide using sodium
cyanoborohydride.
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Figure 3-3: Conjugation of the acceptor peptide to immunoglobulins. (A) Conjugation
scheme. Antibody sugars were oxidized with sodium periodate and the resulting aldehydes were
reacted with a hydrazide-derivatized acceptor peptide. The formed hydrazone was reduced to a
hydrazide using sodium cyanoborohydride. (B) Cell-surface detection of anti-rabbit-AP
conjugates in live HeLa cells. An HA-CFP fusion was targeted to the cell surface using a
transmembrane (TM) domain. Cell-surface HA was detected using rabbit anti-HA, followed by
the anti-rabbit-acceptor peptide conjugate. The AP was then biotinylated by addition of soluble
BirA, biotin, and ATP, and the introduced biotin was then detected with streptavidin conjugated
to Alexa Fluor 568. Live cell images of the introduced Alexa Fluor 568 are shown to the right of
the CFP and DIC images, which highlight the transfected cells. (C) Cell-surface detection of anti-
mouse-AP conjugates in live HeLa cells. Endogenous epidermal growth factor receptor (EGFR)
was detected using mouse anti-EGFR, followed by the anti-mouse-acceptor peptide conjugate.
The AP was then biotinylated and detected as in B. Live cell images of the introduced Alexa
Fluor 568 are shown to the right of the DIC image.
Optimization of the oxidation reaction was performed using fluorescein-hydrazide
as a model small-molecule, as it can be more easily detected than the acceptor peptide.
Although antibody oxidation is typically performed at acidic pH'0 to favor the subsequent
reaction with the hydrazide, we found that pH 7.2 resulted in a significant degree of sugar
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oxidation while leaving the antibody intact, whereas pH 5.5 resulted in - 50% loss of
antigen binding capability (data not shown). Using fluorescein-hydrazide, we also
determined that the oxidation reaction was done after 30 minutes in the presence of 1 mM
sodium periodate (i.e., longer incubation times did not result in an increase of the
fluorescein signal). Excess sodium periodate was then removed by gel filtration using
SephadexTM G25 resin.
In the second step of the conjugation, a hydrazide-derivatized synthetic acceptor
peptide was added in excess (typically 1000-fold) of antibody and reacted for - 16 hours
at pH 5. We tested the conjugation extent by in vitro biotinylation of AP followed by
Western blot detection using streptavidin-HRP (data not shown). Although we had
expected excess AP to be removed from cells during the washes, we later found that the
AP-hydrazide was very sticky in fixed cells (data not shown), probably owing to its
reactivity with the paraformaldehyde fixative. Thus, we thereon purified every batch of
antibody-acceptor peptide conjugate by gel filtration.
Every new batch of conjugates was also tested on a live-cell assay to confirm
retention of antigen binding capability. We stained either a cell-surface HA epitope
(Figure 3-3B) or the epidermal growth factor receptor (Figure 3-3C) with rabbit or mouse
primary antibodies, respectively, followed by the anti-rabbit- or anti-mouse-acceptor
peptide conjugates. After washing excess antibody conjugates, the bound molecules were
biotinylated using soluble biotin ligase, and ligated biotin was detected using streptavidin
conjugated to Alexa Fluor 568. Figure 3-3B and C shows that the antibody conjugates
retained their binding capability as demonstrated by the streptavidin-Alexa Fluor 568
signal. Specificity controls were performed with the primary antibody omitted, and
showed no labeling (data not shown). The lower signal observed for the anti-mouse
conjugates (Figure 3-3C) most probably reflects the lower expression of endogenous
EGFR compared to that of the over-expressed HA cell-surface epitope.
Chemical conjugation of biotin ligase to IgGs
Conjugation of biotin ligase to immunoglobulins turned out to be more difficult
than that of the acceptor peptide. We hypothesized that the main obstacle was a low
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conjugation yield caused by low BirA concentrations in the reaction. For example,
whereas we routinely added a 1000-fold excess of acceptor peptide over antibody (see
above), we could never achieve an excess larger than 20-fold for BirA. Additionally,
BirA derivatization also proved challenging as enzymatic activity was lost in many cases.
Table 3-1 summarizes the various strategies that we tested in order to maximize the
conjugation yield, while preserving BirA enzymatic activity and antibody binding
capability.
Table 3-1: Summary of strategies for conjugation of biotin ligase to immunoglobulins.
MPBH: 4-(4-N-maleimidophenyl) butyric acid hydrazide. SMCC: succinimidyl 4-[N-
maleimidomethyl]cyclohexane-l-carboxylate..
Reactive Group 1
Name
Amine
Hydrazide
Hydrazide
N-hydroxy
succinimide
Reacts
towards
Activated
esters or
carbonyls
Activated
esters or
carbonyls
Activated
esters or
carbonyls
Amines
Reactive Group 2
Name
NA
Hydrazide
Maleimide
Maleimide
Reacts
towards
NA
Activated
esters or
carbonyls
Thiols
Thiols
Chemical structure
NA
O
H2N N, NH 2
O
We first tried direct conjugation of BirA to the antibody via reductive amination,
but this method mostly resulted in antibody self-crosslinking. We then tested the
crosslinking reagent adipic dihydrazide, but its homobifunctional nature translated into a
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Reductive
Amination
Adipic
dihydrazide
MPBH
SMCC
I
i
high degree of BirA oligomerization. Finally, we tested two different heterobifunctional
crosslinkers, among which only SMCC (succinimidyl 4-[N-
maleimidomethyl]cyclohexane- 1 -carboxylate) yielded antibody-biotin ligase conjugates
of controllable stoichiometry and in sufficient quantity. The following sections describe
in detail the results obtained for each strategy.
Reductive amination results in antibody self-crosslinking
The simplest conjugation scheme involved reaction at high pH of the primary
amines in biotin ligase (e.g., N-terminal amine and lysine e-amines) with the aldehydes
generated by oxidation of the antibody sugars (Figure 3-4A). The reaction product, an
imine, was stabilized by reduction to a secondary amine with sodium cyanoborohydride.
Figure 3-4B shows the results obtained for a typical conjugation reaction performed by
reductive amination. We initially thought that the reaction was yielding a fair amount of
antibody-biotin ligase conjugates (green arrows), as it could be inferred by comparing
lanes 1 (BirA only) and 4 (antibody only) with lane 3 (conjugation reaction) in the Silver
staining image. However, we later found that the new protein bands observed were the
result of antibody self-crosslinking, and that their appearance did not require the presence
of biotin ligase (compare lanes 2 and 3 in the Silver staining image and a-goat IgG blot).
Although we had anticipated that the antibody molecules could self-conjugate
through the reaction of the sugar aldehydes with antibody's own amines during the high-
pH reductive amination, we had expected that an excess of biotin ligase could reduce
self-crosslinking to a minimum. Unfortunately, we found that the maximum achievable
concentration of biotin ligase in the conjugation reaction (- 20 ptM) was not enough to
prevent antibody self-crosslinking. We thus hypothesized that conjugation with
periodate-oxidized antibodies would work best if the receiving biotin ligase molecules
were previously modified to contain a hydrazide, and conjugation was done at moderate
pH. It is worth noting that we also observed a certain degree of biotin ligase self-
crosslinking (highlighted by red boxes in the a-His6 and a-goat blots of Figure 3-4B),
which could not be readily explained.
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Figure 3-4: Conjugation of biotin ligase to immunoglobulins by reductive amination. (A)
Conjugation scheme. Antibody sugars were oxidized with sodium periodate and the resulting
aldehydes reacted with the primary amines present in biotin ligase. Conjugation reaction was
performed at high pH to favor nucleophilic attack by the amines. The formed imine was reduced
to an amine using sodium cyanoborohydride. (B) Analysis of the conjugation products by
Western blotting. Oxidized antibody (- 1 gM) was reacted with 10 pM BirA in sodium carbonate
buffer, pH 9.6, followed by reduction with sodium cyanoborohydride. The reaction products were
run on a 10% SDS-PAGE, and the extent of antibody-biotin ligase conjugation was analyzed by
Silver staining and by a-His6 blotting (to detect only biotin ligase) and a-Goat IgG blotting (to
detect only the antibody). The conjugation reaction (lane 3) is compared side-by-side with a
negative control where no biotin ligase was added during the reductive amination (lane 2), and
with the biotin ligase and antibody reagents before conjugation (lanes 1 and 4, respectively). Red
boxes highlight conjugation products containing biotin ligase but no antibody. Green arrows point
to the products of antibody self-crosslinking.
Use of adipic-dihydrazide results in variable conjugate stoichiometry
We chose adipic dihydrazide (Table 3-1) as the crosslinking reagent to introduce a
hydrazide functionality in biotin ligase. Figure 3-5A depicts the conjugation scheme. The
carboxylate groups in biotin ligase were activated using 1-ethyl-3-(3-
dimethylaminopropyl) carbodiimide hydrochloride (EDC) and reacted with adipic
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dihydrazide (ADH). The hydrazide-containing BirA was then combined with oxidized
antibody and the reaction was allowed to proceed at neutral pH to form the hydrazone,
which was then reduced to a hydrazide using sodium cyanoborohydride. During the
conjugation reaction, BirA-hydrazide was always present in excess of antibody to ensure
that each antibody was conjugated to none, one, or more BirA molecules, but that no two
antibody molecules were linked together. This is an important consideration because
antibody crosslinking will ultimately result in large polymers, which could expand long
distances, thereby not reporting on truly interacting proteins.
Initial attempts to perform conjugation following this scheme failed due to both,
incomplete removal of excess ADH, and low protein concentrations. The first problem
was easily solved by substituting the dialysis after the EDC/adipic dihydrazide reaction
with either Ni-NTA purification or gel filtration using a SephadexTM G25 resin. The latter
was usually preferred owing to its simplicity and because its shorter protocol contributed
to prevent biotin ligase self-conjugation. We then studied the effect of protein
concentration on the yield of the conjugation reaction. We found, for example, that
whereas biotin-cadaverine (5 mM) could be efficiently conjugated to a 130 JiM solution
of oxidized invertase (a highly glycosylated 60 kD protein), no conjugation could be
detected under the same conditions to 13 jiM of antibody solution (maximum
concentration achievable) (data not shown). Furthermore, using biotin-hydroxylamine, a
probe that had been previously proven highly reactive towards oxidized antibodies"1 , we
found that we could only observe antibody biotinylation when the biotin-hydroxylamine
was added at concentrations higher than 100 RM (data not shown). This finding explains
the success of the conjugation of acceptor peptide to antibody and the failure of the
conjugation to biotin ligase, for which we could never achieve concentrations higher than
20-30 RiM.
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Figure 3-5: Conjugation of biotin ligase to immunoglobulins using adipic dihydrazide. (A)
Conjugation scheme. First, antibody sugars were oxidized with sodium periodate to generate free
aldehydes. In parallel, carboxylate groups in biotin ligase were activated with 1-ethyl-3-(3-
dimethylaminopropyl) carbodiimide hydrochloride (EDC) and reacted with adipic dihydrazide(ADH) to generate BirA-hydrazide. BirA-hydrazide was then combined with the oxidized
antibody to generate antibody-BirA conjugates covalently bound via a hydrazone linkage.
Finally, the formed hydrazone was reduced to a hydrazide using sodium cyanoborohydride. (B)
Analsysis of the extent of hydrazide modification of biotin ligase by MALDI-TOF. 40 pM biotin
ligase was EDC-activated and then combined with 40 mM ADH (red) or nothing (green) at room
temperature overnight. The reaction mixtures were mixed with matrix in a 1:10 ratio and loaded
directly onto the MALDI target. (C) HPLC activity assay showing that BirA-hydrazide retains
catalytic activity. BirA-hydrazide was synthesized as in B, and then combined with 100 pM AP,1 mM biotin, and 4 mM ATP for 20 minutes at room temperature. Negative controls with no
BirA or un-modified BirA are also shown. (D) Analysis of the conjugation products by SDS-
PAGE. Oxidized antibody (- 1 jM) was reacted with 10 pM BirA-hydrazide in MES buffer, pH6.2, followed by reduction with sodium cyanoborohydride. The reaction products were run on a10% SDS-PAGE, and the extent of antibody-biotin ligase conjugation was analyzed by Silver
staining. The conjugation reaction (lane 4) is compared side-by-side with negative controls withbiotin ligase omitted (lane 2) or with un-oxidized antibody (lane 3). The biotin ligase and
antibody reagents before conjugation are also shown for comparison (lanes 1 and 5, respectively).
Red arrows point to BirA oligomers.
In parallel, we also tried to maximize the yield of hydrazide incorporation on
biotin ligase. We found that incubation of biotin ligase with 50 mM adipic dihydrazide
for 4 hours at room temperature resulted in modification of 100% of the BirA molecules,
- 99 -
ýOH N04 A/
~ Yu u 
- '~-' Y-
I 
+ + + + Bi
A
__I I
as assessed by mass-spectrometry (Figure 3-5B). Importantly, the extent of the
modification under these conditions was sufficiently high that reaction with the small-
molecule fluorescein-monoaldehyde resulted in detectable biotin ligase-fluorescence
signal (data not shown). We also confirmed, using an HPLC activity assay6 , that this
large extent of modification did not affect BirA specific activity (Figure 3-5C). Lower
concentrations of ADH resulted in a significant percentage of unmodified BirA
molecules, whereas higher ADH concentrations or longer reaction times yielded
catalytically inactive BirA, probably caused by modification of glutamate and/or aspartic
residues near the active site12
After optimizing the synthesis of BirA-hydrazide conjugates, we attempted to
perform the conjugation reaction. Figure 3-5D shows that, although higher molecular
weight bands are observed in the conjugation reaction (lane 3), the same bands are
present in the negative control with antibody omitted. This finding confirmed that the
homobifunctional nature of the adipic dihydrazide molecule resulted in the formation of
BirA oligomers. Variations in the BirA:Ab ratio or the BirA-hydrazide purification
method (i.e., to minimize the time in between removal of excess ADH and addition of
antibody) avoided BirA oligomerization to some extent, but did not result in the
formation of a detectable amount of BirA-antibody conjugates. It must be noted that BirA
has a natural dimerization affinity13 , therefore increasing even further the effective
concentration for BirA self-conjugation.
SMCC-mediated conjugation offers highest yield and most controllable stoichiometry
In order to avoid biotin ligase or antibody self-conjugation, we invoked the use of
heterobifunctional crosslinkers.
We first tested 4-(4-N-maleimidophenyl) butyric acid hydrazide (MPBH) because
we had previously shown that the hydrazide functional group present in adipic
dihydrazide reacts very efficiently with EDC activated BirA (see previous section).
MPBH is a heterobifunctional crosslinker containing maleimide and hydrazide moieties
(Table 3-1). Maleimides react with free sulfhydryls at pH 6.5-7.5 to form stable thioether
bonds, whereas hydrazide groups react with activated esters or carbonyls to form stable
hydrazone bonds. As previously mentioned, it was favorable to keep BirA always in
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excess of antibody during the conjugation reactions to avoid antibody crosslinking. For
this reason, we first activated the carboxylate groups in BirA with EDC and then reacted
them with MPBH to generate BirA-maleimide conjugates. Unfortunately, for reasons that
are not yet clear, the extent of BirA modification by the MPBH hydrazide moiety was
never higher than - 15%, much lower than that obtained with ADH. We also tested the
conjugation of MPBH to the sugar aldehydes obtained by antibody oxidation, as it had
been previously reported' 4 , but the modification extent was also very low. The low
reactivity of the hydrazide moiety in MPBH thus limited the usefulness of this reagent.
We next switched our attention to what is probably the most popular of all the
heterobifunctional crosslinkers: SMCC. Succinimidyl-4-(N-maleimidomethyl)
cyclohexane-1-carboxylate (SMCC) is a non-cleavable crosslinker that contains an
amine-reactive N-hydroxysuccinimide ester (NHS ester) and a sulfhydryl-reactive
maleimide group. NHS is an acylating agent that can undergo nucleophilic substitution
with primary amines to form stable amide bonds at pH 7-9. The active NHS ester
chemistry is characteristically the most labile functional group of SMCC, being
susceptible to rapid hydrolysis under the aqueous conditions of a bio-conjugation
reaction. The sulfhydryl-reactive group, however, is usually much more stable to
breakdown in aqueous environments. Furthermore, the maleimide group of SMCC is
unusually stable up to pH 7.5 because of the cyclohexane bridge in the spacer arm.
Therefore, SMCC is usually employed in multi-step conjugations where the amines of
one protein first react with the NHS ester and the resulting protein-maleimide is then
reacted with a sulfhydryl containing biomolecule'5, 16
Our initial conjugation scheme is depicted in Figure 3-6A. The disulfides bonds in
the hinge region of the antibody were reduced with dithiothreitol (DTT) to liberate the
free thiols, which were then reacted with maleimide-conjugated biotin ligase to afford the
biotin ligase-antibody conjugates. Specifically, activation of 10 pM BirA with 1 mM
SMCC was performed in 0.1 M sodium carbonate buffer at pH 8.2 for 30 minutes at 37
'C. Reduction of the antibody was done at 6.7 pM antibody and 20 mM DTT. Excess un-
reacted SMCC and DTT was removed by gel filtration using a SephadexTM G25 resin,
and the purified BirA-SMCC and reduced antibody were mixed in a 5:1 ratio and allowed
to react for 1.5 hours at room temperature. The reaction products were then analyzed by
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SDS-PAGE and Western blotting as described in the experimental section. A typical
result is shown in Figure 3-6B. We found that SMCC resulted in a larger extent of
conjugation than any of the previous strategies. Comparison of lanes 3, 4, and 5 confirms
the appearance of higher-molecular weight bands (highlighted with a red box), which
contained both biotin ligase and antibody. However, three main problems were
encountered with this conjugation scheme.
First, when we tested the conjugates in an HPLC activity assay, they proved
unable to perform biotinylation (data not shown). We hypothesized that the loss of BirA
activity was happening during the initial reaction with SMCC, which could be acylating
BirA's catalytic lysine. Lysine 183 is believed to be involved in the formation of the
biotin-AMP ester, and is thus essential for BirA catalytic activity'2 . We tested our
hypothesis by pre-incubating BirA with biotin-AMP before addition of SMCC. It has
been reported that BirA displays extremely high affinity for the adenylate ester of biotin
(koff - 2.7x 10-4 S-1, QKd 50 pM 17) and it is thus expected that, once bound, biotin-AMP is
not released from the active site unless transferred to the protein substrate. Figure 3-6C
compares the biotinylation activity of un-modified BirA (black trace) with that of BirA
activated with SMCC in the presence or absence of biotin-AMP (purple and blue traces,
respectively). As expected, binding of the biotin-AMP ester partially protected the active
site of BirA. However, complete protection of BirA's active site required milder reaction
conditions. To find optimal conditions for the synthesis of BirA-maleimide conjugates,
we used a combination of HPLC assays, to assess BirA activity, and mass-spectrometry
(MALDI-TOF), to estimate the extent of BirA modification. MALDI-TOF analysis
confirmed that incubation with just 200 pM SMCC instead of 1 mM resulted in
modification of 100% of the BirA molecules (35,125.16 D for un-modified BirA vs.
36,072.72 D for SMCC-BirA). Under these conditions, catalytic activity was completely
preserved in the BirA-SMCC conjugates if pre-incubation with biotin-AMP was
performed.
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Figure 3-6: Conjugation of biotin ligase to immunoglobulins via BirA acylation by SMCC.
(A) Conjugation scheme. First, antibody disulfide bonds were reduced with dithiothreitol (DTT)
to generate free thiols in the hinge region. In parallel, lysine residues in biotin ligase were reacted
with the NHS-ester of SMCC to generate BirA-maleimide conjugates. Reduced antibody was
then combined with BirA-maleimide to generate antibody-BirA conjugates. (B) Analysis of the
conjugation products by SDS-PAGE. BirA (- 10 [M) was reacted with 1 mM SMCC in 0.1 M
sodium carbonate buffer, pH 8.2 for 30 minutes at 37 'C. Reduction of the antibody was done at
6.7 pM antibody and 20 mM DTT. Reduced antibody was combined with biotin ligase in a 1:5
ratio and incubated for 1.5 hours at room temperature. The reaction products were run on a 10%
SDS-PAGE, and the extent of antibody-biotin ligase conjugation was analyzed by Silver staining.
The conjugation reaction (lane 4) is compared side-by-side with negative controls where no biotin
ligase or no antibody was added (lanes 3 and 5, respectively). The biotin ligase and antibody
reagents before conjugation are also shown for comparison (lanes 2 and 4, respectively). Red box
highlights BirA-antibody conjugates. (C) HPLC activity assay showing that BirA-maleimide
looses catalytic activity. BirA-maleimide was synthesized as in B, and then combined with 100
jM AP, 1 mM biotin, and 4 mM ATP for 20 minutes at room temperature (blue trace). Negative
controls with un-modified BirA or just DMSO are also shown (black and red traces, respectively).
Pre-incubation of BirA with biotin-AMP partially protects the active site yielding a % of the BirA
population that is catalytically active (purple trace). (D) Same as B but BirA-maleimide was
synthesized under milder reactions conditions. Specifically, - 10 gM BirA was pre-incubated
with 10 pM biotin-AMP for 5 minutes at room temperature before addition of 1 mM N-
ethylmaleimide (NEM). After 1 hour, SMCC was added to Cf = 200 [iM followed by incubation
in sodium phosphate buffer, pH 7.1 for 1.5 hours at room temperature. Red boxes highlight BirA-
antibody conjugates.
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The second problem we encountered was the fact BirA-antibody conjugates
predominantly formed higher order agglomerates (Figure 3-6B). It is worth noting that
the conjugates remained in the stacking part of the gel, at molecular weights > 200 kD, as
highlighted by the red box in Figure 3-6B. We hypothesized that the high molecular
weight observed was caused by BirA oligomerization during the SMCC reaction.
Oligomerization of BirA could have two distinct origins. First, at a reaction pH of 8.2, the
maleimide moiety could be reacting with BirA lysine residues. We had initially chosen
pH 8.2 because the NHS-ester acylation reaction proceeds faster at higher pH. However,
although at pH 7 the reaction of the maleimide with sulfhydryls proceeds at a rate 1000
times greater than its reaction with amines, at more alkaline pH values, its reaction with
amines becomes more evident. Second, regardless of the pH, the maleimide moiety in
SMCC could be reacting with the unique cysteine in BirA. We tested this hypothesis by
capping BirA only cysteine (Cys 107) with N-ethylmaleimide (NEM). We performed the
SMCC reaction at a range of pH 7.0-8.2 both in the presence and absence of NEM, and
analyzed the reaction products by Western blotting detection of the His6 tag in BirA. We
found that BirA oligomerization could be avoided if NEM was added in a 10-fold excess
and previous to SMCC addition, but only when the SMCC reaction was performed at pH
< 7.5 (data not shown). These results confirmed that, at higher pH, the maleimide moiety
was indeed reacting with the lysine residues.
Figure 3-6D illustrates the outcome of incorporating the previous modifications
into the conjugation procedure. Comparison of Figure 3-6B and D confirmed that lower
pH, combined with NEM capping of BirA Cys 107 and milder SMCC reactions
conditions, resulted in antibody-BirA conjugates of a more defined stoichiometry,
corresponding to the covalent linkage of one antibody heavy chain with 1-3 BirA
molecules (90-200 kD). HPLC activity tests confirmed that the conjugates retained
catalytic activity.
The third problem encountered using this conjugation could however not be
solved. To our surprise, when we tested the antibody-BirA conjugates in cells, we found
that they were self-biotinylated. Biotin signal was observed when an anti-rabbit-BirA
conjugate was added to anti-HA stained cells, even in the absence of any AP and/or
exogenous biotin (data not shown). Subsequent tests by WB confirmed that self-
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biotinylation was happening during the BirA activation with SMCC. We attempted to
avoid self-biotinylation by reducing the concentration of biotin-AMP that we added
during the SMCC reaction to protect the catalytic lysine, followed by extensive dialysis
to remove excess biotin-AMP. Unfortunately, none of these completely removed the
biotin signal. We then decided to reverse the order of the reaction steps, such that we
combined BirA with the maleimide moiety in SMCC, thus eliminating the need for
protecting the catalytic lysine.
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Figure 3-7: Conjugation of biotin ligase to immunoglobulins via antibody acylation by
SMCC. (A) Conjugation scheme. Lysine residues in the antibody were acylated by the NHS-
ester moiety of SMCC, and antibody-maleimide conjugates were then reacted with BirA, to form
antibody-BirA conjugates. (B) Analysis of the conjugation products by SDS-PAGE. Anti-rabbit
antibody (- 13 RM) was reacted with 500 [M SMCC in 50 mM sodium phosphate buffer, pH 7.1,
at room temperature for 1 hour. Antibody-maleimide was then combined with biotin ligase in a
1:10 ratio and incubated for 2-6 hours at room temperature. The reaction products were run on a
10% SDS-PAGE, and the extent of antibody-biotin ligase conjugation was analyzed by Silver
staining. The conjugation reaction (lane 4) is compared side-by-side with a negative control with
biotin ligase omitted (lanes 3). The antibody reagent before conjugation is also shown for
comparison (lane 2). Red boxes highlight BirA-antibody conjugates. (C) Western blot analysis of
elution fractions from the SuperdexTM 200 gel filtration column. Anti-His 6 antibody detects the C-
terminal His6 tag in biotin ligase.
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First, the antibody was activated by allowing lysines to react with the NHS ester
group of the SMCC heterobifunctional crosslinker and, after removing excess un-reacted
SMCC, the activated antibody was conjugated to the BirA enzyme by reaction of the
maleimide group in SMCC with the unique BirA surface cysteine. A schematic
representation of this conjugation scheme can be seen in Figure 3-7A. This new scheme
offered some interesting advantages over the previous one. There was no possibility of
BirA dimerization because BirA has only one cysteine capable of reacting with the
maleimide moiety. This fact eliminated the need for lengthy pre-incubations with biotin-
AMP and/or NEM. Moreover, this scheme also eliminated the antibody reduction step,
thus increasing the amount of antibody available for conjugation. We performed a series
of iterations similar to the ones previously described to optimize the SMCC activation
and final conjugation steps. Figure 3-7B confirmed that the new conjugation scheme
resulted again in antibody-BirA conjugates of a defined stoichiometry. In addition to the
90-200 kD conjugates previously obtained, this scheme also resulted in BirA conjugation
to the light chain of the antibody (e.g., - 65 kD band formed by one light chain and one
BirA molecule).
Purification of antibody-biotin ligase conjugates
We tested several strategies to remove excess un-conjugated BirA and antibody
from the reaction mixture. Removal of excess antibody was most important, as un-
conjugated antibody would compete for antigen binding sites thus decreasing the
biotinylation signal. This new conjugation scheme, however, resulted in > 90% antibody
conjugation, thus eliminating the need for further purification. In contrast, the reaction
mixture contained a large excess of un-conjugated BirA.
Protein G antibody pull-down followed by high-salt elution and reaction of un-
conjugated BirA with biocytin-maleimide followed by pull-down with streptavidin
agarose resulted in removal of up to - 50% of excess un-conjugated BirA. In contrast,
conjugates purification by gel filtration afforded antibody-BirA conjugated with > 90%
purity. We tested several gel filtration media (SephacrylTM S200, SephadexTM G25 and
G50, and SuperdexTM 200), and found that Superdex TM 200 (1.3x10 6 Mr exclusion limit
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and 10000-600000 Mr optimal operation range) was the only one that resulted in
complete separation. Figure 3-7C illustrates the separation obtained using this method.
Whereas antibody-biotin ligase conjugates usually eluted in fractions 25-40, excess BirA
always eluted after fraction 40-45.
Detection of antibody-biotin ligase conjugates in live cells
Before and after purification, every new batch of antibody-biotin ligase
conjugates was tested for antigen binding on live cells. The protocol for live cell
detection of these conjugates was similar to that previously described for the antibody-
acceptor peptide conjugates. Briefly, we stained either an HA cell-surface epitope or the
epidermal growth factor receptor (EGFR) with rabbit anti-HA or mouse anti-EGFR
primary antibodies, followed by the anti-rabbit- or anti-mouse-biotin ligase conjugates.
After washing excess antibody conjugates, bound BirA molecules (i.e., those covalently
linked to the antibodies) were detected using either mouse anti-His 6 or rabbit anti-BirA,
followed by the corresponding secondary antibodies conjugated to Alexa Fluor 568 or
Alexa Fluor 488. Note that anti-rabbit-BirA conjugates were detected using anti-mouse-
Alexa Fluor 568, whereas anti-mouse-BirA conjugates were detected using anti-rabbit-
Alexa Fluor 488 in order to avoid species crossreactivity.
Figure 3-8 shows a typical result for the live cell detection of both the anti-
mouse-BirA (Figure 3-8A) and anti-rabbit-BirA (Figure 3-8B) conjugates. We found that
detection of the anti-mouse conjugates routinely generated a brighter signal than
detection of the anti-rabbit conjugates. We believe that this is a reflection of the poor
binding capacity of the anti-BirA serum compared to the mouse anti-His6 rather than a
consequence of a lower conjugation extent. This hypothesis was later confirmed on the
proximity biotinylation assays (next section).
More importantly, Figure 3-8 shows that the amount of bound conjugates greatly
decreases after the gel filtration purification step. We initially hypothesized that the
higher signal of the un-purified conjugates could be caused by non-specific binding of
un-conjugated BirA. However, a negative control where the antibody was substituted by
bovine serum albumin (BSA) resulted in no detection above background, thus confirming
that un-conjugated BirA was efficiently being removed from the cell-surface during the
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rinses. Therefore, the decrease in signal after purification was most probably just a mere
consequence of lower concentrations. Moreover, the BSA-SMCC-BirA negative control
confirmed that, at least for live cell assays, there was no need for purification of the
antibody-BirA conjugates.
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Figure 3-8: Live cell detection of antibody-biotin ligase conjugates. (A) Cell-surface detection
of anti-mouse-BirA conjugates in live HeLa cells. Endogenous epidermal growth factor receptor
(EGFR) was detected using mouse anti-EGFR, followed by the anti-mouse-BirA conjugate. After
rinsing the cells to remove excess un-bound conjugates, bound BirA was detected with anti-BirA
rabbit serum followed by anti-rabbit conjugated to Alexa Fluor 488. Live cell images of the
introduced Alexa Fluor 568 are shown to the left of the differential interference contrast (DIC)
images. (B) Cell-surface detection of anti-rabbit-BirA conjugates in live HeLa cells. An HA-CFP
fusion was targeted to the cell surface of HeLa cells using a transmembrane (TM) domain. Cell-
surface HA was detected using rabbit anti-HA, followed by the anti-rabbit-BirA conjugate. After
rinsing the cells to remove excess un-bound conjugates, bound BirA was detected using mouse
anti-His6 followed by anti-mouse conjugated to Alexa Fluor 568. Live cell images of the
introduced Alexa Fluor 568 are shown to the left of the DIC images. For comparison, mock
conjugates where the antibody was substituted by BSA are shown as negative controls.
Antibody conjugates are capable of proximity biotinylation in live cells
We next tested the ability of the biotin ligase-antibody conjugates to biotinylate
the acceptor peptide when bound to their cellular antigens. As a first approach, we
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performed the proximity biotinylation on the simplest possible system: having the two
antigens in the same protein, as a surrogate of an 'obligate' protein-protein interaction.
For this assay, we chose HeLa cells stably transfecting a cell-surface cyan fluorescent
protein (CFP), which contains an HA epitope at the N-terminus and a Myc epitope at the
C-terminus. Both epitopes can be recognized by specific monoclonal antibodies, followed
by the corresponding secondary antibodies conjugated to biotin ligase or the acceptor
peptide, as depicted in Figure 3-9A (left). After immunodetection, excess antibody
conjugates were rinsed off the cells and the biotinylation reaction was initiated by
addition of 10 jtM biotin and 500 giM ATP. Ligated biotin was then detected with
streptavidin conjugated to Alexa Fluor 568. The live-cell images in Figure 3-9A (bottom
panel) showed that transfected cells (indicated by CFP fluorescence) were labeled with
Alexa Fluor 568, while neighboring untransfected cells in the same field of view were not
labeled. We performed additional negative controls with omission of biotin (Figure 3-9A,
top panel) or leaving out each one of the primary and secondary antibodies (data not
shown), and observed no labeling in either case.
To gain confidence on the generality of the system, we performed a second assay
of proximity biotinylation in live cells where the antibody conjugates were directed
toward different protein molecules. We chose to detect the homodimerization of the
epidermal growth factor (EGF) receptor upon stimulation with EGF (for more
information on the EGF receptor, refer to next section in this chapter). The EGF receptor
was recognized by a mouse monoclonal antibody against the extracellular domain,
followed by a 1:1 mixture of anti-mouse-AP and anti-mouse-BirA conjugates.
Biotinylation and detection was done as described above for the HA-CFP-Myc assay.
The live cells images in Figure 3-9B show that cells immunostained with both conjugates
were labeled with Alexa Fluor 568, whereas negative controls with biotin omitted from
the labeling reaction (top left panel) or leaving out each one of the secondary antibodies
(bottom panels) showed no labeling. Interestingly, a positive control where bound
antibody-acceptor peptide conjugates were biotinylated by soluble exogenous BirA
(middle right panel) showed a labeling signal similar to that of the proximity
biotinylation, which suggests that the labeling efficiency during the proximity
biotinylation assay was very high.
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Figure 3-9: Antibody conjugates are capable of proximity biotinylation in live HeLa cells.
(A) HeLa cells stably expressing a cell-surface HA-CFP-Myc-TM fusion protein were
immunostained with mouse a-Myc and rabbit a-HA primary antibodies, followed by the
corresponding a-mouse-BirA and a-rabbit-AP conjugates. Biotinylation was initiated by addition
of biotin and ATP, and the introduced biotin was detected with streptavidin conjugated to Alexa
Fluor 568. Live cell images of the introduced Alexa Fluor 568 are shown to the right of the CFP
and DIC images, which highlight the transfected cells. A negative control with biotin omitted
from the labeling reaction is shown. (B) HeLa cells with constitutively over-expressed
endogenous epidermal growth factor (EGF) receptor were immunostained with a-EGFR mouse
monoclonal antibody, followed by a 1:1 mixture of a-mouse-AP and a-mouse-BirA conjugates.
Biotinylation and detection was done as in A. Labeling of cells stimulated with EGF (top right
panel) is compared with un-stimulated cells (middle left panel). A positive control with BirA
added in solution to fully biotinylate the anti-mouse-AP conjugates is shown in the middle right
panel. Negative controls with biotin omitted from the labeling reaction (top left panel), or with
either one of the antibody conjugates omitted (bottom panels) are also shown.
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To our surprise, however, no difference in labeling was observed between EGF-
stimulated (top right panel) and un-stimulated cells (middle left panel). We hypothesized
that the presence of labeling in un-stimulated cells could have three different origins.
First, HeLa cells have extremely high levels of endogenous EGF receptor expression,
which could be causing a significant extent of constitutively active receptor (i.e., in
dimeric form) even in the absence of EGF. Second, it is accepted that cell membranes are
highly dynamic with surface receptors constantly diffusing along it. Thus, during the
labeling time, the EGFR-antibody complexes could move around and occasionally
'bump' into each other, leading to a biotinylation signal. Third, because antibody binding
is bivalent, immunodetection in live cells can itself lead to receptor crosslinking, and in
turn to proximity biotinylation, independently of the EGF stimulus.
To test our second hypothesis, we performed the proximity biotinylation assay on
two non-interacting proteins: the cell-surface HA-CFP-Myc artificial construct and the
EGF receptor. We detected the HA epitope with rabbit ax-HA and the EGFR with mouse
a-EGFR, and we performed proximity biotinylation using our anti-rabbit-AP and anti-
mouse-BirA conjugates. We observed a strong biotinylation signal that was dependent on
the presence of both primary and secondary antibodies and on the addition of biotin (data
not shown). These results confirmed that, indeed, the fluidic nature of the cell-membrane
was allowing the antibody complexes to move around, thus generating a biotinylation
signal that was not a reporter of a true protein-protein interaction. This effect was
probably being enhanced in our model system because both proteins were highly over-
expressed and present at extremely high concentrations at the cell-surface, thereby
increasing the chances of random collision. We then decided to perform the same test on
fixed cells, where we should be able to eliminate the contribution of antibody diffusion of
antibody complexes as well as antibody-mediated antigen crosslinking.
Proximity bionitylation fails to detect interaction of the epidermal growth factor
receptor (EGFR) with its adaptor proteins in fixed cells
Transitioning the proximity biotinylation assay into fixed samples introduced a
new set of challenges; namely, the choice of an adequate fixation protocol, and the need
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to remove the background signal from endogenous biotinylated proteins. We first tested
several fixation protocols and chose a combination of paraformaldehyde (PFA) fixation
followed by methanol permeabilization of the cell membrane. Specifically, we followed a
published protocol that had been reported by Jovin and colleagues to better preserve the
localization of membrane proteins such as the epidermal growth factor receptor18 . In this
protocol, the PFA fixation step ensures proper localization of membrane proteins, while
the methanol permeabilization gives access to cytoplasmic interacting partners.
We next compared different fixation and blocking protocols to minimize
background signal from endogenous biotinylated proteins. Mammalian cells and tissues
contain biotin-dependent carboxylases, which play a key role in the synthesis of cellular
metabolites during fatty acid synthesis, gluconeogenesis, lipogenesis, amino acid
metabolism, and energy transduction 19. These biotin-containing enzymes produce
substantial background signals, often concentrated in the mitochondria, when
biotin-avidin or biotin-streptavidin detection systems are used to identify cellular
targets20. Figure 3-10A shows that, as expected, direct detection of endogenous biotin
using sreptavidin conjugated to Alexa Fluor 568 resulted in punctuated labeling,
characteristic of mitochondrial staining (left panel). We tested several blocking
conditions and found that we could significantly reduce endogenous background by
addition of unlabeled 100 ng/mL avidin (Figure 3-10A, right panel). We found that
avidin was a better blocking reagent than streptavidin at the same concentration. This
could be rationalized by the cationic nature of avidin21, which makes it very sticky to
fixed specimens. It is also worth noting that the biotin blocking protocol worked better
when milk was used as the general blocking reagent, rather than the more common
bovine serum albumin (BSA), and animal sera. Additionally, the surfactant 0.1% Tween
20 (polysorbate 20) was included in all steps as it was found to further reduce
background staining.
An additional source of background was introduced when biotinylation was
performed on fixed cells. We found that addition of biotin at concentrations higher than
10 ýiM resulted in increased background signal even in the absence of covalent biotin
ligation by biotin ligase (Figure 3-10B). Thus, 10 ýtM biotin was used in all subsequent
experiments of proximity biotinylation in fixed cells.
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Figure 3-10: Eliminating background biotin labeling on fixed cells. (A) Endogenous biotin
can be effectively blocked with avidin. HeLa cells were fixed with paraformaldehyde followed by
methanol and blocked with 5% milk. Endogenous biotin was then blocked with 100 ng/mL avidin
for 30 minutes at room temperature. After washing excess avidin, biotin was detected with
streptavidin conjugated to Alexa Fluor 568. Fixed-cell images of the introduced Alexa Fluor 568
are shown to the right of the DIC image. A negative control with the avidin block omitted is also
shown. (B) Excess biotin binds non-specifically to fixed cells. Fixed HeLa cells were first
blocked with milk, followed by avidin as in A. Thereafter, biotin was added at the indicated
concentrations for 1 hour at room temperature, and then washed extensively with phosphate
buffered saline. Biotin was detected with streptavidin conjugated to Alexa Fluor 568.
After we optimized the fixation and blocking protocol, we first proceeded to
reproduce the proximity biotinylation assay on the HA-CFP-Myc construct on fixed cells.
We obtained results analogous to those of the live cell assay, albeit with a slightly lower
labeling signal (data not shown). The labeling signal was probably reduced because of the
need for using lower concentrations of primary and secondary antibodies to avoid non-
specific antibody binding in the highly exposed fixed samples. Lower antibody
concentration likely resulted in reduced antibody binding density; i.e., in live cells, the
antibodies are added at high concentrations and for short periods of time, so that it is not
expected that the binding reaches equilibrium, as it is for fixed-cell immunodetection.
We were then ready to test our protein-protein interaction scheme on a real pair of
interacting proteins. For our initial proof-of-principle, we chose the EGF receptor
interaction with some of its adaptor proteins. The epidermal growth factor receptor
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(EGFR, also known as ErbB 1) is the archetypal member of a family of four receptor
tyrosine kinases, which also include ErbB2, ErbB3 and ErbB4. These receptors are
responsible for mediating several cellular responses such as cell proliferation and
differentiation, and an imbalance in one or more of these receptors has been implicated in
several epithelial carcinomas 22. Epidermal growth factor (EGF) and transforming growth
factor a (TGFa) both bind to EGFR at the plasma membrane. After ligand binding,
EGFR dimerizes, its intrinsic tyrosine kinase is activated, and specific tyrosine residues
in its cytoplasmic tail become auto-phosphorylated 23. These phosphotyrosine residues
then serve as docking sites for the so-called adaptor proteins, which are signal transducers
containing Src homology 2 (SH2) or phosphotyrosine binding (PTB) motifs24. Binding of
the adaptor proteins to EGFR initiates many signalling cascades that ultimately result in a
physiological outcome. Figure 3-11 schematically represents the EGFR with its tyrosine
sites of auto-phosphorylation as well as the tyrosines phosphorylated by the Src kinase.
Among the several signal transducing pathways activated by EGF binding, the best
characterized is the Ras-Raf-MEK-MAPK pathway, which is initiated by Grb2-Sos or
Shc-Grb2-Sos association. In addition, Ras-specific GTPase-activating protein (Gab),
ubiquitin ligase (Cbl), phosphatidyl inositol 3-kinase (PI3K), and phospholipase C y
(PLCy) signaling pathways are initiated from activated EGFR24. Finally, ligand-bound
EGFR is rapidly internalized through receptor-mediated endocytosis and sorted to
multivesicular bodies. The receptor either recirculates to the plasma membrane after
ligand dissociation or is degraded through the lysosomal pathway.
We chose the EGFR interaction with its adaptor proteins because it is a well-
characterized system and because some of these interactions have been previously
studied by co-localization analysis of classic immunofluorescence images. However,
many of these studies reported contradictory results. For example, the localization of the
adaptor protein Shc before EGF stimulation was reported predominantly cytoplasmic by
Oksvold and colleagues 25, whereas other groups claimed that un-phosphorylated Shc was
mainly located in the endoplasmic reticulum 26' 27 of the same A431 cells. Consistently, the
reported extent of co-localization between EGFR and Shc at the plasma membrane upon
addition of EGF is also highly variable, ranging from 5-15%28. In most cases, the
differences in the localization pattern of the whole population of an adaptor protein
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before and after stimulation were so small that no quantification was reported25'29'30. We
hypothesized that these inconsistencies could in part be caused by the technical
difficulties of the co-localization analyses and the intrinsically limited spatial resolution
of the immunofluorescence technique.
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Figure 3-11: Schematic representation of the epidermal growth factor receptor. The
epidermal growth factor (EGF) receptor is a - 180 kD cell-surface protein with an extracellular
N-terminal portion containing the ligand binding and the dimerization domains, and a C-terminal
portion, which includes the kinase domain and the cytoplasmic tail, where the adaptor proteins
bind. Tyrosine residues auto-phosphorylated by the EGF receptor kinase domain are marked in
yellow, whereas Tyrosine residues phosphorylated by the Src kinase are marked in grey. Some of
the adaptor proteins binding to the different phosphorylated tyrosines are indicated, together with
the signaling pathways that they initiate. AP-2: adaptor protein 2. Eps 15: EGFR pathway
substrate 15. PLCy: phospholipase Cy. PKC: protein kinase C. MAPK: mitogen-activated protein
kinase. ERK: extracellular signal-regulated kinase. Cbl: ubiquitin ligase. Grb2: growth factor
receptor-bound protein 2. Gab 1: Ras-specific GTPase-activating protein 1. Shc: Src homologus
and collagen-like protein. Shp 1: Src homology phosphatase 1. Figure taken from the Santa Cruz
Biotechnology website.
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We first performed classical immunofluorescence detection of the EGF receptor
and the adaptor proteins. We routinely worked with three different cell lines - HeLa,
A431, and NR6 - because of their high EGFR expression levels. HeLa and A431 cells
are human epithelial carcinoma cell lines constitutively expressing 104 EGF receptors/cell
and 106 EGF receptors/cell, respectively31'32 .NR6-WT cells were derived from the
EGFR-negative variant of the 3T3 mouse fibroblasts cell-line (NR6 parental) 33, which
were later transfected with over-expressed human receptor (- 104 receptors/cell) 34. In our
hands, the NR6 cell-line was the most responsive to EGF stimulation, however, because
most of our antibodies against the adaptor proteins were specific for human, this cell-line
was only useful for studies of EGFR homodimerization (see below). In contrast, the
A43 1 cells worked best in terms of adaptor protein recognition, but the effect of EGF
stimulation on EGFR activation was highly variable. As it can be seen in Figure 3-12, the
basal levels of phosphorylated EGFR (pEGFR) were relatively high even in un-
stimulated cells, probably due to constitutive dimerization caused by receptor over-
expression. Figure 3-12 also depicts the different localization patterns of the adaptor
proteins before and after stimulation with 100 ng/mL EGF for 10 minutes at room
temperature. As expected, we observed that all the adaptor proteins except CrkII changed
their localization upon EGF stimulation, moving towards the plasma membrane.
However, the extent of the change varied for the different proteins. The most dramatic
differences were observed for Src kinase and the Grb2 adaptor protein, which not only
changed localization, but also showed a marked increased in the overall detected signal.
On the other hand, whereas a certain membrane population of Shc and Nck was observed
upon EGF stimulation, the majority of the signal still remained reticular and cytosolic,
respectively.
Co-localization analysis of several cells and samples from different days revealed
that Grb2 exhibited the largest increase in the co-localization extent with EGFR,
changing from 47% + 3% to 86% + 5% upon EGF stimulation. Co-localization of EGFR
and Shc also changed significantly, varying from 41% + 3% before EGF stimulation to
68% + 3% after 10 minutes incubation with 100 ng/mL EGF. Co-localization percentages
for Src and Nck were too variable among experiments to extract meaningful conclusions.
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Figure 3-12: Immunofluorescence detection of the epidermal growth factor (EGF) receptor
and its adaptor proteins in A431 cells. The localization of the EGF receptor, the Src kinase,
and the adaptor proteins Shc, Grb2, Nck, and CrkII is shown before and after stimulation with
100 ng/mL EGF for 10 minutes at room temperature. Additionally, EGF receptor activation was
confirmed with an anti-phosphotyrosine antibody (pEGFR). Each antigen was detected with a
specific primary antibody (see Experimental section for details) followed by the corresponding
anti-mouse or anti-rabbit conjugated to Alexa Fluor 568 or Alexa Fluor 488, respectively. The
Alexa Fluor images (AF-568 middle panels, AF-488 right panels) are shown to the right of the
DIC images.
Next, we used our biotin ligase and acceptor peptide antibody conjugates to study
the EGF-induced homodimerization of EGFR. We performed the assay as described
above for the live-cell tests (see Figure 3-9B), except that we fixed and permeabilized the
cells prior to immunolabeling. A431 cells were fixed, blocked with milk, and endogenous
biotin was blocked with avidin. The EGF receptor was then recognized by a mouse
monoclonal antibody against the extracellular domain, followed by a 1:1 mixture of anti-
mouse-AP and anti-mouse-BirA conjugates. Biotinylation was initiated by addition of
10 pM biotin and 500 iM ATP to the fixed cells, and ligated biotin was detected with
streptavidin conjugated to Alexa Fluor 568. Figure 3-13 shows the results.
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Figure 3-13: Detection of EGFR homodimerization in fixed A431 cells by proximity
biotinylation. Epidermoid carcinoma A431 cells were fixed with paraformaldehyde (PFA),
permeabilized with methanol, and blocked with milk, followed by an endogenous-biotin blocking
step with avidin. Thereafter, cells were immunostained with a-EGFR mouse monoclonal
antibody, followed by a 1:1 mixture of a-mouse-AP and a-mouse-BirA conjugates. Biotinylation
was initiated by addition of biotin and ATP, and the introduced biotin was detected with
streptavidin conjugated to Alexa Fluor 568. Fixed-cell images of the introduced Alexa Fluor 568
are shown to the left of the DIC images. Labeling of cells stimulated with EGF (top left panel) is
compared with un-stimulated cells (middle left). Negative controls with biotin omitted from the
labeling reaction (top right), or without each one of the primary or secondary antibodies are also
shown. In the case where the secondary antibodies were omitted, they were substituted by soluble
un-conjugated biotin ligase (bottom left) or acceptor peptide (bottom right), respectively.
We observed that A431 cells immunostained with both antibody conjugates
exhibited a clear membrane labeling pattern in the Alexa Fluor 568 channel, whereas
negative controls with biotin omitted from the labeling reaction (top right images) or
leaving out each of the primary or secondary antibodies (middle right, and bottom left
and right images) showed no significant labeling signal above background. It must be
noted that the signal/background ratio observed was overall very low, thus enhancing the
background labeling caused by streptavidin non-specific or specific-binding to
endogenous biotinylated proteins. Unfortunately, as in the live-cell assay, we observed no
difference in labeling between EGF-stimulated (top left) and un-stimulated cells (middle
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left). These results contradicted our previous hypothesis, which stated that the lack of
EGF-induced increase in biotinylation signal was caused by random-biotinylation during
dynamic receptor movement within the membrane of living cells. However, we had
previously found that the response to EGF in A431 cells was highly variable, as detected
by the anti-phosphotyrosine antibody, owing to the high-levels of EGFR over-expression
(106 receptors/cell). Therefore, in order to rule out the possibility that the lack of
difference was caused by absence of EGF-induced EGFR homodimerization, we decided
to repeat the proximity biotinylation test on NR6, a cell-line that had routinely shown a
far more pronounced EGF-induced increase in EGFR phosphorylation than that observed
in A431 cells.
To our discontent, we found that the results were the same as we had observed for
A431 cells (Figure 3-14). Although the signal was a lot higher for NR6 than for A431
cells, we still observed no difference in the labeling extent of EGF-treated and un-
stimulated cells. These results suggested that the biotinylation signal we were observing
was not reporting on a true protein-protein interaction - the homodimerization of EGFR -
but it was rather just an artifact of antibody-conjugates, which, being polyclonal, were
likely binding to the same primary a-EGFR antibody. We tested different EGFR
antibodies in an attempt to eliminate this multivalent binding, but we obtained similar
results with all of them (data not shown). We also observed no difference when we
attempted to enhance the effect of EGF stimulation by co-addition of the phosphatase
inhibitor vanadate, which should result in an overall increase in the number of
phophorylated receptors (data not shown).
Finally, because the artifact was restricted to homodimerization studies, we
sought to eliminate it by applying the proximity biotinylation scheme to the interaction of
EGFR with one of its adaptor proteins. We focused mainly on the Grb2 and Shc adaptor
proteins because they have shown biggest changes in their co-localization with EGFR
upon EGF stimulation (see above). We tested several combinations of a-EGFR and
a-Shc or a-Grb2 antibodies, as well as our three main cell lines (HeLa, NR6-WT, and
A431) and various conditions for EGF stimulation, and had no success. We never
observed biotinylation signal when the antibody-acceptor peptide and antibody-biotin
ligase conjugates were targeted to different proteins.
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Figure 3-14: Detection of EGFR homodimerization in fixed NR6 cells by proximity
biotinylation. Mouse fibroblasts over-expressing human EGF receptor (NR6-WT) were fixed
with PFA, permeabilized with methanol, and blocked with milk, followed by an endogenous-
biotin blocking step with avidin. Thereafter, cells were immunostained with a-EGFR mouse
monoclonal antibody, followed by a 1:1 mixture of a-mouse-AP and c-mouse-BirA conjugates.
Biotinylation was initiated by addition of biotin and ATP, and the introduced biotin was detected
with streptavidin conjugated to Alexa Fluor 568. Fixed-cell images of the introduced Alexa Fluor
568 are shown to the right of the DIC images. Labeling of cells stimulated with EGF (top left
images) is compared with un-stimulated cells (bottom left). Negative controls with biotin omitted
from the labeling reaction (top right), or without anti-mouse-acceptor peptide conjugate (bottom
right) are also shown.
Discussion
While we still think that the concept of proximity biotinylation is powerful, our
experience illustrates that the system requires positioning of biotin ligase and the acceptor
peptide in close enough proximity and in a productive conformation, which is hard to
achieve when the enzyme and peptide are both linked by chemical conjugation to large
antibody molecules. As we describe in Chapter 4 however, we later demonstrated that the
concept of proximity biotinylation is indeed valid and can be successfully applied to the
detection of protein-protein interactions if the appropriate flexibility is provided to BirA
and AP.
We believe that three main factors prevented proximity biotinylation of AP by
BirA in the context of IF. First, the large size of an antibody (- 150 kD) was not only
likely to hinder the acceptor peptide (- 2 kD), but could also potentially separate BirA
- 120-
and AP further than what they could reach. That is, the separation between biotin ligase
and its acceptor peptide within the context of the antibody conjugates was far greater than
the distance intrinsically defined by the protein-protein interaction. Although this
problem is fundamental to the methodology, we feel that it could have been
circumvented, had we implemented better conjugation strategies. Second, the overall
yield of the conjugation reaction between biotin ligase the antibody was very low, which
resulted in inefficient separation from excess un-reacted antibody and biotin ligase
molecules. Third, and perhaps most important, factor was thus the choice of chemical
conjugation strategies. On the one hand, we conjugated the AP to the antibody directly at
the peptide C-terminus. Although BirA has been shown to recognize AP when fused to
the N-terminus, C-terminus, or an internal loop3 5, AP is, in these contexts, within a
flexible protein structure and protruding towards the exterior of the protein. This is
probably not the case in our antibody-acceptor peptide conjugates, where AP was
conjugated via the antibody sugars. Examination of the crystal structure of the
crystallizable portion (Fc) of an immunoglobulin G (Figure 3-15A) reveals that the
carbohydrates attached to the heavy chains lie at the interface between the two heavy
chains, and are thus not highly exposed to the protein exterior. We reason that
conjugation of the acceptor peptide via free hinge-region thiols, or with addition of a
- 10-amino acid linker between the hydrazide functional group and the 15-amino acid
recognition sequence, would have probably improved AP accessibility. On the other
hand, biotin ligase was chemically conjugated to the antibody via its unique Cysteine 107
and using SMCC as the only spacer (- 8 A). Figure 3-15B illustrates the position of
Cys107 relative to the active site. It is clear that the side chain of Cysl07 is extremely
close to the active site (- 8 A calculated distance from the sulfur atom in Cysl07 to one
of the ureido nitrogens in biotin). Although Cysl07 is not essential for catalysis, and we
showed that SMCC conjugation did not affect enzymatic activity, it is likely that
attachment to the antibody via Cys107 holds the enzyme in a rather rigid position, with
its active site very close to the antibody. We propose that a better conjugation strategy
could involve mutating Cysl07 to a serine, and introducing an extra cysteine at the Gly55
position, which is positioned at a f3-turn within the enzyme N-terminal binding domain
(highlighted green in Figure 3-15B). The N-terminal domain is only used for DNA
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binding and it is joined to the C-terminal catalytic domain by a flexible linker. Therefore,
linking BirA to the antibody via its N-terminal domain could perhaps provide the enzyme
with enough freedom to productively recognize the acceptor peptide.
A B
Figure 3-15: Ribbon representations of the Fc of human immunoglobulin G and biotin
ligase. (A) Crystal structure of the crystallizable portion (Fc) of human immunoglobulin G (PDB:
1H3Y). The two heavy chains are colored green and orange. Amino acid residues are represented
in ribbon format, whereas carbohydrate groups are represented as ball and stick. (B) Position of
biotin ligase Cysteine 107 with respect to the active site. The entire amino acid sequence of
E. coli biotin ligase in the crystal structure (PDB: 1HXD) is shown as a solid ribbon. Cysteine
107 (left) and biotin (right) are shown in CPK format. Carbon atoms are colored grey, oxygen
atoms are colored red, nitrogen atoms are colored blue, and sulfur atoms are colored yellow.
These images were generated from the original PDB files using DS Viewer Pro software.
In the last months of development of this project, a new method to detect
endogenous protein-protein interactions was reported that employed an scheme
analogous to ours36. In the proximity ligation technique, each antibody is conjugated to a
single-stranded DNA molecule. When two or more antibodies bind to either the same
molecule (e.g., to detect the presence of a protein) or to two different, interacting
molecules, the DNA strands are brought into proximity and, after addition of a
hybridizing connector oligonucleotide, they can be joined by ligation. The newly formed
chimeric DNA strand can then be detected and quantified by real-time PCR with
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extremely high sensitivity37. For the detection of PPIs in fixed cells, a combination of the
proximity ligation technique with rolling-circle amplification resulted in detection of
endogenous Myc-Max complexes with single-molecule spatial resolution36. Rolling-
circle amplification was used in place of PCR to avoid thermal cycling and to ensure that
the amplification product remains attached to the antigen. Proximity ligation has most
recently also been applied to the detection of post-translational modifications, such as
phosphorylation of the platelet-derived growth factor receptor 38.
The proximity ligation technique is in essence the same as our proposed proximity
biotinylation except that the enzyme-substrate pair is substituted by DNA strands. These
DNA strands are typically 30-35 nucleotides long, and can thus expand much longer
distances that our enzyme-substrate pair. Additionally, the sensitivity of the proximity
ligation method is expected to be higher than what could be obtained using proximity
biotinylation owing to the exceptional signal amplification of the rolling circle
amplification.
Conclusions
In this chapter, we have described our efforts to develop a new methodology for
the detection of endogenous protein-protein interactions. With this method, we sought to
bridge the gap between the immunofluorescence (IF) and FRET studies to be able to
report, for the first time, on true protein-protein interactions between endogenous proteins
within the context of fixed cells. The proposed methodology was an adaptation of the IF
technique, where two antibodies were conjugated to biotin ligase and its acceptor peptide
instead of fluorophores. Upon protein-protein interaction, the enzyme and its substrate
peptide should be brought into close proximity, where biotinylation could occur. We first
developed robust protocols for chemical conjugation of immunoglobulins to the acceptor
peptide and biotin ligase. We then validated the binding capacity and the catalytic activity
of the conjugates both in vitro and in live cells. The antibody conjugates failed however
to detect the interaction between the epidermal growth factor receptor and some of its
adaptor proteins in fixed cells. We hypothesized that the inability of our system to detect
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PPIs in fixed cells was caused by the intrinsically unfavorable geometry imposed by the
antibodies on BirA and AP, by our choice of strategies for chemical conjugation, and by
the overall low yield of the bioconjugation reactions. Finally, a similar method called
proximity ligation was later reported by the laboratory of Ulf Landegren (U. of Upsala,
Sweden), which overcame many of the technical challenges encountered in the proximity
biotinylation scheme. Proximity ligation has successfully been applied to the detection of
interactions between the Myc and Max transcription factors in fixed mammalian cells36 .
It remains to be seen if the method finds widespread application to other protein pairs and
by other research groups.
Experimental
Bacterial expression and purification of E. coli biotin ligase
The pBTac2-BirA plasmid for expression of E. coli biotin ligase was a gift of
Prof. Beckett (University of Maryland). To enhance expression in E. coli BL21(DE3), the
birA gene was subcloned into the EcoRI and Hindll restriction sites of pET21 a for
expression of a C-terminally Hiss6-tagged enzyme. The pET21 a-BirA plasmid was
transformed into E. coli BL21(DE3) cells, which were amplified in LB media
supplemented with 100 pig/mL ampicillin at 37 oC until OD600 0.9. Protein expression
was induced with 100 ýig/mL IPTG for 3 hours at 30 oC. Thereafter, cells were harvested
by centrifugation (6,000 rpm, 10 minutes, 4 oC) and the pellet was resuspended in lysis
buffer (50 mM Tris base, 300 mM NaC1, pH 7.8) containing 2.5 mM
phenylmethylsulfonyl fluoride (PMSF) and protease inhibitor cocktail (Calbiochem).
Cells were lysed by ultrasonic treatment (six 15-second bursts, with 1 minute of cooling
to 4 'C between bursts). The extract was cleared by centrifugation (13,200 rpm,
10 minutes, 4 oC) and the Hiss6-tagged protein was purified using Ni-NTA agarose
(Qiagen). Fractions were analyzed by 10% SDS-PAGE followed by Coomassie staining.
Fractions containing the enzyme were pooled and dialyzed against PBS. Protein
concentrations were measured using the BCA assay (Pierce) with BSA as the reference
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standard. For each new enzyme preparation, catalytic activity was confirmed by running
a standard HPLC activity assay (see below).
HPLC assay of biotin ligase activity
The synthetic acceptor peptide (AP) with sequence KKKGPGGLNDIFEAQKIE
WH was synthesized by the Tufts University Core Facility. The reaction conditions to
test the specific activity of biotin ligase were as follows: 50 mM bicine pH 8.3, 5 mM
magnesium acetate, 4 mM ATP, 100 ItM AP, 200 nM BirA, and 1 mM biotin. The
reaction was incubated at 30 oC for 20 minutes before quenching with the addition of
45 mM ethylenediamine tetraacetic acid (EDTA). Reactions were analyzed on a reverse-
phase HPLC column (Microsorb-MV 300 C18) using a gradient of 10-43%
acetonitrile/water with 0.1% TFA over 20 minutes (flow rate 1.0 mL/min). Retention
times were 8.2 minutes for biotin, 16.3 minutes for the AP, and 17.7 minutes for the AP-
biotin conjugate. Under the above reactions conditions, - 50% of the AP should be
converted to AP-biotin (kcat = 12 min-')4 .
Sodium periodate oxidation of IgG molecules
Antibody solutions (typically 100 gtL at 1-2 mg/mL) were reacted with 1 mM
sodium periodate for 30 minutes at room temperature in PBS, pH 7.2. The reactions were
kept in the dark, and the excess sodium periodate was immediately removed by gel
filtration using a SephadexTM G25 resin (Quick Spin or Nap5 columns, GE Healthcare).
Oxidized-antibody concentrations were calculated from the absorbance at 280 nm using
the extinction coefficient of 1.4 L g-1 cm-~. Typically, affinity purified goat anti-rabbit or
anti-mouse IgGs (Rockland Immunochemicals) were used in the conjugations.
Conjugation of the acceptor peptide to oxidized antibodies
A synthetic N-terminally hydrazide-functionalized AP was synthesized by the
Tufts University Core Facility. The crude peptide was purified by reverse-phase HPLC
(Microsorb-MV 300 C18, 10-39% acetonitrile/water with 0.1% trifluoroacetic acid
- 125 -
(TFA) over 35 minutes, flow rate 4.7 mL/min); the desired peak had a retention time of
28 minutes. Following lyophilization, the peptide was redissolved in water, and the
concentration was determined from the absorbance at 280 nm using the calculated
extinction coefficient of 5690 M-1cm -1.
Purified AP-hydroxylamine was added to the oxidized antibody solution
(- 100 jtL, see above) to a final concentration of 1 mM, and the reaction was allowed to
proceed overnight at room temperature in 10 mM sodium acetate, pH 5. Thereafter, the
formed hydrazone was reduced by reaction with 100 mM sodium cyanoborohydride
(NaBH 3CN) for 6 hours at room temperature, with an additional supplement of
NaBH 3CN after the first 3 hours. Finally, un-reacted aldehydes in the oxidized antibody
were blocked by reaction with 50 mM ethanolamine, pH 9.6 for 30 minutes at room
temperature. The reaction mixture was then dialyzed against PBS pH 7.4 and purified as
described below.
Affinity purification of antibody-acceptor peptide conjugates
Dialyzed antibody-acceptor peptide mixtures were incubated with Protein G
(Calbiochem) resin for 2 hours at room temperature in the presence of 3% BSA. Prior to
sample loading, the resin was pre-blocked by incubation in 3% BSA in PBS-T for
15-30 minutes at 37 "C. The amount of resin required for the purification was calculated
based on a binding capacity of 1-5 mg of goat IgGs per 1 mL of resin (info provided by
the manufacturer). The antibody was eluted from the resin with 100 mM glycine pH 3.0,
and the elution fractions were immediately neutralized to pH 7.0 with 500 mM Tris base,
and dialyzed against PBS. To determine the yield of the conjugation procedure, the
purified mixtures were incubated with 5 giM biotin ligase, 1 mM biotin, 4 mM ATP, and
5 mM magnesium chloride in 50 mM bicine buffer, pH 8.3, and the extent of AP
biotinylation was analyzed by Western blotting as described below.
Conjugation of biotin ligase to oxidized antibodies by reductive amination
Oxidized antibody and purified biotin ligase were first separately dialyzed against
200 mM sodium carbonate/bicarbonate pH 9.6. Thereafter, the solutions were mixed to
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obtain a 4:1 to 15:1 ratio of BirA to antibody and the reaction was allowed to proceed for
2 hours at room temperature. The formed imines were then reduced with 50 mM
NaBH 3CN for 30 minutes at room temperature and the unreacted aldehydes were blocked
by incubation with 50 mM ethanolamine for an additional 30 minutes. Excess reagents
were removed by gel filtration (G25 Quick Spin columns, GE Healthcare) or by dialysis
against PBS, pH 7.4, and the reaction products were analyzed by Western blotting as
described below.
Synthesis of adipic dihydrazide-biotin ligase conjugates
In a 27 liL reaction, 40 jpM biotin ligase was combined with 5 mM 1-ethyl-3-(3-
dimethylaminopropyl) carbodiimide hydrochloride (EDC) in 100 mM sodium carbonate
pH 8.1. After 30 minutes at room temperature, adipic dihydrazide (3 [LL, 500mM) was
added and the reaction was allowed to proceed for 4 hours at room temperature. The
protein was purified from excess EDC, sulfo-NHS, and adipic dihydrazide using size-
exclusion chromatography on Sephadex TM G-25 (Nap5 column, GE Healthcare).
Conjugation of biotin ligase-hydrazide to oxidized antibodies
In a 20 gL reaction, 12.5 gL of biotin ligase-hydrazide (Cf = 10 JIM) were
combined with 2 pL of oxidized antibody (Cf - 1 gM) in 50 mM 2-(N-morpholino)
ethanesulfonic acid (MES) pH 6.2 and incubated at room temperature for 2 hours.
Thereafter, the mixture was cooled down to 4 oC and the hydrazone was reduced by
addition of 50 mM sodium cyanoborohydride (NaBH 3CN) for 30 minutes at room
temperature or 4 "C. Unreacted aldehyde groups were then blocked with 50 mM
ethanolamine pH 9.6 for 30 minutes at room temperature. The final reaction mixture was
dialyzed against PBS, pH 7.4, and analyzed by Western blotting as described below.
Synthesis of SMCC-biotin ligase conjugates
Biotin ligase was reacted with succinimidyl 4-[N-maleimidomethyl] cyclohexane-
1-carboxylate (SMCC). Biotin ligase was first pre-incubated for 5 minutes at room
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temperature with 100 [tM biotin and 400 ptM ATP, followed by 30 minutes incubation
with 1 mM N-ethylmaleimide (NEM), before addition of SMCC. Thereafter, SMCC was
added to 50 giL of BirA solution (- 20-30 [iM) to a final concentration of 200 iM in
50 mM sodium phosphate buffer, pH 7.1 and the reaction was incubated at room
temperature for 1 hour. The biotin ligase-SMCC conjugates were purified from excess
SMCC using size-exclusion chromatography on a NAP-5 (SephadexTM G-25 resin, GE
Healthcare) column. The proteins were eluted from the column in 7x 100 ýIL fractions in
PBS, pH 7.2. The most concentrated fractions (usually fractions 3-5) were combined and
immediately reacted with the reduced antibody (see below).
Antibody reduction to expose free thiols
In a 100 giL reaction, 98 giL of antibody solution (2 mg/mL) were combined with
2 ýtL of of IM dithiothreitol (DTT, Cf= 20 mM) in PBS pH 7.2 and incubated at room
temperature for 30 minutes. Thereafter, excess DTT was quickly removed using size-
exclusion chromatography on a NAP-5 (SephadexTM G-25 resin, GE Healthcare) column.
The antibody was eluted from the column in 6x100 jiL fractions in PBS, pH 7.2 (note
that using larger elution volumes is not recommended as they may elute DTT). The most
concentrated fractions of reduced antibody (usually fractions 3-5) were combined and
immediately combined with the BirA-SMCC solution. Typically, affinity purified goat
anti-rabbit or anti-mouse IgGs (Rockland Immunochemicals) were used for these
conjugations.
Synthesis of SMCC-antibody conjugates
Goat affinity purified anti-mouse or anti-rabbit IgGs (Rockland
Immunochemicals) were reacted with succinimidyl 4-[N-maleimidomethyl] cyclohexane-
1-carboxylate (SMCC). SMCC was added to 50 [tL of antibody solution (2 mg/mL) to a
final concentration of 500 tM in 50 mM sodium phosphate buffer, pH 7.1, and the
reaction was allowed to proceed at room temperature for 1 hour. The antibody-SMCC
conjugates were purified from excess SMCC using size-exclusion chromatography on a
NAP-5 (SephadexTM G-25 resin, GE Healthcare) column. The proteins were eluted from
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the column in 7x 100 tL fractions in PBS, pH 7.2. The most concentrated fractions of
antibody-SMCC (usually fractions 3-5) were combined and immediately reacted with
BirA.
Conjugation of biotin ligase-SMCC-antibodies
For the first method of conjugation, BirA-SMCC (- 300 ýtL) was combined with
reduced antibody (- 300 CgL) in a 5:1 ratio and incubated at room temperature for
1.5 hours. For the second method, antibody-SMCC (- 300 gL), was incubated with a
10-fold excess of BirA at room temperature for 2-6 hours. In both cases, the reactions
were quenched with 100 pM f3-mercaptoethanol for 30 minutes at room temperature,
dialyzed against PBS, pH 7.2, and analyzed by Western blotting as described below.
Western blot analysis of antibody-BirA and antibody-AP conjugates
Conjugate preparations (15-30 jiL) were combined with SDS-PAGE loading
buffer containing 2-mercaptoethanol, boiled, run on a 10% SDS-PAGE gel, and
transferred to nitrocellulose membrane. Membranes were blocked with TBS + 0.05%
Tween 20 (TBS-T) and 3% BSA for 1 hour. For anti-goat IgG blotting, the membrane
was first incubated with 20 jig/mL donkey anti-goat IgG horseradish peroxidase
(Rockland Immunochemicals) in TBS-T + 3% BSA for 45 minutes, then washed three
times. For anti-His 6 blotting, the membrane was first incubated with 10 gg/mL mouse
anti-His6 antibody (Calbiochem) in TBS-T + 3% BSA for 45 minutes, then washed three
times. The membrane was then incubated with anti-mouse horseradish peroxidase
conjugate (Bio-Rad) in TBS-T + 3% BSA at 1:2000 dilution for 45 minutes, followed by
three rounds of 5 minute washes with TBS-T. Blots were developed with Supersignal
West Pico or Femto substrate (Pierce), and images were taken on a Chemilmager 5500
instrument (Alpha Innotech).
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Purification of antibody-biotin ligase conjugates by gel filtration
Biotin ligase-conjugates were purified from excess un-reacted BirA by gel
filtration on a SuperdexTM 200 resin (GE Healthcare). We typically packed 6 mL of resin
for a 250-275 ýtL of conjugation reaction, and the column was pre-equilibrated with 10
column volumes of PBS, pH 7.2 before loading the sample. The conjugate preparations
were centrifuged (13,200 g, 3 minutes, room temperature) and loaded onto the column by
gravity. The proteins were eluted from the column in 60x 100 tL fractions in PBS, pH
7.2. Elution fractions were collected and analyzed by Western blotting as previously
described.
Binding activity of antibody-acceptor peptide conjugates in live cells
Testing of AP conjugates to anti-mouse IgG was performed on HeLa cells using
mouse anti-EGFR (clone LA22, Upstate, 1:25 dilution in DPBS + 3% BSA) as the
primary antibody. AP-anti-rabbit conjugates were tested on HeLa cells stably expressing
AP(ala)-CFP-TM 6 using rabbit polyclonal anti-HA (Rockland Immunochemicals, 1:50
dilution in DPBS + 3% BSA) as the primary antibody. In both cases, HeLa cells were
incubated with primary antibody for 15 minutes at room temperature, followed by
15 minutes at room temperature with anti-mouse or anti-rabbit (Rockland
Immunochemicals) conjugated to AP. Live cells were then rinsed with DPBS, and
labeling was initiated by addition of 1 [tM BirA, 10 ýiM biotin, and 500 1 M ATP in
DPBS. The biotinylation reaction was allowed to proceed for 30 minutes at room
temperature. Biotin detection was performed by incubating the cells with 50 gg/mL
streptavidin-Alexa Fluor 568 conjugate (Invitrogen) in DPBS + 3% BSA for 12 minutes
at room temperature. After washing, the cells were imaged in DPBS with a Zeiss
Axiovert 200M inverted epifluorescence microscope using a 40x oil-immersion lens.
Alexa Fluor 568 (560/20 excitation, 585 dichroic, 605/30 emission), and differential
interference contrast (DIC) images (630/10 emission) were collected and analyzed using
OpenLab software (Improvision).
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Binding activity of antibody-biotin ligase conjugates in live cells
Testing of biotin ligase conjugates to anti-mouse IgG was performed on HeLa
cells using mouse anti-EGFR (clone LA22, Upstate, 1:25 dilution in DPBS-B) as the
primary antibody. BirA-anti-rabbit conjugates were tested on HeLa cells stably
expressing AP(ala)-CFP-TM6 using rabbit polyclonal anti-HA (Rockland
Immunochemicals, 1:50 dilution in DPBS-B) as the primary antibody. In both cases,
HeLa cells were incubated with primary antibody, followed by anti-mouse or anti-rabbit
antibodies (Rockland Immunochemicals) conjugated to BirA. Detection of anti-rabbit-
BirA was performed by incubation with mouse monoclonal anti-His 6 antibody
(Calbiochem, 1:10 dilution in DPBS-B), followed by anti-mouse antibody conjugated to
Alexa Fluor 568 (Invitrogen, 6.7 gg/mL in DPBS-B). Detection of anti-mouse-BirA was
performed by incubation with rabbit anti-BirA serum (21 st Century Biochemicals,
1:20,000 dilution in DPBS-B) followed by anti-rabbit antibody conjugated to Alexa Fluor
488 (Invitrogen, 6.7 gg/mL in DPBS-B). All antibody incubations steps were performed
for 15 minutes at room temperature. Cells were rinsed and imaged as described above.
The Alexa Fluor 488 filter set was 495/20 excitation, 515 dichroic, 530/30 emission.
Assay for proximity biotinylation of antibody-acceptor peptide conjugates by
antibody-biotin ligase conjugates in live cells
HeLa cells were rinsed with DPBS prior to incubation with primary antibodies for
15 minutes at room temperature. Thereafter, cells were rinsed three times with DPBS and
incubated for 15 minutes at room temperature with secondary antibodies conjugated to
either AP or BirA. Subsequent labeling was performed for 30 minutes at room
temperature in the presence of 10 gM biotin and 500 giM ATP, and the biotin was
detected with 50 gg/mL streptavidin-Alexa Fluor 568 conjugate (Invitrogen) in DPBS-B
for 12 minutes at room temperature. Cells were rinsed and imaged as described above.
Two different tests were performed. In the first one, anti-rabbit-BirA biotinylation of
anti-mouse-AP was tested on HeLa cells stably expressing the AP(ala)-CFP-TM plasmid6
and using rabbit polyclonal anti-HA (Rockland Immunochemicals) and mouse anti-c-myc
clone 9E10 (Calbiochem) as the primary antibodies. In the second assay, anti-mouse-
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BirA biotinylation of anti-mouse-AP was tested on HeLa cells by staining endogenous
EGFR with mouse anti-EGFR clone LA22 primary antibody (Upstate).
Fluorescent immunostaining of the epidermal growth factor receptor and some of
its effector proteins
NR6, B82K+ or A431 cells were fixed with 3.7% paraformaldehyde (PFA) for
5 minutes at 4 'C, followed by 10 minutes at room temperature. Excess PFA was washed
three times, 5 minutes each wash, with PBS and quenched with 100 mM glycine, pH 7.2
for 10 minutes at room temperature. After an additional 5-minute wash in PBS, cells were
permeabilized by incubation with 100% methanol for 6 minutes at -20 oC. Finally, cells
were rinsed twice for 10 minutes with PBS and blocked with 5% milk in PBS-Mg for
1 hour - overnight at room temperature or 4 oC with rocking. When appropriate, cells
were serum-starved for 12-24 hours, and then EGF-stimulated by incubation with
100 ng/mL epidermal growth factor (EGF) for 10 minutes at 37 'C before fixation.
Antigen detection was performed by incubating cells with 5 pg/mL of the appropriate
primary antibody for 1 hour - overnight at room temperature in a humidified chamber.
After three 10-minute washes with PBS-Mg + 0.1% Tween20, cells were incubated for
1 hour with 6.7 jtg/mL anti-rabbit or anti-mouse antibody conjugated to either Alexa
Fluor 488 or Alexa Fluor 568 (Invitrogen). After washing, the cells were imaged in PBS-
Mg with a Zeiss Axiovert 200M inverted epifluorescence microscope using a 40x oil-
immersion lens. Alexa Fluor 568 (560/20 excitation, 585 dichroic, 605/30 emission),
Alexa Fluor 488 (495/20 excitation, 515 dichroic, 530/30 emission), and differential
interference contrast (DIC) images (630/10 emission) were collected and analyzed using
OpenLab software (Improvision). The following primary antibodies were used: rabbit
polyclonal ca-EGFR (Upstate, Cat# 06-847), mouse monoclonal a-EGFR Ab-12 (Lab
Vision, Cat# MS-400-P1ABX, a cocktail with clones 111.6 + 199.12 + F4 + 11E8),
mouse a-EGFR clone 199.12 (Lab vision, Cat# MS-396-P1ABX), mouse a-EGFR clone
LA22 (Upstate, Cat# 05-104), rabbit polyclonal ct-Shc (BD Biosciences, Cat# 610081),
mouse ca-Grb2 clone E-1 (Santa Cruz Biotechnology, Cat# sc-17813), a-Src clone GD11
(Upstate, Cat# 05-184), a-Crk II clone 18 (Santa Cruz Biotechnology, Cat# sc-289),
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rabbit polyclonal c-Csk (Upstate, Cat# 06-566), rabbit polyclonal ca-Nck (Chemicon,
Cat# AB3167), and mouse a-phosphotyrosine clone 4G10 (Upstate, Cat# 05-321).
Assay for proximity biotinylation of antibody-acceptor peptide conjugates by
antibody-biotin ligase conjugates in fixed cells
NR6 or A431 cells were stimulated, fixed, and blocked as described above for
antigen immunostaining. Thereafter, blocking of endogenous biotin was performed by
incubation with 50 ýtg/mL of avidin for 1 hour at room temperature, followed by blocking
of the extra avidin sites by incubation with 100 ýiM biotin. Antigen detection was
performed by incubating cells with 5 [tg/mL of the appropriate primary antibody,
followed by the corresponding secondary anti-mouse or anti-rabbit IgGs conjugated to
biotin ligase and the acceptor peptide. After three 10-minute washes, proximity
biotinylation was initiated by addition of 10 ýpM biotin and 500 ýpM ATP in DPBS for
1 hour at room temperature. Biotin detection was performed by incubating the cells with
5 ýpg/mL streptavidin-Alexa Fluor 568 conjugate (Invitrogen) in DPBS + 5% Milk +
0.03% Tween20 for 1 hour at 4 OC followed by three 10-minute washes with DPBS +
0.1% Tween20. After washing, cells were imaged as described above.
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Chapter 4 : Proximity biotinylation for the detection of protein-protein
interactions in live cells
The majority of the work discussed in this chapter is under review for publication at the
J. Am. Chem. Soc. This project was initiated by Scott Chen, a graduate student in our lab.
The experiments described in the first section of the results (Engineering BirA/AP for
protein-protein interaction detection) as well as the determination of the rapamycin dose-
response curve were performed by Scott. Yi Zhen assisted with the in vitro kinetic
characterization of the BirA/AP(-3) pair.
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Introduction
In this chapter, we describe the development of an alternative approach to protein-
protein interaction (PPI) detection in cells, which offers a combination of spatial and
temporal resolution with a low rate of false positives. In comparison to the methods
described in Chapters 2 and 3, live-cell proximity biotinylation merges the advantages of
temporal resolution (like the ribozyme-based methodology described in Chapter 2) and
subcellular localization (like the enhanced immunofluorescence method described in
Chapter 2); albeit at the expense of studying recombinant (not endogenous) proteins.
The method is similar to the protein complementation assays (PCAs) described in
the introductory Chapter 1. In PCAs, two halves of a reporter protein are separately fused
to each interaction partner, and reporter activity or fluorescence is restored by PPI-
induced protein recombination'. Instead of two halves of a reporter protein, we proposed
to use an enzyme-substrate pair (Figure 4-1). As described in Chapter 3, E. coli biotin
ligase (BirA) is a 35 kD enzyme that catalyzes the covalent ligation of biotin to a lysine
sidechain of a 15-amino acid recognition sequence called the "acceptor peptide" (AP)2. A
crucial feature of the BirA/AP pair is that it is highly specific and orthogonal. When
expressed inside or on the surface of mammalian cells, BirA biotinylates only AP fusion
proteins and none of the endogenous mammalian proteins3' 4. Conversely, AP is not
recognized by mammalian biotin ligase5 .
In our scheme, the two proteins of interest (A and B) are fused to BirA and AP,
respectively (Figure 4-1). Upon addition of biotin to cells, BirA will ligate biotin to the
AP only if A and B are in close proximity. Subsequently, biotinylated AP can be detected
with extremely high sensitivity and specificity on fixed cells by streptavidin staining6, in
cell lysate by streptavidin blotting4,5, or on the surface of living cells by labeling with
streptavidin-fluorophore or streptavidin-quantum dot conjugates 4' 7-9. The spatial
resolution of this approach arises from the ability to image AP biotinylation through the
use of streptavidin4' 7-9. The temporal resolution comes from the rapid kinetics of
enzymatic biotinylation (kcat 12 min-') 2, as well as the speed with which biotin can be
delivered to the cytosol of mammalian cells, owing to the presence of biotin transporters
at the plasma membrane' 0 .
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Figure 4-1: Proposed scheme for the detection of protein-protein interaction in living cells
by proximity biotinylation. Each target protein (A and B) is fused to the E. coli biotin ligase
enzyme (BirA) or its 15-amino acid acceptor peptide (AP). Interaction between proteins A and B
brings BirA and AP into close proximity, resulting in the site-specific biotinylation of the
acceptor peptide by biotin ligase.
Results
Engineering BirA/AP for protein-protein interaction detection
We first tested our methodology on a well-characterized interaction. For this
proof of principle, we chose to study the interaction between the 12 kD FK506 binding
protein (FKBP12) and the FKBP12-rapamycin binding domain of the mTor protein
(FRB), whose interaction can be induced by addition of the small-molecule rapamycin 1.
There were several reasons to select this system. First, it is a high-affinity interaction that
can be modulated by addition of a small molecule. On one hand, binding of rapamycin to
FKBP12 has a dissociation constant of 0.2 nM12 . On the other hand, binding of the
FKBP12-rapamycin complex to FRB displays a Kd of 2-12 nM11'13, whereas no binding
has been observed in vitro or in vivo between FKBP12 and FRB in the absence of
rapamycin 11. This means that rapamycin can effectively act as an on-off switch of the
interaction, which eases the characterization of the PPI detection method in terms of its
rate of false positives and negatives. Second, the crystal structure of the FRB-rapamycin-
FKBP12 ternary complex had been previously solved, which showed that the C-terminal
ends of the two proteins are within - 18 A of each other14 (Figure 4-2). The crystal
structure thus served as a guide to choose the optimal enzyme and substrate fusion sites,
which bring the pair into closest proximity upon PPI. Third, the FKBP12-FRB interaction
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1
had been previously used as a proof of principle by other PCA methods1 5-20, which
allowed us to compare features among different methodologies.
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Figure 4-2: Crystal structure of the FKBP12-rapamycin-FRB ternary complex. The 12kD
FK506 binding protein (FKBP12) has been colored orange and the FKBP12-rapamycin binding
domain of the mTor protein (FRB) has been colored green. The N- and C-termina of each protein
are labeled. The small molecule rapamycin, lying at the core of the complex, is represented in a
ball and stick format. Carbon atoms are colored grey, oxygen atoms are colored red, and nitrogen
atoms are colored blue. PDB source: IFAP.
Guided by the crystal structure of the FKBP 12-rapamycin-FRB complex, we thus
created C-terminal fusions of FKBP12 and FRB to BirA and AP. In order to provide the
enzyme and substrate pair with some flexibility to search for a productive conformation,
we also introduced a 10-amino acid Gly-Ser intervening linker (Figure 4-5A; refer to the
Experimental section for a complete description of the constructs). The fusion proteins
were expressed in E. coli, purified, and tested in vitro. We incubated 1 PM of each fusion
protein with 50 pM biotin in the presence or absence of 1 jpM rapamycin, and we ran the
reaction products on an SDS-PAGE, followed by detection of ligated biotin via
streptavidin blotting. We observed stronger biotinylation of FKBP12-AP by FRB-BirA in
the presence than in the absence of rapamycin (Figure 4-3A). Similar results were
obtained when FRB was fused to AP and FKBP 12 to BirA. Quantification of the
streptavidin blot in Figure 4-3A yielded a signal/noise ratio in the presence/absence of
rapamycin of - 5. Although this dynamic range seemed modest, we decided to next test
the system in live cells, where the biotinylation levels could be dramatically different,
both in the presence and absence of rapamycin. It must also be noted that incubation at
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higher protein concentrations and longer biotinylation times both resulted in an increase
in background, which significantly reduced the dynamic range of the in vitro assay.
A B
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Figure 4-3: Proximity biotinylation in vitro and in vivo of full-length AP by FRB-BirA. (A)
In vitro reporter characterization. Purified FRB-BirA and FKBP 12-AP (original full-length AP)
proteins were combined at 1 1tM final concentration and incubated with 50 jtM biotin in the
presence or absence of 1 tM rapamycin. The extent of biotinylation of FKBP12-AP was analyzed
by streptavidin blot. (B) In vivo reporter characterization. HEK cells co-transfected with FRB-
BirA and FKBP12-AP were either treated with 100 nM rapamycin for 1 hour or left untreated.
Biotin was then added to all cells for 1 minute before lysis and analysis by streptavidin blotting.
The lower blot (a-myc) stains the myc tag in the FKBP12-AP construct.
Figure 4-4 depicts our protocol for testing the system in live cells. We transfected
human embryonic kidney (HEK) cells with the two fusion proteins and, 48 hours after
transfection, we treated the cells with rapamycin for 1 hour, followed by 50 jIM biotin for
1 minute. The cells were lysed, and ligated biotin was detected by streptavidin blotting.
add rapamycin
to cells
K>
biotin
Figure 4-4: Live cell detection of rapamycin-mediated FKBP12-FRB interaction. Cells are
first transfected with both fusion constructs; in this case, FRB-BirA and FKBP12-AP'. After
transfection, 100 nM rapamycin is added to cells for 1-3 hours to promote protein-protein
interaction. Thereafter, 50 jtM biotin is added to the cell media. Biotin enters the cells very
rapidly via cell-surface biotin transporters. Once inside, biotin is recognized by FRB-BirA, which
also uses endogenous ATP to biotinylate FKBP12-AP'. Ligated biotin can then be detected by
Western blotting of cell lysates or by immunostaining of fixed cells.
We observed little difference in biotinylation intensity with and without
rapamycin (Figure 4-3B). Because no interaction has ever been detected between FRB
and FKBP 12 in the absence of rapamycin, it was unlikely that background biotinylation
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was being caused by non-rapamycin dependent FRB-FKBP12 interactions. We
hypothesized then that the protein expression levels in HEK were much greater than the
protein concentrations used for our in vitro studies, which resulted in BirA/AP interaction
even in the absence of interaction between FRB and FKBP 12, ultimately giving rise to
increased background biotinylation. The reported KM for the interaction between BirA
and AP is 25 gM (Ref. 2), which is close to the recombinant protein concentrations that
can be expected upon transient transfection in HEK cells. Hence, our first approach to
decrease background biotinylation was to reduce intracellular protein concentrations. We
achieved this by reducing the amount of DNA used for transfection. Although reduced
DNA resulted in decreased protein concentrations as observed by a-myc (FKBPl2-AP)
and a-HA (FRB-BirA) blotting, the signal/background ratio remained almost unchanged
(data not shown). Other variations to the experimental protocol, such as depleting the cell
growth media from biotin after transfection or decreasing biotin concentration during the
labeling, all failed to increase the +/- rapamycin signal ratio in cells to greater than - 1.3.
We thus decided to shift our attention toward a more fundamental change in the system,
that of the interaction affinity between BirA and AP.
We reasoned that reduction of BirA affinity for AP (i.e., increase in KM) could
preferentially decrease the extent of biotinylation of non-complexed AP compared to
complexed AP. This was based on the fact that complexed AP, within the context of a
PPI, should have a much higher effective concentration with respect to BirA than free
AP. Although we acknowledged that it was difficult to engineer AP KM without also
affecting biotinylation kcat, we also recognized that we had some leeway in terms of the
speed of the catalytic reaction. To label protein complexes with half-life greater than
1 minute, we required only a biotinylation kat of 1 min-1 or greater; which matched well
with our typical time of biotin delivery to living cells of - 1 minute.
To engineer the affinity of the BirA/AP interaction, we truncated the 15-amino
acid sequence of the AP at the C-terminus, the N-terminus, or both (Figure 4-5A). We
hoped that these truncations would decrease the interaction surface area with the
BirA active site, potentially leading to a higher KM. Although it was hard to predict how
these mutations would affect the rate of catalysis, we expected that at least some activity
would be retained, since the residues around the catalytic lysine were not perturbed. We
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fused the truncated AP variants to FKBP12 and we expressed them in HEK cells,
together with FRB-BirA. We observed a wide range of biotinylation intensities in the
presence and absence of rapamycin (Figure 4-5B). We were delighted to see that the
signal/background ratio was increased for all the truncated variants compared to that of
the full-length AP. For all the AP truncation mutants, the background level of
biotinylation in the absence of rapamycin did decrease. However, many times the
+rapamycin signal also decreased. The best construct was the AP(-3) peptide, with three
residues deleted from the C-terminal end of AP, which displayed the lowest -rapamycin
signal but a +rapamycin signal comparable in intensity to that of the original full-length
AP (signal/background ratio - 8.5). We selected this new peptide for further
characterization.
A
FRB H G L N D IF E A Q K I E W H E
KLNDIFEAQKIEWHE
GSGSTSGSGK KGNDIFEAQKIEWHE
linker KG G DIFEA Q K IE WHE
FKBP*AP' GLNDIFEA Q K IE WE F
GLNDIFEAQKIEGEF
GSGSTSGSGK K LNDIFEA Q K IE WE F
linker K G N D IF E A Q K I E W E F
Original AP
(-1)AP
(-2)AP
(-3)AP
AP(-2)
AP(-3)
(-1)AP(-2)
(-2)AP(-2)
B
Original AP AP(-2) (-2)AP (-1)AP(-2) (-3)AP (-2)AP(-2) AP(-3)
- + - + - + - + - + - + - + rapamvcin
streptavidin
blot
a-myc blot
+/- rapamycin
1.3 1.5 1.5 1.5 2.5 6.8 8.5 signal ratio
Figure 4-5: Engineering the BirA/AP pair. (A) Left: domain structures of constructs used to
test the methodology in vitro and in living cells. Right: FKBP12 was fused to the original AP
sequence as well as to 7 truncated variants of the AP. The lysine biotinylation site is underlined.
Placeholder amino acids inserted at truncation sites are colored green. (B) Comparison of AP
mutants in a live cell assay. HEK cells co-transfected with FRB-BirA and one of the FKBP12
fusions to a truncated AP (FKBP12-AP') were either treated with 100 nM rapamycin for 1 hour
or left untreated. Biotin was then added to all cells for 1 minute before lysis and analysis by
streptavidin blotting. The lower blot (a-myc) stains the myc tag in each of the FKBP12-AP'
constructs. The +/- rapamycin ratio was calculated from the streptavidin blot signals.
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Characterization of the new BirA/AP(-3) pair
We first performed a series of optimizations to maximize the +/- rapamycin signal
intensity for the FRB-BirA/FKBP12-AP(-3) pair. It had been previously reported that the
effect of rapamycin when added to mammalian cells reaches a maximum after
- 3 hours16 . Increasing the rapamycin incubation time from 1 to 3 hours, in combination
with reduced protein expression levels, resulted in an increase of the signal/background
ratio to - 12.5 (Figure 4-6, lanes 1 and 2) from the original 8.5 (Figure 4-5B, last two
lanes). Second, we used a mitochondrial activity test to determine the effect of biotin-
starvation on cell health. We found that shortening the time of incubation of cells in
biotin-free media from the original 24 hours to - 12 hours, resulted in an optimal balance
between the requirements for minimal background biotinylation of AP(-3), and
maintenance of cell health. With these new conditions, biotin-starved cells exhibited a
99% + 5% of surviving cells when compared to control untransfected cells. Notably,
transient transfection of the same cells resulted in higher toxicity (86% ± 4% of surviving
cells) than that observed for biotin-starvation. Third, we performed several tests of
labeling specificity in live HEK cells. Figure 4-6 shows that biotinylation of FKBP12-
AP(-3) is both site-specific (K-+A mutant, lane 4) and dependent on BirA activity
(K183R mutant, lane 5). We also showed that omission of biotin resulted in no
modification of FKBP12-AP(-3) (lane 3).
1 2 3 4 5
- - - - + BirA K183R mutant
- - - + - AP(-3) K--A mutant
+ + - + + biotin
- + + + + rapamycin
Streptavidin
a-myc
(FKBP detection)
Figure 4-6: Analysis of detection specificity in living cells. HEK cells co-transfected with
FRB-BirA and FKBP12-AP(-3) were treated with rapamycin and biotin, lysed, and analyzed by
streptavidin blotting. Lanes 1 and 2 show the increase in FKBP12-AP(-3) biotinylation upon
rapamycin addition. Lane 3 is a negative control where biotin was omitted. Lane 4 shows a
negative control with FKBP12-AP(-3) replaced by an alanine mutant at the lysine biotinylation
site. Lane 5 shows a negative control in which the FRB-BirA fusion was replaced with a
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catalytically-inactive mutant, FRB-BirA (Ki83R). The ct-myc blot demonstrates equal expression
of FKBP12-AP(-3) in all lanes.
Next, we tested the fusion proteins in vitro and observed good signal to
background ratios at two different protein concentrations, 100 nM and 1 gM (Figure 4-7).
Notably, the -rapamycin background signal using 1 gM protein was much lower than that
obtained using the original BirA/AP pair (Figure 4-3A), which resulted in an increase in
the signal/background ratio in vitro from - 5 for the original AP to - 23 for AP(-3). The
strong +rapamycin signal obtained at 100 nM protein demonstrates the high sensitivity of
this reporter system at low protein concentrations.
A B
1 pM FRB-BirA 100 nM FRB-BirA
1 pM FKBP-AP(-3) 100 nM FKBP-AP(-3)
- 4. ranamrnin
Figure 4-7: In vitro characterization of the BirA/AP(-3) pair. Purified FRB-BirA and
FKBP 12-AP(-3) proteins were combined at either 1 gM (A) or 100 nM (B). After incubation with50 gM biotin for 1 minute (A) or 5 minutes (B) in the presence or absence of 1 gM rapamycin,the extent of biotinylation of FKBP12-AP(-3) was analyzed by streptavidin blot. The +/-
rapamycin signal intensity ratios are - 23 (A) and - 17 (B).
We also performed kinetic measurements to characterize the BirA/AP(-3) pair.
For this purpose, we fused AP(-3) to HP1, a chromodomain protein that we were able to
express at very high levels in E. coli, and that had been previously used in our lab to
determine the biotinylation kinetics of a different acceptor peptide by yeast biotin
ligase 2 1. We used a 3H-biotin filter binding assay to estimate the Michaelis-Menten curve
(Figure 4-8). We obtained a KM of 345 + 19 pM and a kcat of 0.53 ± 0.01 min- '. The new
KM was 14-fold greater than the original KM of 25 pM for full-length AP 2. This increase
in KM explained the lower background in the cellular experiments. Although the kcat for
ligation of biotin to AP(-3) was 23-fold slower than to AP (12 min-') (Ref. 2), the
reaction should still be fast enough to robustly label protein complexes with half-life
greater than - 1 minute in cells.
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Figure 4-8: Kinetics of AP(-3) biotinylation by BirA. The Michaelis-Menten curve shows the
initial rates of BirA biotinylation of an HP1-AP(-3) fusion protein, as a function of HP 1-AP(-3)
concentration. BirA concentration was 3.3 1iM. Each data point represents the average of three
independent experiments. Error bars, ± 1 s.d.
An ideal PPI detection method should also be capable of estimating interaction
Kds. To test if our method was capable of such quantification, we obtained a dose-
response curve for rapamycin in living cells. HEK cells co-expressing FRB-BirA and
FKBPl2-AP(-3) were treated with various concentrations of rapamycin, lysed, and
analyzed by streptavidin blotting. The dose-response curve in Figure 4-9 shows a
saturable single-site binding curve with an apparent Kd of 10 nM, which matches the
reported in vitro Kd for the FKBP12-rapamycin interaction with FRB of 12 nM 13. Our
results are also in accordance with those obtained using the split-luciferase (Kd
1.5 ± 0.3)16 and split-13-lactamase (Kd 5 nM) 15 methodologies.
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Figure 4-9: Dose-response curve of rapamycin in live cells. The sigmoidal curve shows the
biotinylation response to increasing concentrations of rapamycin. HEK cells were co-transfected
with FRB-BirA and FKBP12-AP(-3), incubated with various concentrations of rapamycin for
1 hour, then treated with biotin for 1 minute before lysis. The graph shows the normalized
FKBP12-AP(-3) biotinylation signal intensities from three independent experiments. Error bars,
± 1 s.d.
Optimizing the BirA/AP(-3) pair for the detection of protein-protein interactions in
mammalian cells
Although engineering the affinity between BirA and AP did indeed result in an
increase of the signal/background ratio, it is clear from Figure 4-6 that certain non-PPI-
mediated interaction between BirA and AP(-3) still remained when the constructs were
expressed at high concentrations in mammalian cells. We thus wished to further decrease
the rate of false positives (i.e., -rapamycin signal) by controlling the concentrations of
the FRB-BirA and FKBP12-AP(-3) proteins.
In the previous section, we attempted to decrease protein concentration by
decreasing the amount of DNA added during tranfection. In our experience, however, this
approach has a very limited dynamic range, and it is only successful for moving from
extremely high to high or medium protein concentrations. We then decided to transfer the
FRB-BirA and FKBP12-AP(-3) constructs into a plasmid that expresses the protein under
the regulation of a tetracycline operator. Specifically, we used the T-RExTM System
developed by Invitrogen. Tetracycline regulation in the T-RExTM System is based on the
binding of tetracycline to the Tet repressor, which releases the repressor and results in
derepression of the promoter controlling expression of the gene of interest2 2 . We cloned
the constructs into the tetracycline-inducible plasmid pcDNA4-Tet and we transfected
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HEK cells stably expressing the Tet repressor (T-RExTM-293). We performed the
proximity biotinylation assay as before, except that varying amounts of tetracycline were
added to the cell media after transfection. Briefly, right after transfection, we incubated
the cells in biotin-free media containing tetracycline for - 16-24 hours. Thereafter, we
treated the cells with rapamycin for 3 hours, followed by 50 gM biotin for 1 minute. The
cells were lysed, and ligated biotin was detected by streptavidin blotting. As expected,
reducing protein concentrations resulted in a marked increased in the signal/background
ratio, albeit to the expense of reducing the overall signal (Figure 4-10). In the case of the
FRB-FKBP12 interaction, a tetracycline concentration of - 0.3 plg/mL provided an
optinal balance between minimal false positives and a detectable signal. The optimal
tetracycline concentration would need to be determined for every new protein-protein
interaction under study.
pcDNA4-Tet pcDNA3
0 0.1 0.2 0.4 0.6 0 [tetracycline] ug/mL
- + - + - + - + - + - + rapamycin
streptavidin blot
a-myc blot
ND 28.4 21.1 12.3 12.2 11.5 +/- rapamycin signal ratio
Figure 4-10: Titration of protein concentration in the proximity biotinylation detection of
PPIs. T-RExTM-293 cells were co-transfected with FRB-BirA and FKBP12-AP(-3), and protein
expression was induced with varying amounts of tetracycline ranging from 0-0.6 gg/mL. Cells
were then treated with rapamycin for 3 hours (+rapamycin) or left untreated (-rapamcyin). Biotin
was then added to all cells for 1 minute before lysis and analysis by streptavidin blotting. The
a-myc blot confirms that the expression levels ofFKBP12-AP(-3) increased with increasing
concentrations of tetracycline. The +/- rapamycin ratio was calculated from the streptavidin blot
signals. The same experiment was also performed in parallel on regular HEK cells transfected
with the original non-tetracycline inducible plasmid (pcDNA3). The results are shown for
comparison (last two lanes).
Thus, the new BirA/AP(-3) pair was able to, under optimal conditions, result in a
- 25-fold signal induction upon addition of rapamycin. As previously mentioned, other
PPIs methods have used the same proof of principle interaction, which allowed us to
compare our results. Only the split-P3-galactosidase system was reported to result in a
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higher fold of signal induction (- 30-fold) upon addition of rapamycin to C2C12 cells'.
However, the high signal induction afforded by the 3-galactosidase system is a reflection
of its enzymatic signal amplification, which, although useful for enhancing sensitivity,
renders the system not amenable to quantification and can potentially increase the rate of
false positives. In contrast, the two most popular PCAs, split-P-lactamase and split-
luciferase, both result, under similar conditions, in lower signal induction folds (- 10-fold
for p-lactamase 20 and - 6-fold for luciferase 16).
Finally, we used a mobility shift assay to quantify the extent of FKBP12-AP(-3)
biotinylation under different tetracycline concentrations (Figure 4-11). T-RExTM-293 or
HEK cells were transfected and treated with rapamycin and biotin as before. After lysis,
cell extracts were incubated with excess soluble streptavidin, which bound biotinylated
FKBP12-AP(-3). Binding mixtures were then run in an SDS-PAGE without boiling to
preserve the biotin-streptavidin binding, and both, unmodified and biotinylated protein,
were detected by a-myc blotting. Figure 4-11 shows the mobility shift caused by
streptavidin binding to biotinylated FKBP-AP(-3). It must be noted that, owing to the size
difference, the efficiency of the transfer to nitrocellulose varies for the biotinylated and
unmodified proteins, which explains the much lower ca-myc signal for the streptavidin-
bound protein. For this reason, we quantified the extent of biotinylation by comparing the
a-myc signal for unmodified FKBP12-AP(-3) (lower bands) in the - and + streptavidin
lanes, at each tetracycline concentration. The results are expressed as the percentage of
the total FKBP12-AP(-3) that was biotinylated in the cells (Figure 4-11). The percentage
biotinylation ranged from 6-8%. As expected, no significant differences were observed
for the different tetracycline concentrations. These results are thus in agreement with the
previous ones (Figure 4-10). Since the percentage of biotinylated protein remains
relatively constant across tetracycline concentrations, the overall biotinylation signal
increases solely as a function of the total protein concentration.
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Figure 4-11: Quantification of the extent of biotinylation of FKBP12-AP(-3) at different
cellular protein concentrations. T-REx-HEK cells were co-transfected with FRB-BirA and
FKBP12-AP(-3), and protein expression was induced with varying amounts of tetracycline
ranging from 0.1-0.8 [tg/mL. Cells were then treated with rapamycin and biotin, and lysed. The
lysates were incubated in the presence or absence of excess streptavidin (-/+ streptavidin) and
analyzed by a-myc blotting. Biotinylated protein (FKBP12-AP(-3)-Bio) is separated from
unmodified protein based on the mobility shift caused by streptavidin binding to biotin. The
upper bands correspond to shifted, biotinylated protein, whereas the lower bands correspond to
unmodified FKBP12-AP(-3). The extent of biotinylation was calculated from the -/+ streptavidin
difference in the ct-myc signal of unmodified FKBP12-AP(-3) (lower bands). The same
experiment was also performed in parallel on regular HEK cells transfected with the original non-
tetracycline inducible plasmid (pcDNA3). The results are shown for comparison (last two lanes).
Imaging the rapamycin-dependent interaction between FRB and FKBP12 in
mammalian cells
One of the main features of the proximity biotinylation method is its ability to
provide information on the subcellular localization of the PPI. This is the case because, in
contrast to the diffusible small-molecule substrates of luciferase and 13-lactamase, biotin
remains covalently bound to one of the interacting partners. To demonstrate this feature,
we once again performed detection of the FRB-FKBP12 interaction in live cells, but we
then detected the ligated biotin by streptavidin staining of fixed cells instead of western
blotting. Specifically, HEK cells co-expressing FRB-BirA and FKBP12-AP(-3) were
incubated in biotin-free media for 12 hours, to minimize background both from AP(-3)
and from the four endogenous protein substrates of mammalian biotin ligase23 . The cells
were then treated with 100 nM rapamycin for 3 hours, followed by 50 tM biotin for
1 minute, then fixed and stained with streptavidin conjugated to Alexa Fluor 568.
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Figure 4-12: Imaging the FRB-FKBP12 interaction in the cytoplasm of HEK cells. HEK
cells were co-transfected with FRB-BirA and FKBP12-AP(-3). After 3 hours incubation with
100 nM rapamycin, cells were labeled with biotin for 1 minute, then fixed and permeabilized with
formaldehyde/methanol, and stained with streptavidin-Alexa Fluor 568. Anti-HA staining was
also performed to detect expression of HA-FRB-BirA. Streptavidin labeling is shown in red to the
right of merged DIC (differential interference contrast) and anti-HA (yellow) images. Controls
are shown with rapamycin omitted, an alanine mutation in AP(-3), and a K183R mutation in
BirA.
The top row of Figure 4-12 shows that transfected cells, as indicated by
immunostaining of the HA epitope in the FRB-BirA protein, were biotinylated. In
contrast, neighboring untransfected cells in the same field of view show no signal.
Quantification of several samples gave a +/-rapamycin signal ratio of - 5.1. This 5-fold
induction with rapamycin was similar to results obtained with split-luciferase technology
under similar conditions1 6. Although streptavidin staining of transfected cells in the
-rapamycin control was above background staining of untransfected cells, the signal on
those cells was always significantly lower than the signal observed in the +rapamycin
samples. This demonstrated the low rate of false positives that characterizes the
proximity biotinylation assay. A negative control where the lysine site of modification in
AP was mutated to an alanine showed no labeling, thus confirming the site-specificity of
the labeling. We also performed an additional control by mutating Lysine 183 in BirA,
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which had been previously suggested to be involved in catalysis24. The Lysl83Arg
mutation negative control also showed no labeling, which confirmed the dependence of
the labeling on BirA activity.
To further illustrate the capability of proximity biotinylation to provide
subcellular localization, we appended a nuclear localization signal (NLS) to FRB-BirA
and FKBP12-AP(-3). We performed the imaging experiment as before, except that we
used the tetracycline-inducible system, and treated the T-RExTM-293 cells with
0.4 gg/mL tetracycline, concentration that we found optimal for the nuclear proteins. The
results are shown in Figure 4-13.
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Figure 4-13: Imaging the FRB-FKBP12 interaction in the nucleus of HEK cells. T-Rex HEK
cells were co-transfected with the indicated nuclear or cytosolic FRB-BirA and FKBP12-AP(-3)
plasmids, and protein expression was induced with 0.4 ýtg/mL tetracycline for 16-24 hours. After
3 hours incubation with 100 nM rapamycin, cells were labeled with biotin for 1 minute, then
fixed and permeabilized with formaldehyde/methanol, and stained with streptavidin-Alexa Fluor
568. Anti-HA and anti-myc stainings were also performed to detect expression of HA-FRB-BirA
and Myc-FKBP12-AP(-3). Streptavidin labeling is shown in purple to the right of merged DIC
(differential interference contrast) and anti-HA (yellow) images, and the anti-myc (red) images.
We observed clear nuclear staining when both, FRB-BirA and FKBP12-AP(-3)
were targeted to the nucleus (Figure 4-13, upper panels). The streptavidin signal was
highly concentrated in the nucleoli, where FRB-BirA was also in greater abundance. As
expected, the streptavidin staining remained nuclear when the nuclear constructs were
combined with the non-targeted ones (Figure 4-13, middle and lower panels). Notably,
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FRB-BirA translocated to the nucleus when co-expressed with NLS-FKBP12-AP(-3)
only in the presence, but not in the absence, of rapamycin treatment.
Conclusions
In this chapter, we have described a new methodology to detect PPIs in vitro and
in living cells via an enzyme-substrate interaction rather than reporter protein
reconstitution. We tuned the BirA/AP affinity to reduce background and eliminate false
positives, while still allowing robust detection of relatively transient PPIs (half-life >
1 minute). We demonstrated that the methodology exhibits high specificity for the
detection of PPIs in living mammalian cells, with a fold induction in the detected signal
upon PPI of- 5-25, depending on whether imaging or Western blotting were used for
readout. We also showed that careful control of protein concentration in cells (e.g., using
a tetracycline-inducible system) resulted in a - 2.5-fold increase in the dynamic range of
the assay. As seen for the FRB-FKBP12 system, the BirA/AP(-3) pair was also able to
quantitatively predict interaction Kds. Importantly, we showed that proximity
biotinylation can detect the subcellular localization of the PPI under study, at least in the
cytosol and the nucleus of mammalian cells.
Table 4-1 compares the features of proximity biotinylation to those of the most
popular methods to detect cellular PPIs. Although the methodology is restricted to
analysis of a single time-point, due to the requirement for cell fixation or lysis before
streptavidin detection, it still bridges many of the positive features of existing PCAs,
including good spatial resolution and rapid response time in mammalian cells. Biotin is
readily taken up by all cell types by a combination of passive diffusion and active
transport via biotin transporters 0o. In contrast, the split-13-lactamase technology is limited
by the impermeability of its small-molecule substrate in many cell types25. An additional
improvement over most PCAs is the reversible nature of the BirA/AP interaction, which
minimizes perturbation to the PPI under study.
Last, as it was mentioned in the introductory Chapter 1, an important extension of
any cellular PPI detection method is the discovery of new protein interaction partners
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through library screens. Proximity biotinylation should be particularly well-suited for this
application because the biotin label used for detection can also be a handle for protein
purification using streptavidin-conjugated beads.
Table 4-1: Comparison of proximity biotinylation to FRET and protein fragment
complementation assays. (1) Although, in general the temporal resolution of split-GFP is
limited by the time required for GFP maturation, a recently developed split-GFP system was
reported to mature within minutes of DNA hydridization26. (2) Most reported split-luciferase
systems result in the irreversible re-constitution of luciferase activity; however, a split-luciferase
system capable of quantifying dynamic interactions was recently reported 27
Intermolecular
FRET
Split-GFP
Split-3-
lactamase
Split-
luciferase
Proximity
biotinylation
Moderate
High
High
High
Low
High
Low
Low
Low
Low
Yes
Yes
No
No
Yes
Yes
No (1)
Yes
Yes
No
Yes
Yes
Yes (2)
No
No
No
Yes
No
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Experimental
Cloning and mutagenesis
Note: nucleotides encoding AP sequences are underlined, and nucleotides encoding
epitope tags are italicized.
FRB-BirA-pET21b bacterial expression plasmid
The human FRB gene (a gift from Paul Clemons, Broad Institute) was PCR-
amplified using the primers 5' -AAA AGG ATC CGT ATC CGT ACG ACG TAC CAG ACT
ACG CAA TGT GGC ATG AAG GCC TG and 5' -TTT TGA ATT CTT TGC CCG AGC CCG AGG
TCG AGC CCG AGC CCT TTG AGA TTC GTC GGA A to introduce a BamHI site and an HA
tag (YPYDVPDYA) at the N-terminus, and a 10-amino acid linker (GSGSTSGSGK) and
an EcoRI site at the C-terminus. The E. coli BirA gene was PCR-amplified using the
primers: 5'-AAA AGA ATT CAT GAA GGA TAA CAC CGT G and 5'-TTT TAA GCT TAT
TTT TCT GCA CTA CG, digested with EcoRI and HindIII, and pasted into an
EcoRI/HindIII-digested pRSETb vector (Invitrogen) to create a BirA-pRSETB plasmid.
The FRB PCR product was then digested with BamHI/EcoRI and ligated into
BamHI/EcoRI-digested BirA-pRSETh plasmid, to give an FRB-BirA-pRSETb plasmid.
This gene was then PCR-amplified with the primers: 5' -AAA AGG ATC CGT ATC CGT
ACG ACG TAC CAG ACT ACG CAG AGA TGT GGC ATG AAG GCC TG and 5'-TTT TAA GCT
TTT TTT CTG CAC TAC GCA GGG ATA TT and ligated into the BamHI and HindIII sites
of pET2 Ib (Novagen) to give FRB-BirA-pET2 lb.
FKBP12-AP-pET21b and FKBP12-AP(-3)-pET21b bacterial expression plasmids
PCR of the human FKBP12 gene (a gift from Paul Clemons, Broad Institute) was
performed using the primers 5' -GAT AAG GAT CCG GAA CAA AAA CTT ATT TCT GAA
GAA GAT CTG GGA GTG CCA GGT GGA AAC CAT CTC C and 5'-CAT CAT GAA TTC CTC
GTG CCA CTC GAT CTT CTG GGC CTC GAA GAT ATC GTT CAG GCC TTT GCC CGA GCC
CGA GGT CGA GCC CGA GCC TTC CAG TTT TAG AAG CTC CAC ATC G to introduce a
myc tag (EQKLISEEDL) and a BamHI site at the N-terminus, and the AP sequence
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(GLNDIFEAQKIEWHE), a 10-amino acid linker (GSGSTSGSGK), and an EcoRI site at
the C-terminus. The PCR product was ligated into the BamHI and EcoRI sites of
pRSETb (Invitrogen), to obtain FKBP12-AP-pRSETb.
Using this plasmid as a template, a second PCR was performed using the primers
5'-GAT AAG GAT CCG GAA CAA AAA CTT ATT TCT GAA GAA GAT CTG GGA GTG CCA
GGT GGA AAC CAT CTC c and 5'-TTT TGA ATT CTC GTG CCA CTC GAT CTT CTG
GGc. The PCR product was digested, and ligated into the BamHI and EcoRI sites of
pET2 lb (Novagen) to obtain FKBP 12-AP-pET21 b.
FKBP12-AP(-3)-pET2lb was created using FKBP12-AP-pET2lb as a PCR
template and the primers 5' -GAT AAG GAT CCG GAA CAA AAA CTT ATT TCT GAA GAA
GAT CTG GGA GTG CAG GTG GAA ACC ATC TCC and 5'-TTT TGA ATT CTT AGA ACT
CCC CCT CGA TCT TCT GGG CCT CG. The PCR product was digested, and ligated into
the BamHI and EcoRI sites of pET21b (Novagen).
FRB-BirA-pcDNA3 mammalian expression plasmid
To create the FRB-BirA-pcDNA3 construct, the EcoRI site in FRB-BirA-
pRSETB was first abolished by QuikChange using the forward primer 5' -GGG CTC GGG
CAA AGA GTT CAT GAA GGA TAA CAC and its reverse complement. The FRB-BirA gene
was then amplified by PCR using the primers 5' -AAA AGG ATC CGT ATC CGT ACG ACG
TAC CAG ACT ACG CAG AGA TGT GGC ATG AAG GCC TG and 5'-TTT TGA ATT CTT TTT
CTG CAC TAC GCA GGG ATA TT, followed by ligation into the BamHI and EcoRI sites of
pcDNA3 (Invitrogen).
FKBP12-AP-pcDNA3 and FKBP12-AP(-3)-pcDNA3 mammalian expression plasmids
Both constructs were created by PCR of the corresponding pET2 b templates
using the primers 5' -GAT AAG GAT CCG GAA CAA AAA CTT ATT TCT GAA GAA GAT
CTG GGA GTG CAG GTG GAA ACC ATC TCC and 5' -TTT TGA ATT CCC CCT CGA TCT
TCT GGG CCT CG followed by ligation of the PCR product into the BamHI and EcoRI
sites of pcDNA3 (Invitrogen).
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HPJ-AP(-3)-pET21a bacterial expression plasmid
The HP1 gene was PCR-amplified with the primers: 5' -TTT CGC GGA TCC GCA
CCA CCA CCA CCA CCA CGA GGA GGA GTA CGC CGT G and 5'-TTT TGA ATT CAT TAG
AAC TCC CCC TCG ATC TTC TGG GCC TCG to introduce a BamHI site and a His 6 tag at
the N-terminus, and the AP(-3) tag and an EcoRI site at the C-terminus. The PCR product
was ligated into the BamHI and EcoRI sites of pET2la (Novagen).
Site directed mutagenesis on AP and BirA
The alanine mutant of the FKBP12-AP(-3)-pcDNA3 plasmid was obtained by
QuikChange using 5' -GAT ATC TTC GAG GCC CAG GCG ATC GAG GGG GAA TTC and its
reverse complement. The K183 mutation on FRB-BirA-pcDNA3 was performed by
QuikChange using 5' -CTG CAG GAT CGC AGG CTG GCA GGC ATT CTG G and its reverse
complement.
FRB-BirA-pcDNA4-Tet and FKBP12-AP-pcDNA4-Tet mammalian expression plasmids
Both constructs were created by direct digestion from the corresponding pcDNA3
plasmids followed by ligation into the HindIII and EcoRI sites of pcDNA4-Tet.
NLS-FKBP-AP(-3)-pcDNA4-Tet mammalian expression plasmid
The Myc-FKBP-AP(-3) gene was PCR-amplified from the corresponding
pcDNA3 plasmid with the primers: 5' - GGT ATG GCT AGC ATG ACT GGT G and s' -
TTT GAA TTC TTA CAC CTT GCG CTT CTT CTT GGG CAC CTT GCG CTT CTT CTT GGG
CAC CTT GCG CTT CTT CTT GGG GCC GCC CTC GAT CTT CTG GGC CTC G to introduce
an NheI site at the N-terminus, and three tandemly repeated nuclear localization signals
(NLS, protein sequence PKKKRKVPKKKRKVPKKKRKV) and an EcoRI site at the
C-terminus. The PCR product was ligated into the NheI and EcoRI sites of pcDNA4-Tet
(Invitrogen).
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NLS-FRB-BirA-pcDNA4-Tet mammalian expression plasmid
The HA-FRB-BirA gene was PCR-amplified from the corresponding pCDNA3
plasmid with the primers: 5' - GGT ATG GCT AGC ATG ACT GGT G and 5' - TTT GAA
TTC TTA CAC CTT GCG CTT CTT CTT GGG CAC CTT GCG CTT CTT CTT GGG CAC CTT
GCG CTT CTT CTT GGG GCC TTT TTC TGC ACT ACG CAG GG to introduce an Nhel site
at the N-terminus, and three tandemly repeated nuclear localization signals (NLS, protein
sequence PKKKRKVPKKKRKVPKKKRKV) and an EcoRI site at the C-terminus. The
PCR product was ligated into the NheI and EcoRI sites of pcDNA4-Tet (Invitrogen).
Expression and purification of recombinant FKBP12, FRB, and HP1 fusion proteins
E. coli BL21(DE3) cells transformed with one of the pET21 expression plasmids
were amplified in LB media supplemented with 100 jtg/mL ampicillin at 37 oC until
OD600 0.9. Protein expression was induced with 100 pg/mL IPTG for 3 hours at 30 oC.
Cells were harvested by centrifugation and the pellet was resuspended in lysis buffer
(50 mM Tris base, 300 mM NaC1, pH 7.8) containing 2.5 mM PMSF and protease
inhibitor cocktail (Calbiochem). Cells were lysed by ultrasonic treatment (six 15-second
bursts, with 1 minute of cooling to 4 oC between bursts). The extract was cleared by
centrifugation (17,700 g, 10 minutes, 4 'C) and the His6-tagged protein was purified
using Ni-NTA agarose (Qiagen). Fractions were analyzed by 12-16% SDS-PAGE
followed by Coomassie staining. Fractions containing protein were pooled and dialyzed
against PBS pH 7.4. Protein concentrations were measured using the BCA assay (Pierce)
with BSA as the reference standard. Purified proteins were stored in PBS pH 7.4 at
-80 'C for up to 6 months.
In vitro FKBP12-FRB interaction assay
Purified FRB-BirA and FKBP12-AP(-3) (or FKBP12-AP) proteins were
combined at either 1 jpM or 100 nM in PBS supplemented with 50 PM biotin, 5 mM
MgCl 2, and 1 p.M rapamycin. Parallel reactions were run with rapamycin omitted.
Reactions were initiated with addition of 5 mM ATP, and incubated at room temperature
for 1 minute (for 1 p.M protein reactions) or 5 minutes (for 100 nM protein reactions),
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before quenching with 0.1 volume of 500 mM EDTA pH 8.0. Reaction products were
analyzed by streptavidin blotting, as described below.
Western blotting
Cell lysates or in vitro reaction products were combined with SDS-PAGE loading
buffer containing 2-mercaptoethanol, boiled, run on a 16% SDS-PAGE gel, and
transferred to nitrocellulose membrane. For lysate analysis, approximately 105 cells were
loaded in each lane. For analysis of in vitro reactions, 20 piL of each reaction was loaded
per lane. Membranes were blocked with TBS + 0.05% Tween 20 (TBS-T) and 3% BSA
for 1 hour. For streptavidin blotting, the membrane was incubated with 0.67 gg/mL
ImmunoPure streptavidin-horseradish peroxidase conjugate (Pierce) in TBS-T + 3% BSA
for 40 minutes, followed by four 5-minute washes in TBS-T. For anti-myc blotting, the
membrane was first incubated with 10 gg/mL mouse anti-c-myc antibody (Calbiochem)
in TBS-T + 3% BSA for 45 minutes, then washed three times. The membrane was then
incubated with anti-mouse horseradish peroxidase conjugate (Bio-Rad) in TBS-T + 3%
BSA at 1:2000 dilution for 45 minutes, followed by three rounds of 5 minute washes with
TBS-T. Blots were developed with Supersignal West Pico or Femto substrate (Pierce),
and images were taken on a Chemilmager 5500 instrument (Alpha Innotech). The
intensity of each band was quantified using AlphaEase FC version 3.2.2 software (Alpha
Innotech).
Comparison of FKBP12-AP' truncation mutants in live cells
HEK 293T cells were grown in DMEM with 10% FBS, 50 units/mL penicillin,
and 50 gtg/mL streptomycin, and co-transfected with FRB-BirA-pcDNA3 and FKBP12-
AP'-pcDNA3 in a 1:1 ratio using Lipofectamine 2000 (Invitrogen). After transfection, the
cells were grown in culture media depleted of biotin. Biotin-free media was prepared by
incubating with streptavidin agarose slurry (Novagen) (100 gL agarose per 1 mL media)
for 30 minutes at room temperature, followed by filtering. After 48 hours of transfection,
the appropriate amount of rapamycin (prepared as a 1 mM stock in DMSO) was added to
the culture media to a final concentration of 100 nM, and the cells were incubated for an
additional 1 hour at 37 'C. Thereafter, the media was replaced with pre-warmed PBS-Mg
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and 10 tM biotin for 1 minute. The cells were then washed three times with ice-cold
PBS-Mg to stop the biotinylation reaction. To analyze biotinylated proteins, cells were
resuspended and lysed in triton lysis buffer (1% Triton X-100, 150 mM NaC1, 5 mM
EDTA, 20 mM Tris pH 7.4, 2 mM PMSF, and 1% protease inhibitor cocktail
(Calbiochem)) for 20 minutes on ice. The supernatant was either stored at -80 oC or
analyzed immediately by western blotting as described above.
Analysis of detection specificity in live cells
HEK 293T cells were grown in DMEM with 10% FBS, 50 units/mL penicillin,
and 50 p.g/mL streptomycin, and co-transfected with FRB-BirA-pcDNA3 and FKBP12-
AP(-3)-pcDNA3 in a 1:1 ratio using Lipofectamine 2000 (Invitrogen). For the negative
controls, the appropriate plasmids were co-transfected to express the FRB-BirA(Kl83R)
or FKBP12-AP(-3)-Ala mutants. After transfection, the cells were grown in culture
media supplemented with 50 jig/mL of soluble streptavidin to deplete the biotin in media.
After 12-16 hours of transfection, the cells were incubated for 3 hours at 37 OC in the
presence or absence of 100 nM rapamycin. The media was then replaced with pre-
warmed PBS-Mg and 50 pM biotin for 1 minute. Thereafter, the cells were washed,
lysed, and analyzed as above.
Measurement of kcat and KM for AP(-3) biotinylation by BirA
Kinetic measurements were performed by incubating different concentrations of
the HP1-AP(-3) fusion protein (50-1000 gM) with 3.3 giM BirA, 1 mM biotin, 400 nM
3H-biotin, 5 mM magnesium acetate, and 1% BSA in 50 mM bicine buffer pH 7.4. The
reactions were initiated with addition of 4 mM ATP to the pre-warmed (30 °C) mixture.
The reactions were incubated at 30 oC, and 10 piL aliquots were removed every
30 minutes and quenched with 10% TCA (final concentration). The quenched reaction
mixtures were then diluted to give a final concentration of 50 jIM HP1-AP(-3) and
spotted onto phosphocellulose circles that had been pretreated with 1 mM biotin and 10%
TCA. The circles were then washed twice with cold 10% TCA, once with ethanol, and
dried. All the phosphocellulose washing steps were performed using a vacuum manifold
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(Millipore). The acid-insoluble radioactivity spotted on the circles was measured by
liquid scintillation counting. Negative control reactions omitting ATP were used for
background correction. Kinetic data points were plotted and fitted against the Michaelis-
Menten equation using ORIGIN software.
Rapamycin dose-response curve
This test was performed as described above for the live-cell comparison of the
FKBP12-AP' constructs except that all cells were co-transfected with FRB-BirA-
pcDNA3 and FKBP12-AP(-3)-pcDNA3; and the cells were treated with varying amounts
of rapamycin ranging from 0-330 nM.
Titration of protein concentration for the detection of cellular PPIs
T-RExTM-293 cells (Invitrogen) were grown in DMEM with 10% FBS,
50 units/mL penicillin, 50 gtg/mL streptomycin, and 5 pg/mL blasticidin and co-
transfected with FRB-BirA-pcDNA4-Tet and FKBP 12-AP(-3)-pcDNA4-Tet in a 1:1 ratio
using Lipofectamine 2000 (Invitrogen). After transfection, the cells were grown in
culture media supplemented with 50 jtg/mL of soluble streptavidin to deplete the biotin in
media and with varying concentrations of tetracycline (0-1 gtg/mL). After 16-24 hours of
transfection, the cells were incubated for 3 hours at 37 'C in the presence or absence of
100 nM rapamycin. The media was then replaced with pre-warmed PBS-Mg and 50 tiM
biotin for 1 minute. Thereafter, the cells were washed, lysed, and analyzed as for the
Comparison of FKBP12-AP' truncation mutants in live cells.
Quantification of the extent of biotinylation upon PPI detection in cells
T-RExTM-293 cells (Invitrogen) were transfected, treated, and lysed as above. Cell
extracts were incubated overnight at 4 OC in the presence or absence of 2.8 ýiM soluble
streptavidin, and the binding reactions were run in a 12% SDS-PAGE without boiling the
samples (to preserve the biotin-streptavidin bond). Analysis was done by anti-myc
blotting as described above.
- 161-
Imaging protein-protein interactions in the cytosol of mammalian cells
HEK 293T were grown and transfected as described for the specificity test above.
After the biotin treatment, the cells were fixed with 3.7% paraformaldehyde for
15 minutes at room temperature followed by permeabilization with methanol for
6 minutes at -20 'C. The samples were washed with PBS-Mg and blocked with PBS-Mg
+ 3% BSA for 1 hour at room temperature with rocking. Biotin detection was performed
by incubating the cells with 5 gg/mL streptavidin-Alexa Fluor 568 conjugate (Invitrogen)
in PBS-Mg + 3% BSA + 0.03% Tween20 for 1 hour at 4 OC followed by three 10-minute
washes with PBS-Mg + 0.1% Tween20. Detection of the HA epitope in the FRB-BirA
protein was performed by incubating the cells with 5 jig/mL rabbit anti-HA antibody
(Rockland Immunochemicals) followed by 6.7 gtg/mL anti-rabbit antibody conjugated to
Alexa Fluor 488 (Invitrogen). After washing, the cells were imaged in PBS-Mg with a
Zeiss Axiovert 200M inverted epifluorescence microscope using a 63x oil-immersion
lens and a Cascade 11:512 camera (Photometrics). Alexa Fluor 568 (560/20 excitation,
585 dichroic, 605/30 emission), Alexa Fluor 488 (495/20 excitation, 515 dichroic, 530/30
emission), and differential interference contrast (DIC) images (630/10 emission) were
collected and analyzed using Slidebook software (Intelligent Imaging Innovations).
Fluorescence images were normalized to the same intensity range. Acquisition times
ranged from 10-100 milliseconds.
Imaging protein-protein interactions in the nucleus of mammalian cells
The experiment was performed as described for the cytosolic proteins except that
T-RExTM-293 cells were used. T-RExTM- 2 9 3 cells (Invitrogen) were grown in DMEM
with 10% FBS, 50 units/mL penicillin, 50 gtg/mL streptomycin, and 5 gpg/mL blasticidin
and co-transfected with FRB-BirA-pcDNA4-Tet and FKBP12-AP(-3)-pcDNA4-Tet in a
1:1 ratio using Lipofectamine 2000 (Invitrogen). After transfection, protein expression
was induced by addition of 0.4 jpg/mL tetracycline to the cell media. Cells were then
treated with rapamycin and biotin, fixed, stained, and imaged as above. Additional
detection of the myc epitope in the FKBP-AP(-3) protein was performed by incubating
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the cells with 5 gg/mL mouse anti-c-myc antibody (Calbiochem) followed by 6.7 jtg/mL
anti-rabbit antibody conjugated to Alexa Fluor 568 (Invitrogen). Biotin detection was
performed as above except that streptavidin-Alexa Fluor 647 conjugate was used instead
of streptavidin-Alexa Fluor 568 conjugate. The following filters were used for Alexa
Fluor 647 detection: 630/10 excitation, 660 dichroic, 680/30 emission.
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Introduction
Part I of this thesis dealt with the development of new reporters of protein-protein
interactions in cells. We described how protein interaction networks lie at the core of
most cellular processes, and how these interactions are tightly regulated both in space and
in time. For this reason, elucidating the distribution, dynamics, and chemical environment
of individual proteins is critical, and often comes before any analysis of its interacting
partners. Part II of this thesis, thus focuses on the development of new reporters to
monitor protein localization and trafficking.
Optical and, in particular, fluorescence imaging has revolutionized cell biology by
enabling the visualization and monitoring of proteins inside living cells with high
temporal and spatial resolution. These studies often rely on recombinant fusions of the
target protein to a variant of the green fluorescence protein (GFP). Although fluorescent
protein fusions have shed light into the localization and function of many cellular
proteins', their use has several limitations. Probably the major concern with FPs is their
large size, which has the potential to interfere with the function of the protein under
study. Indeed, GFP fusions have been shown to promote aggregation of several
membrane-targeted proteins2, to cause retention in the endoplasmic reticulum 3, and to
alter the dynamics of receptor recycling4,5. Fluorescent proteins are also not bright or
photostable enough to perform single-molecule imaging in live cells, and they cannot
easily distinguish different protein subpopulations, such as cell-surface and intracellular
(unless photoactivatable FPs are used). Additionally, fluorescent proteins are only passive
reporters, which can report on protein localization but do not provide information on its
biochemical activity or on its age. Finally, FPs are in general only amenable to optical
imaging but not to other forms of imaging such as electron microscopy, which can
provide higher spatial resolution, or magnetic resonance imaging and positron emission
tomography, which can extent imaging studies to living animals.
For this reason, our lab and others are trying to develop new protein labeling
methods that circumvent the limitations posed by GFP. And we are doing so by
combining the enhanced imaging properties and diverse functionalities of chemical (non-
genetically encoded) probes, with the power of genetic targeting. Chemical probes, such
as small-molecules organic fluorophores, inorganic quantum dots, or photoaffinity probes
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overcome many of the limitations of GFP. For example, organic fluorophores are smaller
and brighter than FPs, whereas photoaffinity probes can be used to study protein-protein
interactions. Quantum dots, on the other hand, although bigger than organic probes, are
far brighter than FPs and do not photobleach; and are therefore amenable for single-
molecule imaging in live cells. Although these probes are extensively used in in vitro
studies, their application to cellular imaging has been hampered by the shortage of robust
methods to target them with high specificity to the protein of interest. Because chemical
probes are non-genetically encoded, they cannot be simply genetically fused to the target
protein, as it is done with FPs.
Therefore, in recent years, many new methods have been developed that try to
bridge the exquisite specificity of genetic targeting with the powerful imaging properties
of chemical probes. In the next sections, we describe some of these methods.
Traditional ways of targeting chemical probes to live cells: antibodies and receptor
ligands
As described in Chapter 1, immunostaining is one of the most common ways of
imaging the localization of endogenous cellular proteins. In this method, antibodies
against the target proteins are conjugated to a chemical probe (typically a small organic
fluorophore) and used to stain a biological sample. Although immunostaining has been
traditionally employed to stain fixed samples, it can also be used in living cells to label
cell-surface proteins. Indeed, immunofluorescence (IF) has been extensively used to
study the localization and trafficking of cellular receptors. Receptors are cell-surface
proteins that mediate communication between the cytoplasm and the external
environment through the recognition of signaling molecules and uptake of nutrients.
Because many aspects of receptor function are controlled by spatial localization and
temporal dynamics, imaging is a powerful method to study the behavior of membrane
receptors. Antibody targeting of chemical probes, however, still shares one of the main
disadvantages of GFP; that of its large size. Because antibodies are large (~ 150 kD), they
often interfere with receptor functions, such as ligand binding and protein
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oligomerization. Additionally, because of the bivalent nature of their binding, antibodies
can crosslink receptors, changing their trafficking and causing unintentional activation6,7•
Finally, because binding is non-covalent, antibodies often dissociate from their target
after receptor internalization, thus leading to artifacts in studies of receptor recycling8•
Although the use of monovalent, smaller Fab fragments minimizes the problems of steric
interference and protein crosslinking, they typically display off rates of 10-4-10-3 S-l (i.e.,
half-lives ofminutes to few hours), which results in poor binding and rapid signal
degradation9,I0.
Another common method for imaging receptors is to use fluorescently-tagged
ligands, such as epidermal growth factor (EGF)Il, transferrin12, and low-density
lipoprotein (LDL)13. However, because ligands also dissociate from their receptors after
internalization, this method does not allow tracking of receptor fate and recycling. In
addition, the trafficking behavior of unactivated, ligand-free receptor cannot be studied.
Genetic targeting of chemical probes in live cells
Many new protein labeling methods have been developed in recent yearsI4,15, and
they all share a common underlying goal: to combine the excellent specificity of genetic
targeting with the diverse photophysical properties of chemical probes. The basic
principle is hence to genetically fuse the target protein to a recognition element (i.e., a
peptide or a full-length protein), which is capable of recruiting a chemical probe. Figure
5-1 depicts the three most common approaches that have been devised.
In the first approach (Figure 5-1A), the protein of interest is fused to a peptide
sequence, which then recruits the small-molecule. In this approach, because the binding
of the probe to the protein is not covalent, the usefulness of the method depends on a tight
binding affinity between the peptide and the probe. Examples of this are the His6-
NTAI6-18, the polyaspartateI9-21 , and the tetracysteine (FIAsH)22,23 methodologies. In the
second approach (Figure 5-1B), the target protein is fused to a full-length protein, instead
of a peptide, which can bind to the small-molecule covalently or non-covalently.
Examples of non-covalent attachment using this approach are the methodologies based
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on the FKBP1224 and DHFR25,26 proteins, whereas covalent ligation is employed in the
SNAP_tag27-29 and HaloTag30 techniques.
A recognition peptide
~
B
c
recognition
protein .......
e
-+
C
Figure 5-1: Strategies for chemical targeting of small molecules to proteins in live cells. (A)
Small-molecule labeling using peptide tags. The protein of interest (black, ribbon format) is
genetically fused to a peptide tag (e.g., tetracysteine or hexahistidine; red) that is able to non-
covalently bind to a small-molecule (e.g., biarsenical- or NTA-fluorophore conjugates; green dot)
(B) Small-molecule labeling using protein tags. The protein of interest is genetically fused to a
protein tag (e.g., DHFR or hAGT; red) that is able to bind non-covalently or covalently to a small
molecule (e.g., methotrexate or 06-benzylguanine conjugate; green dot). (C) Small molecule
labeling using enzyme-mediated covalent attachment to a peptide tag. An enzyme (e.g.,
phosphopantetheine transferase or biotin ligase; grey) labels a genetically-fused peptide tag (e.g.,
S6 or AP; red) with the small molecule (green dot) directly or with a functional handle to which
the small molecule probe ligates through a chemoselective reaction.
A survey of the techniques employing the fITst two approaches reveals that a
general trade-off exists between labeling specificity and tag size. Protein-based tags, such
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as SNAP- and Halo-tag generally give higher labeling specificity than peptide tags, such
as FlAsH. However, protein tags have increased potential to interfere with protein
folding, trafficking, and activity, as we have described for GFP. Our lab and others have
tried to bridge the requirements of small tag size and high labeling specificity, by making
use of enzyme ligases. Whereas in the two previous approaches the labeling specificity
was solely determined by the interactions established during the bimolecular reaction
between the recognition element and the probe (Figure 5-1A & B), in the third approach,
an enzyme is employed to mediate the conjugation of the probe to the target sequence
(Figure 5-1C). By capitalizing on the intrinsic sequence specificity of enzymes such as
biotin ligase or phosphopantetheine transferase, highly specific probe conjugation can be
achieved, without sacrificing the small size of the directing tag. Examples of this third
class of techniques are the methods based on the phosphopantetheine transferases (Sfp
and ACpS)31-33, transglutaminase34, and biotin ligase35-37 enzymes.
In the next sections, we will describe each one of these technique in more detail.
We will specifically emphasize their weaknesses and strengths with regard to the labeling
specificity, tag size, stability ofprobe-protein linkage, and their potential to be applied in
any subcellular compartment (summarized in Table 5-1, at the end of the chapter). As it
will be inferred from the analysis, there currently exists no methodology capable of
attaching small-molecule probes to intracellular proteins modified by just a small peptide
tag, with high specificity and without toxic side-effects. It was this lack ofan ideal
method, which motivated our development of a new site-specific protein labeling
methodology based on the lipoic acid ligase (Chapters 6, 7, and siS.
Small-molecule labeling using peptide recognition sequences
In this approach, the protein of interest is genetically fused to a peptide tag that is
capable ofbinding to the desired chemical probe (Figure 5-1A). Whereas the use ofa
peptide is generally preferred because of its small size, attention must be paid to the
affinity of the binding interaction such that a good signal-to-noise ratio can be achieved
of specific peptide-probe binding over background nonspecific interactions of the probe
with other cellular components.
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Probably the most successful demonstration of this type of methodologies is the
FlAsH technique developed in the laboratory of Roger Tsien (U.C. San Diego)39. In this
method, the target protein is fused to a 6-16 amino acid peptide that contains four
cysteines (e.g., CCPGCC) and binds very tightly to a biarsenical dye (the FlAsH and
ReAsH probes), which becomes intensely fluorescent only upon binding to the
tetracysteines. One of the main advantages of this methodology is that the probes are
membrane-permeant, and thus can be used to label intracellular proteins. Most
importantly, what distinguishes this method from all the others in this section, is its high
affinity binding interaction (Kd - 2-4 pM), such that the signal does not deteriorate over
time. Recent improvements to the original methodology have also greatly enhanced its
utility. For example, new biarsenical compounds that span the visible spectrum40, as well
as probes useful for electron microscopy imaging22, and singlet oxygen generators that
inactivate protein function41 have been developed. Unlike most of the other methods
described in this chapter, the combination of tight binding with membrane permeant
probes has allowed the FlAsH methodology to be widely applied in cell biology, where it
has already begun to make significant contributions22,42-45. However, the FlAsH
methodology still has some associated problems that limit its utility. The weak affinity of
the biarsenical dyes for mono- and di-cysteines, which are present in most intracellular
proteins, results in high background labeling unless an antidote such as 1, 2-ethanedithiol
is used. Unfortunately, the use of antidotes translates into a long labeling procedure. For
this reason, the method usually works best on overexpressed proteins46; although new
tetracysteine sequences that bind with higher affinity to the biarsenical probes may
circumvent this limitation4o,47. Other limitations remain, however, such as the arsenic
toxicity and the requirement for the cysteines to be in reduced form for probe attachment,
which prevents the FlAsH technique from labeling proteins in the secretory pathway and
at the cell surface.
Other peptide tags that bind fluorophores directly include the hexahistidine,
polyaspartate and Texas Red binding peptides. The 38-amino acid Texas Red binding
peptide was evolved by Nolan and co-workers to bind with high-affinity (Kd- 25 pM) to
the Texas Red fluorophore, and it was shown to label GFP expressed at the surface of
mammalian cells48 . Even though the measured in vitro binding affinity was relatively
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high, the use of Texas Red presents a problem in live cells because of its intrinsic affinity
for the mitochondrial membrane, which results in high background.
Another labeling method is based on the binding of oligohistidine sequences to
nickel (II) nitrilotriacetic acid (Ni-NTA) complexes16,18A9. However, due to the low
affinity of the complex (initial Kd-- 1-20 flM), this method suffers badly from probe
detachment (i.e., signal deterioration over time) and Ni2+ toxicity. These limitations were
partially addressed by the development of a fluorescein dizinc compound that binds with
nanomolar affinity to hexahistidine sequences50, but the method is still restricted to cell-
surface proteins. An analogous approach has also been developed to label cell-surface
proteins, which involves binding of an oligoaspartate (8-16 amino acids) to a
multinuclear Zn(II) complex (i.e., two Zn(II) atoms complexed to four 2,2'-
dipicolylamine within a tyrosine scaffold)19,21. As in the case of the oligohistidine
technique, the original method suffered from severe probe dissociation. The problem was
later solved by Nonaka and co-workers, who added a chloroacetamide functionality to the
Zn(II) complex2o. Upon binding to the oligoaspartate-tagged protein, the chloroacetamide
reacts with a protein surface cysteine thus forming a covalent bond that prevents probe
dissociation2o. Imperiali and co-workers have also developed genetically encodable
peptide tags that bind with nanomolar affinity to lanthanide ions51 . The most interesting
characteristic of this approach is that lanthanide ions, such as Tb3+, are sensitized by the
tryptophan residue present in the lanthanide-binding peptide, which results in long-life
luminescence emissions. This type of emission (in contrast to fluorescence) is particularly
well suited for x-ray and NMR structure determinations52,53 and for studying protein-
protein interactions using luminescence resonance energy transfer54. Lanthanide-labeling
has not been used yet in live cells, probably because of the need for phototoxic ultraviolet
excitation of the lanthanide ion. Recently, this problem has been addressed by Reynolds
and colleagues, who reported that replacement of tryptophan by unnatural amino acids
(i.e., carbostyril and acridone) allowed for longer wavelength excitation55. However, the
maximum excitation achieved was 390 nm, where phototoxicity is still an issue.
Finally, streptavidin-binding peptides and bungarotoxin-binding peptides have
been used as tags for site-specific protein labeling56. However, the large size of the
streptavidin- and bungarotoxin-probe conjugates partially defeats the purpose ofusing a
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small peptide tag. Additionally, this method is restricted to labeling membrane proteins
because both streptavidin and bungarotoxin are membrane-impermeant.
As it can be readily inferred from the above description, the main common .
limitation of all these methodologies is the high background labeling caused by the
relatively low binding affinity of the probe towards the peptide, when compared to other
non-specific interactions (e.g., monothiols in the case of the biasernical dyes or the
mitochondrial membrane in the case ofTexas Red). In order to overcome this limitation,
other methods have been developed, which use a full-length protein instead of a peptide
recognition element.
Small-molecule labeling using protein recognition sequences
The two main examples ofnon-covalent binding of chemical probes to protein
recognition sequences rely on the high affmity interaction of a small-molecule substrate
to either E. coli dihydrofolate reductase (DHFR) or the F36V mutant of the FK506
binding protein 12 (FKBP12 F36V). DHFR binds to methotrexate and trimethoprim with
picomolar dissociation constants57, and this interaction affinity is retained when the
inhibitors are conjugated to different fluorophores. Importantly, because both,
methotrexate and trimethoprim conjugates are membrane-permeant, this is one of the few
site-specific labeling methodologies that can target intracellular proteins. In their first
report, Cornish and co-workers labeled nuclear and plasma-membrane localized DHFR
fusion proteins in DHFR-deficient Chinese hamster ovary (CRO) cells using a Texas Red
methotrexate conjugate25 . The need to work in DHFR-deficient cell lines was later
avoided by using trimethoprim conjugates, which display a larger discrimination for
binding to E. coli DHFR instead of its mammalian counterpart26,58. In an analogous
approach, the binding interaction of FKBP12 F36V to a fluorescein-conjugate of the
synthetic ligand for FKBP12 (SLF') was exploited by the Nolan laboratory to label
membrane-targeted proteins fused to FKBP12 F36V in living mammalian cells24•
FKBP12 has the advantage over DHFR, that it has a> 1ODD-fold preference for the F36V
mutant (not endogenous to mammalian cells) over wild-type FKBP12. Labeling with the
DHFR and FKBP12 tags is fast and specific, but, like the FPs and antibodies, these
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proteins are large (157 and 108 amino acids, respectively). Furthermore, even with such
high interaction affinities, the methods still suffer from signal deterioration over time. For
example, the Texas Red methotrexate conjugate dissociates from the DHFR fusion
. ft· h 25proteIns a er Just one our .
In order to eliminate the problem ofprobe dissociation, other methods have been
developed that exploit the covalent attachment of a chemical probe to a protein or
enzyme tag. The first example of this strategy was reported by the Johnsson laboratory
and it is based on the irreversible and specific reaction of the human enzyme
0 6-alkylguanine transferase (hAGT) with 0 6-benzylguanine derivatives, leading to the
transfer of the synthetic probe to the reactive Cys 145 in hAGT28 . The authors termed the
fused hAGT as the SNAP-tag, owing to the high speed and covalent nature of the
labeling. Using the SNAP-tag, Kepler and co-workers achieved rapid and specific
labeling of nuclear, cytosolic and membrane proteins fused to hAGT in E. coli, yeast, and
mammalian cells28,29. Although, as in the case ofDHFR, the method was at first restricted
to hAGT-deficient cells lines, evolution of an orthogonal mutant later circumvented the
problem and eliminated background staining59. Recently, the development of an
orthogonal pair based on the reaction of a mutant hAGT with 0 6-propargylguanine
derivatives has enabled two-color labeling of intracellular protein in living mammalian
cells27. This orthogonal pair has been termed the CLIP-tag. Following a similar approach,
Promega has developed a protein labeling method based on a bacterial haloalkane
dehalogenase, engineered to form covalent enzyme-substrate adducts. The method, called
HaloTag™, has been used to covalently attach various chloroalkane-bearing
fluorophores3o and quantum dots60 to cell-surface proteins fused to the dehalogenase
enzyme. Finally, the fungal enzyme cutinase has also been exploited to covalently attach
organic fluorophores and quantum dots to the integrin lymphocyte function-associated
antigen-l (LFA-l) on the surface of living cells61 • All three methods (SNAP-tag,
HaloTag, and cutinase) are characterized by high specificity, fast labeling reactions
(10-30 minutes), and covalent probe attachment, and thus represent an improvement over
the DHFR and FKBP12 F36V labeling methods described above. Unfortunately, they all
still share the common drawback of employing large protein tags (182, 296, and 213
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amino acid residues, respectively), which can potentially interfere with the function of the
protein under study.
Enzyme-mediated ligation of small-molecules to peptide recognition sequences
The two previous approaches rely on the most straightforward form ofjoining a
chemical probe with a peptide or protein recognition sequence: a binding interaction.
However, it has become clear that, when a mere bimolecular interaction is established,
there is necessarily a trade-off between the size of the interactors (e.g., peptide versus
protein) and the specificity of the interaction. If a large protein tag is used, the amount of
interactions created between the probe and the tag are larger, thus resulting in more
specific labeling. To overcome this limitation, our lab and others have developed an
alternative approach, which attempts to increase specificity while using a small peptide
tag. The approach involves using an enzyme to mediate the labeling (Figure 5-1 C). By
using an enzyme, the interaction surface area between the probe and the peptide
increases, thus resulting in more specific labeling. Moreover, enzyme-mediated labeling
results in the covalent attachment of the probe to the peptide recognition, which enables
long-term imaging of the same molecule. Enzyme-mediated labeling should also bring
about faster and more sensitive labeling owing to the enforced proximity between the
probe and the peptide within the enzyme active site.
Phosphopantetheine transferases (PPTases)were the first enzymes exploited for
enzyme-mediated protein labeling31,32,62. PPTases catalyze the transfer of 4'-
phosphopantethine from coenzyme A (CoA) to a serine residue of an acyl or peptidyl
carrier protein (ACP and PCP). One of the main advantages of the use of PPTases for
protein labeling is the fact that they are tolerant of a wide range of substitutions at the
terminal thiol of the cofactor CoA, allowing the transfer of diverse fluorophores or other
chemical probes to ACP- or PCP-tagged proteins. Additionally, although the original
methodology relied on protein tags (ACP and PCP are both'" 80 amino acid long), the
Yin lab recently evolved 12-mer peptide tags that are modified by PPTases with similar
kinetics to the original full-length proteins, greatly enhancing the utility of the
methodology33. However, while the PPTase methodology results in fast, specific, and
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covalent labeling, the highly-charged CoA derivatives are membrane impermeant, which
limits its utility to cell-surface proteins. Nonetheless, the PPTase methodology is,
together with the FlAsH technique, one of the most widely used methods to genetically
target chemical probes to protein in living cells. The method has been used for
fluorophore tagging of the agglutinin receptor Aga2p in yeast and the human G-protein
coupled receptor NKI in mammalian cells63, for FRET studies of the transferrin
receptor64, and for single-molecule studies of the odorant receptor trafficking65•
Our lab has exploited the use of two different enzymes for protein labeling: biotin
ligase and transglutaminase. E. coli biotin ligase (BirA) catalyzes the ATP-dependent
ligation ofbiotin to a lysine side-chain within a I5-amino acid acceptor peptide substrate
(AP). We have used BirA to label AP-tagged cell-surface proteins with fluorophores and
quantum dots conjugated to streptavidin36,37,66,67. Recently, the methodology has also
been extended to multicolor imaging68. The labeling is extremely specific and fast (i.e.,
5-10 minutes), but, as previously noticed, the use of the large streptavidin protein
(-- 56 kD) to detect the ligated biotin defeats the purpose ofusing a small peptides tag, as
well as it restricts the methodology to cell-surface proteins. In a separate effort, Irwin
Chen in our lab found that BirA can also efficiently ligate a ketone isostere ofbiotin35•
Because ketones are absent from cell surfaces, the enzymatically introduced ketone can
be chemoselectively derivatized with hydrazide- or hydroxylamine probes.
Unfortunately, ketones are absent from the cell-surface but are present in the cytosol
(e.g., free sugars, pyruvate), which once again limits the methodology to labeling
membrane proteins. Additionally, the slow kinetics of the ketone-hydrazide (or
hydroxylamine) reaction results in extremely long labeling times. The transglutaminase
methodology was developed by Chi-Wang Lin in our laboratory, and it uses guinea pig
transglutaminase (gpTGase) to catalyze the calcium-dependent ligation of amine-
containing probes to a glutamine side-chain within a seven-amino acid peptide
recognition sequence34• Although gpTGase-mediated cell-surface labeling is fast, the
labeling specificity is not very high. The lack of labeling specificity means that the
methodology cannot be extended to the cytosol, where gpTGase is likely to transfer the
amine-containing probe to other protein substrates. In Chapter 7, we perform a side-by-
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side comparison of the gpTGase, BirA and lipoic acid ligase labeling methodologies that
illustrates the main weaknesses and strengths of each one of them.
Finally, the formylglycine generating enzyme69 and famesyl transferase70 have
also been exploited for protein labeling, although their use has thus far only been
demonstrated in vitro. The natural role of the formylglycine generating enzyme is to
generate the sulfatase active site by converting a conserved cysteine to formylglycine.
The Bertozzi lab has used a six-amino acid sulfatase motif (the "aldehyde tag") to
introduce an aldehyde functionality into proteins69. As described above for BirA-Iabeling,
the aldehyde moiety can then be chemoselectively derivatized with hydroxylamine- or
hydrazide-probes. Famesyl transferase appends famesyl moieties to proteins carrying a
four-amino acid farnesylation motif. Duckworth and co-workers used famesyl transferase
to label a protein C-terminally tagged with the farnesylation motif with an alkyne-
containing famesyl substrate7o• By using the bio-orthogonal [3+2] cycloaddition reaction,
the authors could then fluorescently-Iabel the protein with an azide-derivatized Texas red
fluorophore.
Although it has been shown that enzyme-mediated labeling can result in faster
and specific labeling of proteins tagged with only a small peptide tag, all the currently
available methodologies are, for one reason or another, restricted to the cell-surface.
There is therefore a need to develop a new method that retains the positive features of the
BirA and PPTase techniques, while allowing labeling inside living cells. In Chapters 6, 7,
and 8 we will describe how we have accomplished this by using the enzyme lipoic acid
ligase.
Other approaches to chemically modifying proteins in vivo
Unnatural amino acid mutagenesis71 has also been used to label proteins in living
cells with several photocrosslinkers (e.g., benzophenone, and aryl azide)72-74 and
fluorophores (e.g., dansylalanine and 7-hydroxycoumarin)75,76. Several reports have also
combined unnatural amino acid mutagenesis with the bio-orthogonalligations between
ketones and hydrazides, and azides and alkynes77-79 • Although unnatural amino acid
- 179-
· mutagenesis stands out among all other protein labeling methods because of its perfect
specificity and because it uses the smallest possible tag (i.e., a single amino acid), its
application is still limited in mammalian cells because of the prevalence of amber stop
codons and the low suppression efficiencies, which give rise to truncated by-products80.
Some recent efforts have adapted protein splicing for labeling proteins with small
molecules. Protein splicing is a post-translational modification wherein a protein
autocatalytically rearranges to excise an internal segment (an intein) and ligate the
flanking N- and C-terminal sequences, or exteins81 . Protein splicing has been used for
protein labeling in two different ways. In the first approach, the N-terminal cysteine of
the spliced intein is derivatized via native chemical ligation with a membrane-permeant
thioester functionalized probe82 • Although native chemical ligation displays certain
chemoselectivity for N-terminal cysteines over internal cysteines ofproteins, the latter
can be a source ofbackground staining. Nonetheless, Chattopadhaya and co-workers
recently reported the use ofnative chemical ligation for labeling intracellular proteins in
both, bacterial and mammalian cells with fluorescein, rhodamine, and biotin83 • As
demonstrated in the previous report, one of the main advantages of this method is the
versatility for probe structure. The main drawbacks lie in the facts that, although
temporary, the intein tag is large and the rates of splicing and thioester ligation are slow
(i.e., it usually requires several hours).
In the second approach, developed in the Muir laboratory, site-specific protein
modification is achieved via protein trans-splicing84• In this case, the protein of interest is
fused to one half of the naturally occurring Ssp DnaE split intein, whereas the other half
of the intein is conjugated to a synthetic molecule, and is introduced into the cell using a
protein transduction domain. Inside the cell, the two halves of the intein reconstitute and
cause protein trans-splicing, which results in ligation of the synthetic molecule to the
protein of interest. The strategy has thus far only been reported once, for the
incorporation of a FLAG epitope onto GFP in live Chinese hamster ovary cells84. The
most likely reason for the lack of further demonstrations, specially using fluorescence
tags, is the difficulty in washing out the excess unreacted fluorophore-intein.
Additionally, the strategy suffers from the same drawbacks of using a large protein tag
and of the slow kinetics ofprotein splicing.
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Conclusions
Many protein labeling methods have been developed in recent years I4,15, but none
currently allows the covalent attachment of small fluorophores of any structure onto cell
surface proteins modified only by a small peptide tag, with short labeling times and with
extremely high specificity over a wide range of expression levels and labeling conditions.
To address this shortcoming, we developed a new protein labeling method based on the
E. coli enzyme lipoic acid ligase (LpIA)85.
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Table 5-1: Comparison of methods for genetic targeting of chemical probes in live cells.
Tetracysteine I NA I 6-10 I No I Membrane I Long labeling times. Arsenic I 22, 23, 39-47toxicity
..... Texas Red binding NA 23-38 No Intracellular Texas Red binds non-specifically I 4800 peptide to mitochondrial membranesN
Hexahistidine NA 6-12 No Membrane* & Ni
2
+ quenches fluorescence and 16-18,49,50intracellular it is toxic
Polyaspartate NA 8-16 No Membrane 19-21
Lanthanide NA 15-20 No In vitro Lanthanide toxicity. Ultraviolet I 51-55binding peptide excitation
Streptavidin and Although it uses a small peptide
bungarotoxin NA 13 No Membrane to direct targeting, the final tag is I 56
binding peptides large due to streptavidin
FKBPI2(F36V) NA 98 No (1) Membrane 24
DHFR Intracellular
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Chapter 6 : Re-directing E. coli lipoic acid ligase for site-specific protein
labeling
The work discussed in this chapter has been published in part in: M. Fernindez-Suarez,
H. Baruah, L. Martinez-Hemrnindez, K. T. Xie, J. M. Baskin, C. R. Bertozzi, and A. Y.
Ting. Redirecting lipoic acid ligase for cell surface protein labeling with small-molecule
probes. Nat. Biotechnol. 25(12), 1483-1487 (2007). The syntheses of the alkyl azide and
alkyl alkyne probes were done by Laura Martinez-Hernindez. Determination of the
kinetics of LplA-catalyzed ligation of azide 7 to E2p and LAP was performed in
collaboration with Dr. Hemanta Baruah.
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Introduction
E. coli lipoic acid ligase
In the introductory Chapter 5, we described the various approaches developed in
recent years to site-specifically label proteins with chemical probes in living cells. The
most promising of these strategies employs an enzyme to catalyze the covalent ligation of
the chemical probe to a peptide recognition sequence fused to the protein of interest. Our
lab has previously developed protein labeling methodologies based on the biotin ligase
and transglutaminase enzymes, but both methodologies are restricted to labeling cell-
surface proteins. In this chapter, we describe how we have re-directed the E. coli enzyme
lipoic acid ligase (LplA) for the purpose of protein labeling. In principle, LplA should
retain the excellent labeling specificity of biotin ligase, with the additional benefit that it
has the potential to work inside cells.
In E. coli, LplA catalyzes the ATP-dependent covalent ligation of lipoic acid to
one of three proteins substrates'. The mechanism of lipoic acid transfer proceeds in two
distinct steps (Figure 6-1). First, the enzyme activates the carboxylic acid of the lipoic
acid cofactor using ATP and releasing pyrophosphate (PPi) in the process. In the second
step, the reactive adenylate ester intermediate (lipoyl-AMP) is attacked by the e-amino
group of a lysine residue in the lipoate-acceptor protein (e.g., E2p) to effect lipoic acid
transfer.
lipoic acid + ATP - lipoyl-AMP + PPi
lipoyl-AMP + E2p ------- lipoic acid-E2p + AMP
Figure 6-1: Site-specific lipoic acid transfer catalyzed by E. coli lipoic acid ligase. The
mechanism of lipoylation occurs in two steps. In the first step, the carboxylic acid of lipoic acid is
activated by reaction with ATP to form the lipoic acid adenylate ester (lipoyl-AMP). In the next
step, the reactive lysine of the substrate (e.g., the E2p protein) attacks lipoyl-AMP, effecting
lipoic acid transfer.
R-(+)-lipoic acid is a cofactor widely distributed among living organisms. In E.
coli, lipoic acid is covalently attached to the E2 dihydrolipoamide acetyltransferase
subunit (E2p) of the pyruvate dehydrogenase complex (PDH), to the E2
dihydrolipoamide succinyltransferase subunit (E2o) of the 2-oxoglutarate dehydrogenase
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complex (20GDH), and to the H-protein of the glycine cleavage system 2. Additionally,
in mammals, lipoic acid is also a cofactor of the E2 acyltransferase subunit of the
branched-chain ca-ketoacid dehydrogenase complex (E2b) 3. The four enzyme complexes
are involved in oxidative metabolism and, in mammals, located in the mitochondria. In
the PDH and 20GDH complexes, the El subunits catalyze the initial decarboxylation of
the 2-oxo acid (pyruvate or 2-oxoglutarate), using thiamine diphosphate (TPP) as a
cofactor, and then reductively acylate the lipoyl group attached to a lysine in the E2
subunit4. E2 is then responsible for transferring the acyl group on to coenzyme A (CoA),
to form acetyl-CoA or succinyl-CoA. The dihydrolipoyl group left on E2 is finally
reoxidized to the dithiolane ring by the flavoprotein E3, with the nicotinamide adenine
dinucleotide (NAD+) as the ultimate electron acceptor. The lipoyllysine arm attached to
the E2 subunits plays a pivotal role in the reaction sequence in the complexes, shuttling
the reaction intermediate and reducing equivalents among the active sites of the subunits.
There are two pathways involved in protein lipoylation. The first pathway uses
exogenously supplied lipoic acid. This is the pathway described above, which, in E. coli,
is catalyzed by LplA. In contrast to LplA, which can catalyze both, the adenylation of
lipoic acid and its transfer to the protein substrate, mammalian lipoyltransferases (or
lipoate protein ligases, LPLs) can only catalyze the second step3'5. Therefore, the
contribution of another enzyme, the lipoate-activating enzyme, is required for protein
lipoylation . In E. coli, a second lipoylation pathway uses endogenously synthesized
lipoic acid 7. Lipoic acid is synthesized from the octanoyl-acyl carrier protein provided by
the fatty acid synthesis pathway. The octanoyl moiety is first transferred to the lipoate-
acceptor protein by the action of the LipB enzymes. Then, the sulfur atoms are inserted at
the C6 and C8 positions of the octanoyl moiety by LipA, an S-adenosyl methionine-
dependent [Fe-S] cluster containing enzyme 9. Although not yet demonstrated, it has been
suggested that this second lipoylation pathway is also present in mammals1 .
Three dimensional structures of LPLs from various species have been solved11-14
Bacterial LplAs are formed by two domains, a large N-terminal domain and a small
C-terminal domain. This is the case for example of Escherichia coli (1X2G)" and
Streptococcus pneumoniae (1VQZ). LplAs from Archaea, like Thermoplasma
acidophilum (Ta) (2ART and 2C8M) 13,14 and Sulfolobus solfataricus are however
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composed by just one domain, corresponding to the bacterial N-terminal domain. This
lack of a C-terminal domain may explain the observation that Ta LplA can only catalyze
the first step of lipoic acid adenylation14 . In Ta, a second protein has been suggested to
perform the transfer of the adenylate intermediate 14. The lipoic acid binding site and the
catalytic center are situated in the N-terminal domain in all LplAs. The case of the
mammalian LPLs is however harder to explain based on the enzyme structures. Although
the mammalian lipoyltransferases share about 30% identity with that of E. coli LplA12,
showing specially high identity in the N-terminal half, mammalian LPLs have been
suggested to be unable to activate lipoic acid5'6 . It remains to be shown how this lack of
function relates to their structure.
Using LplA for site-specific protein labeling
E. coli LplA thus catalyzes the type of reaction that is needed for protein labeling:
ligation of a chemical probe onto a protein substrate. However, to be useful for labeling
proteins in living cells, LplA still needed to meet three requirements:
1. Because lipoic acid is not amenable for imaging, we needed to find a small-
molecule substrate, such as a fluorophore or a functional group handle (e.g.,
azide, ketones, alkynes), that can be ligated by LplA and that is useful for imaging
or protein-protein interaction studies.
2. LplA naturally catalyzes the transfer of lipoic acid to one of three protein
substrates. In order to minimize perturbation of the target protein, we needed to
find a small peptide substrate that can be recognized by LplA and be fused to the
target protein with minimal steric interference.
3. LplA should also display excellent specificity towards its peptide substrate, such
that it does not recognize any endogenous protein within the mammalian
proteome.
In the previous section, we have described how LplA naturally exhibits extremely
high sequence specificity towards its protein substrate, as it only transfers lipoic acid to
three proteins in E. coli. Thus, we expected LplA to easily comply with the third
requirement. In contrast, and to our advantage, previous work had shown that the enzyme
- 194 -
has a much more relaxed specificity towards its small-molecule substrate. In E. coli,
LplA can also ligate octanoate and selenolipoate, if the bacteria are grown in the absence
of its natural substrate R-(+)-lipoic acid is . Furthermore, the enzyme has been shown to
accept other analogs of lipoic acid in vitro. Green and co-workers showed that LplA can
ligate, in order of highest to lowest ligation efficiency, 6-thiooctanoate, S-(-)-lipoate,
dihydrolipoate, 8-methyl-lipoate, octanoate, and selenolipoate (Figure 6-2A)1. These data
suggested that the small-molecule binding site in LplA has considerable plasticity, and
encouraged us to look for other small-molecule probes that could be incorporated by the
enzyme.
A
HO HO HO
S-S SH SH
Lipoic acid Octanoic acid Dihydrolipoic acid
HO HO HO
SH SeSe -S
6-thiooctanoic acid Selenolipoic acid 8-methyl-lipoic acid
B
OF ON OH
I H
HO"4 n N 3  HON HO 0 0
F
w-azido carboxylic acid Acetylenic carboxylic acid 6,8-fluorine-7-hydroxycoumarin derivative
Figure 6-2: Structure of lipoic acid and several lipoic acid analogs. (A) Structure of lipoic
acid and analogs reported to be ligated by LplA in vitro. (B) Structure of small-probes useful for
protein labeling that have been tested in our lab for incorporation by LplA.
We considered a range of small molecule structures to replace lipoic acid. Direct
ligation of a fluorophore, such as the coumarin probe depicted in Figure 6-2B, would
offer a simpler and shorter labeling procedure, but incorporation of a "functional group
handle" is more feasible due to the small size of the lipoate binding pocket, and provides
greater versatility for subsequent incorporation of probes of any structure. Many
functional group handles have been used in chemical biology, including ketones, organic
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azides, and alkynes' 6 . In previous work in our lab, Irwin Chen had found that biotin
ligase could accept a ketone isostere of biotin, which could then be chemoselectively
derivatized with hydrazide- or hydroxylamine-conjugated probes 17 . Although Irwin
demonstrated that this two-step procedure could afford labeling of membrane proteins,
the method is restricted to the cell-surface because ketones are absent from the cell-
surface but exist naturally inside cells.
Alkyl azides and alkynes (Figure 6-2B) are useful functional groups for protein
labeling because they are both absent from biological organisms, but possess selective
reactivity towards each other1 6. The classic [3+2] dipolar cycloaddition reaction between
azides and alkynes was developed by Huisgen and requires high temperatures or
pressures to proceed efficiently' 8. Sharpless, Finn, and coworkers developed a Cu(I)-
catalyzed version 19 (Figure 6-3, above), which occurs with high efficiency and selectivity
in pH 7.4 water at room temperature and 1 atmosphere, even in complex environments
such as whole-cell lysates, or the surface of mammalian cells, bacteria, and virus
particles 9-22. The reaction is highly toxic to cells, however, due to the requirement for
Cu(I). For this reason, the Staudinger ligation between azides and triarylphosphines 23
(Figure 6-3, middle) has often been preferred for protein labeling inside mammalian
cells 2 4 -2 6 . Unfortunately, the second-order rate of the Staudinger ligation is - 30-fold
lower than that of the Cu(I)-mediated cycloaddition 27, and triarylphosphines tend to
rapidly oxidize in the eukaryotic cytosol when they are conjugated to fluorophores
(Bertozzi, C.R. and Baskin, J.M., personal communication). To overcome these
limitations, the Bertozzi lab recently developed a copper-free version of the [3+2]
cycloaddition that makes use of a highly strained alkyne presented in the context of a
cyclooctyne ring28 (Figure 6-3, below). The greatly increased reactivity of the alkyne
makes it undergo rapid cycloaddition with azides, even in the absence of Cu(I). Addition
of one or two electron-withdrawing fluorines adjacent to the alkyne increases the speed
of the ligation yet further (- 2-fold or - 22-fold, respectively) 27' 29'30 . In Chapter 7, we
describe how we have employed this improved strain-promoted [3+2] cycloaddition
reaction for cell-surface protein labeling.
In the results section of this chapter, we describe our three-stage process of LplA
engineering. First, we show that wild-type LplA can efficiently ligate an alkyl azide with
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similar kinetics to lipoic acid. Second, we describe the rational design of a 22-amino acid
peptide substrate that is modified by LplA only at a 2-fold slower rate than the full-length
protein substrate. Finally, we demonstrate that LplA does not recognize any endogenous
mammalian protein.
Cu(I)-mediated
[3+2] Cycloaddition
HO a-N3 Staudinger ligation
H
1'N
* T I '0 , 0OH
Ph- P=O O
Ph
Strained-promoted
[3+2] Cycloaddition
Figure 6-3: Bio-orthogonal reactions of azides. Azides react with terminal alkynes to form
stable triazols. In the Sharpless version of the [3+2] cycloaddition (above), Cu(I) is added as a
catalyst such that the reaction proceeds at physiological conditions. Azides can also undergo
Staudinger ligation with triarylphosphines to form a stable adduct that incorporates the phosphine
oxide byproduct (middle). Bertozzi's Huisgen ligation between an azide and a strained
cyclooctyne proceeds at physiological conditions in the absence of copper owing to the increased
reactivity of the alkyne (below).
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Results
E. coli LplA accepts alkyl azide and alkyne substrates in place of lipoic acid
For the first stage of LplA engineering, we synthesized eight alkyl azide and
alkyne substrates for LplA of varying lengths. The synthesis of all these probes was
performed by Laura Martinez-Hernindez according to the reaction scheme in Figure 6-4.
The alkyl azides were synthesized either by nucleophilic substitution of the
corresponding bromoalkanoic acid with sodium azide31, or by copper-catalyzed diazo
transfer onto the amine precursor 32. The alkynes were synthesized from the
bromoalkanoic acid precursor, by displacement with lithium acetylide33
A
B NaN3 N
HO DMF
B
.,• · TfN3' CuSO4, K2CO3  n
H n MeOH, H20 H
C
Br ethylenediamine
HO I n DMSO H0
Figure 6-4: Syntheses of o-azido and acetylenic carboxylic acid analogs of lipoic acid. (A)
Alkyl azides can be prepared by nucleophilic substitution of the corresponding bromoalkanoic
precursor with sodium azide. Alkyl azides with n=5 and 7-10 were prepared following this
procedure. (B) An alkyl azide with n=6 was obtained by copper-catalyzed diazo transfer of its
amine precursor. (C) Acetylenic carboxylic acids with n=5 and 7 were prepared from the
bromoalkanoic precursor by displacement with lithium acetylide.
In order to test if these substrate analogs could be used by LplA, we developed an
assay for incorporation onto a hybrid lipoyl domain derived from the full-length E2p
protein34. The E2p subunit of the pyruvate dehydrogenase complex contains three N-
terminal highly conserved tandemly repeated lipoyl domains, each containing one lysine
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site of lipoylation 35. Miles and Guest initially demonstrated that the number of lipoyl
domains in E2p can be reduced from three to one without impairing catalytic activity36.
They next cloned a hybrid lipoyl domain comprised by residues 1-33 and 238-289 from
the first and third lipoyl domains, and showed that the domain was lipoylated in E. coli to
levels comparable to those of the full-length subunit36 . The 9 kD hybrid lipoyl domain
can be recombinantly expressed in E. coli in high quantities34. We used this hybrid lipoyl
domain to test incorporation of lipoic acid analogs using an HPLC assay. From hereon,
we will refer to this hybrid domain as E2p domain, or simply E2p.
A B
E2p-azide
conjugate
E2p azide 7
reaction
- LplA control
- ATP control
ipoic acid
reaction
10 15 20
Figure 6-5: Incorporation of lipoic acid analogs by wild-type LplA. (A) HPLC assay showing
the ligation of lipoic acid and the azide 7 substrate to the E2p domain. The starred peak was
analyzed by mass-spectrometry in Figure 6-6. (B) Comparison of alkyl azide and alkyne
substrates of LplA. The extent of LplA-catalyzed E2p conversion in the presence of each
substrate was assessed by HPLC. Conversions are given relative to lipoic acid, which is
normalized to 100%.
Figure 6-5A shows that the E2p domain had a retention time of-- 12 minutes,
which increased to - 15-18 minutes after covalent conjugation to lipoic acid or an analog.
Controls with enzyme or ATP omitted demonstrated that the product peak resulted from
enzymatic ligation. We were surprised to find that all the tested alkyl azides and alkynes
were incorporated to some degree by wild-type LplA (Figure 6-5B). It is worth noting
that the azides were in general incorporated at a higher rate than the alkynes. Among the
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Substrate % Conversion
lipoic acid 100 + 3
azide n=5 14.9 + 0.6
n=6 11.3 ± 0.4
n=7 55.4 + 5.7
N3
HO n=8 10.2 ± 0.4
n=9 4.57 ± 0.11
n=10 3.28 ± 0.17
alkyne n=4 3.59 ± 0.23
O n=5 3.15 ± 0.19
n=7 6.37 ± 0.15
HO n n=8 5.15 ± 0.23
alkyl azides, we also observed a clear length dependence, with the n=7 azide (azide 7)
giving the best kinetics; both shorter and longer azides were not incorporated as
efficiently, perhaps because of non-optimal binding in the lipoate binding pocket.
So that we could make use of the copper-free [3+2] cycloaddition reaction with
cyclooctyne probes, we selected the azide 7 probe for further characterization. Although
we have not demonstrated it yet, LplA-catalyzed site-specific alkyne ligation could be
useful for in vitro or lysate experiments, where the use of a Cu(I) catalyst accelerates the
[3+2] reaction without posing a toxicity problem. We also tested other small-molecules
for incorporation by wild-type LplA such as biotin, biotinamido caproate, and glutamate,
but none of them was ligated by the wild-type enzyme to a detectable level.
Characterization of azide 7 ligation by LplA
To demonstrate the site-specificity of azide 7 ligation, we collected the product
peak (starred) from the top HPLC trace in Figure 6-5A and we analyzed it by
electrospray ionization mass-spectrometry (ESI-MS).
[M+7H+1Na]8B [M+7H] 7*
1112550•1 12805200
Calc. Obs.
E2p 8787 8788 11
E2p-azide 8953 8957
[M+8H+1 Na] *
9744
9).200
U
00
[M+6H] 6+
1405.3800
4.3000
W00 800 700 00 00 1000 11O 00 2 1300 140 1500 1000
m/z (amu)
Figure 6-6: Mass-spectrometry characterization of the E2p-azide 7 conjugate. Overlay of
the ESI-MS spectra of the apo-E2p (blue) and the product peak from an LplA ligation of azide 7
(magenta, from the HPLC trace in Figure 6-5). Peaks for the +6, +7, +8, and +9 charge states are
observed. The observed mass for the apo-protein matched the calculated mass. The observed
mass for the modified protein corresponded to the addition of a single molecule of azide 7 with
the concomitant loss of water.
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Figure 6-6 shows that the observed mass for the E2p-azide 7 product
corresponded to the addition of a single molecule of azide 7 with the concomitant loss of
water. This assay demonstrated that the ligation of azide 7 is site-specific since no
ligation was observed to any of the other lysines present in the E2p domain. The
spectrum for the unmodified domain is also shown for comparison. The observed mass
for the apo protein matched the calculated mass.
We next wished to determine the kinetics of the LplA-catalyzed ligation of azide
7 to E2p. We first confirmed the suitability of the HPLC assay to perform kinetic analysis
by determining the initial rate of the lipoic acid ligation, which we could compare with
previously reported values (Figure 6-7). We obtained an initial rate of 0.25 + 0.3x10 -2 s1,
which was in accordance to the reported value of 0.5 s-1 (Ref. 1), thus validating our
assay.
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Figure 6-7: Time course of lipoic acid ligation to E2p using 50 nM LplA. Reactions were
incubated at 30 OC under the following reaction conditions: 200 pM E2p, 50 nM LplA, 750 ýpM
lipoic acid, 1 mM ATP, and 2 mM magnesium acetate in 25 mM sodium phosphate pH 7.0.
Aliquots were removed at the indicated times, quenched with EDTA, and analyzed by HPLC.
Each data point represents the average of three experiments. Error bars, 1 s.d.
To determine the kcat and Km for the ligation of azide 7, we measured the initial
reaction rates at a range of azide 7 concentrations (25-750 jtM). From the Michaelis-
Menten plot (Figure 6-8) we determined a Vmax of 1.33 ± 0.04 tM/min using 200 nM
LplA, corresponding to a keat of 0.11 ± 0.03x10 -' s-1. This keatwas only 2.3-fold lower
than the measured initial rate for lipoic acid ligation. The Km for azide 7 was 127 ± 11
jiM, which is 75- or 30-fold higher than the two reported Km values for lipoic acid (1.7
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ýpM' and 4.5 pM"). Thus, replacement of lipoic acid with the linear azide 7 substrate
does not significantly change kcat, although Km increases by one to two orders of
magnitude. For labeling reactions, however, it is feasible to use azide 7 at concentrations
higher than the measured Km, so that LplA-catalyzed ligation occurs at maximal velocity.
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Figure 6-8: Kinetic characterization of LplA-catalyzed ligation of azide 7 to E2p. Michaelis-
Menten plot for azide 7 ligation to E2p. Initial rates are shown as a function of azide 7
concentration. LplA concentration was 200 nM. From the fitted value of Vmax, we calculated a kcat
value of 0.11 ± 0.03x10 -' s-1. Each data point represents the average of three experiments. Error
bars, Is.d.
Rational design of a peptide substrate for LplA
For the second stage of engineering, we wished to design a peptide substrate for
LplA to replace the protein substrates. It was necessary for the peptide to be fully
transposable (recognized when fused to the N- or C-terminal ends of any protein) and to
be recognized by LplA with similar efficiency to the natural protein substrates.
To rationally design a peptide substrate, we examined the NMR structure of the
E2p domain, which presents the lysine lipoylation site at the tip of a sharp P-tum37
(Figure 6-9). Although we acknowledged that this conformation was difficult to
recapitulate in a short peptide, several studies indicated that reducing the size of E2p
could indeed be possible. Initial mutagenesis studies had suggested that, while accurate
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positioning of the target lysine within the p-turn was essential for LplA recognition, the
residues flanking the lysine could be varied38. In contrast, it was later shown that deletion
of a surface loop located close to the lipoyl-lysine p-turn (colored magenta in Figure 6-9)
renders the domain incapable of reductive acylation, while leaving it still capable of
being lipoylated, albeit at a reduced rate39. Importantly, NOESY analysis of the mutant
domain confirmed that it was partially unfolded, with no clear lipoyl-lysine p-turn. These
data suggested that the positioning of the lysine within the sharp 1-turn may not be as
essential for LplA recognition as it had been initially proposed. The same effect was also
observed for E. coli E2040 and the E2p subunit from Bacillus stearothermophilus41.
Figure 6-9: Solution structure of a hybrid lipoyl domain from E. coli E2p. The E2p domain
folds into a flattened antiparallel P-barrel consisting of two 4-stranded P-sheets. The lipoylated
lysine residue is prominently displayed in a highly conserved DKA sequence at the tip of a single
p-turn in the P-sheet opposite to the N- and C-terminal residues. The lysine site of lipoylation is
represented in ball and stick format. Carbon atoms are colored grey, oxygen atoms are colored
red, nitrogen atoms are colored blue, and sulfur atoms are colored yellow. The residues forming
the surface loop essential for reductive acylation are colored magenta. Residues incorporated in
the rationally-designed peptides are colored orange.
Table 6-1 summarizes the amino acid sequences of the peptides tested (the lysine
site of lipoylation is underlined). We designed three candidate peptides (4, 6, and 7) by
copying the 17-amino acid stretch encompassing the lysine lipoylation sites in each of the
three E. coli natural substrate proteins E2p, E2o, and H-protein. Three more peptides
were designed to resemble the natural protein substrate (BCCP, peptides 2 and 3) or the
artificial peptide substrate (AP, peptide 1) of the mechanistically related enzyme E. coli
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biotin ligase (BirA). The E. coli biotin carboxyl carrier protein (BCCP) is the only natural
protein substrate of BirA. BCCP and E2p have similar overall folds, with similar
positioning of their acceptor lysines within P-turns38. It had been previously reported that
substitution of the consensus MKM biotinylation sequence in BCCP by the lipoylation
triad DKA resulted in reduced biotinylation of BCCP, accompanied by gain of certain
ability to be lipoylated by LplA 42. We thus designed a peptide based on the amino acid
sequence of the mutant BCCP with the MKM motif replaced by DKA (peptide 2). Later,
Reche and Perham showed that further mutation of residues within the biotinyl-lysine
turn of BCCP from the original MKMMNQ to the E2p-like DKASME sequence
complete abolished recognition by BirA, while increasing its lipoylation rate by
- 100-fold 38. Based on this information, we designed peptide 3. We also tested a peptide
derived from E2p of Bacillus stearothermophilus (peptide 5), as it had been previously
shown to be recognized by E. coli LplA4 3.
Table 6-1: Engineering a peptide substrate for LplA. A series of peptides (1-10) were cloned
as N- or C-terminal fusions to the histone protein 1 (HP1). The extent of conversion in an azide 7
ligation reaction was assessed by HPLC assay and compared to that of the best peptide
(peptide 8). All measurements were performed in triplicate. Results are expressed as mean ± s.d.
Peptide Sequence Derived from Fused to % Conversion
1 GLNDIFEADKAEWHE BirA AP N term. <5
2 GDTLCIVEADKAMNQIE E. coli BCCP N term. <5
3 GDTLCIVEADKASMEIP E. coli BCCP N term. 53.9 ± 1.9
4 EQSLITVEGDKASMEVP E. coli E2p N term. <5
5 DDVLCEVQNDKAVVEIP B. stearoth. E2p N term. 11.9 + 3.1
6 DEVLVEIETDKVVLEVP E. coli E2o N term. 99.0 ± 7.5
7 GDDCAVAESVKAASDIY E. coli H-protein N term. <5
8 DEVLVEIETDKAVLEVP E. coli E2o N term. 100 + 8
9 DEVLVEIETDKAVLEVP E. coli E2o C term. 18.9 ± 2.4
10 DEVLVEIETDKAVLEVPGGEEE E. coli E2o C term. 51.7 ± 3.5
Peptides 1-7 were cloned as N-terminal fusions to the histone protein 1 (HP1) 44, a
protein that our lab can express in high quantities and that we had previously used to
determine the biotinylation kinetics of an acceptor peptide of the yeast biotin ligase4 5. We
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expressed and purified the fusions, and we tested them using our HPLC assay. Table 6-1
summarizes the results. We observed large differences in the extent of lipoylation among
the different peptides. We were surprised to find, for example, that the peptide derived
from E. coli E2p (peptide 4) was not recognized by LplA to a detectable level. In
contrast, three other peptides (3, 5, and 6) were significantly lipoylated by wild-type
LplA, with peptide 6 derived from E. coli E2o giving the best conversion. It is worth
noting that peptide 5 was derived not from a lipoate-acceptor domain, but rather from the
mutant biotinyl domain.
Next, we attempted to further improve peptide 6 by introducing point mutations.
We compared the amino acid sequences of the three peptides that were lipoylated (3, 5
and 6), and we incorporated those residues that were different in the sequence of peptide
6. The results are illustrated in Figure 6-10. Only one of the point mutants, the
Val(+ 1)Ala mutant (peptide 8), gave an increase in ligation rate (Table 6-1).
-10 -9 -8 -7 -6 -5 -4 -3 -2 -1 +1 +2 +3 +4 +5 +6
DEVLVEIE TDKAVLEVP
D T TVQ S ,V I
0.7x 0.8x ? 0.2x 0.9x
1.1x 0.5x No 0.5x 0.7x
Figure 6-10: Mutagenesis analysis of an LpIA peptide recognition sequence. Amino acid
residues of peptide 6 were mutated to the corresponding residues present in peptides 3 or 5. For
example, Leu(+3) from peptide 6 was mutated to either Met (peptide 3) or Val (peptide 5). The
resulting change in the lipoylation rate is expressed as a fold (x) difference with respect to the
original peptide 6 sequence. Acidic amino acids are colored orange, non-polar amino acids are
colored blue, and polar uncharged residues are colored green. The strictly conserved Lys and
Pro(+6) were not mutated and are colored black.
To test the transposability of peptide 8, we fused it to the C-terminal end of HP1
(to give peptide 9). The lipoylation rate dropped 5-fold, but was then partially recovered
by adding five extra C-terminal amino acids to give peptide 10. Further addition of extra
amino acids at the N- or C-terminus of peptide 10 did not affect the extent of lipoylation.
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This final 22-amino acid sequence was named the LplA acceptor peptide, or LAP, and
was used in all subsequent experiments.
Finally, we measured the kinetics for LplA-catalyzed ligation of azide 7 to
peptide 8. We calculated an initial rate of 0.048 ± 0.001 s' (Figure 6-6), which is only
2.3-fold slower than the corresponding rate for E2p (0.111 ± 0.003 s-', Figure 6-8).
However, we estimate that the affinity of LplA for the peptide is much lower than its
affinity for E2p.
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Figure 6-11: Time course of azide 7 ligation to LAP using 2 pM LplA. Reactions were
incubated at 30 'C under the following reaction conditions: 1.3 mM LAP, 2 jtM LplA, 750 jtM
azide 7, 1 mM ATP, and 2 mM magnesium acetate in 25 mM sodium phosphate pH 7.0. Aliquots
were removed at the indicated times, quenched with EDTA, and analyzed by HPLC. Each data
point represents the average of three experiments. Error bars, 1 s.d.
LplA does not recognize any endogenous mammalian proteins
Finally, for the third stage of engineering, we asked whether LplA retains its high
sequence specificity towards its engineered peptide substrate over all the other
endogenous mammalian proteins. Previous studies had shown that protein substrates
from bacteria, archaea, and plant organisms are lipoylated when recombinantly expressed
in E. coli43'46-48 . In contrast, protein substrates from mammalian LPLs have been shown
to either not be lipoylated at all (e.g., bovine E2b)49 or to a barely detectable extent (e.g.,
human E2p)50 in E. coli. In the latter study, Quinn and co-workers showed that human
E2p can be lipoylated in vitro by LplA under forcing conditions, albeit at a rate - 0.005-
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fold lower than its E. coli counterpart 50 . We thus decided to perform these tests ourselves
using azide 7 instead of lipoic acid.
+ + - - LAP-CFP
- - + - LAP(Ala)-CFP
+ - + + LplA
- + - - LplA(Ala)
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Figure 6-12: Specificity test for the ligation of azide 7 to recombinant LAP-CFP in
mammalian cell lysates. Lysates from HEK cells expressing a LAP fusion to CFP were labeled
in vitro with LplA and azide 7. The azide was derivatized with phosphine-FLAG via the
Staudinger ligation, and the FLAG epitope was detected by blotting with anti-FLAG antibody.
Controls are shown with LAP-CFP replaced by its alanine point mutant (lane 3), or with LplA
replaced by its catalytically inactive Lysl33Ala mutant (lane 2). Coomassie staining demonstrates
equal loading in all lanes. Fluorescence visualization of CFP demonstrates equal expression
levels of the LAP fusion in lanes 1-3.
To test the sequence specificity of LplA, and hence the suitability for mammalian
cell labeling applications, we tested LplA activity on mammalian lysates. We created a
LAP fusion to cyan fluorescent protein (CFP), and expressed it in human embryonic
kidney (HEK) cells. HEK lysates were then labeled with LplA, azide 7 and ATP, and the
ligated azide was detected by western blot analysis, after functionalization with a FLAG
peptide through the Staudinger ligation24. Figure 6-12 shows the anti-FLAG stained
western blot. In the presence of thousands of mammalian proteins in the cell lysate, only
LAP-CFP was labeled by LplA (lane 1). The expression level of LAP-CFP was so low
that it could not be seen above that of endogenous proteins in the Coomassie-stained gel.
Lysates from untransfected cells showed no detectable labeling (lane 4). To test the site-
specificity of the reaction, we created a mutant of LAP-CFP with the lysine modification
site mutated to alanine (LAP(Ala)-CFP). Lysates of cells expressing this construct,
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instead of LAP-CFP, showed no labeling with FLAG (lane 3). We also performed a
control in which a catalytically inactive mutant of LplA (Lysl33Ala) replaced the wild-
type LplA in the in vitro lysate labeling reaction. Lane 2 of Figure 6-12 shows that LAP-
CFP labeling in lysate also depends on LplA enzymatic activity.
Conclusions
In this chapter, we have described our three-stage engineering process to re-direct
E. coli lipoic acid ligase for the purpose of site-specific protein labeling. In previous work
in our laboratory, we exploited the very high sequence specificity ofE. coli BirA to
incorporate a ketone isostere of biotin onto AP-fused target proteins17 . Because we found
that BirA is also highly specific for the biotin structure, however, many of the other
biotin analogs that we synthesized and tested, including azide analogs, were rejected by
the enzyme. This finding limited the usefulness of BirA for protein labeling applications.
In contrast, we have shown that LplA exhibits very high specificity for its peptide or
protein substrate, but relaxed specificity for its small molecule substrate. This property
allowed us to incorporate alkyl azide and alkyne functional group handles, amenable for
bioorthogonal ligation. To create a minimally invasive tag to direct the ligation of the
alkyl azide, we engineered, through iterative cycles of rational design, a 22-amino acid
replacement for LplA's natural protein substrates, which can be fused to the N- or C-
terminus of any protein of interest. The successful compliance with the three
aforementioned requirements (i.e., acceptance of alkyl azides, recognition of a small
peptide, and high sequence specificity) makes LplA a useful platform for protein labeling
applications. As explained in the introduction to this chapter, we can now use the strain-
promoted [3+2] cycloaddition to site-specifically label proteins according to the two-step
protein labeling procedure depicted in Figure 6-13. In the following Chapters 7 and 8, we
will describe how we have used this two-step protocol to label proteins both, at the cell-
surface and in the cytosol of mammalian cells.
More recently, Dr. Hemanta Baruah, a post-doctoral fellow in our lab, has found a
mutant of LplA (W37I) that can efficiently ligate a small fluorophore probe based on
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7-hydroxycoumarin (Figure 6-2B). In Chapters 7 and 8, we will show that direct ligation
of a fluorophore by the W371 mutant results in faster labeling of cell-surface and
cytosolic proteins.
lipoic acid ligaseS (LplA)
azide 7, ATP cyclooctyne-
probe conjugate
Figure 6-13: Two-step protein labeling using lipoic acid ligase. In the first step of the
reaction, the E. coli enzyme lipoic acid ligase (LplA) catalyzes the ATP-dependent ligation of an
azide-bearing analog of lipoic acid (azide 7) to the lysine chain in the LplA acceptor peptide
(LAP). In the second step of the labeling reaction, the azide undergoes [3+2] cycloaddition with a
cyclooctyne-probe conjugate (red) to form a stable cycloadduct.
Experimental
General synthetic methods
Reagents were purchased from Sigma-Aldrich, Alfa Aesar, TCI America,
Invitrogen, or GE Healthcare and used without further purification. Analytical thin layer
chromatography was performed using 0.25 mm silica gel 60 F254 plates and visualized
with ninhydrin or bromocresol. Flash column chromatography was carried out using
silica gel (ICN SiliTech 32-63D). Mass spectra were recorded on an Applied Biosystems
200 QTRAP Mass Spectrometer using electrospray ionization. HPLC was performed on a
Varian Prostar Instrument equipped with an autosampler and photo-diode-array detector.
For analytical HPLC, a reverse-phase 250 x 4.6 mm Microsorb-MV 300 C18 column was
used. For preparative HPLC, a reverse-phase 250 x 10 mm Microsorb-MV 100 C18
column was used. Chromatograms were recorded at 210 nm unless otherwise noted. 1H
NMR spectra were recorded on a Varian Mercury 300 MHz instrument. Chemical shifts
are reported in delta (6) units, parts per million (ppm), and referenced to the residual
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solvent peak. Coupling constants (J) are reported in hertz (Hz). The following
abbreviations for multiplets are used: s, singlet; dt, doublet of triplets; t, triplet; m,
multiplet. Probes were stored as DMF solutions (3-5 M) at -20 OC.
Synthesis of alkyl azide probes
Synthesis of 7-azidoheptanoic acid32
To an ice-cooled solution of sodium azide (1.78 g, 27.5 mmol) in water (4.5 mL)
was added dichloromethane (7.5 mL). The biphasic mixture was stirred vigorously and
trifluoromethanesulfonic anhydride (0.93 mL, 5.5 mmol) was added slowly over 5
minutes. The reaction was allowed to proceed for 2 hours at 4 oC. The aqueous layer was
then separated from the organic phase and extracted twice with dichloromethane (2 x
25 mL). The combined dichloromethane extracts were washed with saturated sodium
carbonate solution and concentrated to 13 mL under reduced pressure. This crude triflyl
azide was used without further purification. 7-aminoheptanoic acid (0.35 g, 2.4 mmol)
was dissolved in water (7.8 mL) and combined with potassium carbonate (0.52 g, 3.8
mmol) and copper sulfate pentahydrate (6.6 mg, 26.4 ýpmol). Methanol (15.6 mL) was
added to dissolve the mixture, followed by crude triflyl azide. The reaction was allowed
to proceed at 21 oC overnight. The mixture was concentrated under reduced pressure,
treated with NaH2PO 4 buffer (45 mL, 250 mM, pH 6.2) and extracted with ethyl acetate
(4 x 50 mL) to remove byproduct sulfonamide and excess triflyl azide. The pH of the
aqueous solution was further reduced to 2.0 using concentrated HC1. The product was
extracted with ethyl acetate (4 x 50 mL), dried over magnesium sulfate, and finally
evaporated to dryness under reduced pressure to afford the desired product as a pale
yellow oil (42 mg, 0.26 mmol, 10.7%). 1H NMR (CDC13): 8 3.27 (t, 2H, J= 6.9), 2.37
(t, 2H, J= 7.5), 1.62 (m, 4H), 1.39 (m, 4H). ESI-MS calculated for [M - H]-: 170.22;
observed 170.16.
General procedure for synthesis of n = 5, 7-10 azides31
To a solution of the corresponding bromo-alkanoic acid (10 mmol of 6, 8, 9, 10 or
11-bromo-alkanoic acid) in DMF (20 mL) was added sodium azide (0.98 g, 15 mmol).
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The mixture was allowed to stir at 21 oC overnight. The progress of the reaction was
monitored by thin layer chromatography (0-40% ethyl acetate in hexanes). DMF was
removed under reduced pressure and the resulting residue was re-suspended in HCI
(25 mL, 1 N) and subsequently extracted with ethyl acetate (4 x 25 mL). The combined
organic layers were dried over magnesium sulfate, and evaporated to dryness under
reduced pressure to afford the desired azido-alkanoic acid as a pale yellow oil. Typical
yields ranged from 35-65%.
Characterization data for n = 5 azide (6-azidohexanoic acid). 1'H NMR (CDC13): 6 3.28
(t, 2H, J= 6.9), 2.37 (t, 2H, J= 7.5), 1.64 (m, 4H), 1.35 (m, 2H). ESI-MS calculated for
[M - H]-: 156.17; observed 156.12.
Characterization data for n = 7 azide (8-azidooctanoic acid). 'H NMR (CDCl3): 8 3.26
(t, 2H, J= 6.8), 2.36 (t, 2H, J= 7.5), 1.62 (m, 4H), 1.35 (m, 6H). ESI-MS calculated for
[M - H]-: 184.22; observed 184.14.
Characterization data for n = 8 azide (9-azidononanoic acid). 'H NMR (CDC13) 8 3.25
(t, 2H, J= 6.9), 2.34, (t, 2H, J= 7.5), 1.60 (m, 4H), 1.32 (m, 8H). ESI-MS calculated for
[M - H]- : 198.25; observed 198.18.
Characterization data for n = 9 azide (10-azidodecanoic acid). 1H NMR (CDCl3) 8 3.25
(t, 2H, J= 7.1), 2.35, (t, 2H, J= 7.5), 1.61 (m, 4H), 1.31 (m, 10H). ESI-MS calculated for
[M - H]-: 212.28; observed 212.16.
Characterization data for n = 10 azide (11-azidoundecanoic acid). 1H NMR (CDCl3)
8 3.25 (t, 2H, J= 7.1), 2.35, (t, 2H, J= 7.5), 1.62 (m, 4H), 1.29 (m, 12H). ESI-MS
calculated for [M - H]-: 226.31; observed 226.20.
Synthesis of alkyne probes
Synthesis of n = 5 and n = 7 alkynes33
To a solution of 10 mmol 6- or 8-bromo-alkanoic acid in DMSO (23 mL) was
added lithium acetylide ethylenediamine (0.92 g, 10 mmol) slowly over a period of
5 minutes. The reaction mixture was stirred overnight at 21 'C. Subsequently, water
(25 mL) was added and the product extracted with dichloromethane (3 x 25 mL).
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Dichloromethane was removed under reduced pressure to yield the desired alkynoic acid
as a brownish solid. Yields ranged from 5-7%.
Characterization data for n = 5 alkyne (7-octynoic acid). 'H NMR (CDC13) 62.36 (t, 2H,
J= 7.1), 2.19, (t, 2H, J= 6.9), 1.94 (t, 1H, J= 2.6), 1.69-1.34(m, 6H). ESI-MS calculated
for [M - H]-: 139.18; observed 139.08.
Characterization data for n = 7 alkyne (9-decynoic acid). 1H NMR (CDC13) 6 2.35 (t, 2H,
J= 7.5), 2.18, (dt, 2H, J= 6.9, J= 2.7), 1.94 (t, 1H, J= 2.7), 1.63 (m, 2H), 1.51 (m, 2H),
1.35 (m, 6H) ESI-MS calculated for [M - H]-: 167.23; observed 167.22.
Cloning of HP1-peptide fusions for recombinant expression in bacteria
For peptides 1-7, the histone protein 1 (HP1) gene44 was PCR-amplified using a
forward primer that introduced the desired peptide sequence after an NheI site (forward
primer sequences below), and the reverse primer HP1-EcoRI.R (5' TTTT GAA TTC GGA
TCC TTG CGG CTC GCC TCG TAC). The resulting PCR product was digested with NheI
and EcoRI and ligated in-frame to an NheI/EcoRI digested pET2 lb vector. The vector
introduced a C-terminal His 6 tag.
Peptide Forward Primer Sequence (NheI sites are italicized)
5' AAAA GCT AGC GGC CTG AAC GAC ATC TTC GAA GCC GAC AAA GCT
1
GAA TGG CAC GAG GGC GGT GAG GAG GAG TAC GCC GTG G
5' AAAA GCT AGC GGC GAT ACC CTG TGC ATC GTT GAA GCC GAC AAA
2
GCT GAA AAC CAG ATC GAA GGC GGT GAG GAG GAG TAC GCC GTG G
5' AAAA GCT AGC GGC GAT ACC CTG TGC ATC GTT GAA GCC GAC AAA
3
GCT TCT ATG GAA ATC CCG GGC GGT GAG GAG GAG TAC GCC GTG G
5' AAAA GCT AGC GAA CAG TCG CTG ATC ACC GTA GAA GGC GAC AAA
4
GCT TCT ATG GAA GTT CCG G GGGGT GAG GAG GAG TAC GCC GTG G
5' AAAA GCT AGC GAC GAT GTA CTG TGC GAA GTA CAG AAC GAC AAA
5
GCT GTA GTT GAA ATC CCG GGC GGT GAG GAG GAG TAC GCC GTG G
5' AAAA GCT AGC GAC GAA GTA CTG GTT GAA ATC GAA ACC GAC AAA
6
GTA GTT CTG GAA GTA CCG GGC GGT GAG GAG GAG TAC GCC GTG G
5' AAAA GCT AGC GGC GAT GAC TGC GCT GTT GCT GAA TCT GTA AAA
7
GCT GCC TCG GAC ATC TAT GGC GGT GAG GAG GAG TAC GCC GTG G
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Peptide 8 was obtained by mutagenesis on peptide 6, using the QuikChange
primer 5' GAA ATC GAA ACC GAC AAA GCA GTT CTG GAA GTA CCG GGC and its reverse
complement. To clone peptide 9, the HP1 gene was PCR-amplified using the primer
NdeI-HP1.F (5' AAAA CAT ATG GAG GAG GAG TAC GCC GTG G), which incorporates an
NdeIsite, and the primer HP1-LAP-Stop-BamHI.R (5' TTTT GGA TCC TCT TAC GGT
ACT TCC AGA ACT GCT TTG TCG GTT TCG ATT TCA ACC AGT ACT TCG TCG CTA GCA
TCC TTG CGG CTC GCC TCG TAC), which introduces the peptide sequence and a BamHI
site. The resulting PCR product was digested with NdeI and BamHI and ligated in-frame
to an Ndel/BamHI digested pET15b vector, which introduces an N-terminal His6 tag. To
clone peptide 10, the gene encoding peptide 9 was PCR-amplified using the same
forward primer NdeI-HP1.F, and the reverse primer LAP-AAs-Stop-BamHI.R (5' TTTT
GGA TCC TCT TAC TCC TCC TCA CCG CCC GGT ACT TCC AGA ACT GCT TTG TC). The
PCR product was digested and ligated as above.
Cloning of LAP-CFP for cytoplasmic mammalian expression
The sequence for the LAP peptide was inserted in the Nhel site of a modified
form of the pcDNA3 vector (Invitrogen). The vector contained the CFP gene between the
BamHI and EcoRIsites17 . Primers 5' AAAA ACT AGT CGG GCT GAC GAA GTA CTG GTT
GAA ATC GAA ACC GAC AAA GCA GTT CTG GAA GTA CCG GCA TCA GCA GAC GGC GCT
AGC AAAA and its reverse complement were annealed together, digested with SpeI and
Nhel, and ligated in-frame to Nhel digested pcDNA3-CFP vector. To create the
LAP(Ala)-CFP mutant, we performed QuikChange with the primer 5' G GTT GAA ATC
GAA ACC GAC GCC GCA GTT CTG GAA GTA CCG G and its reverse complement.
Site directed mutagenesis of LplA
The pYFJ16 plasmid, a gift from John Cronan, encodes an N-terminally His6-
tagged LplA within the pQE-2 vector (Qiagen). To create the catalytically inactive
mutant, Lys133 was mutated to alanine by QuikChange using 5' CGA AGG CGA CCG CGC
AGT CTC AGG CTC GG and its reverse complement.
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Bacterial expression and purification of E. coli LplA
LplA was expressed from the plasmid pYFJ16, a gift from John Cronan, which
encodes an N-terminally His6-tagged LplA within the pQE-2 vector (Qiagen). pYFJ16
was transformed into E. coli BL2 I1(DE3) cells, which were amplified in LB media
supplemented with 100 ýpg/mL ampicillin at 37 'C until OD 600 0.9. Enzyme expression
was induced with 200 jtg/mL IPTG for 3 hours at 30 oC. Thereafter, cells were harvested
by centrifugation (6,000 rpm, 10 minutes, 4 oC) and the pellet was resuspended in lysis
buffer (50 mM Tris base, 300 mM NaCl, pH 7.8) containing 2.5 mM
phenylmethylsulfonyl fluoride (PMSF) and protease inhibitor cocktail (Calbiochem).
Cells were lysed by ultrasonic treatment (six 15-second bursts, with 1 minute of cooling
to 4 'C between bursts). The extract was cleared by centrifugation (17,700 g, 10 minutes,
4 oC) and the His6-tagged enzyme was purified using Ni-NTA agarose (Qiagen).
Fractions were analyzed by 12% SDS-PAGE followed by Coomassie staining. Fractions
containing LplA were pooled and dialyzed against PBS pH 7.4. Enzyme concentration
was determined by measuring A280 and using the reported extinction coefficient
(46,250 M-' cm 1 )1.
Bacterial expression and purification of E2p
A single hybrid lipoyl domain derived from the second subunit of the E. coli
pyruvate dehydrogenase was expressed from the E. coli K12 strain, TM245, which was a
gift from John Cronan7,34. Transformants of strain TM245 were grown at 37 'C in LB
media supplemented with 100 gpg/mL ampicillin until OD 600 0.2. Protein expression was
induced with 10 [tg/mL IPTG for 17 hours at 25 'C. Harvested bacteria were resuspended
in 20 mM sodium phosphate buffer pH 7.4 containing 2 mM EDTA, 2.5 mM PMSF, and
protease inhibitor cocktail (Calbiochem). Cells were lysed by ultrasonic treatment (eight
30-second bursts, with 30 seconds of cooling to 4 oC between bursts). The extract was
cleared by centrifugation (17,700 g, 40 minutes, 4 oC), before lowering the pH to 3.8 with
1 M HC1. Insoluble material was removed by two rounds of centrifugation (17,700 g,
20 minutes, 4 oC and 17,700 g, 10 minutes, 4 oC), before increasing the pH to 7.0 with
1 M NaOH. The supernatant was dialyzed against 10 mM ammonium acetate pH 5.0,
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then subjected to fast flow anion-exchange chromatography on a 1 mL Q-Sepharose
column with a 10-600 mM ammonium acetate pH 5.0 gradient generated over 20 column
volumes. Eluted fractions were analyzed by 19% SDS-PAGE followed by Coomassie
staining. Fractions containing E2p were pooled and dialyzed against PBS pH 7.4. Protein
concentration was measured using the BCA (bicinchoninic acid) assay with BSA as the
standard.
Bacterial expression and purification of HP1-peptide fusions
E. coli BL21(DE3) cells transformed with one of the HPI expression plasmids
were amplified in LB media supplemented with 100 gg/mL ampicillin at 37 oC until
OD600 0.9. Protein expression was induced with 100 gg/mL IPTG for 4 hours at 30 OC.
Cells were harvested by centrifugation and purified as described above for LplA.
Purification fractions were analyzed by 16% SDS-PAGE followed by Coomassie
staining. Fractions containing HP1-peptide protein were pooled and dialyzed against PBS
pH 7.4. Protein concentration was measured using the BCA assay with BSA as the
reference standard.
In vitro LplA activity assays
LplA reactions contained 2 gM LplA, 200 pM E2p, 350 gM probe, 1 mM ATP,
2 mM magnesium acetate, and 25 mM sodium phosphate pH 7.0. Reactions were
incubated at 30 oC for 30 minutes, and then quenched with EDTA (final concentration
50 mM). Conversion to product was determined by HPLC on a C 8g reverse-phase column
with a 40-57% gradient of acetonitrile in water with 0.1% trifluoroacetic acid over
20 minutes (flow rate 1.0 mL/minute). Unmodified E2p had a retention time of - 12
minutes while E2p-probe conjugates eluted at 15-18 minutes. Percent conversion to
product was calculated from the ratio of the E2p-probe peak area to the sum of (E2p +
E2p-probe) peak areas. All measurements were performed in triplicate.
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Measurement of LplA-probe ligation kinetics
To measure the kcat for LplA ligation of lipoic acid to E2p, 50 nM LplA was
combined with 200 ýiM E2p, 750 itM lipoic acid, 1 mM ATP, and 2 mM magnesium
acetate in 25 mM sodium phosphate pH 7.0. The reaction was initiated with addition of
1 mM ATP to the pre-warmed (30 oC) mixture. The reaction was incubated at 30 oC, and
90 [tL aliquots were removed every 5 minutes and quenched with 50 mM EDTA (final
concentration). Samples were analyzed by C18 reverse-phase HPLC as described in the
"Methods" section. Measurements were performed in triplicate. A calibration curve was
obtained that correlated the ratio of integrated HPLC peak areas (E2p : E2p-probe) to the
actual protein ratio, in order to compensate for differences in the extinction coefficients
of E2p and lipoylated E2p. The amount of product obtained at each time point was
plotted against time, to obtain the Vmax of the reaction. From this, the klat value was
obtained using the equation Vmax = kcat [E]total.
To measure the Km and kcat for ligation of azide 7, 200 nM LplA was combined
with 200 tM E2p, 1 mM ATP, 2 mM magnesium acetate in 25 mM sodium phosphate
pH 7.0, and various concentrations of azide 7 (25, 50, 66, 100, 240, 360 and 750 gM).
90 gIL aliquots were removed from the 30 'C reactions at 5 minutes intervals, up to
30 minutes, and quenched with 50 mM EDTA (final concentration). Samples were
analyzed by HPLC as above. The amount of product obtained at each time point was
plotted against time, to obtain the initial velocity for each concentration of azide 7. The
collection of initial velocities (Vo) was then plotted against azide 7 concentration
(25-750 jM), and fit to the Michaelis-Menten equation (Vo = Vmax [azide 7]/(Km +
[azide 7])), using Origin 6.1 software, to obtain the Km for azide 7. From the Vmax value,
keat was calculated using the equation Vmax = kcat [E]total.
Mass-spectrometric analysis of E2p-azide 7 conjugate
2 giM LplA was combined with 200 iM E2p, 350 gM azide 7, 1 mM ATP, and
2 mM magnesium acetate in 25 mM sodium phosphate pH 7.0. The ligation reaction was
allowed to proceed to completion by incubating at 30 OC for 2 hours. The reaction
mixture was desalted by extensive dialysis against water (2 x 4 h, followed by overnight
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dialysis). Thereafter, the sample was diluted to a final concentration of 25 piM E2p-azide
7 in 50% methanol with 2% acetic acid. Mass spectra were recorded under the positive
enhanced multi-charge mode of an ESI-MS.
HPLC analysis of LplA modification of HPi-peptide fusions
To compare the conversion rates for different peptide substrates, reactions were
assembled as follows: 1.5 jpM LplA, 150 piM HP1-peptide fusion, 750 PiM azide 7, 1 mM
ATP, and 2 mM magnesium acetate in 25 mM sodium phosphate pH 7.0. Reactions were
incubated at 30 oC for 2 hours, then quenched with 50 mM EDTA (final concentration),
and subsequently analyzed by C18 reverse-phase HPLC using a gradient of 30-45%
acetonitrile in water with 0.1% trifluoroacetic acid over 20 minutes with a 1 mL/minute
flow rate. Retention times for unmodified HP1-peptide fusions ranged from 8-12
minutes, and shifted to 16-21 minutes after ligation to azide 7. Measurements were
performed in triplicate. The extent of modification was calculated from the ratio of HP 1-
peptide-azide 7 peak area to the sum of (HP 1-peptide + HP1-peptide-azide 7) peak areas.
The conversion with HP 1-peptide 8 was normalized to 100% and other conversions were
reported relative to this.
Measurement of kcat for LplA-catalyzed azide 7 ligation to LAP
To measure the kcat for LplA-catalyzed ligation of azide 7 to LAP, the reaction
conditions were as follows: 2 piM LplA, 1.3 mM LAP-HP 1 (N-terminal fusion of peptide
10 to HP1), 750 jiM azide 7, 1 mM ATP, and 2 mM magnesium acetate in 25 mM
sodium phosphate pH 7.0. The reaction was initiated with addition of 1 mM ATP to the
pre-warmed 30 'C mixture. The mixture was incubated at 30 oC, and 10 jPL aliquots were
removed every 5 minutes and quenched with 50 mM EDTA (final concentration).
Samples were analyzed by C18 reverse-phase HPLC as above. The amount of product
obtained at each time point was plotted against time, to obtain the Vmax of the reaction.
From this, the kct value was obtained using the equation Vmax = kcat [E]total.
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LplA specificity test on mammalian lysates
Human embryonic kidney (HEK) 293T cells were transfected with LAP-CFP-
pcDNA3 plasmid using Lipofectamine 2000 (1 tg DNA/well of a 6-well plate). Lysates
were generated 48 hours later by hypotonic lysis to minimize protease release, as follows.
Cells were lifted from the plates, concentrated by centrifugation, and resuspended in
1 mM HEPES pH 7.5, 5 mM magnesium chloride, 1 mM phenylmethylsulphonyl
fluoride, and protease inhibitor cocktail (Calbiochem). After incubation at 4 oC for
10 minutes, the cells were lysed by vigorous vortexing for 2 minutes at 21 OC. Crude
lysate was clarified by centrifugation, and stored at -80 oC. Lysate was labeled by
incubating at 30 oC for 10 hours with 25 mM sodium phosphate pH 7.0, 1 giM LplA,
250 iM azide 7, 1 mM ATP, and 4 mM magnesium acetate. Thereafter, Staudinger
ligation was performed by adding FLAG-phosphine2 4 to a final concentration of 500 jtM,
and incubating at 30 'C for 16 hours. Each reaction sample was then divided into thirds.
The first third was analyzed by 12% SDS-PAGE followed by Western blotting with anti-
FLAG(M2)-peroxidase antibody conjugate (Sigma, 1:1000 dilution). The second sample
was analyzed by 12% SDS-PAGE followed by Coomassie staining. The last third was
analyzed by 12% SDS-PAGE without boiling the samples, in order to prevent unfolding
of CFP, and in-gel fluorescence was visualized on a Storm 860 instrument (Amersham).
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Chapter 7 : Site-specific labeling of cell-surface proteins with lipoic acid
ligase
The work discussed in this chapter has been published in part in: M. Fernndez-Suirez,
H. Baruah, L. Martinez-Hernindez, K. T. Xie, J. M. Baskin, C. R. Bertozzi, and A. Y.
Ting. Redirecting lipoic acid ligase for cell surface protein labeling with small-molecule
probes. Nat. Biotechnol. 25(12), 1483-1487 (2007). The cyclooctyne conjugates and
coumarin probes were synthesized by Dr. Hemanta Baruah. Jeremy Baskin provided the
cyclooctyne starting material.
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Introduction
In Chapter 6, we demonstrated that LplA was a promising platform to develop a
new protein labeling methodology. We engineered small molecule and peptide substrates
for LplA and we demonstrated that LplA is highly specific for labeling its peptide
substrate in the context of cell lysates. We were then ready to test the methodology for
labeling proteins in the live cell context. We started by testing LplA labeling at the cell
surface because it was less demanding than intracellular labeling. For example, whereas
for cell-surface protein labeling, LplA can be added in solution, intracellular labeling
requires that the enzyme be transfected and expressed inside cells. Additionally, cell-
surface protein labeling eliminated the need to find probes capable of permeating across
the cell membrane. In this chapter, we first demonstrate that LplA can be used to label
LAP-tagged proteins with a variety of probes at the surface of mammalian cells, and we
then apply the methodology to one- and two-color cell-surface receptor labeling. We also
characterize the speed, sensitivity, and specificity of the method, and we compare it to
our previously reported biotin ligase and transglutaminase methods.
Results
Site-specific labeling of LAP fusion proteins with small organic fluorophores
Building onto our finding that LplA can accept alkyl azide analogs of lipoic acid,
we devised a two-step labeling methodology to biotinylate or fluorescently tag the LplA
acceptor peptide (LAP) on the surface of mammalian cells. In our scheme for cell-surface
labeling (Figure 7-1), the LAP peptide is expressed as a fusion to the extracellular
domain of a membrane protein, and then labeled with LplA, azide 7 and ATP. In the
second step of the reaction, we use the [3+2] cycloaddition reaction to introduce a variety
of probes (e.g., biotin or a small organic fluorophore).
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Figure 7-1: Two-step cell-surface labeling of LAP-tagged proteins. The labeling procedure is
performed in two steps. In the first step, azide 7 is enzymatically ligated to cell-surface LAP. In
the second step, after washing the LplA, azide 7, and ATP reagents, a cyclooctyne conjugate
chemoselectively reacts with the azide-derivatized LAP-tagged proteins.
One of the most important determinants when performing chemical labeling in
live cells is the choice of appropriate probes. In the case of cell-surface protein labeling,
the molecules need to be highly hydrophilic to render the molecule membrane
impermeant and to avoid non-specific binding with the hydrophobic cell membrane.
Hydrophilicity thus minimizes background staining from endocytosed and non-
specifically bound fluorophore. We chose Alexa Fluor and cyanine dyes because they are
the brightest red-emitting, impermeant fluorophores, and because they are commercially
available in the form of activated esters. We used these activated esters to synthesize
fluorophore conjugates of monofluoro-cyclooctyne (OCT)'. As previously mentioned in
the introduction of Chapter 6, cyclooctynes react with azides to form stable triazoles
under physiological conditions without the need for a metal catalyst2 . Introduction of an
electron-withdrawing fluorine atom alpha to the alkyne increases the second order rate of
the cycloaddition reaction by about 2-fold'. Although it was later shown by the Bertozzi
group that introduction of a second fluorine further accelerates the reaction by - 18-fold,
those probes were not yet available at the time when we were performing these
experiments. We obtained the cyclooctyne starting material (OCT acid, 1) from Jeremy
Baskin (Bertozzi lab). The synthesis of the OCT-fluorophore conjugates was performed
by Dr. Hemanta Baruah, a post-doctoral fellow in our lab following the scheme in Figure
7-2. OCT acid (1) was first activated as a pentafluorophenyl (PFP) ester using PFP-TFA,
and the OCT-PFP (2) was then conjugated to O,O'-Bis(3-aminopropyl)diethylene glycol
(diamino-PEG) linker to give OCT-PEG (3). The use of PEG improves water solubility
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and minimizes non-specific interactions with the cell membrane. The OCT-PEG 3
conjugate was then coupled to the N-hydrosuccinimidyl esters of Alexa Fluor 568 and
Cy3 to give OCT-PEG-Alexa Fluor 568 (4) and OCT-PEG-Cy3 (5). We confirmed the
structures of all these probes by mass spectrometry and by reaction with unconjugated
azide 7 followed by detection of the triazole adduct (data not shown).
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Figure 7-2: Synthetic routes to cyclooctyne-fluorophore conjugates. OCT acid 1 was
activated as the pentafluorophenyl (PFP) ester 2, and then conjugated to a diamino polyethylene
glycol (PEG) linker to give OCT-PEG 3. Reaction of 3 with the activated N-hydroxysuccinimidyl
(NHS) esters of Cy3 or Alexa Fluor 568 gave the final fluorophore conjugates 4 and 5.
Figure 7-3 shows the chemical structures of the OCT-PEG-Alexa Fluor 568 (4)
and OCT-PEG-Cy3 (5) conjugates used for cell-surface labeling in this chapter.
Additionally, a third probe, an OCT-PEG-biotin (6) conjugate was obtained from the
Bertozzi lab.
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Figure 7-3: Chemical structure of OCT-probe membrane impermeant conjugates.
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Next, to express the LplA acceptor peptide (LAP) at the surface of mammalian
cells, we created an artificial construct by fusing LAP to the N-terminus of cyan
fluorescence protein (CFP), which was in turn fused to the extracellular side of the
transmembrane (TM) helix of the PDGF receptor (Figure 7-4, top). To perform live cell
labeling, HEK cells expressing LAP-CFP-TM were treated first with LplA, azide 7, and
ATP for 1 hour at 32 'C. The introduced azide was then selectively modified with the
OCT-fluorophore conjugates by reaction at 25 'C for 20 minutes. Unlike sodium azide,
organic azides such as the clinically approved drug AZT3 are not known to be toxic to
cells, but we nevertheless examined the effect of 48-hour exposure to azide 7 on
mitochondrial respiration, and found no effect at concentrations less than 750 gM (data
not shown).
Figure 7-4 shows the labeling results. We observed specific labeling of
transfected (CFP-positive) cells, without labeling of neighboring untransfected cells in
the same field of view. We also performed negative controls with azide 7 omitted, or the
LAP-CFP-TM construct replaced by its alanine point mutant (alanine at the lysine
modification site within LAP), demonstrating the azide-dependent and site-specific
nature of the ligation. Interestingly, labeling with Alexa Fluor 568 generated higher
background than Cy3 labeling, due to faster non-specific internalization of the probe. We
also observed that the extent of non-specific probe internalization was highly cell line-
dependent. For example, in contrast to HEK and the cervical carcinoma HeLa cells,
which displayed relatively slow endocytosis of the OCT-fluorophores, both Chinese
hamster ovary (CHO) cells and African green monkey kidney (COS-7) cells rapidly
internalized the OCT-fluorophores, resulting in high background staining, which
precluded the cell-surface labeling signal. Recently, Sujiet Puthenveetil, a post-doctoral
fellow in our lab, has shown that labeling with OCT-Cy3 can be performed in COS-7
cells if the total labeling time is reduced to - 10-15 minutes. This reduction in the
labeling time was made possible by the improved ligation kinetics of a different azide
analog (an aryl azide derivative) by a mutant of LplA (W37V).
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Figure 7-4: Site-specific incorporation of Cy3 and Alexa Fluor 568 fluorophores onto cell-
surface proteins in live cells. A LAP-CFP fusion was targeted to the cell surface using a
transmembrane (TM) domain. Cell-surface LAP was first labeled with azide 7 by LplA, and the
introduced azide was then labeled with a cyclooctyne probe conjugated to Cy3 (left) or Alexa
Fluor 568 (right). Live cell images of the introduced fluorophores are shown to the right of the
merged CFP and DIC images, which highlight the transfected cells. Negative controls with azide
7 omitted from the labeling reaction, or with the LAP-CFP-TM replaced by its alanine point
mutant are shown.
Site-specific labeling of LAP fusion proteins with biotin and quantification of the
labeling sensitivity
We also performed labeling with an OCT-biotin conjugate. In this case, labeling
was performed in three steps. HEK cells expressing LAP-CFP-TM were treated first with
LplA, azide 7, and ATP for 1 hour at 32 'C, followed by reaction of the azide with OCT-
PEG-biotin (6) for an additional 15 minutes. Ligated biotin was detected by incubation
with streptavidin conjugated to Alexa Fluor 568 for 15 minutes at room temperature. As
before, labeling of cell-surface LAP-CFP with the OCT-biotin probe was highly specific
(Figure 7-5). Despite the addition of an extra step, the sensitivity of this labeling
experiment was higher than that for the Cy3 and Alexa Fluor 568 labeling. We used the
wedge method4 to quantify this sensitivity and determined that cells expressing as little as
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5 p.M LAP-CFP-TM could be specifically labeled with OCT-biotin, with a signal to
background ratio > 3:1. The improved sensitivity may have been a consequence of the
multiple copies of Alexa Fluor 568 on each molecule of streptavidin, as well as the
absence of background signal from non-specifically internalized biotin probe, which
allowed us to increase the temperature of the [3+2] cycloaddition step from 25 'C to
32 oC, and to ultimately reduce the total labeling time for this probe to a minimum of
- 20 minutes (compared to - 1.5 hours for the direct incorporation of Alexa Fluor 568
and Cy3).
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Figure 7-5: Site-specific labeling of LAP-tagged cell-surface proteins with a cyclooctyne-
biotin conjugate. A LAP-CFP fusion was targeted to the surface of HEK cells using a
transmembrane (TM) domain. Cell-surface LAP was first labeled with LplA and azide 7 followed
by OCT-biotin (6). Ligated biotin was then detected with streptavidin conjugated to Alexa Fluor
568. Live cell images of the Alexa Fluor 568 fluorophore are shown to the right of the CFP and
DIC images, which highlight the transfected cells. Negative controls with azide 7 omitted from
the labeling reaction, or with the LAP-CFP-TM replaced by its alanine point mutant are shown.
In terms of sensitivity, the ultimate goal would be to image a real receptor when it
is expressed at levels that are physiologically relevant, that is, when it is not highly over
expressed. Thus, to further illustrate the sensitivity of LplA labeling for receptor
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imaging, we created a LAP fusion to the low-density lipoprotein receptor (LDLR), which
functions in the uptake of cholesterol in peripheral tissues of the body5. The LAP-LDLR
construct was expressed in HEK cells and labeled as above using OCT-biotin. Figure 7-6
shows that when LAP-LDLR levels were similar to endogenous LDLR levels, as
measured by staining with LDL conjugated to 1,1'-dioctadecyl-3,3,3',3'-
tetramethylindodicarbocyanine (DiD)6, LplA labeling with OCT-biotin was still clearly
detectable.
Streptavidin
CFP/GFP & DIC DiD-LDL Alexa Fluor 568
Alexa Fluor 568
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Figure 7-6: LplA detectably labels LAP-tagged low-density lipoprotein receptor expressed
at endogenous levels. N-terminally LAP-tagged low density lipoprotein receptor (LDLR) was
labeled with LplA and azide 7 followed by OCT-biotin (6). Ligated biotin was then detected with
streptavidin conjugated to Alexa Fluor 568. Detection of the entire population of LDL receptors
(LAP-tagged and endogenous) was achieved using DiD-conjugated LDL. Live cell images of the
Alexa Fluor 568 fluorophore are shown to the right of the DiD images. The merged CFP/GFP and
DIC images highlight the transfected cells.
Finally, we asked the question of what was the extent of the labeling that resulted
in such a high sensitivity. We used a mobility shift assay to quantify the percentage of
cell-surface LAP-CFP molecules being modified by azide 7 and OCT-biotin 6. HEK cells
expressing LAP-CFP were first labeled with LplA, azide 7, and ATP, followed by OCT-
biotin. Thereafter, the cells were lysed and the cell extracts were incubated with soluble
streptavidin. In-gel fluorescence of the lysates showed that only - 3% of the LAP-CFP
-230-
·--
molecules were modified with azide 7 and biotin, as visualized by their in-gel mobility
shift upon binding to streptavidin (Figure 7-7). The low yield of modification was
probably a reflection of the slow ligation of azide 7 to LAP, under conditions in which
the concentration of LAP is likely below KM, combined with the poor kinetics of the
[3+2] cycloaddition reaction. Indeed, the Bertozzi group has recently demonstrated that
LplA-mediated labeling of cell-surface LAP with a difluorinated-cyclooctyne 7 results in a
larger extent of protein modification (J.M. Baskin, personal communication).
LAP LAP(ala)
- + - + Strfntfvirin
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Figure 7-7: Mobility shift assay to quantify cell-surface labeling with LplA and azide 7.
HEK cells expressing cell-surface LAP-CFP were labeled with LplA and azide 7 followed by
OCT-biotin. After lysis, cell extracts were incubated with soluble streptavidin, and run on SDS-
PAGE. CFP fluorescence was visualized in-gel. Negative controls with streptavidin omitted
(lanes 1 and 3) or with LAP-CFP replaced by its alanine mutant are shown. Arrows point to
unmodified LAP-CFP (below) and labeled LAP-CFP-biotin (above), which displays reduced
mobility due to the binding of streptavidin.
LplA labeling is superior to ketone/biotin ligase and transglutaminase labeling in
speed, sensitivity, and specificity
Our lab has previously reported two other methods for site-specific labeling of
peptide-fused cell surface proteins with small molecule probes. In ketone/biotin ligase
labeling, a 15-amino acid "acceptor peptide" (AP) tag is site-specifically conjugated to a
ketone analog of biotin by E. coli biotin ligase (BirA)8 . The ketone is then selectively
derivatized with a hydrazide or hydroxylamine fluorophore. Transglutaminase labeling
uses the guinea pig liver transglutaminase (TGase) to covalently ligate cadaverine-
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functionalized fluorophores to proteins fused to a 7-residue glutamine-containing
"Q2-tag" recognition sequence for transglutaminase 9.
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Figure 7-8: Cell-surface labeling of AP-tagged proteins using biotin ligase and a ketone
isostere of biotin. An AP-CFP fusion was targeted to the surface of HEK cells using a
transmembrane (TM) domain. (A) Cell-surface AP was first labeled with E. coli biotin ligase
(BirA) and ketone followed by biotin-hydrazide. Ligated biotin was then detected with
streptavidin conjugated to Alexa Fluor 568. (B) Cell-surface AP was first labeled with BirA and
ketone followed by Alexa Fluor 568-hydrazide. In both cases (A and B), live cell images of the
Alexa Fluor 568 fluorophore are shown to the right of the CFP and DIC images, which highlight
the transfected cells.
We directly compared the speed, sensitivity, and specificity of LplA labeling to
these methods in side by side labeling experiments. The ketone/biotin ligase labeling was
performed on cells expressing an AP-CFP-TM construct (exactly analogous to LAP-CFP-
TM) under optimized conditions, using a previously described biotin-benzophenone-
hydrazide probe 8. While the total labeling time for LplA-mediated ligation of OCT-biotin
was 45 minutes (Figure 7-5), ketone/biotin ligase labeling required 2 hours and
15 minutes to achieve similar signal to background intensity ratios (Figure 7-8A). Due to
the long labeling time, as well as the reduced pH and temperature required for the
hydrazone formation step, many cells became unhealthy and rounded. We also tested
ketone/biotin ligase labeling for direct incorporation of Alexa Fluor 568 hydrazide
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(Figure 7-8B), in a manner analogous to LplA-mediated incorporation of Alexa. Over a
wide range of Alexa hydrazide concentrations and different reaction times, the labeling
was uniformly unsuccessful. At higher probe concentrations, the non-specific background
from Alexa internalization obscured any potential specific cell surface signal. One
explanation for the difference in sensitivity is the faster second-order rate constant for the
azide-alkyne [3+2] cycloaddition reaction compared to ketone-hydrazide ligation1 .' 0
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Figure 7-9: Cell-surface labeling of Q2-tagged proteins using transglutaminase. A Q2-CFP
fusion was targeted to the surface of HEK cells using a transmembrane (TM) domain. Cell-
surface Q2 was labeled with 0.3 gtM (A) or 1 pM (B) transglutaminase (TGase) and biotin-
cadaverine. Ligated biotin was then detected with streptavidin conjugated to Alexa Fluor 568.
Live cell images of the Alexa Fluor 568 fluorophore are shown to the right of the CFP and DIC
images, which highlight the transfected cells.
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Transglutaminase labeling was performed on HEK cells expressing the Q2-CFP-
TM construct under optimized conditions, using biotin cadaverine, followed by detection
with streptavidin-Alexa Fluor 568 conjugate (Figure 7-9). Labeling was comparable to
LplA ligation of OCT-biotin, in speed and sensitivity. However, the specificity of
transglutaminase labeling was highly variable and difficult to optimize. For example,
Figure 7-9A shows good labeling specificity with 0.3 iM transglutaminase, when
comparing the Q2-CFP-TM image to the Q2(Ala)-CFP-TM negative control image.
However, increasing the enzyme concentration by only 3-fold resulted in the loss of
labeling specificity (Figure 7-9B). By contrast, LplA was completely specific for the LAP
sequence at enzyme concentrations ranging from 1 gM to 20 gM (data not shown).
LplA labeling is orthogonal to BirA labeling
For many imaging studies, it is desirable to visualize two different receptors at
once in the same cell, in order to compare their distribution or trafficking patterns. To
develop this capability, we investigated the compatibility of LplA labeling with biotin
ligase/streptavidin targeting, a strategy previously developed in our lab by the post-
doctoral fellow Mark Howarth1 14 . Unlike ketone/biotin ligase labeling, our biotin
ligase/streptavidin targeting method makes use of site-specific biotin ligation onto AP
fusion proteins, followed by recognition with streptavidin conjugates to fluorophores or
quantum dots (QDs). While the use of streptavidin increases the total size of the label, the
femtomolar affinity of the biotin-streptavidin interaction makes this labeling approach
much faster and much more sensitive than ketone/biotin ligase labeling".
E. coli LplA and biotin ligase are mechanistically related, and their natural
acceptor proteins share some structural and sequence overlap . We showed in Chapter 6,
for example, that a peptide derived from a modified biotin carboxyl carrier protein
(BCCP) was recognized by LplA in vitro. We also showed, however, that a modified AP
(with the triad surrounding the lysine site of modification mutated to the lipoylation
consensus DKA sequence) was not modified by LplA to any detectable level. Although,
the engineered LAP and AP sequences are thus dissimilar, as are the azide 7 and biotin
structures, we nonetheless wished to undoubtedly confirm that the two enzyme-mediated
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labeling strategies were indeed orthogonal. To test the orthogonality of the two methods,
we prepared separate dishes of HEK cells expressing LAP-LDLR with a GFP tag to serve
as a marker for transfection, or AP-EGFR (AP fused to the extracellular N-terminus of
the EGF receptor8) together with a CFP transfection marker. After 16-24 hours of
expression, the cells were re-plated together in a single dish. We performed labeling by
first adding a mixture of LplA, BirA, azide 7, biotin, and ATP to the cells. Thereafter,
OCT-Cy3 (5) was added to derivatize the azide, and streptavidin-QD655 was added to
detect the biotin. Figure 7-10 (top) shows that cells expressing LAP-LDLR (as indicated
by GFP fluorescence) were selectively labeled with Cy3, while cells expressing AP-
EGFR (as indicated by CFP fluorescence) were selectively labeled with QD655. The
same results were obtained using LDLR-expressing cells plated beside AP-EphA3-
expressing cells (AP fused to the extracellular N-terminus of the receptor for ephrin A3)
(Figure 7-10, bottom). Thus, simultaneous labeling of cells with LplA and BirA is
possible, without sacrificing the extremely high specificity of each enzyme.
Streptavidin
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Figure 7-10: Orthogonality test for the simultaneous dual-color labeling of cell-surface
proteins with lipoic acid ligase and biotin ligase. Top: Separate dishes of HEK cells were
transfected with LAP-GFP-LDLR or AP-EGFR (plus a CFP co-transfection marker). After
24 hours, transfected cells were re-plated together in the same dish. Two-color labeling was
performed by treating first with LplA, BirA, azide 7, and biotin, followed by OCT-Cy3, followed
by streptavidin-QD655 (Quantum Dot 655). LAP-GFP-LDLR cells are specifically labeled with
Cy3, while AP-EGFR cells (indicated by CFP marker) are specifically labeled with QD655.
Bottom: Same, but AP-EGFR was replaced by AP-EphA3.
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Two-color receptor labeling on polarized cells using LplA and biotin ligase
We next used the two-color labeling approach to also image LAP- and AP-fused
receptors co-expressed in the same cell. EGF receptor and EphA3 are both known to
function in cell migration 16' 17, and thus we performed imaging on cells migrating toward
an artificial wound. HEK cells were co-transfected with either LAP-LDLR and AP-
EGFR, or LAP-LDLR and AP-EphA3. After 16-24 hours of expression, the confluent
cells were wounded with a pipet tip. We allowed the wound to partially close over 12-18
hours, and then performed simultaneous labeling with Cy3 and Alexa Fluor 488
conjugated to monovalent streptavidin. Monovalent streptavidin was engineered by Mark
Howarth in our lab, and it has a single femtomolar-affmity biotin binding site12.
Monovalent streptavidin is preferred for receptor imaging over the tetravalent wild-type
protein (four biotin binding sites) because it eliminates artifacts introduced by
streptavidin-mediated receptor crosslinking. Figure 7-11 shows the results of the two-
color imaging experiment. We observed that Cy3-labeled LDLR was evenly distributed
on the surface of the HEK cells, whereas Alexa Fluor 488-labeled EGFR and EphA3
were both asymmetrically concentrated at the leading edge of the polarized cells. The
same patterns were also observed when the LAP and AP tags were swapped (AP-LDLR
and LAP-EGFR), suggesting that the localization patterns do not reflect artifacts of AP
and LAP labeling (data not shown). It must be noted however, that the signal obtained for
LplA-mediated labeling of LAP-EGFR with OCT-Cy3 was much lower than the LAP-
LDLR signal. We think that this is a reflection of the relative expression levels of both
proteins at the cell-surface, since we observed the same trend for BirA-mediated labeling
of the corresponding AP-tagged receptors (Mark Howarth, personal communication).
While the polarization of AP-EGFR to the leading edge of migrating cells was an
expected result, and it had previously been observed using antibody detection on
epithelial cells' 8, the pattern of AP-EphA3 staining was somewhat surprising. Previous
work had shown that trans interactions between EphA3 and ephrin ligand expressed on
the surface of contacting cells play a role in developmental cell migration19 and tumor
invasion2o. However, it was unclear that un-liganded EphA3 should function in migratory
processes. Our observation of EphA3 accumulation at the free, leading edge of polarized
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cells suggested that unactivated EphA3 may play a role in cell signaling, or that EphA3
may be constitutively linked to the actin cytoskeleton.
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Figure 7-11: Simultaneous labeling and imaging of two receptors in polarized cells in a
wound healing assay. HEK cells co-expressing a LAP-LDLR fusion and either AP-EGFR (A)
or AP-EphA3 (B) were labeled during wound healing by first treating with LplA, BirA, azide 7,
and biotin, followed by OCT-Cy3 to derivatize the azide, followed by monovalent streptavidin-
Alexa Fluor 48812 to detect the biotin. The Cy3 images show the non-polarized distribution of
surface LAP-LDLR. The Alexa Fluor 488 images show the polarized distribution of AP-EGFR
(A) and AP-EphA3 (B) at the wound edge. CFP is a transfection marker. The images on the far
right depict the intensity ratios of Alexa Fluor 488 and Cy3. The white arrows point toward the
wound.
One-step cell-surface labeling with LplA using a coumarin probe
In a separate effort, Dr. Hemanta Baruah and others in our laboratory have
explored the substrate tolerance of several LplA point mutants. As previously mentioned
in Chapter 6, direct incorporation of a fluorophore or a photoaffinity probe is desirable
because it could in principle shorten the labeling time compared to the use of functional
group handles followed by bioorhotogonal ligation.
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Figure 7-12: LplA gatekeeper residues mutated to allow incorporation of larger analogs of
lipoic acid. View of the active site of Thermoplasma acidophilum around the bound lipoyl-AMP(PDB: 2ART)21. Lipoyl-AMP is shown in CPK format. Important amino acid residues are shown
in ball and stick format. The catalytic Lysine 145 is colored magenta. Residues colored red(Asp21 and Tyr39) are the analogous residues to those mutated in E. coli that allowed
incorporation of coumarin derivatives (E. coli LplA Glu20 and Trp37). Residues colored blue(Tyr73, Thr74, His80, and Leu158) are the analogous residues to those mutated in E. coli that
allowed incorporation of other probes, such as an aryl azide photoaffinity probe (E. coli LplA
Ser71, Ser72, His79, and Phe147).
As expected, none of the most interesting probes were incorporated by the wild-
type enzyme. Based on the published crystal structure of Thermoplasma acidophilum
LplA in complex with lipoyl-AMP21, 22, Dr. Hemanta Baruah and Prof. Alice Ting
rationally designed a panel of LplA mutants, which were then tested by Dr. Baruah for
incorporation of several probes. Figure 7-12 highlights those residues that have proven
important as active site gatekeepers, and whose mutation resulted in the incorporation of
one or more probes. The main objective for the tested mutations was to enlarge the active
site cavity that encloses the dithiolane ring, in an attempt to accommodate larger groups.
Of particular interest was the tryptophan 37 residue (Tyrosine 39 in Ta LplA), which
appears in the Ta crystal structure at - 4 A from one of the sulfur atoms in the dithiolane
ring. Mutation of Trp37 to a hydrophobic valine or isoleucine allowed incorporation of a
coumarin fluorophore (coumarins 1 and 2, Figure 7-14A), whereas mutation to a polar
residue such as serine resulted in the highly efficient ligation of an aryl azide
photoaffinity probe (Figure 7-14A). Remarkably, Dr. Baruah has now shown that ligation
of the aryl azide derivative by LplA-W37S onto LAP is catalytically more efficient than
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the ligation of lipoic acid by the wild-type enzyme (Baruah et al., Angew. Chem. Int. Ed
Engl., in press).
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Figure 7-13: LplA-catalyzed ligation of coumarin fluorophores. (A) Structure of coumarin
probes and the aryl azide photoaffmity probe incorporated by the W37I and W37V mutants of
LplA. (B) One-step cell-surface labeling of LAP-tagged proteins. Cell-surface LAP is labeled in a
single step by an LplA mutant (e.g., W37I) using a coumarin derivative (e.g., coumarin 1) and
ATP.
We thus decided to test the direct incorporation of coumarins 1 and 2 by W37I on
the surface of HEK cells. Unfortunately, the W371 mutant does not recognize the LAP as
efficiently as WT LplA. Therefore, we created an artificial construct by fusing the hybrid
lipoyl domain derived from E2p 23 to the N-terminus of cyan fluorescence protein (CFP),
which was in turn fused to the extracellular side of the transmembrane (TM) helix of the
PDGF receptor, to give E2p-CFP-TM; a construct analogous to the previously described
LAP-CFP-TM. Because the excitation and emission spectra of coumarin and CFP
overlap, we mutated Trp66 in CFP to leucine to abolish its fluorescence (E2p-CFP*-TM,
Figure 7-14, top). To perform one-step live cell labeling, HEK cells expressing E2p-
CFP*-TM were treated with LplA, the coumarin probe, and ATP for 10 minutes at 32 'C
(Figure 7-13B). Even with such a short labeling time, we observed robust and specific
labeling of HEK cells expressing cell-surface E2p (Figure 7-14). Both, coumarin 1 and its
non-fluorinated version coumarin 2, resulted in a labeling signal that was - 3-fold higher
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than that obtained using azide 7 and OCT-Cy3. Although the signal observed with
coumarin 2 may seem dimmer, this was a mere reflection of its higher pKa (- 7.5), which
means that at the imaging pH of 7.4, approximately half of the molecules were in a non-
fluorescent state. The lower signal could also be caused by faster photobleaching of
coumarin 2. A combined labeling with coumarin 1 and the pH-sensitive coumarin 2
should in principle allow ratiometric studies of receptor endocytosis.
I E2p CFP*
DIC Pacific Blue DIC 7-hydroxycoumarin
LplA labeling with
coumarin I or 2
alanine mutant of E2p
negative control
Figure 7-14: Direct fluorophore incorporation onto cell-surface proteins in live cells. An E2p
fusion to a modified non-fluorescent CFP was targeted to the surface of HEK cells using a
transmembrane (TM) domain. Cell-surface E2p was labeled with LplA W37I and either coumarin
1 (Pacific Blue, left) or coumarin 2 (7-hydroxycoumarin, right). Live cell images of the coumarin
fluorophore are shown to the right DIC images. A negative control with the E2p-CFP-TM
replaced by its alanine point mutant is shown.
Conclusions
In summary, we have developed a new methodology for labeling cell surface
proteins fused to a 22-amino acid recognition sequence for E. coli LplA. Small, non-
crosslinking probes such as Cy3 and Alexa Fluor were site-specifically and covalently
conjugated to the LAP peptide in about 1 hour, whereas biotin could be ligated in as little
as 20 minutes. An important feature of this methodology is its generality; any cell surface
protein in any cell type can be labeled with any chemical moiety that can be
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functionalized with a cyclooctyne. Direct comparison of LplA labeling to our two
previous methods showed that LplA was superior to ketone/biotin ligase tagging in speed
and sensitivity, and far superior to transglutaminase labeling in specificity over a wide
range of conditions.
We used LplA methodology in combination with biotin ligase labeling to image
two different receptors in the same cell. We found that the EGF receptor and EphA3 both
localized to the leading edge of fibroblasts migrating towards a wound. Many problems
in receptor biology would benefit from simultaneous imaging of two or more different
proteins at once in the same living cell, instead of separate experiments involving one-
color labeling of each receptor. The combination of LplA and BirA tagging, which can be
performed simultaneously due to the orthogonality of the labeling reaction components,
should provide access to such experiments.
Finally, we have also shown that direct fluorophore ligation is possible, and can in
fact accelerate the reaction to result in a total labeling time of 10 minutes. This procedure
should allow studies of faster biological processes and is better suited to imaging the
trafficking of cell surface receptors.
Experimental
General synthetic methods
Reagents were purchased from Sigma-Aldrich, Alfa Aesar, TCI America,
Invitrogen, or GE Healthcare and used without further purification. Analytical thin layer
chromatography was performed using 0.25 mm silica gel 60 F254 plates and visualized
with ninhydrin or bromocresol. Flash column chromatography was carried out using
silica gel (ICN SiliTech 32-63D). Mass spectra were recorded on an Applied Biosystems
200 QTRAP Mass Spectrometer using electrospray ionization. HPLC was performed on a
Varian Prostar Instrument equipped with an autosampler and photo-diode-array detector.
For analytical HPLC, a reverse-phase 250 x 4.6 mm Microsorb-MV 300 C18 column was
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used. For preparative HPLC, a reverse-phase 250 x 10 mm Microsorb-MV 100 C18
column was used. Chromatograms were recorded at 210 nm unless otherwise noted.
Synthesis of OCT-fluorophore conjugates
Synthesis of OCT-PEG (3)
To a solution of OCT acid 11 (32 mg, 123 ptmol) in dry dichloromethane (DCM,
750 1tL) was added triethylamine (TEA, 34 [tL, 246 gtmol). The mixture was stirred for
5 minutes at ambient temperature. Pentafluorophenyl trifluoroacetate (PFP-TFA, 42 CgL,
246 timol) was added slowly to the reaction mixture over 3 minutes and the reaction was
allowed to proceed for 3 hours. The reaction mixture was concentrated in vacuo, then
purified by silica chromatography (10% ethyl acetate in hexane) to afford OCT-PFP 2 as
a colorless solid (45.6 mg, 107 ptmol, 87.3%). The solid was immediately dissolved in
dry DCM (1 mL), and combined with TEA (29 gpL, 214 [tmol). O,O'-Bis(3-
aminopropyl)diethylene glycol (diamino-PEG, 71 tL, 535 tmol) was added, and the
reaction mixture was allowed to stir overnight at 21 oC. The crude mixture was purified
on a silica flash column (5:3:1 ethyl acetate : methanol : water with 4.3% triethylamine).
The purified product was concentrated under reduced pressure to yield OCT-PEG 3
(27.8 mg, 60 jimol, 56%). ESI-MS calculated for [M + H]+: 463.29; observed 463.44.
Synthesis of OCT-PEG-Alexa Fluor 568 (4) and OCT-PEG-Cy3 (5)
To a solution of OCT-PEG 3 (0.6 mg, 1.3 gmol) in anhydrous DMSO (200 gpL)
was added TEA (0.6 piL, 4 p~mol). The N-hydroxysuccinimidyl ester of either Cy3 or
Alexa Fluor 568 (1.3 timol) was then added and the reaction was allowed to stir for
4 hours at 21 oC. The crude product was purified by HPLC on a reverse phase column.
Chromatograms were recorded both at 210 nm and 550 nm. The following conditions
were used for elution: 30-80% acetonitrile in water over 30 minutes; flow rate
5.0 mL/minute. Solvent was removed in vacuo to afford the OCT-PEG-fluorophore
conjugates. Estimated yield 50-65%. ESI-MS for OCT-PEG-Alexa Fluor 568 (4):
calculated for [M - H]-: 1137.42; observed 1137.54. ESI-MS for OCT-PEG-Cy3 (5):
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calculated for [M + H]+: 1075.48; observed 1075.08. In addition, the presence of an intact
OCT moiety was confirmed by reaction of 100 gtM OCT-PEG-Alexa Fluor 568 (4) or
OCT-PEG-Cy3 (5) with 1mM azide 7 in DMSO at 30 oC for 6 hours and detection of the
triazole cycloadduct product by MS. ESI-MS for OCT-PEG-Alexa Fluor 568-
cycloadduct: calculated for [M - H]-: 1322.54; observed 1322.22. ESI-MS for OCT-
PEG-Cy3-cycloadduct: calculated for [M - H]-: 1258.60; observed 1258.56.
Synthesis of coumarin probes
Synthesis of coumarin 1
To a solution of 5-aminovaleric acid (1.6 mg, 14 gtmol) in anhydrous DMSO (100
jtL) was added the N-hydroxysuccinimidyl ester of 3-carboxy-6,8-difluoro-7-
hydroxycoumarin (2.5 mg, 7 jtmol) and the reaction mixture was stirred overnight at
ambient temperature in the dark. Excess insoluble 5-aminovaleric acid was discarded by
centrifugation. The product was used without further purification. ESI-MS for coumarin
1 calculated for [M - H]-: 340.07; observed 340.26.
Synthesis of coumarin 2
To a solution of 5-aminovaleric acid (65.5 mg, 560 ipmol) in anhydrous DMSO
(400 pL) was added the N-hydroxysuccinimidyl ester of 3-carboxy-7-hydroxycoumarin
(34 mg, 112 ptmol) and the reaction mixture was stirred overnight at ambient temperature
in the dark. Excess insoluble 5-aminovaleric acid was discarded by centrifugation. The
product was used without further purification. ESI-MS for coumarin 2 calculated for [M
- H]-: 304.09; observed 304.26.
Cloning of LAP-CFP-TM for mammalian surface expression
The LAP peptide was inserted between the BgllI and AscI sites of the AP-CFP-
TM plasmid8. Primers 5' AAAAA AGA TCT GGC GGC GAC GAA GTA CTG GTT GAA ATC
GAA ACC GAC AAA GCA GTT CTG GAA GTA CCG GGC GGT GAG GAG GAG GGC GCG CCA
AAAA and its reverse complement were annealed together, digested with BglII and AscI,
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and ligated in-frame to Bglll/AscI digested AP-CFP-TM. To create the LAP(Ala) mutant,
we performed QuikChange using the primer 5' G GTT GAA ATC GAA ACC GAC GCC GCA
GTT CTG GAA GTA CCG G and its reverse complement.
Cloning of LAP-LDLR and LAP-GFP-LDLR
To clone LAP-GFP-LDLR, the LAP sequence was inserted in the leader sequence
of LDLR, between Ser27 and Thr28, using the inverse PCR method described by Gama
and Breitwieser24 with the primers 5' CG GGC GGT GAG GAG GAG ACT GTG AGC AAG
GGC GAG GAG and 5' GTA CCT CCA GAA CTG CTT TGT CGG TTT CGA TTT CAA CCA
GTA CTT CGT CAC TTC TGT CGC CAA CTG CAG. The PCR template was the pEGFP-
LDLR plasmid, a gift from Tom Kirchhausen. To clone LAP-LDLR, the GFP gene was
deleted by QuikChange using primers 5' GGA GGT ACC GGC ATC AGC AGA CGG CGG
GGG AGA ATT CGA CAG ATG TG and its reverse complement.
Cloning of E2p-CFP*-TM for mammalian surface expression
The gene encoding for a 9kD hybrid lipoyl domain derived from the second
subunit of the E. coli pyruvate dehydrogenase 23 was inserted between the BglII and AscI
sites of the AP-CFP-TM plasmid8 . The gene was PCR-amplified from the original
pGS331 plasmid23, a gift from John Cronan, using primers 5' AAAA AGA TCT GGC GGC
ATG GCT ATC GAA ATC AAA GTA CCG G and 5' TTTT GG CGC GCC CGC AGG AGC TGC
CGC AGG CG. The resulting PCR product was digested with BglII and AscI and ligated in-
frame to Bglll/AscI digested AP-CFP-TM, to give E2p-CFP-TM. To create the non-
fluorescent mutant E2p-CFP*-TM, we performed QuikChange using the primer 5' G ACC
ACC CTG ACC CTG GGC GTG CAG TGC TTC and its reverse complement. To create the
E2p(Ala) mutant, we performed QuikChange using the primer 5' C ACC GTA GAA GGC
GAC GCA GCT TCT ATG GAA GTT CCG and its reverse complement.
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Live cell labeling of cell surface LAP-CFP-TM with OCT-fluorophore conjugates
HEK 293T cells were transfected with the LAP-CFP-TM expression plasmid
using Lipofectamine 2000. After 36-48 hours at 37 OC, the cells were washed twice with
fresh growth media (Dulbecco's Modified Eagle's Medium with 10% fetal bovine serum
and 1% penicillin/streptomycin). Enzymatic ligation of azide 7 was performed in
complete growth media with 10 ptM LplA, 350 ptM azide 7, 1 mM ATP, and 5 mM
magnesium acetate for 60 minutes at 32 'C. Cells were rinsed three times with growth
media, and incubated for 20 minutes at 21 OC with 200-400 gpM OCT-Cy3 or
100-200 gpM OCT-Alexa Fluor 568. Thereafter, the cells were washed once with growth
media, twice with a 1% bovine serum albumin (BSA) solution in Dulbecco's Phosphate-
Buffered Saline (DPBS) pH 7.4, and twice more with DPBS alone. Labeled cells were
imaged in the same buffer on a Zeiss Axiovert 200M inverted epifluorescence
microscope using a 40x oil-immersion lens. CFP (420/20 excitation, 450 dichroic, 475/40
emission), Cy3 and AlexaFluor568 (560/20 excitation, 585 dichroic, 605/30) and
differential interference contrast (DIC) images (630/10 emission) were collected and
analyzed using Slidebook software (Intelligent Imaging Innovations). Fluorescence
images were normalized to the same intensity range. Acquisition times ranged from
10-250 milliseconds.
Live cell labeling of cell surface LAP-CFP-TM with OCT-biotin
HEK 293T cells were transfected with the LAP-CFP-TM plasmid using
Lipofectamine 2000. After 36-48 hours at 37 'C, the cells were washed twice with fresh
growth media (DMEM supplemented with 10% FBS and 1% penicillin/streptomycin).
Enzymatic ligation of azide 7 was performed in complete growth media with 10 pM
LplA, 350 p.M azide 7, 1 mM ATP, and 5 mM magnesium acetate for 15 minutes at
32 OC. Cells were then rinsed three times with growth media, and incubated for
15 minutes at 32 oC with 250 pM OCT-biotin. Thereafter, the cells were washed twice
with growth media and incubated with 30 p[g/ml streptavidin-Alexa Fluor 568
(Invitrogen) for 15 minutes at 21 oC. The cells were washed once with growth media at
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21 'C and twice with ice-cold DPBS, pH 7.4, and imaged in the same buffer on a Zeiss
Axiovert 200M as described above.
Determination of LplA labeling sensitivity with LAP-CFP-TM using the wedge
method
We used the wedge method to estimate the concentration of CFP in single cells
expressing the LAP-CFP-TM construct4' 8. A wedge-shaped microchamber was
constructed from three glass cover slips. The length along the x direction was 6.5 mm and
the height of the chamber (z-direction) increased linearly from 0 to 150 p[m. The chamber
was filled with a solution of 10 pM purified CFP in PBS pH 7.4. The fluorescence of the
wedge was imaged under conditions identical to those used for cellular imaging. We
assumed an average cell thickness of 5 gpm and therefore interpolated to the region of the
wedge with thickness 5 pm and used the fluorescence intensity measured there as a
reference standard for CFP concentration measured in single cells. Using the wedge for
comparison, we imaged two samples of HEK and HeLa cells expressing LAP-CFP-TM.
Examination of the CFP channel images for cells that display clear OCT-biotin labeling
(signal to background > 3:1) showed that the CFP concentrations ranged from 5 ptM to
>1 mM. We therefore concluded that cells expressing as little as 5 pM LAP-CFP-TM
could be labeled by our method. This represents an upper limit to the labeling sensitivity
of our methodology.
Live cell labeling of LAP-LDLR with OCT-biotin and DiD-LDL
HEK 293T cells were either singly transfected with LAP-GFP-LDLR or co-
transfected with a mixture of LAP-LDLR and CFP-pcDNA3 in a 6:1 ratio using
Lipofectamine 2000. After 36-48 hours at 37 'C, cells were washed twice with fresh
growth media (DMEM supplemented with 10% FBS and 1% penicillin/streptomycin).
Enzymatic ligation of azide 7 was performed in complete growth media with 10 p.M
LplA, 350 gpM azide 7, 1 mM ATP, and 5 mM magnesium acetate for 20 minutes at
32 'C. Cells were then rinsed three times with growth media, and incubated for
30 minutes at 32 'C with 250 ptM OCT-biotin. Thereafter, the cells were washed twice
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with growth media and incubated with 30 jpg/ml streptavidin-Alexa Fluor 568
(Invitrogen) and DiD-LDL (1 jtg/ml)6 for 15 minutes at 4 OC. The cells were washed
once with growth media at 4 oC and twice with ice-cold DPBS, pH 7.4, and imaged in the
same buffer as described above. DiD was imaged using 630DF 10 excitation, 660DRLP
dichroic, and 680DF30 emission. Acquisition times ranged from 10-200 ms.
Determination of LplA labeling sensitivity with LAP-CFP-TM using a mobility shift
assay
HEK 293T cells were transfected and labeled with azide 7 and OCT-biotin as
above. After incubation with OCT-biotin, cells were washed twice with DPBS and lysed.
Lysates were generated using a RIPA lysis buffer to efficiently extract membrane
proteins, as follows. Cells were lifted from the plates, concentrated by centrifugation, and
resuspended in 25 mM Tris-HCl pH 7.6, 150 mM NaCI, 1% Triton X-100, 1% sodium
deoxycholate, 0.1 % sodium dodecyl sulfate (SDS), 1 mM phenylmethylsulphonyl
fluoride (PMSF), and protease inhibitor cocktail (Calbiochem). After incubation at 4 oC
for 30 minutes, the crude lysates were clarified by centrifugation. 10 jiM streptavidin was
then added to the lysates and incubated at room temperature for 1 hour. The reaction
mixtures were analyzed by 12% SDS-PAGE without boiling the samples, in order to
prevent unfolding of CFP and to preserve the biotin-streptavidin binding. In-gel
fluorescence was visualized on a Storm 860 instrument.
Live cell labeling of cell surface AP-CFP-TM with BirA and ketone
HEK 293T cells were transfected with AP-CFP-TM plasmid8 using
Lipofectamine 2000. After 36-48 hours at 37 oC, the cells were washed twice with DPBS
pH 7.4 and labeling was performed as previously reported 8. Briefly, enzymatic ligation of
ketone to AP-CFP-TM was performed in DPBS pH 7.4, with 0.2 pLM BirA, 1 mM
ketone 18, 1 mM ATP, and 5 mM magnesium acetate for 60 minutes at 32 'C. Cells were
then washed twice with DPBS, pH 6.2 and incubated for 60 minutes at 16 'C (to reduce
endocytosis) with 1 mM benzophenone-biotin-hydrazide 8 in DPBS pH 6.2. Thereafter,
the cells were washed twice with ice-cold DPBS pH 7.4, and incubated with 30 jtg/mL
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streptavidin-Alexa Fluor 568 (Invitrogen) in DPBS pH 7.4 and 1% BSA for 15 minutes at
4 'C. The cells were washed twice with DPBS pH 7.4, and imaged in the same buffer as
described above.
Live cell labeling of cell surface Q2-CFP-TM with transglutaminase
HEK 293T cells were transfected with Q2-CFP-TM plasmid9 using
Lipofectamine 2000. After 36-48 hours at 37 'C, the cells were washed twice with
DMEM, and labeling was performed as previously reported9 . Briefly, enzymatic ligation
of biotin cadaverine to Q2-CFP-TM was performed in DMEM, with 0.3 [M or 1 [IM
guinea pig liver transglutaminase (TGase, NZyme BioTec GmbH), 0.5 mM biotin
cadaverine, and 12 mM CaCl2 for 30 minutes at 37 'C. Cells were then washed twice
with DPBS pH 7.4, and incubated for 15 minutes at 4 oC (to reduce endocytosis) with
30 [tg/mL streptavidin-Alexa Fluor 568 (Invitrogen) in DPBS pH 7.4, and 1% BSA. The
cells were washed three times with ice-cold DPBS pH 7.4, and imaged in the same buffer
as described above.
Orthogonality test for two-color labeling with LplA and BirA
HEK 293T cells were either singly transfected with LAP-GFP-LDLR or co-
transfected with a mixture of AP-EGFR (or AP-EphA3) and CFP-pcDNA3 in a 6:1 ratio
using Lipofectamine 2000. 24 hours after transfection, the cells were re-plated together in
a 1:1 ratio. After further incubation for 24 hours at 37 'C, the cells were washed twice
with fresh growth media (DMEM with 10% FBS and 1% penicillin/streptomycin).
Simultaneous enzymatic ligations of azide 7 and biotin were performed in complete
growth media with 5 jM BirA, 10 jM LplA, 50 jiM biotin, 350 [tM azide 7, 1 mM ATP,
and 5 mM magnesium acetate for 60 minutes at 32 "C. Cells were then rinsed three times
with growth media, and incubated for 20 minutes at 21 "C with 200-400 jiM OCT-Cy3.
Biotin was detected with streptavidin-QD655 (13 nM, Invitrogen) for 10 minutes at 4 oC.
Thereafter, the cells were washed once with ice-cold 1% BSA in DPBS, pH 7.4 and twice
more with ice-cold DPBS, pH 7.4. Labeled cells were imaged as described above. The
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GFP filter set was 495/20 excitation, 515 dichroic, 530/30 emission; the QD655 filter set
was 405/20, 585 dichroic, and 655/20 emission.
Two-color live cell labeling with LplA and biotin ligase
HEK 239T cells were co-transfected with the LAP-LDLR and AP-EGFR 16
plasmids in a 1:2 ratio, or with the LAP-LDLR and AP-EphA3 (a gift from M.
Lackmann, Monash University) plasmids in a 2:1 ratio. 24 hours after transfection, the
cells were wounded with a pipet tip and allowed to heal over 16-24 hours. For labeling,
cells were washed twice with complete growth media, and then incubated with 5 jtM
BirA, 10 jtM LplA, 50 pM biotin, 350 jiM azide 7, 1 mM ATP, and 5 mM magnesium
acetate for 60 minutes at 32 'C. Cells were then rinsed three times with growth media,
and incubated for 20 minutes at 21 OC with 200-400 jiM OCT-Cy3. Biotin was detected
by staining with 50 jtg/mL monovalent streptavidin-Alexa Fluor 488 (prepared as
previously described"2) for 10 minutes at 4 OC. The cells were washed once with ice-cold
1% BSA in DPBS pH 7.4, then twice with ice-cold DPBS, before imaging in the same
buffer using the configuration described above. The Alexa Fluor 488 filter set was 495/20
excitation, 515 dichroic, 530/30 emission.
One-step live cell labeling of cell surface LAP-CFP-TM with coumarin fluorophores
HEK 293T cells were transfected with the E2p-CFP*-TM expression plasmid
using Lipofectamine 2000. After 36-48 hours at 37 'C, the cells were washed twice with
fresh growth media (Dulbecco's Modified Eagle's Medium with 10% fetal bovine serum
and 1% penicillin/streptomycin). Enzymatic ligation of the coumarin fluorophore was
performed in complete growth media with 3 piM LplA W37I, 340 piM coumarin 1 or
coumarin 2, 1 mM ATP, and 5 mM magnesium acetate for 10-30 minutes at 32 'C.
Thereafter, the cells were washed once with growth media and twice with DPBS. Labeled
cells were imaged as described above. The coumarin filter set was 405/20 excitation, 425
dichroic, 460/40 emission.
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Chapter 8 : Intracellular protein labeling with lipoic acid ligase
The work discussed in this chapter is unpublished. The cyclooctyne-fluorophore
conjugates and coumarin probes were synthesized by Dr. Hemanta Baruah.
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Introduction
In Chapter 7 we demonstrated that LplA-catalyzed labeling offers an excellent
platform for sensitive and specific cell-surface protein labeling. Although LplA offered
certain advantages over previously developed cell-surface labeling methods, such as
biotin ligase and transglutaminase, what excited us the most about this new methodology
was its potential to work inside cells. We described in the introductory Chapter 5 that
none of the currently available methods for genetic targeting of chemical probes has been
able to accomplish intracellular labeling of proteins fused to just a small peptide tag. For
example, SNAP-tag' and HaloTag2 allow labeling of intracellular proteins but they both
impose a large tag on the target protein (182 and 296 amino acid residues, respectively).
In contrast, biotin ligase3 and phosphopantetheine transferase 4 recognize 15- and 11-mer
peptide tags, but they are both restricted to the cell-surface. As we have shown, E. coli
lipoic acid ligase (LplA) recognizes a 22-amino acid peptide recognition sequence (the
LAP peptide) and can ligate small-molecule probes such as a coumarin fluorophore or an
alkyl azide functional group handle. On one hand, we expect the coumarin derivative to
be membrane permeable because it is small and uncharged and because other derivatives
of coumarin have been used in the intracellular milieu before5'6. On the other hand, azides
can chemoselectively react with alkynes via the [3+2] cycloaddition. Both azides and
alkynes are abiotic and possess extremely selective reactivity toward each other; thus,
inside the cells, they will only react with each other. Although there had been no previous
reports of intracellular strain-promoted [3+2] cycloaddition, we expected the alkyl azide
to be membrane pemeant, and we could design the cyclooctyne conjugate to be so, as
well.
Figure 8-1 depicts the general scheme for two-step intracellular labeling. In
contrast to cell-surface labeling, where only the LAP-tagged protein needed to be
transfected, for intracellular labeling, both the LAP-fused protein and the LplA enzyme
are co-transfected and expressed in the cytosol (or other subcellular compartment) of
mammalian cells. Azide 7 is then added in the cell growth media, and we expect it to
passively diffuse through the plasma membrane, and once inside the cell, be ligated by
LplA, which uses endogenous ATP. Thereafter, excess azide 7 can be removed from the
cells by extensive washes before adding the membrane-permeant
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cyclooctyne-fluorophore conjugate. Intracellular [3+2] cycloaddition results in
fluorescent tagging of only the LAP-tagged proteins.
add azide
to cells
add cyclo-octyne- LplA
fluorophore to cells
QON
Figure 8-1: LplA-mediated two-step labeling of intracellular proteins. Cells are first co-
transfected with plasmids encoding a LAP- or E2p-fused protein and the lipoic acid ligase (LplA)
enzyme. The first step of the labeling is the enzymatic ligation of a membrane-permeant alkyl
azide probe (azide 7) by the intracellular LplA, which uses endogenous ATP. The second step of
the labeling is the chemoselective reaction of azide-derivatized proteins with a membrane-
permeant cyclooctyne-fluorophore conjugate to form a stable cycloadduct between the target
protein and the fluorophore.
Results
LplA catalyzes the ligation of azide 7 to E2p inside mammalian cells
We first wished to demonstrate the first step of LplA-catalyzed intracellular
ligation of azide 7. In order to maximize our labeling signal, initial proof of concept
experiments were performed on the hybrid lipoyl domain derived from the second
subunit of the E. coli pyruvate dehydrogenase complex (the E2p domain) because the
kinetics of the LplA-catalyzed ligation of azide 7 are faster than those of the engineered
LplA acceptor peptide (LAP). We created plasmids for intracellular expression of E2p
and LplA and we expressed them in human cervical carcinoma (HeLa) cells. Cells were
grown in normal cell growth media supplemented with 750 CtM azide 7 for - 48 hours
after transfection. We had previously determined, using a mitochondrial respiration
assay, that 48-hour exposure to azide 7 had no effect in cell health at concentrations equal
or less than 750 ýpM (data not shown). HeLa cells were lysed and the ligated azide 7 was
detected using a mobility shift assay. This assay had been previously developed by Ali
-254-
and Green and it is based on the fact that modified E2p moves faster than the apo protein
in a native gel owing to the loss of the positively charged lysine7. E2p was detected by
blotting its N-terminal hemagglutinin (HA) epitope with an anti-HA antibody. The results
shown in Figure 8-2 demonstrated that intracellular ligation of azide 7 by LplA was
possible. Lane 1 shows the mobility of the apo protein, which is different from the
mobility of the E2p protein after co-expression with LplA and in-cell treatment with
azide 7 (lane 6). Lane 2 is a positive control, where E2p is modified in vitro with azide 7
by purified LplA, and it shows the mobility shift of the E2p domain upon modification of
its lysine site of attachment. Lanes 3 and 4 demonstrate that the E2p domain is not
modified by the mammalian lipoic acid ligase (LPL) neither in cells nor in vitro. Lane 6
shows that E2p is not modified by LplA unless azide 7 is added to the medium, that is,
LplA does not ligate endogenous lipoic acid to the E2p substrate. This is probably a
reflection of the much higher concentration of azide 7 present in the cells over that of the
endogenous lipoic acid.
- - -+ - + Azide 7
S + + FLAG-LplA In cells
+ + + + + + HA-E2p
-+ + - - - Azide 7
In lysate
- + - - - - LplA
1 2 3 4 5 6
4-- apo-E2p
- E2p-azide 7
Figure 8-2: Intracellular ligation of azide 7 detected by a gel shift assay. HEK cells
expressing intracellular LplA (pcDNA3-FLAG-LplA) and E2p (pcDNA3-HA-E2p) were grown
in the presence of 750 ýiM azide 7 for - 48 hours before lysis. Cell extracts were run in a native
20% PAGE and the E2p domain was detected by anti-HA blotting. Lane 1 shows the mobility of
unmodified E2p domain. Lane 6 demonstrates intracellular ligation of azide 7 by LplA. Negative
controls are shown with LplA or azide 7 omitted (lanes 4 and 5, respectively). Additional controls
are shown with azide 7 omitted from the cell labeling but added later to the lysates with or
without addition of purified LplA (lanes 2 and 3).
Overall, this experiment confirmed three essential requirements for LplA-
mediated intracellular labeling: that the azide 7 is membrane permeant, that the E2p
substrate is not pre-modified with lipoic acid by neither LplA nor the mammalian LPL,
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u-HA blot
and that the transfected LplA is active and can ligate azide 7 to E2p in the cytosol of
mammalian cells. Importantly, we found that, under the above conditions, the
intracellular ligation of azide 7 ligation to E2p displayed a 100% yield. However, two
other important requirements were not tested by the gel-shift assay. First, the gel shift
assay did not provide information on whether other proteins in the cells were also being
modified by LplA. In Chapters 6 and 7, we demonstrated that LplA is extremely specific
toward its protein or peptide substrates both in the context of a cell lysate (Figure 6-12)
and at the surface of mammalian cells (Figures 7-4 and 7-5). Here, we wished to confirm
that LplA retained such high specificity when expressed in the cytosol of mammalian
cells. Second, because the mobility shift is caused by the loss of the positively charged
lysine, it was unclear whether it would distinguish between the ligation of an intact azide
or an azide that had been reduced to a primary amine. Azide reduction to amines had
been previously reported to occur in the cytosol of mammalian cells and it was therefore
a major concern for us.
We thus tested the sequence specificity of LplA, and the retention of azide
reactivity of the ligated azide 7 with a western blot assay similar to the one already
described in Chapter 6 (Figure 6-12). Briefly, human embryonic kidney (HEK) cells
expressing intracellular E2p and LplA were grown in normal cell growth media
supplemented with 750 jIM azide 7 for - 48 hours after transfection. Thereafter, cells
were lysed and azide-tagged proteins were derivatized in vitro via Cu(I)-mediated [3+2]
cycloaddition using a biotin-alkyne probeS. Ligated biotin-alkyne was detected by
streptavidin blotting. Figure 8-3 shows the streptavidin stained western blot. The results
suggested that, similar to Figure 6-12, in the presence of thousands of mammalian
proteins in the cell lysate, only E2p-CFP was labeled by LplA (lane 2). We performed
negative controls with azide 7 omitted (lane 1), the lysine site of E2p modification
mutated to alanine (E2p(ala)-CFP, lane 4), or with wild-type LplA replaced by a
catalytically inactive mutant of LplA (LplA(arg), lane 4), and saw no labeling in all
cases. These results thus suggested that LplA retained its specificity when expressed
inside cells and that the azide 7 probe was not, at least in part, being reduced to an amine.
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Figure 8-3: Intracellular ligation of azide 7 detected by secondary reaction with biotin-
alkyne. HEK cells expressing intracellular LplA (pcDNA3-FLAG-LplA) and E2p (pcDNA3-
E2p-CFP) were grown in the presence of 750 ýtM azide 7 for - 48 hours before lysis. The azide
was derivatized in vitro with biotin-alkyne in the presence of copper catalyst via the [3+2]
cycloaddition and the ligated biotin was detected by streptavidin blotting. Controls are shown
with azide 7 omitted (lane 1), with E2p-CFP replaced by its alanine point mutant (lane 3), or with
LplA replaced by its catalytically inactive Lys 33Arg mutant (lane 4). Coomassie staining
demonstrates equal loading in all lanes. Fluorescence visualization of CFP demonstrates equal
expression levels of the E2p fusion in all lanes.
Synthesis and testing of membrane-permeant cyclooctyne conjugates to detect
azide 7 ligation inside live cells
Next, we wished to detect the ligation of azide 7 directly in living cells via the
strained-promoted [3+2] cycloaddition. We synthesized and tested a panel of cyclooctyne
conjugates to several organic fluorophores. The structures of some of these probes are
shown in Figure 8-4. All the OCT-fluorophore probes were synthesized by Dr. Hemanta
Baruah following a scheme analogous to the one described for the OCT-PEG-fluorophore
conjugates in Chapter 7 (Figure 7-2). In contrast to our cell-surface OCT-PEG-
fluorophore conjugates, the intracellular labeling probes needed to be membrane-
permeant, such that they could passively diffuse inside the cells, where they react with
azide-derivatized proteins. Excess unreacted probe could then either diffuse out or be
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pumped-out by non-specific endogenous anion transporters, such as the human organic
anion transporters (hOATs) 9 or the ATP-binding cassette (ABC) transporters'0 .
o
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Figure 8-4: Structures of OCT-fluorophores conjugates tested for intracellular labeling
applications.
We chose carboxyfluorescein diacetate (CFDA)1' 1-14 , SNARF®-1-acetate'5, and
the green and red BODIPY dyes (BODIPY-FI and BODIPY-TR) 14 because they had all
been previously used in intracellular labeling applications. As depicted in Figure 8-4, the
hydroxyl groups in carboxyfluorescein and SNARF@-1 were acetate-protected to render
the molecules neutral, thus capable of crossing the cell membrane. Once in the cytosol,
the acetate groups are readily hydrolyzed, probably by non-specific endogenous
esterases . We also compared two different linkers: a short ethylenediamine (EDA) and a
longer more hydrophobic N,N'-dimethyl-1,6-diaminohexane (HDDA).
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We tested the cyclooctyne derivatives for compliance with our two main
requirements: fast kinetics of loading into the cells and coming out of the cells, and
minimal background staining. HeLa cells were incubated for 5-60 minutes with different
concentrations of each probe at different temperatures. After loading, the probes were
allowed to be released from the cells for 15-120 minutes. We imaged the cells before and
after the washes. Table 8-1 summarizes the results.
Table 8-1: Comparison of several OCT-fluorophore conjugates for intracellular labeling
applications. CFDA: 5/6-carboxyfluorescein diacetate. HDDA: N,N'-dimethyl-1,6-diamino
hexane. EDA: ethylenediamine. BODIPY-FL: green BODIPY. BODIPY-TR: red BODIPY.
Optimal TimeTime IN Staining
Fluorophore Linker Endocytosis Concentration OUT(minutes) (minutes) pattern(IpM) (minutes)
No Diffuse
CFDA HDDA at T < 30 1-5 5-15 30-45 cytosolicat T < 30 oC cytosolic
No DiffuseCFDA EDA 5 30 60-90at T < 30 0C cytosolic
Punctate
BODIPY-FL HDDA No 0.1 5-15 No Punctate(mitochondrial)
Punctate
BODIPY-FL EDA No 0.1 5-15 No Punctate(mitochondrial)
Yes Punctate
BODIPY-TR HDDA Y0.1 
5 No
at T > 16 oC 
(mitochondrial)
No Mitochondrial
SNARF®-1 HDDA 5 30 Noat T < 30C C and perinuclear
We observed very different loading kinetics and staining patterns for all the
probes tested. BODIPY dyes, for example, diffused inside the cells most efficiently,
requiring only 5 minutes of loading at a very low dye concentration (100 nM). They did
not, however, wash out of the cells even after 2 hours. Their staining pattern was highly
punctated and excluded from the nucleus. Co-localization with the mitrochondrial stain
MitoTracker Red suggested that the OCT-BODIPY probes were non-specifically bound
to the mitochondrial membrane. A similar staining pattern was observed for OCT-
SNARF®-1, except that its non-specific staining pattern was more general, co-localizing
also with the endoplasmic reticulum and the golgi apparatus. Additionally, OCT-
SNARF®-1 required higher dye concentrations and longer loading times than BODIPY
dyes. In contrast, OCT-HDDA-CFDA conjugates were able to both diffuse in and wash
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out of cells, with OCT-HDDA-CFDA displaying better kinetics than OCT-EDA-CFDA.
Additionally, because endocytosis, but not passive diffusion, is blocked at 4 OC, we used
the temperature dependence of the loading as well as the staining pattern (i.e., punctate if
endocytosed) to determine whether a probe was being uptaken by endocytosis or not.
Importantly, the OCT-HDDA-CFDA probes did not exhibit any endocytosis at
temperatures lower than 30 'C. It must be noted that addition of 0.1% pluronic, a
nonionic surfactant, aided the loading of all the probes tested.
We thus chose to use the OCT-HDDA-CFDA conjugate to test LplA-mediated
intracellular protein labeling in live cells. As schematically shown in Figure 8-1, HeLa or
HEK cells expressing intracellular E2p-CFP and LplA were first grown for 24 hours in
the presence of 500 gM azide 7. After allowing the excess azide 7 to passively diffuse out
of the cells (- 1 hour), azide-modified proteins were derivatized by incubation for 1 hour
with 5 gM OCT-HDDA-CFDA. Initial tests in HeLa cells resulted in non-detectable
signal. Increasing the labeling time with OCT-HDDA-CFDA alone did not help, because
the acetate protecting groups of CFDA were cleaved in the cell media after - 1 hour, thus
rendering the molecule membrane impermeant. Addition of 2.5 mM probenecid, an
inhibitor of the anion transporters that pump carboxyfluorescein out of the cells, did
however increase the labeling signal to a level that was clearly detectable by imaging
(data not shown). By using probenecid, OCT-HDDA-CFDA could be retained inside
cells for 2-4 hours, thus allowing it enough time to react. In HEK cells, the labeling
signal was a lot higher, even in the absence of probenecid, presumably because of the
higher transfection and protein expression levels. Figure 8-5 illustrates a typical result of
live-cell detection of azide 7 ligation in HEK using OCT-HDDA-CFDA.
The images were striking. Although we observed a signal (fluorescein panel) that
was dependent on azide 7 treatment and on LplA enzymatic activity, the signal intensity
was comparable on cells expressing E2p-CFP or its alanine mutant (E2p(ala)-CFP).
Additional experiments confirmed that the labeling persisted even in the absence of E2p
(data not shown). These results, which suggested that LplA was labeling other proteins
inside the cells, were in stark contrast with the specificity test shown in Figure 8-3. The
fact that the background staining was dependent on LplA activity ruled out the possibility
that the non-specific labeling was generated by non-specific reactivity of the
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OCT-HDDA-CFDA probe. The western blot results also made it unlikely that the
background labeling was being originated by LplA self-labeling or labeling of the four
mammalian lipoate-acceptor proteins, because such a high background signal (as seen in
Figure 8-5), if concentrated on a single or four other proteins, should have been clearly
detectable by western blot.
IE2p CFP + I LplA I
rrf irE Ch 11 m.,rnin
LplA labeling with
azide 7
OCT-HDDA-CFDA
- azide 7
negative control
alanine mutant of E2p
negative control
alanine mutant of LplA
negative control
Figure 8-5: Background staining during the live-cell detection of intracellular ligation of
azide 7 using OCT-HDDA-CFDA. An E2p-CFP fusion and LplA were expressed in the cytosol
of HEK cells. Intracellular E2p was first labeled with azide 7 by the expressed LplA, and the
introduced azide was then derivatized with a cyclooctyne probe conjugated to carboxyfluorescein
diacetate (OCT-HDDA-CFDA). Live cell images of the introduced fluorescein are shown to the
right of the CFP and DIC images, which highlight the transfected cells. Negative controls with
azide 7 omitted from the cell media, with E2p replaced by its alanine point mutant, or with LplA
replaced by a catalytically inactive mutant (Lys 133Ala) are shown.
We reasoned that the discrepancy between the western blot and imaging results
was caused by the fact that, when western blot was used as a readout, the background
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labeling of many other endogenous proteins was distributed among the different
molecular weights. Therefore, labeling of E2p dominated the image simply because it
was concentrated at a single molecular weight. In contrast, when imaging was used as a
readout, all the proteins were indistinguishably expressed in the cytosol, and thus the E2p
signal was not significantly higher than the sum of the signal of other labeled endogenous
proteins. We will later describe how this hypothesis was confirmed when we performed
more careful comparisons using western blot detection (see Figure 8-8 and Figure 8-10).
Attempts to reduce background staining by lowering the expression levels of
intracellular LplA (i.e., by decreasing the amount of DNA used during transfection) and
by decreasing the azide 7 concentration and labeling time were all unsuccessful. We did
however found, during our troubleshooting, that the enzyme was not expressing properly
inside cells. When we performed fixed-cell immunostaining of HeLa cells expressing
LplA, we observed that the enzyme was highly aggregated. In fact, LplA staining was
concentrated on strikes (or sometimes in large vesicles) in the perinuclear region (Figure
8-6). We thus hypothesized that enzyme overexpression and aggregation was the main
cause of LplA's loss of ligation specificity.
In the next sections, we describe our iterative process to improve LplA folding
and expression inside cells, which ultimately resulted in the recovery of its labeling
specificity.
Figure 8-6: Fixed-cell immunodetection of LplA expressed inside HeLa cells. HeLa cells
were co-transfected with E2p-CFP and LplA. 48 hours after transfection, cells were fixed and
permeabilized with formaldehyde/methanol. Anti-FLAG staining detects expression of FLAG-
LplA.
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Improving expression and folding of LplA inside mammalian cells
We attempted to improve enzyme expression by fusing LplA to the fluorescence
protein mCherry. Fusion of hard-to-express or unstable proteins to certain fluorescence
proteins had been previously reported to improve protein expression and solubility'6 . We
chose the mCherry protein because its excitation and emission spectra are well-separated
from those of CFP and fluorescein. Although fusion of LplA to mCherry resulted in a
marked increase in the expression levels of intracellular LplA (as assessed by anti-FLAG
blotting) and partially reduced aggregation, the background staining upon azide 7 and
OCT-HDDA-CFDA labeling remained almost unchanged (data not shown). It is worth
mentioning that expression of the mCherry-LplA construct in HeLa (but not HEK) cells,
where enzyme expression levels were lowest, sometimes but not reproducibly, resulted in
specific OCT-HDDA-CFDA labeling when short azide 7 labeling times were employed.
The signal obtained was however very low (signal/background ratio < 1.5) and thus
hardly reproducible.
We also created a series of LplA mutants, where we mutated each LplA surface
cysteine to serine. The rationale behind this approach was that perhaps aggregation was
being caused in the oxidizing environment of the endoplasmic reticulum because of
enzyme oligomerization via disulfide-bonding. Cysteines 22, 55, 200, 300, and 311 were
mutated to serines, and the intracellular expression levels and aggregation patterns of the
single-point mutants were visualized by anti-FLAG immunostaining. Cys200Ser and
Cys330Ser mutants behaved analogously to the wild-type enzyme in terms of expression
levels and background staining with OCT-HDDA-CFDA, whereas Cys22Ser did not
express at all. In contrast, both Cys55Ser and Cys311Ser seemed to retain high
expression levels while significantly reducing enzyme aggregation, although this
reduction was not accompanied by a decrease in background OCT-HDDA-CFDA
staining.
In parallel, we also created mutants of Trp37. As described in Chapter 7, Trp37
lays in the crystal structure of Thermoplasma acidophilum (Ta) LplA in close proximity
to the lipoic acid dithiolane ring. Dr. Hemanta Baruah in our lab had found that mutation
of this gatekeeper residue to either valine or isoleucine resulted in an LplA mutant
capable of efficient ligation of a coumarin derivative. Additionally, mutation of the same
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Trp37 to serine enabled incorporation of an aryl azide photoaffinity probe. We tested the
intracellular activity of the W371, W37V, and W37S mutants fused to mCherry, and we
were surprised to observe that the three mutants behaved dramatically different. Whereas
W37S expression levels were very similar to those of the wild-type enzyme, W37V
expression was highly aggregated in the form of large puncta (similar to the original
FLAG-LplA), and W37I expression levels were too low to be detected by imaging. It
must be noted that the three mutants behaved similarly well when overexpressed in E.
coli.
Taken together, the results of the Cys-to-Ser mutants and the W37 mutant series
suggested that the intracellularly expressed LplA enzyme was so unstable that a single
point mutant, even if buried in the enzyme active site, could cause unfolding and
aggregation or even completely abolish enzyme expression. This problem, although
somewhat alleviated, was not completely solved by fusing the enzyme to mCherry.
We thus decided to express LplA from a gene sequence optimized for expression
in human cell lines. We purchased the synthetic codon-optimized gene and we cloned it
as a fusion to mCherry for intracellular expression. To differentiate it from the enzyme
expressed from the original E. coli gene, we called the enzyme expressed from the codon-
optimized gene, hLplA, which stands for humanized LplA. We transfected HEK cells
with the new mCherry-hLplA construct together with E2p-CFP and we performed the
azide 7 labeling followed by detection with OCT-HDDA-CFDA as described above. The
results were, once again, striking, as they suggested that expression of LplA from the
codon-optimized had finally recovered the loss of labeling specificity (Figure 8-7). We
observed what seemed specific labeling of transfected (CFP- and mCherry-positive) cells,
without labeling of neighboring untransfected cells in the same field of view. More
importantly, the negative control where E2p-CFP was replaced by its alanine point
mutant (alanine at the lysine modification site within E2p) showed no labeling, which
suggested that the ligation of azide 7 was site-specific. Interestingly, enzyme expression
from the codon optimized gene resulted in much higher intracellular concentrations, as
assessed by the mCherry signal. Aggregation was also almost eliminated, except for a
few cells that still displayed few brighter rounded dots (indicated by white arrows in
Figure 8-7). We later found, however, that the labeling results were a mere artifact
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introduced by the fact that the enzymatic activity of hLplA was inhibited by the alanine
mutant of E2p. hLplA was however not inhibited by the alanine mutant of the LAP
peptide, and labeling performed in cells that expressed either LAP(ala) or no protein or
peptide substrate at all resulted, once again, in high background staining. To date, we
have not found a plausible explanation for why hLpla but not eLplA (expressed from the
E. coli gene) displays enzyme inhibition by E2p(ala).
E2p IC mCherr hLuorescein
P nir DImCherrv Fluorescein
LplA labeling with
azide 7
OCT-HDDA-CFDA
- azide 7
negative control
alanine mutant of E2p
negative control
arginine mutant of LplA
negative control
Figure 8-7: Live-cell detection of intracellular ligation of azide 7 by a codon-optimized LplA
enzyme using OCT-HDDA-CFDA. E2p-CFP and mCherry-hLplA fusions were expressed in the
cytosol of HEK cells. Intracellular E2p was first labeled with azide 7 by the expressed hLplA, and
the introduced azide was then labeled with a cyclooctyne probe conjugated to carboxyfluorescein
diacetate (OCT-HDDA-CFDA). Live cell images of the introduced fluorescein are shown to the
right of the merged CFP and DIC, and the mCherry images, which highlight the transfected cells.
Negative controls with azide 7 omitted from the cell media, with E2p-CFP replaced by its alanine
point mutant, or with LplA replaced by a catalytically inactive mutant (Lysl33Arg) are shown.
White arrows point to spots cells were the enzyme is partially aggregated in the form of brighter
dots.
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The confusion introduced by the previous imaging results motivated us to embark
in a systematic study of the ligation specificity of all the LplA constructs, with the
ultimate goal of elucidating the source of background staining. We first tested the
specificity of the intracellular ligation of the natural substrate lipoic acid, both by western
blot and by imaging. We then compared the results with those obtained for the ligation of
azide 7. We also created an additional construct, by fusing LplA (both, eLplA and
hLplA) to the FKBP-rapamycin binding domain of the mTor protein (FRB), with the
intention of promoting enzyme turnover. If, as we hypothesized, the loss of specificity
tightly correlated with the enzyme expression levels, we reasoned that introducing protein
turnover could perhaps introduce a second layer of regulation that resulted in more
physiological enzyme concentrations. Table 8-2, at the end of this section, summarizes
the results of the comparative study. In the following experiments, we refer to the LplA
enzyme expressed from the E. coli gene as eLplA to differentiate it from hLplA. It must
be noted that eLplA is the same enzyme that we have been thus far calling simply LplA.
First, to compare the specificity and yield of intracellular lipoic acid ligation, we
co-transfected HEK cells with either E2p-CFP or LAP-CFP and each one of the LplA
constructs. Cells were grown in the presence of 500 pM lipoic for 24 hours, and ligated
lipoic acid was detected by anti-lipoic western blotting. Figure 8-8 shows the results. We
observed that, whereas all constructs were able to efficiently lipoylate E2p, expression of
LplA from both hLplA constructs resulted in high background labeling of many other
proteins present in the lysate (seen as a smear in Figure 8-8). It was also interesting to see
that hLplA expression achieved much larger yields of LAP labeling than eLplA. The
observed LAP-CFP labeling was mostly site-specific, as it was not seen in the negative
control where cells were transfected with the alanine mutant of LAP. We observed no
difference in the labeling specificity or yield between the corresponding mCherry and
FRB fusions.
We were very surprised to find such a stark difference in labeling specificity
between the eLplA and hLplA constructs. We rationalized this difference based on the
increased expression levels of the hLplA enzyme rather than on an intrinsic property.
This hypothesis was later confirmed by Dr. Shah, who cloned the mCherry-hLplA
construct downstream of a tetracycline operator for inducible protein expression. As
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explained in Chapter 4, the tetracycline regulation in the T-RExTM System is based on the
binding of tetracycline to the Tet repressor, which releases the repressor and results in
derepression of the promoter controlling expression of the gene of interest"7 . Thus,
increasing concentrations of tetracycline result in increased protein expression. Dr. Shah
demonstrated that mCherry-hLplA can in fact achieve highly specific ligation of lipoic
acid when it is expressed at very low concentrations (- 0-0.03 ug/mL tetracycline; - 10-
fold lower expression than that obtained from the non-tetracycline regulated plasmid).
Endogenous
lipoylated
proteins
E2p-CFP
SLAP-CFP
, * a blmo.. .
Figure 8-8: Western blot detection of LplA-mediated intracellular ligation of lipoic acid.
HEK cells were transfected with constructs for expression of intracellular E2p-CFP or LAP-CFP
together with one of the four LplA fusion constructs (FRB-eLplA, FRB-hLplA, mCherry-eLplA,
or mCherry-hLplA). All cells were then grown in the presence of 500 pM lipoic acid for - 24
hours before lysis. Ligated lipoic acid was detected in lysates by anti-lipoic blotting. A negative
control with E2p and LAP replaced by the alanine mutant of LAP (LAP(ala)) is also shown. We
used LAP(ala) as the negative control instead of alanine mutant of E2p because of the
demonstrated enzyme inhibition of hLplA by E2p(ala). eLplA stands for the enzyme expressed
from the original E. coli lpla gene. hLplA stands for the enzyme expressed from a gene sequence
optimized for expression in human cell lines.
To further confirm the specificity of mCherry-eLplA (and FRB-eLplA) we
repeated the same assay for intracellular lipoic acid ligation with the inclusion of
additional controls. The results seen in Figure 8-9 confirmed that the intracellular ligation
of lipoic acid by mCherry-LplA is site-specific (lane 2) and depends on the enzymatic
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activity of the transfected LplA (lane 3). This means that the mammalian LPL is not
capable of ligating azide 7 to E2p. Furthermore, the lipoylation levels of the endogenous
lipoate-acceptor proteins did not change upon transfection with LplA (compare lanes 2
and 4), which confirmed that cytosolic LplA did not label endogenous lipoate-acceptor
proteins. This property may be a reflection of LplA not being expressed in the
mitochondria, where the endogenous lipoylated proteins are located. It remains to be seen
if the specificity holds on if LplA is targeted for mitochondrial expression. Additionally,
treatment of untransfected cells with lipoic acid did not affect the basal levels of
lipoylation of the endogenous lipoate-acceptor proteins (compare lanes 4 ad 5),
suggesting that the labeling procedure should not be toxic to cells. This is probably true
because of the biological function of the mammalian LPL proteins substrates, which
requires that the proteins be 100% lipoylated at all times, and because of the slow
turnover characteristic of these proteins.
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+ + - - - LplA
- + - - LplA(arg)
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Figure 8-9: Intracellular ligation of lipoic acid by mCherry-LplA is specific and orthogonal
in mammalian cells. HEK cells expressing intracellular LplA (pcDNA3-mCherry-LplA) and
E2p-CFP (pcDNA3-E2p-CFP) were grown in the presence of 500 ýtM lipoic acid for - 24 hours
before lysis. Ligated lipoic acid was detected by anti-lipoic acid blotting. Controls are shown with
E2p-CFP replaced by its alanine point mutant (lane 2), or with LplA replaced by its catalytically
inactive Lys 33Arg mutant (lane 3). Lysates from untransfected cells, treated with lipoic acid
(lane 4) or left untreated (lane 5) are also shown.
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In summary, this assay unequivocally demonstrated that, if expressed at
physiological concentrations, the intrinsic specificity of LplA is good enough for
intracellular ligation of, at least, its natural substrate lipoic acid. Furthermore, the labeling
is orthogonal as it is not affected by the endogenous mammalian lipoylation activity.
Figure 8-10: Western blot detection of LplA-mediated intracellular ligation of azide 7. HEK
cells were transfected with constructs for expression of intracellular E2p-CFP or LAP-CFP
together with one of the four LplA fusion constructs (FRB-eLplA, FRB-hLplA, mCherry-eLplA,
or mCherry-hLplA). All cells were then grown in the presence of 500 VtM azide 7 for - 24 hours
before lysis. The azide was derivatized in vitro with biotin-alkyne in the presence of copper
catalyst via the [3+2] cycloaddition and the ligated biotin was detected by streptavidin blotting. A
negative control with E2p and LAP replaced by the alanine mutant of LAP (LAP(ala)) is also
shown. eLplA stands for the enzyme expressed from the original E. coli lpla gene. hLplA stands
for the enzyme expressed from a gene sequence optimized for expression in human cell lines.
We next performed the comparison of the specificity and yield of intracellular
ligation of the unnatural substrate azide 7 by the different LplA constructs. Figure 8-10
shows that the difference in specificity observed between the eLplA and hLplA
constructs for lipoic acid ligation disappeared in the case of azide 7 ligation. We observed
that mCherry-eLplA, which was specific for lipoic acid ligation, was now ligating azide 7
to other mammalian proteins. FRB-eLplA was the only construct that did not display
background labeling of cellular proteins, although its site-specific labeling signal of E2p
was so low that it was hard to assess whether the signal/background was higher than for
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the other LplA constructs. Both the low signal and low background were originated by
the extremely low expression levels of intracellular FRB-eLplA. Later in this chapter, we
will describe the imaging experiments that confirmed that FRB-eLplA was indeed
specific for azide 7 ligation (see Figure 8-13).
Table 8-2 summarizes the results obtained from the systematic comparison of the
different LplA constructs. The comparative study highlighted two origins for the
observed background labeling: first, and most important, enzyme over expression, but
also, de-coupling of the two steps involved in the mechanism of catalysis when going
from the natural substrate lipoic acid to the unnatural azide 7 probe. First, the lipoic acid
ligation results confirmed that background labeling was caused by LplA-catalyzed
ligation of lipoic acid to many other cellular proteins, but not the endogenous lipoate-
acceptor proteins. Second, we observed that the specificity of intracellular lipoic acid
ligation is directly correlated to the enzyme expression levels. LplA looses its protein
substrate specificity when highly over expressed. Third, transition from the ligation of
lipoic acid to azide 7 also resulted in an additional loss of specificity. We hypothesized
that this may be caused by a certain degree of de-coupling between the first step of azide
7 adenylation, and the second step of azide 7-AMP transfer to the E2p or LAP substrates.
If the enzyme displays higher affinity for the azide 7-AMP than for azide 7, the activated
ester could then be released from the active site before transfer. Once in the cellular
milieu, the azide 7 would react with any nucleophile, such as protein surface lysine
residues, thus resulting in background labeling. Although plausible, this hypothesis does
not explain the observation that, at very low expression levels, such as those obtained
with the FRB-LplA construct or with tetracycline regulated mCherry-hLplA, site-specific
ligation of azide 7 is possible. On the contrary, enzymatic de-coupling could also be
caused by high enzyme affinity for the azide 7-AMP ester, such that transfer to the
protein substrate is not efficient and becomes the rate limiting step. Background labeling
would thus be caused by azide 7-AMP retention in the active site of LplA. In the lysate,
this azide 7-AMP would be released and could react with any surrounding protein. This
theory would readily explain the fact that background staining using azide 7 is also higher
at higher enzyme concentrations.
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Finally, it should be highlighted that, when extremely low levels of enzyme
expression were achieved by either endogenous protein regulation (FRB-eLplA) or by
regulation with tetracyline (Tet-mCherry-hLplA), the enzyme recovered its ligation
specificity for both lipoic acid and azide 7. Although the results for the Tet-mCherry-
hLplA are still preliminary, a comparison between the two constructs, suggested that, at
similar expression levels, the improved folding and stability of hLplA over eLplA results
in higher yields of specific labeling, thus generating higher signal/background ratios.
Table 8-2: Comparison of the specificity and extent of the lipoic acid and azide 7 by several
LplA intracellular constructs.
FLAG
mCherry
FRB
Tet System
E. coli
human
E. coli
human
E. coli
human
E. coli
human
Low
Medium
Medium
High
Low
Medium
Regulated
Regulated
NU
High
Medium
High
Medium
High
Low
Mediumn
NIO
No
Yes
No
Yes
No
Yes
Yes
100 low
Medium
Medium
High
Low
High
Too low
Medium
INIV
No
No
No
Yes
No
ND
Yes
The herein described western blot results were in all cases supported by the
corresponding imaging data. The remaining sections in this chapter will show the
imaging results confirming the site-specific ligation of the natural lipoic acid substrate,
and of the unnatural substrates azide 7 and coumarins 1 and 2 .
Imaging the LplA-catalyzed site-specific incorporation of lipoic acid inside
mammalian cells
We wished to confirm the specificity of mCherry-eLplA for the ligation of lipoic
acid using the more demanding imaging readout. To more rigorously test the site-
specificity of the ligation, we constructed a fusion of E2p-CFP to a C-terminal nuclear
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localization signal (NLS), for nuclear expression of E2p. We transfected HEK cells with
E2pCFP-NLS and the mCherry-eLplA plasmids, and, 24 hours after transfection, we
added 500 ýiM lipoic to the cell growth media to initiate intracellular lipoic acid ligation.
24h later, cells were fixed and permeabilized, and ligated lipoic acid was detected by
anti-lipoic acid immunostaining.
A IE2p NLS+ LIpA
LplA labeling with
lipoic acid
alanine mutant of LAP
negative control
LAP + LpIA I
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lipoic acid
Figure 8-11: Imaging the site-specific intracellular ligation of lipoic acid to E2p and LAP.
(A) HEK cells were co-transfected with nuclear targeted E2p-CFP and mCherry-eLplA. After 24
hours incubation with 500 ýtM lipoic acid, cells were fixed and permeabilized with
formaldehyde/methanol, and stained with anti-lipoic acid antibody followed by anti-rabbit-Alexa
Fluor 488. Anti-lipoic acid labeling is shown in green to the right of DIC (differential interference
contrast), CFP (cyan), and mCherry (red) images. A negative control is shown where E2p-CFP
was replaced by the alanine mutant of the LAP peptide. (B) Same as A, except that cells were co-
transfected with mCherry-eLplA and LAP-CFP.
We were very happy to observe robust nuclear labeling on transfected cells,
whereas untransfected cells or cells transfected with the LAP(ala) construct showed no
labeling (Figure 8-11A). It must be noted that we used LAP(ala) as a negative control
instead of E2p(ala) to avoid potential artifacts caused by enzyme inhibition. Furthermore,
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the labeling was clearly nuclear, closely resembling the nuclear localization of E2p (CFP
signal) and different from that of the predominantly cytoplasmic LplA (mCherry signal).
The strong labeling signal observed for E2p encouraged us to test, for the first time,
intracellular lipoic acid ligation onto the LAP peptide. We observed clear and
reproducible labeling of cytosolic LAP-CFP (Figure 8-11B). As expected, the overall
signal was reduced from that of lipoic acid, owing to the slower kinetics of LAP
recognition by LplA.
Imaging the LplA-catalyzed site-specific incorporation of azide 7 inside mammalian
cells
Next, we attempted to detect the ligation of azide 7 in live cells expressing FRB-
eLplA. As previously described, western blot results suggested that expression of
intracellular FRB-eLplA resulted in the site-specific ligation of azide 7 to E2p, albeit with
a very low signal/background ratio. We transfected HEK cells with the FRB-eLplA
construct together with E2p-CFP, and we performed the azide 7 labeling followed by
detection with OCT-HDDA-CFDA as described above. Unfortunately, we could not
reliably detect a significant site-specific fluorescein signal above background staining.
Only under very forcing conditions, where azide 7 ligation was performed for 48 hours
and the [3+2] cycloaddition reaction with OCT-HDDA-CFDA was allowed to proceed
overnight, did we observe some specific labeling signal, albeit the signal/background
ratio was < 1.5. We attempted to improve the signal/background ratio by using a faster
cyclooctyne molecule with two electron withdrawing fluorines adjacent to the alkyne1 8
(DIFO2-HDDA-CFDA), but we found that the increased reactivity was also accompanied
by a marked increase in its non-specific reactivity toward other cellular nucleophiles.
J 2 DMSO
Figure 8-12: Synthesis of Cy3-alkyne for click chemistry detection of azide 7 ligation.
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To undoubtedly demonstrate the site-specificity of azide 7 ligation by FRB-
eLplA, we decided to increase the labeling signal by employing the faster Cu(I)-mediated
[3+2] cycloaddition. We synthesized a terminal alkyne conjugated to the Cy3 fluorophore
by direct coupling of the N-hydroxysuccinimidyl ester of Cy3 to propargylamine (Figure
8-12). Because Cu(I) is toxic to mammalian cells, we performed azide 7 ligation in live
cells as above, but we then fixed and permeabilized the cells before detecting the azide by
click chemistry with Cy3-alkyne. We were very happy to see clear and specific detection
of azide 7 ligation to E2p (Figure 8-13A). As predicted by the Western blot results, the
signal obtained for ligation to the LAP peptide was barely detectable (Figure 8-13B).
A
IE2p + I FRB LplA
LplA labeling with
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alanine mutant of LAP
negative control
B LAP + FRB I LplA
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Cy3-alkyne
Figure 8-13: Fixed-cell detection of intracellular ligation of azide 7 via click chemistry. (A)
E2p-CFP and FRB-eLplA fusions were expressed in the cytosol of HEK cells. Intracellular E2p
was first labeled with azide 7 by the expressed eLplA before cells were fixed and permeabilized
with formaldehyde/methanol, and the introduced azide was detected by click chemistry reaction
with Cy3-alkyne. Fixed-cell images of the introduced Cy3 fluorophore are shown to the right of
the CFP and DIC images, which highlight the transfected cells. A negative control is shown
where E2p-CFP was replaced by the alanine mutant of the LAP peptide. (B) Same as A, except
that cells were co-transfected with mCherry-eLplA and LAP-CFP.
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These results were extremely exciting because they showed, for the first time, that
specific ligation of azide 7 by intracellular LplA is possible. Since these results were
obtained, Dr. Shah in our lab has been working on using the tetracycline-regulated
system to increase the signal/background ratio such that live-cell detection using OCT-
HDDA-CFDA is possible. He recently reported that, under forcing conditions like the
ones previously described for FRB-eLplA (i.e., 48 hours treatment with azide 7 followed
by overnight [3+2] cycloaddition with OCT-HDDA-CFDA in the presence of
probenecid), specific ligation of azide 7 can be detected in live cells with a decent
signal/background ratio. He has also shown that decreasing the concentration of azide 7
from 500 jpM to - 100-200 pM further improves the signal, probably owing to a more
efficient wash out of excess probe from cells. Importantly, targeting of E2p to the nucleus
resulted in a clearly nuclear-localized fluorescein signal, thus reinforcing the fact that the
labeling is site-specific.
Direct fluorophore ligation to intracellular proteins in live mammalian cells
Finally, we reasoned that, if the rate limiting step that was preventing the reliable
detection of azide 7 ligation in live cells was the poor kinetics of the strained-promoted
cycloaddition reaction, perhaps the problem could be circumvented by employing a one-
step labeling protocol, using the direct ligation of a coumarin fluorophore. The labeling
procedure for direct fluorophore ligation is much simpler, as it only requires co-
expression of the LplA W37I mutant together with E2p, followed by incubation with a
membrane-permeant coumarin derivative (Figure 8-14A). Dr. Hemanta Baruah
synthesized several protected versions of coumarins 1 and 2 (Figure 7-13). Although the
use of coumarin 1 was preferred for intracellular applications because of its lower pKa
(i.e., higher percentage of fluorescent molecules at physiological pH), protection of the
hydroxyl group proved intractable, owing as well to the low pKa. Protection with a bulky
tertbutyl group rendered the molecule stable in aqueous solutions, but we observed
extremely slow deprotection kinetics inside cells, which lengthened the required labeling
time. Thus, we opted to use an acetate-protected version of coumarin 2, which was
relatively stable in the cell loading media (coumarin 2-acetate, Figure 8-14B).
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Figure 8-14: One-step fluorophore tagging of intracellular proteins in live mammalian cells.
(A) Labeling procedure. Cells are first co-transfected with plasmids encoding a LAP- or E2p-
fused protein and a mutant of the lipoic acid ligase enzyme (LplA-W37I). Labeling is performed
in single step by addition of a membrane-permeant coumarin probe. (B) Structure of coumarin 2-
acetate (6,8-fluoro-7-hydroxycoumarin acetate). (C) Live cell detection of intracellular coumarin
ligation. HEK cells were co-transfected with a fusion of E2p to a non-fluorescence mutant of CFP
(W66L) (E2p-CFP*) and a tetracycline-regulated fusion of the W37I mutant of LplA to mCherry
(Tet-mCherry-hLplA-W371). Protein expression was induced 24 hours after transfection by
addition of 0.5 Vtg/mL tetracycline. Intracellular ligation was performed 24 hours later, by
incubation with 500 tiM coumarin 2-acetate for 2 hours at 32 'C. Live cell images of the
introduced coumarin fluorophore are shown to the right of the mCherry and DIC images, which
highlight the transfected cells. A negative control is shown where E2p-CFP was replaced by the
alanine mutant of the LAP peptide.
To perform live cell labeling, we transfected HEK cells with the non-fluorescent
E2p-CFP* and the tetracycline-regulated mCherry-hLplA(W371) constructs. Enzyme
expression was induced by addition of tetracycline, and labeling was performed 16-24
hours later by incubation with 500 jiM coumarin 2-acetate for 2 hours at 32 "C. The
results are shown in Figure 8-14C. We were delighted to observe specific ligation of
coumarin to cytosolic E2p, as these results represented the first time that LplA-catalyzed
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probe ligation to intracellular proteins was detected in live cells. Unfortunately, as
previously described, the W37I mutant of LplA does not recognize the LAP peptide as
efficiently as the wild-type enzyme, and thus we have not been able to detect coumarin
ligation to the peptide substrate yet.
Dr. Hemanta Baruah, Tao Uttamapinant, Katie White, and Dr. Sujiet Puthenveetil,
in our lab, are actively working on synthesizing better coumarin probes, finding faster
mutants of LplA, and evolving and testing improved peptide substrates. For example,
Sujiet Puthenveetil has found, using yeast display evolution, a peptide that is recognized
by LplA with similar kinetics to E2p in vitro. Furthermore, Katie White has just recently
shown that intracellular lipoylation of the improved peptide yields a signal that is
comparable to that obtained for the E2p protein substrate. We expect that a combination
of all the above efforts will ultimately allow the direct visualization of intracellular
tagging of LAP-fused proteins in living cells.
Conclusions
We have shown that the site-specific intracellular ligation of unnatural probes by
lipoic acid ligase is possible and that this ligation can be used to fluorescently label E2p-
tagged intracellular proteins. As expected, adaptation of lipoic acid ligase for intracellular
protein labeling proved a lot more challenging than its application to label cell-surface
receptors. We found that LplA misfolded and aggregated when expressed inside
mammalian cells, and that this aggregation, together with enzyme overexpression,
resulted in the loss of specificity for its protein substrate. Strikingly, high levels of
enzyme overexpression inside cells resulted in LplA-catalyzed ligation of lipoic acid and
azide 7 to myriad cellular proteins. Through an iterative process, we were able to recover
the lost enzyme specificity. We decreased enzyme aggregation by fusion to the mCherry
fluorescent protein, we improved enzyme folding by using a gene sequence optimized for
mammalian expression, and we introduced protein regulation (i.e., turnover) by fusion to
the human FRB protein. Expression of LplA under the regulation of a tetracyline operator
further enhanced our capability to tightly control enzyme concentration inside cells. After
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implementation of all these changes, we were able to show specific ligation of lipoic acid
both by western blot and by immunostaining. We also demonstrated the site-specificity of
the azide 7 ligation by western blot and by performing click chemistry on fixed cells.
Unfortunately, the toxicity of the Cu(I)-mediated [3+2] cycloaddition and the poor
kinetics of the strained-promoted counterpart, prevented us from visualizing azide 7
ligation in live cells. We nonetheless circumvented this problem by eliminating the need
for bioorthogonal ligation. The discovery that a W37I mutant of LplA could efficiently
ligate coumarin derivatives to E2p-tagged proteins enabled, for the first time,
visualization of LplA-catalyzed probe ligation in living cells.
Finally, it must be noted that fixed-cell detection of azide 7 ligation using click
chemistry can already be applied for super-resolution imaging of intracellular proteins
using a recently developed imaging technique called STORM (stochastic optical
reconstruction microscopy)'19. In STORM imaging, proteins labeled with cyanine
fluorophores can be localized inside cells with the astounding precision of - 20 nm, a
- 12-fold improvement over conventional wide-field or confocal microscopy20'21
Cyanine dyes are however targeted for STORM imaging using antibodies, which add
- 50 nm uncertainty in the localization precision, thus partially defeating the purpose of
super-resolution imaging. Therefore, in order to optimally utilize the intrinsic imaging
resolution of the super-resolution techniques, new strategies to target the cyanine dyes
without significantly increasing the size of the tag and with high labeling efficiency are
needed. We have now demonstrated that LplA labeling can do so. Furthermore, Tao
Uttamapinant has recently demonstrated that performing both labeling steps (enzymatic
ligation of azide 7 and click chemistry with Cy5-alkyne) after cell fixation, allows the
fluorescent labeling of LAP-tagged intracellular proteins with a signal/background ratio
of- 4.
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Experimental
General synthetic methods
Reagents were purchased from Sigma-Aldrich, Alfa Aesar, TCI America,
Invitrogen, or GE Healthcare and used without further purification. Analytical thin layer
chromatography (TLC) was performed using 0.25 mm silica gel 60 F254 plates and
visualized with ninhydrin or bromocresol. Flash column chromatography was carried out
using silica gel (ICN SiliTech 32-63D). Mass spectra were recorded on an Applied
Biosystems 200 QTRAP Mass Spectrometer using electrospray ionization. HPLC was
performed on a Varian Prostar Instrument equipped with an autosampler and photo-
diode-array detector. For analytical HPLC, a reverse-phase 250 x 4.6 mm Microsorb-MV
300 C18 column was used. For preparative HPLC, a reverse-phase 250 x 10 mm
Microsorb-MV 100 C 18 column was used. Chromatograms were recorded at 210 nm
unless otherwise noted.
Synthesis of membrane-permeant OCT-fluorophore conjugates
Synthesis of OCT-PFP (2)
To a solution of OCT acid 122 (17 mg, 65 gimol) in dry dichloromethane (DCM,
750 IiL) was added triethylamine (TEA, 18 pL, 130 [Lmol). The mixture was stirred for
5 minutes at ambient temperature. Pentafluorophenyl trifluoroacetate (PFP-TFA, 22 gL,
130 ýtmol) was added slowly to the reaction mixture over 3 minutes and the reaction was
allowed to proceed for 3 hours. The reaction mixture was concentrated in vacuo, then
purified by silica chromatography (10% ethyl acetate in hexane) to afford OCT-PFP 2 as
a colorless solid (25 mg, 56 gimol, 90%).
Synthesis of OCT-HDDA (3)
Freshly prepared OCT-PFP 2 solid (100mg, 234 ýtmol) was immediately
dissolved in dry DCM (4 mL), and then combined with TEA (65 giL, 468 ptmol) and
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N,N'-dimethyl- 1,6-diaminohexane (HDDA, 169 mg, 1170 ltmol). The reaction mixture
was allowed to stir overnight at ambient temperature. The crude mixture was purified on
a silica flash column (10% methanol in DCM). The purified product was concentrated
under reduced pressure to yield OCT-HDDA 3 (50 mg, 129 imol, 55%). ESI-MS
calculated for [M + H]+: 387.27; observed 387.36.
Synthesis of OCT-EDA (4)
Freshly prepared OCT-PFP 2 solid (30 mg, 70 gmol) was immediately dissolved
in dry DCM (2 mL), and then combined with TEA (29 gL, 210 tmol) and ethylene
diamine (EDA, 38 gL, 560 gmol). The reaction mixture was allowed to stir overnight at
ambient temperature. The crude product was purified by HPLC on a reverse phase
column. The following conditions were used for elution: 30-100% acetonitrile in water
over 30 minutes; flow rate 10.0 mL/minute. The purified product was concentrated under
reduced pressure to yield OCT-EDA 4 (50 mg, 129 gmol, 55%). ESI-MS calculated for
[M + H]+: 303.18; observed 303.30.
Synthesis of HDDA-CF (5)
To a solution of the N-hydroxysuccinimidyl ester of 5/6-carboxyfluorescein (50
mg, 105 glmoles) in anhydrous DMSO (300 gL) was added TEA (41 iL, 300 gmoles).
The mixture was stirred for 1 minute before N,N'-dimethyl-1,6-diaminohexane (72 mg,
500 gmol) was added to the mixture. The reaction was allowed to proceed overnight at
30 'C. The crude product was purified by HPLC on a reverse phase column. The
following conditions were used for elution: 30-100% acetonitrile in water over 30
minutes; flow rate 10.0 mL/minute. Solvent was removed in vacuo to afford HDDA-CF
5. ESI-MS calculated for [M + H]+: 503.21; observed 503.16.
Synthesis of OCT-HDDA-CFDA (6)
To a solution of HDDA-CF 5 (15 mg, 29 [mol) in anhydrous DMF (100 jgL) was
added TEA (8 itL, 58 tmol). OCT-PFP 2 (10 mg, 23 jimol) was then added to the
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mixture and the reaction was allowed to stir overnight at ambient temperature. Thereafter,
acetic anhydride (17 pL, 174 gmol) was added and the reaction was allowed to stir for 5
minutes at ambient temperature. The solution turned from yellow to colorless indicating
formation of the desired product. The crude product was purified by HPLC on a reverse
phase column. The following conditions were used for elution: 30-100% acetonitrile in
water over 30 minutes; flow rate 10.0 mL/minute. Solvent was removed in vacuo to
afford OCT-HDDA-CFDA 6. ESI-MS calculated for [M - H]-: 829.34; observed 829.34.
Synthesis of OCT-HDDA-BODIPY TR (7)
To a solution of OCT-HDDA 3 (1 mg, 2.5 plmol) in anhydrous DMSO (100 giL)
was added TEA (0.7 [tL, 5 imol) and the solution was stirred for 2 minutes. The 4-
sulfotetrafluorophenyl (STP) ester of BODIPY TR (1 mg, 1.25 gtmol) was then added and
the reaction was allowed to stir for 4 hours at ambient temperature. The crude product
was purified by HPLC on a reverse phase column. Chromatograms were recorded both at
210 nm and 550 nm. The following conditions were used for elution: 30-80% acetonitrile
in water over 30 minutes; flow rate 5.0 mL/minute. Solvent was removed in vacuo to
afford OCT-HDDA-BODIPY TR (7). Estimated yield 35%. ESI-MS calculated for [M +
H]+: 906.43; observed 906.36.
Synthesis of OCT-HDDA-BODIPYFL (8)
To a solution of OCT-HDDA 3 (1 mg, 2.5 jimol) in anhydrous DMSO (100 [iL)
was added TEA (0.7 gtL, 5 jmol) and the solution was stirred for 2 minutes. The 4-
sulfotetrafluorophenyl (STP) ester of BODIPY FL (1 mg, 1.8 gImol) was then added and
the reaction was allowed to stir for 4 hours at ambient temperature. The crude product
was purified by HPLC on a reverse phase column. The following conditions were used
for elution: 30-80% acetonitrile in water over 30 minutes; flow rate 5.0 mL/minute.
Solvent was removed in vacuo to afford OCT-HDDA-BODIPY FL 8. Estimated yield
50%. ESI-MS calculated for [M - H]-: 659.38; observed 659.34.
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Synthesis of OCT-HDDA-SNARF®-1 (9)
To a solution of OCT-HDDA 3 (0.2 mg, 0.5 gmol) in anhydrous DMSO (100 CgL)
was added TEA (0.2 tL, 1.5 jlmol) and the solution was stirred for 2 minutes. The
N-hydroxysuccinimidyl ester of SNARF®-1 acetate (0.3 mg, 0.5 glmol) was then added
and the reaction was allowed to stir for 4 hours at ambient temperature. The crude
product was used without further purification. ESI-MS calculated for [M + H]÷: 864.39;
observed 864.42.
Synthesis of OCT-EDA-CFDA (10)
To a solution of OCT-EDA 4 (1.1 mg, 3.6 [tmol) in anhydrous DMSO (100 jtL)
was added diisopropylethylamine (DIEA, 2 [tL, 10.8 jpmol) and the solution was stirred
for 2 minutes. The N-hydroxysuccinimidyl ester of 5/6-carboxyfluorescein diacetate
(2 mg, 3.6 jmol) was then added and the reaction was allowed to stir for 4 hours at
ambient temperature. During the course of the reaction, the acetate groups hydrolyzed.
Re-protection was afforded by addition of excess acetic anhydride. The crude product
was purified by HPLC on a reverse phase column. The following conditions were used
for elution: 30-80% acetonitrile in water over 30 minutes; flow rate 5.0 mL/minute.
Solvent was removed in vacuo to afford OCT-EDA-CFDA 10. Estimated yield 58%.
ESI-MS calculated for [M - H]-: 701.24; observed 701.10.
Synthesis of OCT-EDA-BODIPY FL (11)
To a solution of OCT-EDA 4 (1.1 mg, 3.6 pmol) in anhydrous DMSO (100 tL)
was added TEA (2 .L, 10.8 jimol) and the solution was stirred for 2 minutes. The 4-
sulfotetrafluorophenyl (STP) ester of BODIPY FL (1 mg, 1.8 glmol) was then added and
the reaction was allowed to stir for 4 hours at ambient temperature. The crude product
was purified by HPLC on a reverse phase column. The following conditions were used
for elution: 30-80% acetonitrile in water over 30 minutes; flow rate 5.0 mL/minute.
Solvent was removed in vacuo to afford OCT-EDA-BODIPY FL 11. Estimated yield
44%. ESI-MS calculated for [M + Na]÷: 599.19; observed 599.58.
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Synthesis of membrane-permeant DIFO2-CFDA
Synthesis ofDIFO2-HDDA-CFDA (14)
To a solution of DIFO2 acid 1222 (10 mg, 36 gmol) in dry DCM (750 gL) was
added TEA (10 pL, 70 ýimol). The mixture was stirred for 5 minutes at ambient
temperature. PFP-TFA (19 ýpL, 108 ptmol) was added slowly to the reaction mixture over
3 minutes and the reaction was allowed to proceed for 3 hours. The reaction mixture was
concentrated in vacuo, then purified by preparatory TLC (10% ethyl acetate in hexane) to
afford DIFO2-PFP 13 as a colorless solid (2 mg, 4.5 pmol, 12%).
To a solution of HDDA-CF 5 (5 mg, 9.6 pmol) in anhydrous DMF (100 jiL) was
added TEA (2.7 [iL, 29 Cpmol). DIFO2-PFP 13 (2 mg, 4.5 imol) was then added to the
mixture and the reaction was allowed to stir overnight at ambient temperature. Thereafter,
acetic anhydride (2.6 giL, 27 [imol) was added and the reaction was allowed to stir for 5
minutes at ambient temperature. The solution turned from yellow to colorless indicating
formation of the desired product. The crude product was purified by HPLC on a reverse
phase column. The following conditions were used for elution: 30-100% acetonitrile in
water over 30 minutes; flow rate 10.0 mL/minute. Solvent was removed in vacuo to
afford DIFO2-HDDA-CFDA 14. ESI-MS calculated for [M - H]-: 847.33; observed
847.68.
Synthesis of Cy3-alkyne
To 18 gL of a solution of the N-hydroxysuccinimidyl ester of Cy3 (1 mg,
1.3 gmol) in anhydrous DMSO (80 pL) was added propargylamine (214 gg, 0.3 jiL, 3.9
pmol) and the reaction mixture was stirred at ambient temperature for 3 hours. The crude
product was purified by HPLC on a reverse phase column. Chromatograms were
recorded both at 210 nm and 550 nm. The following conditions were used for elution:
10-50% acetonitrile in water over 30 minutes; flow rate 5.0 mL/minute. Solvent was
removed in vacuo to afford Cy3-alkyne. Estimated yield 70-80%. ESI-MS calculated for
[M - H]-: 666.23; observed 666.36.
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Synthesis of a membrane-permeant coumarin probe (coumarin 2-acetate)
To a solution of coumarin 2 (5 mg, 16 gimol) in anhydrous DMSO (100 giL) was
added TEA (4.4 gL, 32 jimol) and excess acetic anhydride and the reaction mixture was
stirred for 1 hour at ambient temperature in the dark. The crude product was purified by
HPLC on a reverse phase column. The following conditions were used for elution:
30-80% acetonitrile in water over 30 minutes; flow rate 10.0 mL/minute. Solvent was
removed in vacuo to afford coumarin 2-acetate. Estimated yield 37%. ESI-MS calculated
for [M - H]-: 346.10; observed 346.08.
Cloning of HA-E2p for cytoplasmic mammalian expression
The gene encoding for a 9kD hybrid lipoyl domain derived from the second
subunit of the E. coli pyruvate dehydrogenase 7 was inserted between the BamHI and
EcoRI sites of a modified form of the pcDNA3 vector (Invitrogen). The gene was PCR-
amplified from the original pGS331 plasmid7, a gift from John Cronan, with primers 5'
AAAAG GAT CCA TAT CCG TAC GAC GTA CCA GAC TAC GCA ATG GCT ATC GAA ATC
AAA GTA CCG Gand5' TTTT GAA TTC TTA CGC AGG AGC TGC CGC AGG CG to
introduce an HA tag (YPYDVPDYA) and a BamHI site at the N-terminus, and a stop
codon and EcoRI site at the C-terminus. The resulting PCR product was digested with
BamHI and EcoRI and ligated in-frame to BamHI/EcoRI digested pcDNA3, to give
pcDNA3-HA-E2p.
Cloning of E2p-CFP for cytoplasmic mammalian expression
The gene encoding for a 9kD hybrid lipoyl domain derived from the second
subunit of the E. coli pyruvate dehydrogenase 7 was inserted between the NheI and BamHI
and sites of a modified form of the pcDNA3 vector (Invitrogen). The vector contained the
CFP gene between the BamHI and EcoRI sites 3.The E2p gene was PCR-amplified from
the original pGS331 plasmid 7, a gift from John Cronan, with primers 5' AAAA GCT AGC
ATG GCT ATC GAA ATC AAA GTA CCG G and 5' TTTT GG ATC CTT CGC AGG AGC TGC
CGC AGG CG. The resulting PCR product was digested with NheI and BamHI and ligated
in-frame to NheI/BamHI digested pcDNA3, to give pcDNA3-E2p-CFP. To create the
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E2p(Ala)-CFP mutant, we performed QuikChange with the primer 5' C ACC GTA GAA
GGC GAC GCA GCT TCT ATG GAA GTT CCG and its reverse complement. To create a non-
fluorescent E2p-CFP (pcDNA3-E2p-CFP*), Trp66 was mutated to leucine by
QuickChange with primer 5' G ACC ACC CTG ACC CTG GGC GTG CAG TGC TTC and its
reverse complement.
Cloning of E2p-CFP-NLS for nuclear mammalian expression
The E2p-CFP gene was PCR-amplified from the corresponding pCDNA3 plasmid
with the primers: 5' AAAA GCT AGC ATG GCT ATC GAA ATC AAA GTA CCG G and 5'
TTTT GAA TTC CTT TAC ACC TTG CGC TTC TTC TTG GGC ACC TTG CGC TTC TTC TTG
GGC ACC TTG CGC TTC TTC TTG GGG CCG CCG GAG GAC TCC TTG TAC to introduce an
NheI site at the N-terminus, and three tandemly repeated nuclear localization signals
(NLS, protein sequence PKKKRKVPKKKRKVPKKKRKV) and an EcoRI site at the C-
terminus. The PCR product was ligated into the NheI and EcoRI sites of pcDNA3
(Invitrogen). To create the E2p(Ala)-CFP-NLS mutant, we performed QuikChange with
the primer 5' C ACC GTA GAA GGC GAC GCA GCT TCT ATG GAA GTT CCG and its
reverse complement.
Cloning of LAP-CFP for cytoplasmic mammalian expression
Cloning of this construct was described in Chapter 6.
Cloning of FLAG-LplA for cytoplasmic mammalian expression
The original E. coli gene encoding for E. coli lipoic acid ligase (LplA) was
inserted between the BamHI and EcoRI sites of a modified form of the pcDNA3 vector
(Invitrogen). The gene was PCR-amplified from the original pYFJ16 plasmid, a gift from
John Cronan, with primers 5' AAAA G GAT CCA GAC TAC AAG GAT GAC GAC GAT AAG
TCC ACA TTA CGC CTG CTC ATC and 5' TTTT GAA TTC TTA CAG CCC CCG CCA TCC
ATG to introduce a FLAG tag (DYKDDDDK) and a BamHI site at the N-terminus, and a
stop codon and EcoRI site at the C-terminus. The resulting PCR product was digested
with BamHI and EcoRI and ligated in-frame to BamHI/EcoRI digested pcDNA3, to give
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pcDNA3-FLAG-LplA. To create the catalytically inactive mutant, Lys133 was mutated
to arginine by QuikChange using 5' CGT CGA AGG CGA CCG CAG AGT CTC AGG CTC
GGC CTA T and its reverse complement.
Cloning of mCherry-LplA for cytoplasmic mammalian expression
A plasmid containing the gene encoding for the fluorescence protein mCherry
was a gift from Roger Tsien. The plasmid contained the mCherry gene inserted between
the NheI and BamHI of the pcDNA3 vector (Invitrogen). The LplA gene was digested out
of pcDNA3-FLAG-LplA with BamHI and EcoRI and ligated in-frame to BamHI/EcoRI
digested pcDNA3-mCherry, to give pcDNA3-mCherry-LplA (with the FLAG epitope in
between both proteins). To create the catalytically inactive mutant, Lys133 was mutated
to arginine by QuikChange using 5' CGT CGA AGG CGA CCG CAG AGT CTC AGG CTC
GGC CTA T and its reverse complement.
Cloning of FRB-LplA for cytoplasmic mammalian expression
The human FRB gene (a gift from Paul Clemons) was PCR-amplified using the
primers 5' AAAA GCT AGC TAT CCG TAC GAC GTA CCA GAC TAC GCA ATG TGG CAT
GAA GGC CTG and 5' TTTT GGA TCC TTG CCC GAG CCC GAG GTC GAG CCC GAG CCC
TTT GAG ATT CGT CGG AA to introduce an NheI site and an HA tag (YPYDVPDYA) at
the N-terminus, and a 9-amino acid linker (GSGSTSGSG) and a BamHI site at the C-
terminus. The PCR product was digested with NheI and BamHI and ligated in-frame to
Nhel/BamHI digested pcDNA3-mCherry-LplA, to give pcDNA3-FRB-LplA (with the
FLAG epitope in between both proteins).
Cloning of FLAG-hLplA (codon optimized) for cytoplasmic mammalian expression
The codon-optimized gene for mammalian expression of E. coli lipoic acid ligase
(LplA) was inserted between the BamHI and EcoRI sites of a modified form of the
pcDNA3 vector (Invitrogen). The synthetic gene corresponding to a DNA sequence
optimized for expression of the LplA enzyme in human cell lines was purchased from the
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GeneScript Corporation. The gene was PCR-amplified with primers 5' AAAA G GAT CCA
GAC TAC AAG GAT GAC GAC GAT AAG ATG AGC ACC CTG AGA CTG CTG ATC and 5'
TTTT GAA TTC TTA TCT CAC GGC GCC GGC CAT CCA G to introduce a FLAG tag
(DYKDDDDK) and a BamHI site at the N-terminus, and a stop codon and EcoRI site at
the C-terminus. The resulting PCR product was digested with BamHI and EcoRI and
ligated in-frame to BamHI/EcoRl digested pcDNA3, to give pcDNA3-FLAG-hLplA
(where hLplA stands for 'humanized' LplA).
Cloning of mCherry-hLplA (codon optimized) for cytoplasmic mammalian
expression
To construct the pcDNA3-mCherry-hLplA plasmid, the PCR product obtained
above was ligated in-frame to BamHI/EcoRI digested pcDNA3-mCherry. To create the
catalytically inactive mutant, Lys133 was mutated to arginine by QuikChange using 5'
GAG GGC GAC AGA AGG GTG AGC GGC AGC and its reverse complement.
Cloning of FRB-hLplA (codon optimized) for cytoplasmic mammalian expression
The human FRB gene was PCR-amplified as above and ligated in-frame to
Nhel/BamHI digested pcDNA3-mCherry-hLplA, to give pcDNA3-FRB-hLplA (with the
FLAG epitope in between both proteins).
Cloning of mCherry-hLplA (codon optimized) for cytoplasmic mammalian
expression under the regulation of a tetracycline operator
The pcDNA4-TO-mCherry-hLplA construct was created by direct digestion from
the corresponding pcDNA3 plasmid followed by ligation into the HindII and EcoRI sites
of pcDNA4-Tet. To create the LplA mutant that ligates the coumarin probes, Trp37 was
mutated to isoleucine by QuikChange using 5' CCA GAG AGT GCT GTT CCT GAT CAG
AAA CGC CGA CAC CGT G and its reverse complement.
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Detection of intracellular azide 7 ligation to E2p by native-gel mobility shift assay
Human cervical carcinoma (HeLa) cells were transfected with the pcDNA3- HA-
E2p and pcDNA3-FLAG-LplA plasmids using Lipofectamine 2000 (0.8 [ig of each DNA
per well of a 24-well plate). From the moment of transfection, cells were grown in the
presence of 750 pM azide 7. Lysates were generated 48 hours later by hypotonic lysis to
minimize protease release, as follows. Cells were lifted from the plates, concentrated by
centrifugation, and resuspended in 1 mM HEPES pH 7.5, 5 mM magnesium chloride, 1
mM phenylmethylsulphonyl fluoride, and protease inhibitor cocktail (Calbiochem). After
incubation at 4 'C for 10 minutes, the cells were lysed by vigorous vortexing for 2
minutes at 21 'C. Crude lysate was clarified by centrifugation, and either analyzed
immediately or stored at -80 oC. When indicated, lysate was further labeled in vitro by
incubating at 30 oC for 10 hours with 25 mM sodium phosphate pH 7.0, 1 gM LplA,
250 iM azide 7, 1 mM ATP, and 4 mM magnesium acetate. Thereafter, cell extracts
were analyzed by 20% native PAGE followed by Western blotting with rabbit anti-HA
antibody (Rockland Immunochemicals, 1:1000 dilution) followed by anti-rabbit-
horseradish peroxidase conjugate (Pierce, 1:2000 dilution).
Detection of intracellular azide 7 ligation to E2p via [3+2] cycloaddition with biotin-
alkyne
Human embryonic kidney (HEK) 293T cells were transfected with the pcDNA3-
E2p-CFP and pcDNA3-FLAG-LplA (Figure 8-3) or pcDNA3-mCherry/FRB-e/hLplA
(Figure 8-10) plasmids using Lipofectamine 2000 (0.8 jig of each DNA per well of a 24-
well plate). 0-24 hours after transfection, 500-750 jiM azide 7 was added to the cell
growth media (DMEM with 10% FBS, 50 units/mL penicillin, and 50 jig/mL
streptomycin). Lysates were generated 24-48 hours later by hypotonic lysis to minimize
protease release, as follows. Cells were lifted from the plates, concentrated by
centrifugation, and resuspended in 1 mM HEPES pH 7.5, 5 mM magnesium chloride,
1 mM phenylmethylsulphonyl fluoride, and protease inhibitor cocktail (Calbiochem).
After incubation at 4 OC for 10 minutes, the cells were lysed by vigorous vortexing for
2 minutes at 21 'C. Crude lysate was clarified by centrifugation, and stored at -80 OC.
-288 -
Thereafter, azide derivatization via the [3+2] cycloaddition was performed by adding
biotin-alkyne (BALK, prepared by Irwin Chen as described in his thesis 8) to a final
concentration of 500 [tM in the presence of 1 mM CuSO4, 2 mM tris(triazolyl)amine
ligand (Sharpless ligand), and 4 mM tris(2-carboxyethyl)phosphine (TCEP) and
incubating at 30 oC for 16 hours. Each reaction sample was then divided into thirds. The
first third was analyzed by 12% SDS-PAGE followed by Western blotting with
streptavidin-peroxidase conjugate (Pierce, 1:3000 dilution). The second sample was
analyzed by 12% SDS-PAGE followed by Coomassie staining. The last third was
analyzed by 12% SDS-PAGE without boiling the samples, in order to prevent unfolding
of CFP, and in-gel fluorescence was visualized on a Storm 860 instrument (Amersham).
Assay of membrane permeability of the OCT-fluorophore conjugates
Stocks of all OCT-fluorophores conjugates were prepared in dry DMSO at 200x
the final concentration, to ensure that the concentration of DMSO in the final cell-loading
solution was kept constant for all probes at 1%. The cell-loading solution was prepared
by dilution of 100x OCT-fluorophore stock to lx in regular cell growth media (DMEM
with 10% FBS, 50 units/mL penicillin, and 50 jtg/mL streptomycin) containing 0.1%
Pluronic F-127 (Invitrogen) and 1% DMSO. HEK 293T or HeLa cells were incubated
with cell loading for a given period of time ranging from 5-60 minutes at a range of
temperatures 16-37 oC. Thereafter, cells were rinsed three with cell growth media and
imaged immediately. After imaging, cells were incubated further at 21-37 'C to allow
the corresponding OCT-fluorophore to diffuse or be pumped-out of the cells. After 15-60
minutes, cells were imaged again. In all cases, cells were imaged in DPBS on a Zeiss
Axiovert 200M inverted epifluorescence microscope using a 40x oil-immersion lens.
Bodipy-fluorescein and carboxyfluorescein (495/20 excitation, 515 dichroic, 530/30
emission), Bodipy-TexasRed and SNARF-1 (560/20 excitation, 585 dichroic, 605/30
emission) and differential interference contrast (DIC) images (630/10 emission) were
collected and analyzed using OpenLab software (Improvision).
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Live-cell detection of azide 7 ligation using OCT-HDDA-CFDA
HEK 293T cells were transfected with the pcDNA3-E2p-CFP and pcDNA3-
FLAG-LplA (Figure 8-5) or pcDNA3-mCherry-hLplA (Figure 8-7) plasmids using
Lipofectamine 2000 (0.6 jtg of E2p DNA and 0.2 jtg of LplA DNA per well of a 48-well
plate). 24 hours after transfection, 500 jiM azide 7 was added to the cell growth media
and cells were incubated at 37 "C for an additional 16-24 hours. Thereafter, azide 7 was
removed from the cells by changing cell media three times every 20 minutes. The [3+2]
cycloaddition reaction was initiated by addition of cell-loading media (5 [LM OCT-
HDDA-CFDA, 0.1% pluronic, 1% DMSO in DMEM with 10% FBS, 50 units/mL
penicillin, and 50 [tg/mL streptomycin) and incubation at 32 "C for 1-2 hours. Cells were
washed and imaged as above except that images were analyzed using Slidebook software
(Intelligent Imaging Innovations). The following filters were used to image CFP: 420/20
excitation, 450 dichroic, 475/40 emission. mCherry was imaged using the following
filters: 560/20 excitation, 585 dichroic, 605/30 emission.
Fixed-cell immunostaining
HEK 293T or HeLa cells were fixed with 3.7% paraformaldehyde (PFA) for
5 minutes at 4 "C, followed by 10 minutes at room temperature. Excess PFA was washed
three times, 5 minutes each wash, with DPBS and quenched with 100 mM glycine, pH
7.2 for 10 minutes at room temperature. After an additional 5-minute wash in DPBS,
cells were permeabilized by incubation with 100% methanol for 6 minutes at -20 oC.
Finally, cells were rinsed twice for 10 minutes with DPBS and blocked with 3% bovine
serum albumin (BSA) in DPBS for 1 hour-overnight at room temperature or 4 "C with
rocking. Antigen detection was performed by incubating cells with 5 tg/mL of the
appropriate primary antibody for 1 hour-overnight at room temperature in a humidified
chamber. After three 10-minute washes with 1% BSA and 0.03% Tween-20 in DPBS,
cells were incubated for 1 hour with 6.7 [tg/mL anti-rabbit or anti-mouse antibody
conjugated to either Alexa Fluor 488 or Alexa Fluor 568 (Invitrogen). After washing, the
cells were imaged in DPBS as above. Alexa Fluor 568 (560/20 excitation, 585 dichroic,
605/30 emission), Alexa Fluor 488 (495/20 excitation, 515 dichroic, 530/30 emission),
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and differential interference contrast (DIC) images (630/10 emission) were collected and
analyzed using OpenLab software (Improvision) or Slidebook software (Intelligent
Imaging Innovations). The following primary antibodies were used: mouse monoclonal
anti-FLAG®-M2 (Sigma, Cat# F3165) and rabbit polyclonal anti-lipoic acid
(Calbiochem, Cat# 437695).
Detection of intracellular lipoic acid ligation to E2p by western blotting
Human embryonic kidney (HEK) 293T cells were transfected with the pcDNA3-
E2p-CFP and pcDNA3-mCherry/FRB-e/hLplA plasmids using Lipofectamine 2000 (0.8
jig of each DNA per well of a 24-well plate). 24 hours after transfection, 500 jiM R-(+)-
lipoic acid was added to the cell growth media (DMEM with 10% FBS, 50 units/mL
penicillin, and 50 [tg/mL streptomycin). Lysates were generated 24 hours later by
hypotonic lysis to minimize protease release, as described above for the detection of
intracellular azide 7 ligation with biotin-alkyne. Cell extracts were analyzed by 12%
SDS-PAGE followed by Western blotting with anti-lipoic antibody (Calbiochem, 1:1000
dilution) and anti-rabbit-peroxidase antibody conjugate (Pierce, 1:2000 dilution).
Detection of intracellular lipoic acid ligation to E2p in fixed cells by immunostaining
Human embryonic kidney (HEK) 293T cells were transfected with the pcDNA3-
E2p-CFP and pcDNA3-mCherry-LplA plasmids using Lipofectamine 2000 (0.6 jig of
E2p DNA and 0.2 jig of LplA DNA per well of a 48-well plate). 24 hours after
transfection, 500 giM R-(+)-lipoic acid was added to the cell growth media (DMEM with
10% FBS, 50 units/mL penicillin, and 50 jg/mL streptomycin). Cells were fixed and
stained 24 hours later as described above (fixed-cell immunostaining).
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Fixed-cell detection of azide 7 ligation using Cy3-alkyne
HEK 293T cells were transfected with the pcDNA3-E2p-CFP and pcDNA3-FRB-
LplA plasmids using Lipofectamine 2000 (0.4 .tg of each DNA per well of a 48-well
plate). From the moment of transfection, cells were grown in media supplemented with
750 jtM azide 7. 48 hours after transfection, azide 7 was removed from the cells by
changing cell media three times every 20 minutes, and cells were fixed as described
above. After blocking, azide derivatization via the [3+2] cycloaddition was performed by
adding Cy3-alkyne to a final concentration of 50 jiM in the presence of 1 mM CuSO4,
2 mM tris(triazolyl)amine ligand (Sharpless ligand), and 4 mM
tris(2-carboxyethyl)phosphine (TCEP) and incubating at room temperature for 16-24
hours. After three 10-minute washes with 1% BSA and 0.03% Tween-20 in DPBS, cells
were imaged in DPBS as described above. Cy3 was imaged using the following filters:
560/20 excitation, 585 dichroic, 605/30 emission.
Live-cell detection of coumarin ligation
T-RExTM-293 cells were transfected with the pcDNA3-E2p-CFP and pcDNA4-
TO-mCherry-hLplA(W371) plasmids using Lipofectamine 2000 (0.4 Ptg of each DNA per
well of a 48-well plate). From the moment of transfection, cells were grown in media
supplemented with 0.5 jig/mL tetracycline to induce protein expression. 48 hours after
transfection, cell-loading media containing 500 ptM of coumarin-acetate and 0.1%
pluronic was added to the cells for 2 hours at 32 oC. Cells were washed for 1 hour and,
thereafter, labeled cells were imaged as described above. The coumarin filter set was
405/20 excitation, 425 dichroic, 460/40 emission.
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